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1 SUMMARY (ENGLISH/GERMAN VERSION) 
The main objective of this work was the elaboration of a systematic pathway for the development of 
formulations suitable for nebulisation. Furthermore, it was also an objective of this work to investigate 
the taste masking ability of the cyclodextrins not only for water insoluble drugs but also for water 
soluble drugs.  
In this work, we investigated the solubility enhancement of 3 water insoluble drugs by using 
cyclodextrins in two pharmaceutical delivery forms: Solutions and Suspensions. 
A preliminary conclusion was that through the use of cyclodextrins it was possible to increase the 
solubility of the 3 water insoluble drugs, Cyclosporin A, Azithromycin and Budesonide. In addition, 
all the formulations were stable and suitable to be nebulised using the intended eflow device.  
Cyclosporin A (CSA): it was possible not only to increase its water solubility but also to 
obtain droplets sizes suitable for nebulisation. For example, the nebulisation of the CSA 
lyophilizate resulted in an average droplet size of 3.58 µm with a TOR of 415 mg/ml. In 
addition, the lyophilizate of the cyclosporin A/cyclodextrin (CSA/CD) formulation kept at 
25°C and 60% relative humidity was stable for at least 5 months. 
Azithromycin: in order to improve the solubility and also the taste of the azithromycin 
formulation, a new approach was developed. It involved increasing the intrinsic solubility of 
azithromycin with the help of pH adjustments in order to maximize the solubilisation capacity 
of the cyclodextrins without the formation of non-inclusion complexes. Consequently, the 
resulting formulation showed an improvement in masking the taste although the bitterness was 
not entirely removed. However, the taste of the formulation was tolerable for inhalation. 
Alternatively, the solubility of water insoluble drugs, such as cyclosporin A and azithromycin 
can also be increased by the preparation of nanosuspensions of Drug:CD nanospheres. For 
example, in the case of cyclosporin A nanosuspensions, the particle size of the nanospheres 
were 249 nm (P.I. =0.33).  
Budesonide: the results showed that is possible to have a general method that can be applied to 
several water insoluble drugs. For example, trough the use of cyclodextrins we were able to 
obtain a sterile and stable aqueous solution of budesonide that can be efficiently nebulised 
through the eflow® (MMD of 3.00 µm with a TOR of 330 mg/ml).  
The taste masking ability of the cyclodextrins was also investigated. As a model drug, a water soluble 
substance, Pentoxifylline was used. The results obtained show that it is possible to prepare a 
pentoxifylline formulation with a taste suitable for pulmonary administration. In addition, the 
formulations can also be efficiently nebulised through the use of eflow®. As an example, a 
formulation containing 50 mg/ml pentoxifylline and 50 mg/ml 2-HP- -CD was nebulised using the 
eflow®. The droplet size was 3.25 µm with a TOR of 485 mg/ml.  
It was also an objective of this work the elaboration of a systematic pathway for the development of 
formulations suitable for nebulisation. Based on the knowledge collect during this work, a database 
system was built as an aid tool for the pharmaceutical formulation development process.  
This system is able not only to reduce the time in the development formulation process but also 
decrease costs by reducing not only the development time but also by a more effective use of 
materials.   
In conclusion, it was able to increase the solubility/stability and also to taste mask formulations 
containing both water insoluble and water soluble drugs. This opens new possibilities to the 
pulmonary delivery as an alternative non-invasive method of delivering drugs that currently can only 
be delivered orally or intravenously.   
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Das Hauptziel dieser Arbeit war die Weiterentwicklung eines systematischen Pfads für die 
Entwicklung von für Zerstäubung passenden Formulierungen. Außerdem war das auch ein Ziel dieser 
Arbeit zu untersuchen, der Fähigkeit des Cyclodextrins, nicht nur für unlösliche Wasserrauschgifte 
sondern auch für auflösbare Wasserrauschgifte, den Geschmack zu maskieren.  
In dieser Arbeit untersuchten wir die Löslichkeitserhöhung von drei unlöslichen Wasserrauschgiften, 
indem wir Cyclodextrins in zwei pharmazeutischen Lieferformen verwendeten: Lösungen und 
Suspendierungen.  Ein einleitender Beschluss war, dass durch den Gebrauch von Cyclodextrins es 
möglich war, die Löslichkeit der drei unlöslichen Wasserrauschgifte, Cyclosporin A, des 
Azithromycin und des Budesonide zu vergrößern. Außerdem waren alle Formulierungen stabil und 
passend, um zerstaübt durch das Verwenden des beabsichtigten eflow® Geräts zu sein. 
 
Cyclosporin (CSA): es war nicht nur möglich, seine Wasserlöslichkeit zu vergrößern sondern 
auch für Zerstäubung passende Tröpfchen-Größen zu erhalten. Zum Beispiel, lief der 
Zerstäubung des CSA lyophilizate auf eine durchschnittliche Tröpfchen-Größe 3.58 µ hinaus 
M mit einem TOR von 415 mg/ml. Außerdem war der lyophilizate des Cyclosporin 
A/Cyclodextrin (CSA/CD) Formulierung an 25°C behalten und relative Feuchtigkeit von 60 % 
seit mindestens 5 Monaten stabil. 
Azithromycin: um die Löslichkeit und auch der Geschmack der Azithromycin Formulierung 
zu verbessern, wurde eine neue Annäherung entwickelt. Es schloß die Erhöhung der inneren 
Löslichkeit von Azithromycin mit der Hilfe von pH Anpassungen ein, um die Solubilisierungs 
Kapazität des Cyclodextrins ohne die Bildung von Nichteinschließungskomplexen zu 
maximieren. Folglich zeigte die resultierende Formulierung eine Verbesserung in der 
Maskierung des Geschmacks, obwohl die Bitterkeit nicht völlig entfernt wurde. Jedoch war 
der Geschmack der Formulierung für die Einatmung erträglich. 
Wechselweise kann die Löslichkeit von unlöslichen Wasserrauschgiften, wie Cyclosporin A 
und Azithromycin auch durch die Vorbereitung von nanosuspensions von Drug:CD 
nanospheres vergrößert werden. Zum Beispiel, im Fall von Cyclosporin A nanosuspensions, 
war die Partikel-Größe des nanospheres 249 nm (P.I. =0.33). 
Budesonide: die Ergebnisse zeigten, dass das möglich ist, eine allgemeine Methode zu haben, 
die auf mehrere unlösliche Wasserrauschgifte angewandt werden kann. Zum Beispiel, durch 
den Gebrauch von Cyclodextrins wir waren im Stande, eine sterile und stabile wässrige 
Lösung von Budesonide zu erhalten, der effizient zerstäubt durch den eflow® sein kann 
(MMD 3.00 µ M mit einem TOR von 330 mg/ml).   
Der Geschmack, der Fähigkeit des Cyclodextrins maskiert, wurde auch untersucht. Als ein 
Musterrauschgift, eine auflösbare Wassersubstanz, wurde Pentoxifylline verwendet. Die 
Ergebnisse erhielten zeigen dass es möglich ist, eine Pentoxifylline Formulierung mit einem für 
die Lungenverwaltung passenden Geschmack vorzubereiten. Außerdem können die 
Formulierungen auch effizient zerstäubt durch den Gebrauch von eflow® sein. Als ein Beispiel, 
eine Formulierung, die 50 mg/ml Pentoxifylline und 50 mg/ml 2-HP-ß-CD enthält; - CD war 
zerstäubtet durch das Verwenden des eflow®. Die Tröpfchen-Größe war 3.25 µ M mit einem 
TOR von 485 mg/ml.  
Es war auch ein Ziel dieser Arbeit die Weiterentwicklung eines systematischen Pfads für die 
Entwicklung von für Zersträubung passenden Formulierungen. Gestützt auf die Kenntnisse 
versammeln während dieser Arbeit, ein Datenbanksystem wurde als ein Hilfswerkzeug für den 
pharmazeutischen Formulierungsentwicklungsprozess gebaut. Dieses System ist nicht nur im 
Stande, die Zeit mit dem Entwicklungsformulierungsprozess zu sparen sondern auch Abnahme-
Kosten zu reduzieren. Anderseits, es führt nicht nur zu einer Reduzierung der Entwicklungsdauer 
sondern auch zu einem wirksameren Gebrauch von Materialien. 
Schließlich es war im Stande, die Löslichkeit/Stabilität zu vergrößern und auch Maske-
Formulierungen zu kosten, die sowohl auflösbaren als auch unlöslichen Wasserwasserrauschgifte 
enthalten. Das öffnet neue Möglichkeiten zur Lungenübergabe als eine alternative 
nichtangreifende Methode, Rauschgifte zu liefern, die nur zurzeit mündlich oder intravenös 
geliefert werden können. 
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2 INTRODUCTION 
Pulmonary drug delivery has constantly being considered as a way to directly target disorders 
of the lung, as well as a non-invasive alternative for systemic conditions that can not be 
treated using, for example, with oral medications. While pulmonary delivery is routinely used 
for specific conditions such as asthma, recent advances in inhalation technology have 
provided the opportunity to increase the applications for pulmonary delivery to many 
therapeutic molecules. 
The applications for pulmonary drug delivery are many, particulary in four key areas:   
Targeted treatment of lung disorders; 
A non-invasive alternative to macromolecule drugs; 
Faster onset of action; 
Efficacious and patient-friendly therapies.  
2.1 The Inhalative Therapy 
Growing attention has been given to the potential of the pulmonary route as a means for non-
invasive administration for the local delivery of therapeutic agents and also for the systemic 
delivery (mainly peptides and proteins). This is because the lungs could provide a large 
absorptive surface area (up to 100 m2) but extremely thin (0.1 µm 0.2 µm) absorptive 
mucosal membrane and good blood supply. Consequently, the interest of using drug delivery 
systems for the treatment of pulmonary diseases is steadily increasing.  
Furthermore, this route has the ability to deposit large concentrations at disease sites, to 
reduce the amount of drugs administered to patients (for example, only 20 10% of the 
amount administered by the oral route), to increase the local activity of drugs released at such 
sites, and to avoid the metabolization of drugs due to a hepatic first-pass effect.  
No other non-invasive route of drug delivery provides the bioavailability potential of the 
pulmonary epithelium. The lungs are more permeable to macromolecules than any other 
portal of entry into the body (Lit. [1]). Some of the most promising therapeutic agents are 
peptides and proteins, which could be inhaled instead of being injected, thereby improving 
compliance. The lungs are even more permeable to small molecules than the gastrointestinal 
(GI) tract (Lit. [2]).  
In contrast to oral delivery, where a drug can be heavily metabolized and altered by the 
enzymes of stomach and liver, the lungs exhibit only a small drug-metabolizing and efflux 
transporter activity (Lit. [3] Lit. [5]). Consequently, small molecules can be efficiently 
delivered into the body through the lungs without the production of a complex array of 
metabolites.   
Introduction 
4 
No non-invasive route of delivery provides the speed of action that an inhaled drug can 
provide. Pulmonary drug targeting has long been used to treat lung diseases, particularly 
asthma and chronic obstructive pulmonary disease (COPD), non-cystic fibrosis (nCF) and 
cystic fibrosis (CF), bronchiectasis, bronchiolitis and recently influenza. Potentially, other 
pulmonary diseases such as parenchymal fibrosis, acute bronchitis, pneumonia and even 
carcinoma of the lung in situ can be treated by inhalation1.  
By facilitating the systemic delivery of large and small molecule drugs through deep 
inhalation into the lungs, a unique and innovative delivery alternative is provided for therapies 
that must currently be administered by injection (i.v., i.m., s.c.) or oral delivery, which causes 
adverse effects or poor absorption. 
In fact, the main advantage of a therapy via the lungs is the potentially improved therapeutic 
index, i.e. the ratio of therapeutic benefit to adverse effects. This applies mainly to the therapy 
of pulmonary diseases, but may also be applicable to systemic diseases due to reduced first-
pass metabolism that may be associated with hepatocellular injury. Pulmonary delivery also 
offers the potential for better and possibly more economical treatment or prophylaxis of 
respiratory and systemic diseases (e.g. viral vaccines).  
Pulmonary delivery provides a non-invasive method of delivering drugs into the bloodstream 
for those molecules that currently can only be delivered by injection. These include peptides 
and proteins, such as insulin for diabetes or interferon-beta for multiple sclerosis and most of 
the drugs developed in recent years by biotechnology companies. This direct delivery often 
results in a better treatment outcome while potentially requiring lower doses than given 
systemically - either orally or by injection. 
Another advantage lies on the very rapid onset of action similar to the i.v. route and quicker 
than either oral delivery or subcutaneous injections2. More rapid delivery could benefit 
treatments for pain, seizures, panic/anxiety attacks, hypertensive crises, anaphylaxis (severe 
allergies food, insect bites), nausea, cardiovascular conditions (arrhythmia, strokes), and 
Parkinson's lock-up , where speed is important. 
Inhalative therapy, in comparison to the oral route, can help avoid gastrointestinal tract 
problems such as poor solubility at low pH, low bioavailability, gut irritability, unwanted 
metabolites, food effects and dosing variability.  
Natural mammalian peptides, (less than 30 amino acids), are broken down in the lung by 
ubiquitous peptidases and have very poor bioavailabilities. In general, proteins with molecular 
weights between 6,000 and 50,000 D are relatively resistant to most peptidases and have good 
bioavailabilities following inhalation. For larger proteins, the bioavailability picture is not 
clear.  
                                                          
 
1  With regard to pulmonary infections, much higher concentrations of antibiotics can be achieved in the lungs 
by inhalation, which should accomplish greater and more rapid bacterial killing with less likelihood of 
developing bacterial resistance. Furthermore, topical delivery achieves reduced systemic side effects for 
equivalent therapeutic benefit. 
2  One of the advantages, of inhaled insulin is, for example, that it is more rapidly absorbed than subcutaneously 
injected insulin and provides a more physiological response to a meal (Lit. [6]). Small molecules, particularly 
hydrophobic molecules, are absorbed within seconds after inhalation and can, this way, be used to treat a wide 
variety of symptoms that arise suddenly or require a quick response. Pain, panic, anxiety, nausea, 
cardiovascular crises, bronchoconstriction, sleep induction, spasms, Parkinson's lock-up, and hot flashes are 
some of the rapid-onset conditions that are addressable with inhaled medicines (Lit. [7] Lit. [9]).   
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Although the lung is rich in antiproteases, aggregation of inhaled proteins will stimulate 
opsonization (coating) by special proteins in the lung lining fluids, which will then mark the 
aggregated proteins for phagocytosis and intracellular enzymatic destruction. Small peptides 
and proteins are absorbed more rapidly after inhalation than after subcutaneous injection. For 
other small molecules, inhalation is also a fast way to get into the body because drug efflux 
transporters and metabolizing enzymes are present in the lung at much lower levels than in 
the gastrointestinal tract:  
- Lipophilic small molecules are absorbed extremely fast: t1/2 (abs) approximately 1 to 2 
minutes; 
- Water-soluble small molecules are absorbed rapidly: t1/2 (abs) approximately 65 minutes. 
Small molecules can exhibit prolonged absorption if they are highly insoluble or carry 
extremely negative charges.  
For several years, inhaled drugs have been used for the treatment of many lung diseases but 
there are currently no inhaled drugs on the market for systemic disease. However, in several 
companies large and small molecules are under investigation as inhaled formulations for 
systemic applications3.  
Due to the potential of localized topical therapy in the lungs, the interest of using drug 
delivery systems for the treatment of pulmonary diseases is steadily increasing. Furthermore, 
this route offers the ability to deposit large concentrations at disease sites, to reduce the 
amount of drugs administered to patients (for example, only 20 10% of the amount 
administered by the oral route), to increase the local activity of drugs released at such sites, 
and to avoid the metabolization of drugs due to a hepatic first-pass effect (Lit. [10]). 
As an example, it is known that asthma (in particular chronic persistent asthma) is related to 
the terminal bronchioles. For this reason and, aimed at improving the pulmonary targeting of 
a potentially useful therapy, several scientific articles have  focused on the design of suitable 
dosage forms to specifically target the small airways and to increase the local bioavailability 
of drugs combined with carrier systems. 
In addition, the design of a carrier system has a very important influence because of the 
limitations of chronic oral administration with respect to systemic side effects, including 
hepatic dysfunction, skeletal malformations, hyperlipidemia, and hypercalcemia (Lit. [11]).  
At the present state, there are clinical results obtained with particular carrier systems which 
suggest that some of these may offer a practical alternative to systemic oral administration for 
chemoprevention trials or the treatment of lung diseases. This method can reduce the systemic 
complications associated with long-term administration and, consequently, increase the 
therapeutic value of targeted compounds. 
Although the lungs are rich in enzymes, they also contain several protease inhibitors. For this 
reason, exogenous proteins may be protected from proteolytic degradation by these inhibitors. 
These characteristics allow the airways to be a useful route of drug administration in the 
inhaled or aerosol form.  
                                                          
3  Recent advances in the development of particle technologies and devices make it possible to formulate, 
stabilize, and accurately deliver almost any drug to the lungs. More than 25 inhalation drugs on the market for 
treatment of lung diseases are all absorbed to some extent into the body, most of them quickly, and with very 
high systemic bioavailabilities (Lit. [56]).  
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However, the mechanisms of drug delivery to the lungs are more complex than for other 
routes. For the drug to reach the lungs, it depends on numerous factors, such as:  
 
The amount and rate of inhaled air; 
The respiratory pause; 
The particle size and characteristics (homogeneity, shape, electric charges, density, 
and hydrophobicity).  
Nevertheless, the pulmonary delivery of a variety of drugs such as bronchodilators and 
steroids has been very successful (Lit. [12]). 
In order to improve bioavailability and also to optimize the release of drugs targeted to 
specific sites into the lungs, several approaches have been investigated. These include 
advances in the fields of aerosol therapy, such as aerosol generators and drug delivery 
systems (for example, liposomes or nano- and microparticles).  
2.2 Respiratory System 
The human lung is an attractive route for systemic drug administration (Lit. [12]) due to its 
previously mentioned enormous adsorptive surface area (140 m2) and thin (0.1 0.2 m) 
absorption mucosal membrane in the distal lung (Lit. [13]).  
Approximately 90% of the absorptive area of the lung is attributed to the alveolar epithelium, 
which primarily consists of type I pneumocytes.4 Because pulmonary drug administration is 
directly related to the respiratory structure and function, a small description of the basics of 
the lung and also of the drug entrance mechanisms is given below.  
The human respiratory system is a complicated organ system of very close structure function 
relationships.  
In functional terms, the respiratory system consists of three major regions: the oropharynx, 
the nasopharynx, and the tracheobronchial pulmonary region. The conducting airway is 
composed of the nasal cavity and associated sinuses and the nasopharynx, oropharynx, larynx, 
trachea, bronchi, and bronchioles, including the first 16 generations of the airways of 
Weibel s tracheobronchial tree (Lit. [55]). 
The conducting airway is responsible for the filtration, humidification and warming of 
inspired air. The respiratory region is composed of bronchioles, alveolar ducts, and alveolar 
sacs, including generation 17 23 of Weibel s tracheobronchial tree (Figure 1).   
                                                          
4  Type I pneumocytes are extremely thin epithelial cells lining the alveoli of the respiratory tree. Although there 
as many type II pneumocytes as type I within each alveolus, type I occupies up to 90% of the surface area 
due to its arrangement into a squalors layer. Type I cells, joined to each other by tight junctions, form 
specialised connections with underlying capillaries at the thin portions of the alveolar-capillary complexes. It 
is at the complexes that the type I cells are in close enough proximity to the capillaries - 0.5 micrometers - to 
permit gaseous diffusion which is their key function (Lit. [55]).   
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Figure 1: Tree structure of the lung (Lit. [14]).      
Figure 2: Schematic representation of the lung according to the model described by 
Weibel (Lit. [55]). 
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The respiratory gases circulate from air to blood and vice versa through 140 m2 of internal 
surface area of the tissue compartment. This gas-exchange tissue is called the pulmonary 
parenchyma. 
It consists of 130,000 lobules, each with a diameter of about 3.5 mm and containing 
approximately 2200 alveoli. The terminal bronchioles branch into approximately 14 
respiratory bronchioles, each of which then branches into the alveolar ducts (Figure 2). The 
ducts carry 3 or 4 spherical atria that lead to the alveolar sacs supplying 15 20 alveoli. 
Additional alveoli are located directly on the walls of the alveolar ducts and are responsible 
for approximately 35% of total gas exchange.  
It has been estimated that there are 300 million alveoli in an adult human lung. The diameter 
of an alveolus ranges from 250 to 290 m; its volume is estimated to be 1.05 × 10-5 ml, and its 
air tissue interface to be 27 × 10 4 cm2. For these calculations, it is assumed that the lung has 
a total volume of 4.8 liters and a respiratory volume of 3.15 liters and that the air tissue 
alveolar interface is 81 m2.  
 
Figure 3: Structure and perfusion of the alveoli (Lit. [14]).         
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2.3 Barriers present in the lungs 
The lungs also serve as biological barriers and defence mechanisms that protect the 
respiratory system. These barriers and mechanisms are listed below.  
2.3.1 Pulmonary Surfactant 
The elastic fibers of the lung and the wall tension of the alveoli could cause the lungs to 
collapse if these were not counterbalanced by the presence of the pulmonary surfactant 
system. This covers the alveolar surface to a thickness of 10 20 nm and is constantly renewed 
from the cell layer below. The surfactant is composed of 90% in weight of phospholipids, 
including 40 80% in weight of dipalmitoyl phosphatidylcholine (DPPC). Other main 
ingredients are phosphatidylcholines, phophatidylglycerols, other anionic lipids, and 
cholesterol (Lit. [15]). 
The remaining fraction (10% in weight) is composed of 4 specific proteins: the hydrophiles 
SP-A and SP-C and the hydrophobes SP-B and SP-D. Enzymes, lipids, or detergents can 
destroy this surfactant. 
If the pulmonary surfactant is removed quickly by pulmonary irrigation, no damage occurs 
because it is quickly replaced (half-life: 30 hours). The surfactant is only produced form the 
time of birth onwards, which is why premature babies (including premature caesarean babies) 
suffer from respiratory distress syndrome (RDS). In this case, replacement surfactants are 
administered to substitute for the missing natural surfactant (Lit. [16]-Lit. [18]).  
2.3.2  Epithelial Surface Fluid 
A thin fluid layer called the mucus blanket, 5 m in depth, covers the walls of the respiratory 
tract. This barrier serves to trap foreign particles for subsequent removal and prevents 
dehydration of the surface epithelium by unsaturated air during inspiration. Hypersecretion of 
mucus is a result of cholinergic or -adrenergic antagonists, which act directly on the 
secreting cells of the submucosal glands. Peripheral granules, in which mucus is stored, 
release a constant discharge and form a reservoir that will be secreted after exposure to an 
irritating stimulus. A state of disease can modify the distribution of the cell goblets and the 
composition of the fluids of the respiratory tracts.  
2.3.3 Epithelium 
The upper respiratory tract is made up of pseudostratified, ciliated, columnar epithelium cells 
(Lit. [19]). The bronchi, but not the bronchioles, have mucous and serous glands present. 
However, the bronchioles possess goblet cells and smooth muscle cells capable of narrowing 
the airway. The epithelium of the terminal bronchioles consists mainly of ciliated, cuboidal 
cells and a small number of secretory Clara cells (Figure 3). Each ciliated epithelial cell has 
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around 20 cilia with an average length of 6 m and a diameter of 0.3 m. Clara cells become 
prevalent in respiratory bronchioles.  
In the alveolar ducts and alveoli, the epithelium is 0.1 0.5 m thick. The alveoli are packed 
narrowly and do not have partitioning walls; the adjacent alveoli are separated by an alveolar 
septum with communication between alveoli via alveolar pores. The alveolar surface is 
covered with a lipoprotein film, which is the pulmonary surfactant. The alveolar surface is 
mainly composed of a single layer of epithelial cells Type I alveolar cells approximately 5 
m thick. Type II cells, cuboidal in shape, 10 15 m thick, and situated at the junction of 
septa, are responsible for the production of alveolar lining fluid and the regeneration of type I 
cells during repair following cell damage from viruses or chemical agents. 
The alveolar-capillary membrane, which separates blood from alveolar gases, is composed of 
a continuous epithelium, 0.1 0.5 m thick (Figure 4). The maximum absorption occurs in the 
area where the interstitium is the finest (80 nm) because the pulmonary surfactant is also thin 
in this area (15 nm). The thickness of the air blood barrier ranges from 0.2 to 10 m. The 
most efficient gas exchange takes place if this air blood barrier is less than 0.4 m in 
thickness.  
2.3.4  Interstitium 
The interstitium is the extracellular and extravascular space between cells in tissue. In order 
for a molecule to be absorbed from the airspaces to the blood, it must pass through the lung s 
interstitium. Within the interstitium there are fibroblasts, tough connective fibers (i.e., 
collagen fibers and basement membrane), and interstitial fluid, which slowly diffuses and 
percolates through the tissue.  
2.3.5 Vascular endothelium 
The endothelium is the final barrier to a molecule being absorbed from the airspace into the 
blood. Endothelial cells form capillaries that lie under Type I cells in the alveoli (Figure 4). 
The basic alveolar structure is the septum, which is composed of capillaries sandwiched 
between two epithelial monolayers (Lit. [20]).  
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Figure 4: Typical lung epithelia in the different pulmonary regions and thickness of 
the surface fluid. (a) The bronchial epithelium (Ø 3 5 mm) showing the 
pseudostratified nature of the columnar epithelium, principally comprising ciliated 
cells 6 µm (c), interspersed with goblet cells (g) and basal cells (b). (b) The 
bronchiolar epithelium (Ø 0.5 1 mm) showing the cuboidal nature of the epithelium, 
principally comprising ciliated cells (c), and interspersed with Clara cells (cl). (c) 
The alveolar epithelium is comprise of  extremely thin (Ø 5 µm) type I cell (I), which 
accounts for approximately 95% of the epithelial surface, and the cuboidal (Ø 10 15 
µm) type II cell (II) (Lit. [20]).   
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Figure 5: Alveolar capillary membrane (Lit. [20]).       
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2.4 Factors Affecting Deposition of Particles 
Deposition of aerosol particles in the bronchial tree depends on the granulometry of the 
particles and the anatomy of the respiratory tract. Aerosols used in therapy are composed of 
droplets or particles with different sizes and geometries. Generally, four parameters can be 
used to characterize the granulometry of an aerosol:  
Mass median diameter (MMD) corresponding to the diameter of the particles for which 50% 
w/w of particles have a lower diameter and 50% w/w have a higher diameter.  
Percentage in weight of particles with a geometrical diameter of less than 5 m.
 
Geometric standard deviation  (GSD) corresponding to the ratio of the diameters of 
particles from aerosols corresponding to 84% and 50% on the cumulative distribution curve 
of the weights of particles. The use of a geometric standard deviation to describe the particle 
size distribution requires that particle sizes are log-normally distributed. If, as is frequently the 
case, particles are not log-normally distributed, the geometrical standard deviation is 
meaningless and a misleading representation of the distribution. Heterogeneous aerosols 
have, by definition, a GSD of greater than or equal to 1.22 (Lit. [20]).  
Mass median aerodynamic diameter (MMAD), which makes it possible to define the 
granulometry of aerosol particles by taking into account their geometrical diameter, shape, 
and density: MMAD = MMD × Density.  
2.5 Mechanisms of Particle Deposition in the Airways 
There are three main particle deposition mechanisms in the lung: inertial impaction, 
sedimentation and Brownian diffusion.  
The deposition of particles administered by an aerosol in specific areas of the respiratory tract 
is related to the deposition mechanism along with the particle diameter (Lit [21]).  
Inertial impaction is the most significant mechanism for the deposition of aerosol particles 
with an MMAD of more than 5 m. It occurs in the upper respiratory tracts when the velocity 
and mass of the particles involve an impact on the airway. It is supported by changes in 
direction of inspired air and when the respiratory tracts are partially blocked. Hyperventilation 
can influence impaction, too.  
Sedimentation occurs in the peripheral airways and concerns small particles from an aerosol 
with an MMAD ranging from 1 to 5 m. Sedimentation is a phenomenon resulting from the 
action of gravitational forces on the particles. It is proportional to the square of the particle 
size (Stokes law) and is thus less significant for small particles. This kind of deposition is 
independent of particle motion. Sedimentation is mainly influenced by breath holding, which 
can improve deposition.  
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Brownian diffusion is a significant mechanism for particles with an MMAD of less than or 
equal to approximately 0.5 m. The particles move by random bombardments of gas 
molecules and run up against the respiratory walls. Generally, 80% of particles with an 
MMAD of less than or equal to 0.5 m are eliminated during exhalation.
  
The behaviour of the aerosolized particles in the body can be summarized in Figure 6.  
Figure 6: Behaviour of aerosolized particles into the body (Lit. [21]).   
Figure 7: Dependence of deposition of particulates on particle size. (Lit. [21])  
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2.6 Influence of Particle Size 
Big particles (>10 m) come into contact with the upper respiratory tract and are quickly 
eliminated by mucociliary clearance. Particles with a diameter of 0.5 5 m settle according to 
various mechanisms. The optimum diameter for pulmonary penetration was studied on 
monodispersed aerosols and is around 2 3 m (Lit. [22]). Smaller particles can be exhaled 
before they are deposited; holding breath prevents this. Extremely small particles (<0.1 m) 
appear to settle effectively by means of Brownian diffusion but are difficult to produce 
(Figure 6). Often the particle size does not remain constant once it reaches the respiratory 
tract: 
Volatile aerosols become smaller with evaporation, and hygroscopic aerosols grow bigger 
with moisture from the respiratory tract. In addition, it has not yet been proven that the 
retention of inhaled particles depends on their geometric diameter (Lit. [23]).  
2.7 Lung Permeability 
The alveolar epithelium and the capillary endothelium have a very high permeability to water, 
to most gases and to lipophilic substances. However, there is an effective barrier for many 
hydrophilic substances of large molecular size and for ionic species. The alveolar Type I cells 
have tight junctions, limiting the penetration to molecules with a radius of less than 0.6 nm. 
Endothelial junctions are larger, with gaps of around 4 6 nm. Normal alveolar epithelium is 
almost completely impermeable to proteins and small solutes. Microvascular endothelium, 
with its larger intercellular gaps, is far more permeable to all molecular sizes, allowing 
proteins to flow into the systemic circulation. Pulmonary permeability increases in smokers 
and in states of pulmonary disease. 
Soluble macromolecules can be absorbed from the lung by passing either through the cells 
(absorptive transcytosis) or between the cells (paracellular transport) (Lit. [24]). It has been 
postulated that molecules larger than ~40 kDa may be absorbed by transcytosis and then enter 
blood either via transcytosis in the capillary or post capillary venules; molecules smaller than 
~40 kDa may directly enter the blood, primarily via the tight junctions of both the Type I cell 
and the capillary.  
2.8 Clearance of Inhaled Particles from the Respiratory Tract 
Particles deposited and not transported across the epithelium of the respiratory tract are 
cleared by either mucociliary clearance or a combination of mucociliary and alveolar 
clearance mechanisms.  
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2.8.1 Mucociliary clearance 
The respiratory tract possesses series of defences against inhaled materials because of its 
constant exposure to the outside environment. The lung has an efficient self-cleaning 
mechanism known as the mucociliary escalator, in addition to other mechanisms such as 
coughing and alveolar clearance. The mucus gel layer (5 m thick) floats above the sol layer, 
which is approximately 7 m thick. The cilia extend through this layer so that the tip of the 
villus protrudes into the gel. 
The coordinated movement of the cilia propels the mucus blanket and deposited foreign 
materials at a rate of 2 5 cm.min 1 outwards towards the pharynx, where they are swallowed. 
It has been estimated that 1 liter of mucus is cleared every 24 hours. Mucociliary clearance is 
influenced by various factors: physiological, environmental (S2, CO2, tobacco, etc.) and 
diseases (asthma, cystic fibrosis, etc.) (Lit. [25]).  
2.8.2 Alveolar clearance 
Particles deposited in the terminal airway units can be removed either by a nonabsorptive or 
an absorptive process (Lit. [26]). The nonabsorptive process involves the transport of particles 
from the alveoli to the ciliated region, where they are removed by the mucociliary clearance 
mechanism present in the conducting airway. 
The absorptive process may involve either direct penetration into the epithelial cells or uptake 
and clearance by alveolar, interstitial, intravascular, or airway macrophages. In addition to 
their role in cleaning particles, macrophages also play an important part in inflammatory 
processes through the release of chemotactic factors to attract polymorphonuclear neutrophils 
from the pulmonary vascular bed to the area. Alveolar macrophages, 15 50 m in diameter, 
lie in contact with the surfactant lining the alveoli. Foreign particles adhere to macrophages 
through either electrostatic interaction or interaction with receptors for some macromolecules, 
such as immunoglobulins. Following adhesion, macrophages ingest the particles by 
interiorization of vacuoles, surface cavitation, or pseudopod formation. The uptake of 
particles by macrophages is size dependent. Particles with a diameter of 6 m are 
phagocytosed to a much smaller extent than those with a diameter of 3 m. Moreover, 
particles with a diameter of less than 0.26 m are minimally taken up by macrophages. The 
nature of the coating material also influences the rate of phagocytosis by alveolar 
macrophages (Lit. [27-28]).  
2.9 Mechanism of absorption 
The precise mechanisms of macromolecule absorption in the lungs are not well known. Most 
exogenous macromolecules are thought to be absorbed from the airspaces non-specifically 
through a combination of tight junctions and endocytic vesicles by processes that are 
diffusion-limited (Lit. [27]). Thus a large molecule takes longer to find its "opening" than a 
small molecule simply because the large molecule's random walk is at a slower pace than the 
small molecule. But the picture may be more complex. There is evidence that for certain 
endogenous molecules that normally occur in lung lining fluids, e.g. albumin (Lit.[28]), 
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immunoglobulins (Lit.[29]) and transferrin (Lit.[30]), there are specific receptor-mediated 
transport mechanisms on the alveolar epithelial cell that enable these proteins to be absorbed 
at higher rates than expected.   
2.9.1  Small molecule drug absorption 
Most small molecules that exhibit some water solubility are rapidly and efficiently absorbed 
from the lungs. Those that are more hydrophobic are absorbed even more rapidly within 
seconds to a few minutes. Those that are more hydrophilic are absorbed within minutes to tens 
of minutes. Lewis Schanker and colleagues, in a series of papers between 1973 and 1986, 
explored many facets of pulmonary drug absorption in a variety of different animals (Lit. [31]-
Lit. [47]). They quantitatively analyzed the amount of radiolabeled drug absorbed across the 
pulmonary epithelium following intratracheal and aerosol delivery and determined the 
comparative rates of absorption for different classes of compounds. They compared the 
characteristics between different species, sexes, and ages of animals and determined the effect 
of various noxious agents that damage epithelia on pulmonary absorption, as described in the 
following chapter.  
2.9.1.1 Mechanism of small molecule absorption 
Putting that data of Schanker and co-workers in the context of our current understanding of 
the molecular basis of transepithelial transport allows one to draw certain inferences about the 
potential mechanisms of absorption of the different classes of molecules. Lipid-soluble 
compounds are rapidly absorbed presumably because they can integrate into the lipid bilayer 
surrounding the cells. This constitutes the "transcellular pathway" in which compounds pass 
from the apical to basolateral side by travelling through the cellular membrane. Lipid-
insoluble compounds, by contrast, most likely traverse the epithelium via a paracellular route, 
in which they pass through aqueous pores in the intercellular tight junctions. Although the 
nature of these junctions is not fully understood, it appears that a combination of molecular 
weight and degree of ionization determine the rate at which molecules can pass through. The 
less ionized a molecule, the faster its absorption rate, because it forms fewer interactions with 
the proteins and lipids that line the pore. The work of Schanker and associates suggests that 
for small hydrophilic compounds in the range of 100 to 1,000 D, the degree of ionization is 
likely to dominate, whereas for larger ones the molecular weight becomes an influential 
factor, too (Lit. [31]-Lit. [36]).   
2.9.1.1.1 Active Transport 
A number of compounds (e.g., disodium cromoglycate and cycloleucine) undergo active or 
"carrier-mediated" transport (Lit. [47]). Their absorption rates are saturable, such that the 
percent dose absorbed decreases with increasing concentration. In addition, their absorption is 
energy-dependent and can be inhibited by other compounds that share common structural 
features. These molecules enter cells by binding to specific carrier proteins on the cell surface, 
and use an energy-driven exchange to drive uptake against a concentration gradient. 
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Nonetheless, these molecules do not deviate significantly from other molecules of similar 
lipophilicity or molecular weight in terms of their absorption characteristics (Figures 1 and 2).   
2.9.1.1.2 Slow Absorption of Inhaled Small Molecules 
Although the rapid absorption of small molecules has many conceivable medical uses, there 
are situations when one might want to slow the absorption of an inhaled small molecule, 
either to keep it acting longer locally in the lung, or to regulate its absorption into the body. 
There appear to be at least two instances in which small molecules are much slower absorbed 
than the data of Schanker and co-workers might suggest. Very insoluble small molecules that 
slowly dissolve from the inhaled particle may stick in the lung for many hours or even days. 
Fluticasone propionate, amphotericin B, and all-trans retinoic acid are absorbed from the lungs 
over a period of hours due in part to their slow dissolution rate from relatively insoluble 
lipophilic particles (Lit. [48]- Lit. [49]). There may also be specific interactions (e.g., 
amphotericin B with endogenous sterols) that help to slow absorption.  
Another instance in which soluble small molecules stay in the lungs longer than expected is 
the case with tobramycin and pentamidine, which are absorbed over a period of several hours 
following inhalation in humans (Lit.[50]- Lit. [51]). Here the mechanism of retention may be 
related to the multiple positive charges on the molecules that bind to the ubiquitous negative 
charges on the surface of cell membranes.  
The absorption of small molecules can also be slowed via encapsulation in slow release 
particles such as liposomes (Lit. [52], - Lit. [53]).  
2.9.2 Hydrophobic versus Hydrophilic small molecules 
Table 1 provides a summary of a subset of the different molecules studied by Schanker and 
colleagues (Lit. [31]-Lit. [47]). The observed trend in half-life with lipophilicity (as estimated 
from the octanol-water partition coefficient, log P) is captured in Figure 7.  
A natural break seems to occur for compounds that are hydrophilic (lipid insoluble, log P < 0), 
and lipophilic (lipid soluble, log P > 0). Hydrophilic materials cluster around a mean half-life 
of about 1 hour, whereas lipophilic drugs cluster around a half-life of about 1 minute. 
Interestingly, there does not seem to be a strong dependence of the half-life with log P, other 
than the clustering which occurs for the two classes of molecules. That is, decreasing log P 
from 0 to 5.0 results in little deviation in the measured half-life. Similarly, increasing log P 
from 0.0 to 4.0 results in no discernable difference. Absorption of lipophilic molecules 
appears to be nonsaturable over a wide concentration range. Certain molecules classified as 
lipid-soluble by Schanker and co-workers are absorbed more slowly than might be expected, 
based on their classification. These include tetracycline, sulphaguanidine and ethambutol. 
Each of these molecules had a log P < 0 indicating that they possessed significant hydrophilic 
character. Erythromycin was also absorbed more slowly than one might expect despite its log 
P value of 3.06. Erythromycin and other macrolides have been shown to interact with 
phospholipids, and such an interaction with lung lipids may slow down absorption of this 
class of antibiotics through the lung.  
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Table 1: The effect of molecular weight and lipophilicity on the rate of absorption of 
small molecules following intratracheal instillation in rats (Lit. [31]-Lit. [47]). 
Compound Class Molecular Weight (D) log P t1/2 (min) k (min 1)
Guanidine Lipid insoluble 59 3.56 6.3 0.11 
Urea Lipid insoluble 60 2.11 4.7 0.147 
AIB (-aminobutyric acid) Lipid insoluble 103 2.54 57 0.012 
Erythritol Lipid insoluble 122 2.29 35 0.02 
N-methylnicotinamide Lipid insoluble 136 0 50 0.014 
Mannitol Lipid insoluble 182 3.1 60 0.012 
p-Aminohippuric acid Lipid insoluble 194 0.89 41 0.017 
3-o-methyl-D-glucose Lipid insoluble 194 1.69 58.7 0.012 
Decamethonium Lipid insoluble 258 4.78 90 0.008 
Sucrose Lipid insoluble 342 3.7 84 0.008 
Cyanocobalamin (Vitamin 
B12) Lipid insoluble 1,355 3.57 190 0.0036 
Heparin Lipid insoluble 6.000 20.000 4.31 552 0.0013 
Dextran Lipid insoluble 20,000  668 0.001 
Amitrole Lipid soluble 84 0.86 1.3 0.533 
Isoniazid Lipid soluble 137 0.7 1.9 0.365 
Salicylic acid Lipid soluble 138 2.26 1.0 0.693 
Barbital Lipid soluble 184 0.65 0.93 0.745 
Sulphaguanidine Lipid soluble 218 1.22 41 0.017 
Pentobarbital Lipid soluble 226 2.1 1.0 0.693 
Phenobarbital Lipid soluble 232 1.47 1.0 0.693 
Ethambutol Lipid soluble 232 0.41 40 0.017 
Procainamide Lipid soluble 235 0.55 2.3 0.301 
Sulphamethoxypyridazine Lipid soluble 280 0.32 1.0 0.693 
Sulphadimethoxine Lipid soluble 310 1.63 1.0 0.693 
Hydrocortisone Lipid soluble 362.5 1.61 1.0 0.693 
Dexamethasone Lipid soluble 392.5 1.83 1.7 0.408 
Tetracycline Lipid soluble 444 1.3 14 0.05 
Erythromycin Lipid soluble 734 3.06 6.3 0.11 
Digitoxin Lipid soluble 765 1.85 0.3 2.31 
Digoxin Lipid soluble 781 1.26 1 0.693 
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Figure 8: Pulmonary absorption data from Schanker and colleagues (Lit. [31]-Lit. 
[47]), demonstrating that the rate of drug absorption from the lungs is dependent on 
drug lipophilicity. Here, t1/2 represents the time taken for absorption of 50% of the 
initial dose through the lung following intratracheal administration in rats, and log 
P represents the octanol-water partition coefficient. Molecules characterized by 
Schanker and co-workers as lipid-insoluble or as lipid-soluble are shown as squares 
and triangles, respectively. Molecules with active uptake are denoted by inverted 
triangles.   
It is interesting that within the molecular weight range from about 100 to 1,000 g/mol, there 
appears to be no dependence of half-life on molecular weight (Figure 8) (Lit. [31]-Lit. [36]). 
Again, the data seem to be classified simply on the basis of lipophilicity. More lipophilic 
drugs in this range pass through the lung rapidly, whereas more hydrophilic compounds pass 
much slower, but still fast compared with higher molecular weight compounds. Only when the 
molecular weight exceeds 1,000 D does the half-life increase significantly. Schanker and 
colleagues examined a series of high molecular weight carbohydrates which showed -similar 
to peptides and proteins much slower absorption at molecular weights in the tens of thousands 
(Lit. [31]-Lit. [36]).   
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Figure 9: Relationship between molecular weight and rate of absorption through the 
lung (data from Schanker and co-workers (Lit. [31]-Lit. [47]). Molecules 
characterized by Schanker and colleagues as lipid-insoluble or as lipid-soluble are 
shown as squares and triangles, respectively. Molecules with active uptake are 
denoted by inverted triangles. (1Dalton=1 g/mol).  
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2.10 Technological Problems 
Pulmonary drug administration imposes strong requirements on the delivery device. This is 
due to the fact that the particle size of the powder or droplet greatly influences the delivery 
site, and thus the degree of drug absorption from the lungs. 
The devices that are currently available for pulmonary drug administration were mostly 
developed to achieve local effects of the drug in the conducting airways, such as in asthma. 
These devices include:  
a) Nebulisers, 
b) Metered-dose inhalers (MDIs), 
c) Dry-powder inhalers (DPIs).  
The basic function of these three completely different devices is to generate a drug-containing 
aerosol cloud that contains the highest possible fraction of particles in the desired size range.  
2.10.1 Nebulisers 
Nebulisers are applied to aerosolize drug solutions or suspensions. There are two basic types: 
the air jet and ultrasonic nebuliser. The jet nebuliser is powered by compressed air while the 
ultrasonic nebuliser receives the energy required to aerosolise drugs from high frequency 
sound waves.   
2.10.1.1 Jet nebulisers 
Jet nebulisers have a two-fluid nozzle for atomizing the drug solution. Compressed air passes 
through a narrow hole and entrains the drug solution from one or more capillaries mainly by 
momentum transfer. The liquid break-up process depends on the design of the nozzle, the air 
pressure and the physical properties of the drug solution. Droplets in the required size range 
are entrained by the airflow from the nozzle. 
Larger droplets impact on a baffle and are returned to the reservoir. Auxiliary airflows, 
generated by the patient, may pass through special vents to the nebulisation cup in order to 
improve droplet entrainment from the nozzle area.  
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Figure 1: Schematic diagram of a jet nebuliser output. Droplets small enough will be 
carried out by air stream (route A), and the large droplets will be either recycled to 
the nebuliser  reservoir (route B) or carried out by the outgoing air stream (route 
B1). Some of the solvent will be evaporated (route C). Adapted from Lit. [9].  
Figure 2: Schematic view of a jet nebuliser.  
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Figure 3: Image of PARI TurboBOY N jet nebuliser.  
2.10.1.2 Ultrasonic nebulisers 
Ultrasonic nebulisers use ultrasonic energy to convert liquid, usually an aqueous solution, into 
an aerosol for inhalation. The energy required to atomize a liquid is produced by a 
piezoelectric crystal transducer, usually a synthetic ceramic material, vibrating at a high 
frequency (1 3MHz). The frequency and the properties of the drug solution determine the 
droplet size distribution of the mist. 
When an alternating electric current is applied, the crystal shrinks and expands and the 
resultant vibrations are transmitted to the nebulized fluid, either directly or via a coupling 
liquid, usually water. A fountain of liquid is produce at the liquid surface, with large droplets 
being emitted from its apex and a mist of small droplets being produced from the lower part. 
Figure 4 illustrates the two mechanisms proposed for the processes of liquid disintegration 
and aerosol generation within ultrasonic nebulisers.  
Figure 4: Proposed ultrasonic nebuliser aerosolization mechanisms. (A) Cavitation 
bubble formation at low frequency; (B) capillary-wave formation at high frequency 
(Lit. [10]).   
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Ultrasonic nebulisers exist in a number of basic designs that differ in the configuration of the 
piezoelectric crystal transducer, nebuliser chamber, baffles and auxiliary airflow systems (see 
Figure 5).  
Figure 5: Schematic diagram of a typical ultrasonic nebuliser. (A) Face mask or 
mouthpiece; (B) Baffles; (C) Geyser of respiratory solution or suspension; (D) 
Piezoelectric crystal; (E)Internal fan; (F) Battery or electrical source. (Lit [10]).  
Once the aerosol cloud is generated from the nebuliser fluid, it is transferred from the 
chamber and made available to the patient. Ultrasonic nebulisers produce a large number of 
droplets per unit volume, which tend to aggregate and settle in the absence of air circulating 
through the device. Larger droplets impact on the baffles or internal surfaces to return to the 
reservoir surface for recirculation under the influence of gravity.  
Smaller droplets leave the device aided by an internal fan (e.g., Medix Electronic®, Easimist®) 
or by entrainment into the inspiratory flow of the patient (e.g., DeVilbiss Pulmosonic®).  
Air velocity over the reservoir surface may be modified by fan speed (and flow constrictors), 
thereby influencing both droplet size and aerosol output rate. For instance, changing the fan 
speed setting of the Sonix 2000® (Medix) ultrasonic nebuliser can vary flow output between 
1ml per 1min and 1ml per 6 min. So flow output is strongly dependent on device construction. 
The important design features influencing mass output and the particle size of the generated 
aerosols are summarized in Table 1.        
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Table 1: Design features of ultrasonic nebulisers determining particle size 
distribution and mass output (Lit. [11]). 
Design features Nebuliser characteristics 
Frequency of vibration 
Amplitude of vibration 
Surface morphology (flat or curved)
 
Piezoelectric 
crystal   
Coupling between crystal and fluid 
Size 
Shape Fluid reservoir  
Baffles 
Auxiliary air flow Velocity 
Whereas air-jet nebulisers are usually disposable or sterilizable, ultrasonic nebulisers are too 
expensive to be produced as disposable units and are thus used repeatedly, running the risk of 
bacterial contamination. 
Cleaning nebulisers and connecting tubing is difficult, and the transfer of Gram-negative 
bacteria between nebulisation equipment and patients has been reported (Lit. [12] - Lit. [14]).   
Although most ultrasonic devices share a basic design, some novel devices have been 
developed. For example:   
a) The Standard Ultrasonic Nebuliser (Shimed Inc.): 
Figure 6: Image of the Standard Ultrasonic nebuliser from Shimed Inc, Taiwan.   
b) Bespak Piezo Electric Actuator® (Bespak plc) is a novel aerosol delivery system based on a 
piezoelectric crystal combined with an electroformed mesh.   
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Figure 7: Schematic diagram of the spray head of the Bespak Piezo Electric 
Actuator. (Reproduced courtesy of Bespak plc, UK.)   
Nebulisers represent ideal delivery systems for drugs that cannot be conveniently formulated 
into metered-dose inhalers or dry powder inhalers or when the therapeutic dose is too large 
for delivery with these systems. 
Nebulized drugs may be inhaled during normal tidal breathing through a mouthpiece or face 
mask, permitting their use for patients, such as the hospitalized, the elderly, children and 
patients with arthritis, who experience difficulties with other devices.  
However, the use of nebulisers has important limitations due to drug sensitivity: For example, 
drugs are often very unstable in aqueous solutions, and easily hydrolyzed. In addition, the 
process of nebulisation exerts high shear stress on the compounds, which can lead (in the case 
of proteins) to protein denaturation. Also, the droplets produced by nebulisers are rather 
heterogeneous, which results in very poor drug delivery to the lower respiratory tract.    
2.10.2 Metered Dose Inhalers  
Metered dose inhalers are pharmaceutical delivery systems designed for oral or nasal use, 
which can deliver aerosolised drugs to the respiratory tract. Typically, the MDI contains the 
active substance, dissolved or suspended in a liquefied propellant system held in a pressurized 
container that is sealed with a metering valve. Actuation of the valve discharges a metered 
dose of medicament as an aerosol spray through an actuator during oral or nasal inhalation5. 
The release of the liquid causes a fast evaporation of the propellant that produces a finely 
dispersed aerosol spray. The deposition, and hence the clinical efficacy, are therefore 
dependent on the mass of inhaled particles, which must have an appropriate aerodynamic size, 
usually below 5 µm, to be deposited in the lungs.  
                                                          
5  MDIs are able supply to several hundred actuations, containing normally from about 10 to 500 µg of drug 
dispersed in a 25 to 100 µl metered volume of liquid.  
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Despite their apparent simplicity in use, MDIs are complex devices involving the integration 
of formulation, container, metering valve and actuator (see Figure 9). Changes to any one of 
these components will affect the overall performance of the MDI, which is designed to ensure 
that the delivered dose and the particle size distribution of the drug in the aerosol spray are 
consistent over both the labelled number of actuations in the MDI and for the duration of the 
shelf-life. 
 
Figure 9: Sectional view of a metered dose inhaler (Lit. [6]).  
The fine particle mass of a finely aerosolized drug delivered from an MDI is highly dependent 
on the atomization of the formulation and the subsequent spray dynamics. The aerosol 
characteristics depend heavily on interactions between:  
The propellant; 
The micronized drug particles; 
The formulation excipients; 
The design and dimensions of the metering valve; 
The key actuator variables (stem block, atomization orifice, actuator airflow paths, and 
mouthpiece design).  
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Figure 10: Image of the Autohaler® Inhaler from 3M Pharmaceuticals (Lit. [16]).  
As discussed above, aerosol formation from MDI is a complex process influenced not only by 
the propellant but also by properties of the formulation and device design (e.g., valve volume 
and orifice size). 
After aerosol droplets form at the exit of the spray nozzle, an aerosol plume begins to expand, 
and large particles travel along the axis of the actuator. Figure 11 shows photographs of 
aerosol formation using a commercially available MDI.   
Figure 11: Formation of the aerosol plume as a function of time. Each frame has a 
time interval of 30 milliseconds(Lit. [17]).    
The propellant or propellant mixtures used in the MDIs provide the energy necessary to 
generate a fine aerosol of drug particles suitable for delivery to the lungs or nasal cavity. 
Liquefied compressed gases are preferred over nonliquefied compressed gases such as 
nitrogen or carbon dioxide due to the following advantages in the inhalation therapy:   
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The discharge of defined aliquots of propellant from the MDIs will undergo flash evaporation 
to give an aerosol of very small particles.  
The pressure inside the MDIs should remain consistent throughout the use of the entire 
contents, thus ensuring that the aerosol characteristics remain uniform during repeated 
discharges. At constant temperature, the vapour pressure remains constant while liquefied 
propellant remains. In contrast, aerosols generated using nonliquefied compressed gases 
coarsen during emptying of the MDI due to the decrease in gas pressure.   
The ideal propellant for use in an MDI will exhibit the following properties (Lit. [7]):   
 
Non-toxic; 
Inert and non-reactive in the formulation; 
Chemically stable under a range of conditions; 
High purity; 
Acceptable taste and odour; 
Compatible with the packaging components (can, valve, actuator); 
Suitable vapour pressure; 
Suitable density to facilitate suspension stability; 
Suitable solvency properties; 
Preferably non-flammable; 
Acceptable cost.  
The search for propellants of low or zero ozone depletion potential has led to the 
identification of a number of potential compounds.  
Of the alternatives identified, the Hydrofluoroalkanes (HFCs) were targeted for development 
as replacements for the Chlorofluorocarbons (CFCs) in MDIs. Within this class, 134a and 
227ea were adopted for inhalation after toxicity testing by two consortia of pharmaceutical 
companies: IPACT 1 for 134a and IPACT 2 for 227ea (IPACT: International Pharmaceutical 
Aerosol Consortium for Toxicity Testing)6.  
Although the MDI is simple to use for most people, there are certain sectors of the patient 
population that may have difficulties with the use of this device type. For example, very 
young children and older people have significant difficulty in coordinating their actuation of 
the device with breathing in.  
Patients who have this coordination difficulty can, for example, be supplied with a dry 
powder inhaler, where the inspiration through the device is also responsible for the release 
and aerosolization of the powdered drug.  
In addition, MDIs utilize propellants (CFCs and, increasingly, HFCs) to atomize the drug 
solution, which results in a more uniform spray than that achieved with nebulisers. However, 
proteins and peptides are susceptible to denaturation when they come into contact with these 
                                                          
6
 See Appendix 1.for a more detailed description. 
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propellants or with the large air liquid interfaces that are constantly being generated during 
aerosolization (Lit. [1]).   
The MDI technology is also limited by the drug dose that can be administered. The normal 
dose range for a MDI is between of 50 500 µg / actuation. Smaller doses may cause 
problems regarding dose uniformity. On the other hand, doses above 500 µg cannot be 
delivered with an acceptable percentage of respirable particles. Generally, increasing the 
dose/actuation above 500 µg is usually related with a decline of the fine particle fraction. This 
is especially clear with hygroscopic drugs such as disodium-cromoglycate.     
2.10.3 Dry powders inhalers 
A promising alternative to MDIs and nebulisers are the DPIs. Like the MDIs, most DPIs that 
are currently approved are made for pulmonary drug administration of locally acting drugs 
used for the management of asthma and chronic obstructive pulmonary diseases (COPDs), 
such as anti-asthmatic agents7.   
These devices differ not only in their forms of particle generation and delivery, but also with 
regard to design differences such as discrete or reservoir drug containment, the number of 
doses and the presence of a dose counter.   
Figure 11: Image of the Autohaler® Inhaler from GlaxoSmithKline 
Pharmaceuticals (Lit. [18]).   
                                                          
7  Examples of such devices include the Turbohaler (AstraZeneca, Wilmington, DE, USA), Diskhaler 
(GlaxoSmithKline, Research Triangle Park, NC, USA), Diskus (known as the Accuhaler in some countries, 
for example the UK, GlaxoSmithKline), Rotahaler (GlaxoSmithKline) and Aerolizer (Novartis Pharma, Basel, 
Switzerland). 
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Table 2 presents some of the most recent devices used in the field of DPI, most of them still 
focusing on local delivery of small molecule drugs to the airway for the treatment of asthma 
or COPDs. Nevertheless, some are also being used in clinical trials for systemic delivery of 
macromolecules such as insulin via the deep lung.  
Table 2: More recent dry powder inhalation systems. 
Name Manufacturer
 
Packaging/metering Energy source(s) 
Pulvinal Chiesi Reservoir Mechanical, patient inspiration 
Easyhaler Orion Reservoir Mechanical, patient inspiration 
Clickhaler ML Labs Reservoir Mechanical, patient inspiration 
Discus Glaxo Multidose blister Mechanical, patient inspiration 
Monohaler Astra Unit dose Mechanical, patient inspiration 
AIRb Alkermes Unit dose Mechanical, patient inspiration 
Spirosb Dura Multidose blisters 
Mechanical, not driven by 
patient inspiration 
Inhance  Inhale Unit dose 
Mechanical, not driven by 
patient inspiration 
bIn clinical trials; not yet available on the market.  
Dry powder inhalers are generally described as breath actuated devices, because the 
inspiratory air stream releases the dose from the dose system and supplies the energy for the 
generation of fine drug particles from the powder formulation. Because the efficiency of dose 
release and powder disintegration increases with increasing inspiratory flow rate for most 
DPIs, these devices would be better described as breath controlled devices.  
Basically, devices used as dry powder inhalers contain four basic functional elements:  
Powder container: Dry powder inhalers may contain the dry powder formulation in 
many different forms. The first DPI, the Spinhaler contained single doses in 
capsules. Other systems, like the Diskus or Diskhaler may contain the metered 
dose in blisters, whereas systems like the Turbohaler , or Novolizer , have multi-
dose containers. 
Dosing system: It can be a Unit-dose, Multidose or Reservoir system. 
Disintegration principle: In general, the powders in the inhaler are not formulated as 
single particles, but as adhesive mixtures or spherical pellets. These mixtures or pellets 
are suitable for processing and metering. However, the particle size of these mixtures 
or pellets is far too large for lung deposition. Therefore, the pellet or mixture has to be 
disintegrated to make an aerosol cloud with the desired particle size (< 5 µm). Many 
different disintegration principles exist. They may vary from a simple screen 
 Introduction   
35 
(Rotahaler ) to twisted powder channels (Turbuhaler ) or a cyclone chamber as 
used in the Novolizer . 
A mouthpiece: The mouthpiece may be used to control the direction of the aerosol 
cloud in the mouth and throat, in order to reduce drug deposition in the oropharyngeal 
cavities. 
One of the current DPIs in the market is the HandiHaler® in combination with the Spiriva® 
capsules (tiotropium bromide inhalation powder).8  
The HandiHaler® inhalation device has the following components (Figure 12):  
1) Dust cap; 
2) Mouthpiece; 
3) Base; 
4) Piercing button; 
5) Center chamber.  
Figure 12: Schematic view of from HandiHaler® Boehringer Ingelheim 
International GmbH (Lit. [15]).  
The normal operation procedure of a DPI is described below, using the HandiHaler® and 
SPIRIVA® capsules as an example. It requires the following steps:   
a) Open the blister (Figure A and B). 
b) Open the HandiHaler® device (Figure 1). 
c) Insert the SPIRIVA® capsule and close the mouthpiece (Figure 2 and 3). 
d) Press the HandiHaler® button (Figure 4). 
e) Breathe out completely (Figure 5). 
f) Inhale the medication (Figure 6).   
                                                          
8  SPIRIVA®/ HandiHaler® are indicated for the long-term, once-daily, maintenance and treatment of 
bronchospasm associated with chronic obstructive pulmonary disease.  
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Figure 13: Operation steps in using the HandiHaler® and SPIRIVA® (Lit. [15]).   
Drug delivery to the lower respiratory tract performed by these DPIs depends strongly on 
inspiratory air velocity. Consequently, delivery efficiency in children, elderly persons or 
adults with certain disease conditions will not always result in reproducible pharmacokinetics 
and pharmcodynamic responses with some devices. Additionally, dose-to-dose variations are 
greater. Furthermore, dose emission for some can be dependent on inhalation flow rates (Lit. 
[3], Lit. [4]).  
The deposition pattern of the inhaled dry powder aerosol can be strongly influenced by the 
patient's inhalation dynamics and lung anatomy. At high inhalation flow rates, a given particle 
will have a greater tendency to impact the back of the throat or to deposit in the upper 
airways. For those delivery systems requiring high flow to deaggregate the powder particles, 
deep lung deposition is less accessible. The proliferation of device designs has been in part 
the result of attempts to minimize dosing variability regardless of source.  
The target for lung deposition varies depending on the therapy under consideration. In the 
treatment of asthma by -adrenergic agonists, the central airways are generally targeted. On 
the other hand, therapies intended to treat alveolar disease, chronic obstructive pulmonary 
disease or systemic conditions must reach the peripheral regions of the deep lung.  
As a summary, table 3 presents the main advantages and disadvantages of dry powder 
inhalers:       
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Table 3: Advantages and disadvantages of dry powder inhalers. 
Advantages 
of  dry powder inhalers 
Disadvantages of 
dry powder inhalers 
Propellant free  Potential difficulties to obtain dose 
components uniformity 
Less need for patient coordination 
inspiratory flow profile More expensive 
Less potential for formulation 
problems 
Less protection from environmental 
effects and patient abuse 
Less potential problems with drug 
stability parameters ------- 
 
Subchapter conclusion 
In conclusion, using the inhalation route to deliver therapeutic aerosols is a common practice 
in the treatment of patients with various airway diseases. Drug delivery via inhalation offers 
many advantages in the administration of pharmaceutical compounds, because the drugs are 
delivered directly to the site of action. Therefore, the required therapeutic dose for each 
treatment is lower than if the dose is administrated via oral or parenteral routes. Consequently, 
the inhalation route reduces adverse effects due to systemic absorption and intensifies the 
amount of drug deposited to the targeted tissue. 
The delivery of drugs to the lung depends on administration by any one of three methods: 
nebulisers, metered-dose inhalers and dry powder inhalers.   
The nature of the drug substance and its therapeutic target may influence which lung-delivery 
dosage form is more appropriate for the drug. For example, nebulisation is based on the fact 
that the drug can be well dissolved in an aqueous medium at a concentration suitable for 
convenient dosing.  
Conversely, drugs developed for the metered-dose inhalers must be dissolved or suspended 
well in a nonaqueous propellant medium at a concentration appropriate for doses metered in 
volumes. On the other hand, for the dry powder inhalers, the physical properties of the drug 
substance determine the degree with which processing will give a stable powder. This powder 
can, in turn, be effectively aerosolized in milligram quantities by the inhaler device to deliver 
the proper drug dosage.  
Subchapter references  
[1]  Banga, AK, Therapeutic Peptides and Proteins: Formulation, Processing and Delivery 
Systems . Lancaster: Technomic; (1995).  
[2]  Gupta, S, Moussy, F, Dalby, RN, Meikka, SI, Bruley, DF: Pulmonary delivery of human 
protein C and factor IX.In: Textbook of Advances in Experimental Medicine and Biology or 
Oxygen Transport to Tissue , vol 411, Edited by Nemoto EM, LaManna J. New York: Plenum 
Press; (1997): 429-435. 
Introduction 
38 
[3]  Engel, T, Heinig, JH, Malling, HJ, Scharling, B, Nikander, K, Madsen F: Clinical comparison of 
inhaled busesonide delivered either via pressurized metered dose inhaler or 
Turbuhaler®. Allergy (1989): 44:220-225. 
[4]  Nielsen, KG, Skov, M, Klug, B, Iversen, M, Bisgaard, H: Flow-dependent effect of formoterol 
dry powder inhaled from the Aerolizer® . Eur Respir J (1997): 10:2105-2109. 
[5]  Purewal, TS, Grant, DJW (Ed.): Metered Dose Inhaler Technology . Interpharm Press Inc., 
Buffalo, IL (1998). 
[6]  http://www.fmshk.com.hk/publications/hkps/200301.htm 
[7]  IPAC (International Pharmaceutical Aerosol Consortium), Ensuring Patient Care  The Role of 
the HFC MDI, 2nd Ed., 1999. 
[8]  Data of E.I. du Pont de Nemours & Co Ltd., except for propellants HFA-134a and HFA-227 
[9]  Niven Ralph W. Atomization and Nebulizers . Inhalation Aerosols, Hickey A. J. Marcel 
Dekker, Inc., New York, (1996):273 312. 
[10]  Dalby R. N., Hickey A. J., Tiano S. L. Medical Devices for the Delivery of Therapeutic 
Aerosols to the Lungs , Inhalation Aerosols: Physical and Biological Basis for Therapy, 
Hickey A. J. Marcel Dekker, Inc., New York, (1996): 441 473. 
[11]  Hardy J. G., Newman S. P., Knoch M., Lung Deposition from Four Nebulizers . Respir. Med., 
87 (1993): 461 465. 
[12]  Greenspan B. J. Ultrasonic and Electrodynamic Methods of Aerosol Generation . Inhalation 
Aerosols: Physical and Biological Basis for Therapy, Hickey A. J. Marcel Dekker, Inc., New 
York, (1996):313 335.  
[13]  The Nebuliser Project Group of the British Society Standards of Care Committee. Current 
Best Practice for Nebuliser Treatment . Thorax (1997): 52:S1 S106.  
[14]  Rhoades E. R., Ringrose R., Mohr J. A., Brooks L., McKown B. A., Felton F., Contamination 
of Ultrasonic Nebulization Equipment with Gram Negative Bacteria . Arch. Intern. Med., 127 
(1971):228 232.  
[15]  http://www.boehringer-ingelheim.de 
[16]  http://www.3M.com 
[17]  Morén F. Aerosol Dosage Forms and Formulation, Aerosols in Medicine, Principle, Diagnosis 
and Therapy . Elsevier Science Publisher, Amsterdam, (1993): 321 350. 
[18]  http://www.gsk.com  
2.11 eFlow Electronic Inhaler 
Several parameters have to be taken in consideration in order to optimize drug delivery by 
inhalation products. The device design along with the formulation properties, play a very 
important role in the desired performance characteristics:  
 
Particle size distribution; 
Delivered dose; 
Delivery efficiency; 
Treatment time.   
Nebuliser performance depends largely on their design and mode of operation (Lit. [1]-Lit. 
[2]). Advanced delivery efficiency was achieved by so called breath enhanced jet nebulisers 
using inspiratory and expiratory valves to control flow through the system and, more recently, 
by mechanical breath triggering (Lit. [3] -Lit. [4]).  
However, new electronic aerosolisation techniques enable the use of miniaturized sensors as a 
mean of controlling the activation of the device (Lit. [5]-Lit. [6]).  
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The novel eFlow electronic inhaler (PARI GmbH, Germany) utilizes two different concepts 
(Lit.[7]):   
A patent protected valved aerosol chamber (Lit.[8]) 
A sensor based breath controlled activation mechanism.  
The eFlow® (PARI GmbH, Germany) is a novel electronic nebuliser platform, that creates 
the maximum benefit for the patient when the device is optimized together with the drug 
formulation to be administered. The ability of an inhalation device to be used in a wide range 
of applications, particularly with new inhaled medications, must deal with several challenges 
during development:   
variable viscosities of the distinct drug formulation; 
fragile molecules (like with proteins and peptides); 
suspensions; 
variable fill volumes and dosages; 
environmental issues; 
critical dose-response relations; 
need to avoid systemic and local side effects; 
patient compliance.  
Nebulization of liquids is an effective means of aerosol generation for pulmonary drug 
delivery. 
Atomisation theories predict that aerosol size and output characteristics are dependent not 
only upon the operating principles, conditions and mechanical construction of the nebuliser 
but also upon the physicochemical properties of the nebulised fluids (Lit. [14]). 
Nebulisers have the ability of delivering drugs in large doses, especially in cases where, for 
technical reasons, formulation as metered dose or dry powders inhalers is not feasible. In 
addition, since the drug can be delivered during the relaxed tidal breathing, there are no 
atomisation or actuation synchronization requirements.  
The therapeutic efficiency relies on the pulmonary penetration and deposition of the aerosol. 
Thus, several factors, in particular, the droplet size and mass output have a very important 
influence on the therapeutic efficacy. 
In regard to that particle size, the respirable doses are designated as those droplets less than 
approximately 5 µm, which are assumed to penetrate into the peripheral regions of the lung 
(Lit. [6]). Several factors can influence the particle size and output characteristics of a 
nebuliser. These can include:  
Rate air flow (Lit.[13] -Lit. [14]); 
Intrinsic design (Lit. [15]); 
Volume of nebuliser fluid (Lit. [16]); 
Physicochemical properties of the formulation (Lit. [17]).  
The aerosol quality, especially size and output characteristics, depends not only on the 
operating principles and conditions, mechanical construction and geometry of nebulisers, but 
also on the physicochemical properties, such as surface tension and viscosity of the nebulised 
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fluid. An aerosol can be defined in terms of the increase in the liquid surface area resulting 
from nebulisation. The surface area before break-up of the solution9 is simply that of the 
liquid cylinder as it emerges or the free surface of the fluid mass in the chamber of the 
nebulisers. After atomisation, the area is the sum of the surface areas of all the individual 
droplets. Consequently, surface tension is important for nebulisation because it represents the 
force that resists the formation of new surface area. The minimum energy required for 
nebulisation is related to the surface area and also to the increase in liquid surface area. 
Therefore, surface tension forces tend to impair atomisation quality by opposing any 
distortion or irregularity on the liquid surface, thereby delaying formation.  
Since most of the currently used pharmaceutical nebuliser solutions are aqueous (normally 
with low solute concentration), the surface tension and viscosity may not vary significantly.  
However, surfactants are required in specific formulations to suspend the drug and these 
agents will evidently lower surface tension.  
In accordance to Lit.[18] -Lit. [21], it was concluded that mean droplet size of liquid sprays 
was directly related to liquid viscosity and surface tension while the overall effect of liquid 
density on drop size was small. In Lit. [21] it is reported that the presence of a surface active 
agent (dodecylbenzene sulphonate 0.1-1.0%) influenced the spraying of aqueous solutions: In 
average, the drop size decreased by approximately 30% in comparison with water and the 
polydispersity of the system increased.   
In addition to the effect of the surface tension on the aerosol droplet size, viscosity also plays 
an important part in the aerosol quality. In (Lit. [23]), the effect of viscosity was investigated 
using water, sucrose (10-60% w/v) and sodium citrate (7-36% w/v) as tests solutions. The 
results showed that, in the case of ultrasonic devices, the droplets size was proportional to the 
viscosity. 
However, in this work a new electronic nebuliser (eflow®, Pari GmbH, Germany) is used to 
nebulize the drug formulations. It is based on a vibrating membrane principle (Lit. [24]) 
which differs from the commonly used jet nebulisers. For this reason, the effect of viscosity 
and surface tension on the eflow® nebulisation efficiency was investigated. This information 
will be very important as a guide to the future drug development formulations as a way of 
screening possible formulations.  
2.12 Vibrating Membrane Principle 
The working principle behind the eFlow® nebuliser is the Vibrating Membrane Principle.  
The eFlow® has the ability to deliver a wide range of drug volumes (0.5 5 ml) and dosages 
(0.01 1000 mg), allowing the patient to take its treatment during consecutive spontaneous 
breathing.  
The core component of the system is the aerosol head. It contains the perforated membrane 
and ring-shaped piezo-electric actuator which is driven by an electronic circuit to vibrate the 
membrane. The membrane is made of stainless steel with the holes being precisely shaped by 
a laser drilling process. 
                                                          
 
9  
 For a more detailed description of the break-up processes please refer to the chapter 2.10. 
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The process of generating an aerosol by the eFlow® nebuliser is explained below:   
Figure 1: Aerosol generation principle.  
Description:  
The atomizing head consists of an annular, metallic substrate, a thin membrane 
in the center and an annular piezo ceramic; 
Activation of the piezo with a high frequency current causes the membrane to 
vibrate; 
A patent protected bending mode design allows for highly efficient energy 
utilization; 
Several thousand holes are drilled in the centre of the membrane using a high 
precision laser drilling process; 
The pressure variations caused by the vibration force the fluid to be ejected 
from the holes on one side of the membrane thus creating well defined aerosol 
droplets; 
Many different parameters such as droplet size or the physical-chemical 
properties of the drugs, must be taken into account in order to optimize an 
inhalation device for a specific drug, therapy, or patient group; 
In addition, interdependencies between these factors require an increased effort 
in the fine-tuning; 
The optimization can be performed with respect to : 
A) Particle size distribution; 
B) Aerosol generation rate; 
C) Drug delivery rate; 
D) Patient guidance; 
E) Delivered dose; 
F) Formulation aspects (e.g. surface tension, viscosity).   
Vibration  
(Patent protected US 5,518,179)
Piezo
Mesh
Substrate
Atomizing Head  
with fluid reservoir, cover, 
and connection cable 
Droplet Generation
Air vent.
Precision
 
Laser Drilled Holes
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A) Particle Size Distribution  
 
MMD range: 2.5 µm to > 5 µm  
GSD approx. 1.5   
Primary parameter: Hole exit size (Figure 2) with precise control of MMD 
and GSD by laser drilling process and inline quality assurance   
Figure 2: SEM pictures of different exit hole sizes.  
B) Aerosol Generation Rate 
Generation rate: 0.4 ml/min (@ MMD = 3.0 µm) to 1.2 ml/min (@ MMD = 4.5 µm)  
Highly efficient aerosol generation due to bending mode activation  
Parameters:   
Hole size; 
Number and distribution of holes (Figure 3); 
Power input to Atomizing Head; 
Design and dimensions of Atomizing Head; 
Manufacturing processes.   
Figure 3: Pictures of different holes distributions (same magnification).   
Ø 2.7 µm Ø 3.5 µm
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Figure 4: Different parts of the Atomizing Head.    
Figure 5: View of the different components of the eFlow.   
C) Drug Delivery Rate (example):   
32.1 mg/min (100 mg/ml Tobramycin) compared to 8.6 mg/min (60 mg/ml Tobramycin) with 
jet nebuliser  Lit.[9]    
All nebulizer components are autoclavable 
Reservoir
Cap
Aerosol head
Valve
Aerosol chamber
Mouthpiece with valve
Mesh
Substrate 
Capton
Head Mount
Piezo 
Head assembled
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Parameters:  
 
Aerosol generation rate; 
Activation mode (breath trigger vs. continuous); 
Nebuliser design (valves, aerodynamics).  
D) Patient Guidance  
Sensors and feedback mechanisms may increase patient compliance:  
Passive approach: Adaptation to breathing pattern; 
Active approach: Feedback to influence breathing pattern.  
E) Delivered Dose  
Adjustable over a wide range  
Parameters (Figure 6):   
Nebuliser  design (aerodynamics); 
Valve System; 
Activation mode (breath trigger vs. continuous).   
Figure 6: Drug distribution of salbutamol following nebulisation by different 
eFlow® devices (Lit.[10]).         
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Examples
 
for Clinical Trials   
For customization with novel nebuliser medications (Lit.[11]). 
The device was used in several clinical studies, gamma scintigraphy deposition 
studies and patient acceptance tests. 
Treatment can be as fast as 2  3 minutes.   
Fill volume: 0.5  4 ml 
Delivered dose: > 60 % 
Tailored droplet size     
Fill volume: 0.5  4 ml 
Delivered dose: >60 % 
Droplet size:  2.8 µm  
Baby
Baby
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For novel paediatric nebuliser  medications (Lit.[12]). 
Available for clinical studies. 
Treatment time < 5 min.       
Highly efficient delivery of novel nebuliser medications (Lit.[10]). 
Available for clinical studies      
Fill volume 2  6 ml 
Delivered dose >20 % 
Droplet size 3.8  4.2 µm  
Adapted for equivalent delivered dose with current nebuliser  medications in 
CF. 
Treatment time cut by half (3  7 min) in comparison with the standard therapy.   
Fill volume: 0.5  4 ml
Delivered dose: >80 % 
Tailored droplet size 
(MMD 2.5 µm to > 5 µm) 
Breath-Trigger
BT (breath trigger)
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Adapted for current nebuliser  medications used in Japan with a treatment time 
cut by half in comparison with the standard therapy.  
Fill volume: 0.5  4 ml 
Delivered dose:  ~ 40 % 
Droplet size: 4.2 µm  
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3 WORK OBJECTIVES 
The respiratory tract has become an increasingly attractive route of application for a wide 
range of active substances with either topic or systemic pharmacological activity. The major 
advantages are a rapid onset of the therapeutic effect, a lowering of the required dose (as 
compared to systemic administration) and a reduction in unwanted side-effects (increased 
therapeutic index).  
However, the delivery of the drug substances via nebulisation constitutes an interesting 
challenge. This is not only due to the natural properties of the respiratory system but also to 
the physicochemical properties of the drugs, which combined have an important influence. In 
addition, the operation requirements of the eflow device also play a very important role. 
As model drugs, the following actives substances were investigated:  
Cyclosporin A; 
Azithromycin; 
Pentoxifylline; 
Budesonide.  
Although the drugs chosen share common physicochemical properties such as poor water 
solubility or strong bitter taste, the development of a nebulised formulation constituted an 
unique challenge for each of them. 
One of the drugs investigated in this work was cyclosporin A. It is a hydrophobic cyclic 
peptide and a first line immunosuppressive drug used in the treatment and prevention of graft 
rejection.  
However, its poor water solubility constituted an important hurdle to overcome, especially in  
the development of a formulation suitable for nebulisation10. 
In fact, its low value of water solubility in an aqueous solution (water solubility of 
cyclosporin A at 23°C: 10.41 µg/ml) and its solubility only in organic solvents such as 
acetone or chloroform reduced the field of possibilities that could be used in the formulation 
development. 
Furthermore, the stability and taste of the formulation also represented an important objective 
to be reached. 
In addition, in the development of the formulation, the parameters and requirements of the 
eflow® (for example, viscosity limits) also needed to be taken in consideration. For example, 
the use of oils as a way of solubilising the cyclosporin A has the disadvantage of greatly 
increasing the viscosity of the formulation. Consequently, the nebulisation of such 
formulations is not possible due to it s the high viscosity value. 
                                                          
10  The use of CSA has been limited due to a broad toxicity profile, including nephrotoxicity and hepatotoxicity. 
As an example, it has also been reported that Cremophor EL®, a solubilizing agent, present in the 
commercially available intravenous dosage form of cyclosporin A, was nephrotoxic and haemolytic (Lit. [89]- 
[90]). 
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Given the above-mentioned reasons, it was decided to use cyclodextrins as a way of 
overtaking these difficulties. Cyclodextrins have the potential of being not only 
solubility/stability enhancers for water insoluble drugs but also for the pulmonary delivery of 
proteins.   
The development of a formulation for azithromycin shares the same main objectives as the 
development of a cyclosporin A formulation but at a different level. For example, the taste 
and also the stability of the formulation are very important parameters to take in consideration 
in the formulation development. 
In fact, the taste of the azithromycin formulation is essential in the formulation development 
process due to patient compliance. If  patients, particularly a young patients, do not like the 
taste, it is more difficult to persuade them to continue with the therapy. Consequently, taste 
masking is an important factor in patient compliance. This represents a very difficult 
challenge in the development process because of the extremely bitter taste of the azithromycin 
molecules. 
On the other hand, the stability of an azithromycin formulation also constitutes a considerable 
challenge. Furthermore, azithromycin can degrade in aqueous solutions, especially in the 
presence of acids.  
Equally important, azithromycin is a water insoluble drug, which means that the increase of 
it s the water solubility  is also one of the objectives to be achieved. 
Similar to cyclosporin A, it was also decided to investigate the use of cyclodextrins as means 
of improving the solubility/stability and also the taste of the azithromycin formulations.   
Pentoxifylline is a water soluble drug that possesses, however, a bitter taste. Therefore, the 
main objective in the development process was the improvement of the taste of the 
formulation.  
To that end, it was considered the use of cyclodextrins due to their taste masking ability.  
Budesonide is a water insoluble drug and it was also studied in this work. The development 
process shared the same problems and objectives as the development processes for 
cyclosporin A and azithromycin. Consequently, the development of the budesonide 
formulation was based on the work previously developed for cyclosporin A and azithromycin. 
It had as main objectives the improvement of the water solubility and the stability of 
budesonide formulations.   
As a conclusion, for the development of formulations suitable for nebulisation one has to take 
in consideration not only the physicochemical properties of the drugs and the respiratory 
system but as operation requirements of the eflow device. All this variables need to weighted 
and considered in the development process in order to achieve the proposed objectives for 
each of the drug formulations.  
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4 CYCLODEXTRINS 
Cyclodextrins have gained most attention in the pharmaceutical area and drug delivery by 
improving solubility and/or stability of various drug molecules.  
Cyclodextrins (CDs) were first isolated by Villiers in 1891, and characterized by Schardinger 
in 1904.    
Figure 1: Cyclodextrin with n glucose units. According to Lit.[1].   
Cyclodextrins are capable of forming inclusion complexes with various molecules, altering 
this way their physical/chemical properties. There are three well-known naturally produced 
cyclodextrins, -, -, and -cyclodextrin ( -,  -, and  -CD), consisting of 6, 7, or 8 glucose 
units, respectively.  
Figure 2: Chemical structure of -, -, -CDs. According to (Lit. [1]).  
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Figure 3: Dimensions and hydrophilic/hydrophobic regions of the CD molecules. 
According to (Lit. [1]).   
Cyclodextrins containing more than eight glucose units have been reported, but due to low 
yield and complicated purification, these cyclodextrins are less characterized and have 
presently no value in commercial applications (Lit. [1]- Lit. [2]).  
Cyclodextrins with less than six glucose units in the ring cannot be formed enzymatically due 
to steric reasons, but can be obtained by chemical synthesis (Lit. [1]- Lit. [3]). Like the large 
cyclodextrins, those are also currently of minor commercial interest.  
4.1 Physicochemical Properties of Cyclodextrins 
Because of their specific properties, cyclodextrins have gained attention, which is partly 
explained by their unique structures. As a consequence of the (1,4)-linked of the glucose 
units, all the secondary hydroxyl groups are situated at the one side of the two edges, whereas 
all the primary hydroxyl groups are situated on the other edge (see Figure 9).  
The cyclodextrin structure provides a molecule shaped like a segment of a hollow cone with 
an exterior hydrophilic surface and interior electron rich hydrophobic cavity (for 
characteristics of -, - and -CD see Table 1). 
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The hydrophilic surface generates a relative good water solubility for the cyclodextrins and 
the hydrophobic cavity provides a favourable environment for the hydrophobic parts of a 
guest molecule to be held in. This association isolates the guest molecules from the aqueous 
solvent and may increase the guest's water solubility and/or stability.  
Figure 4: Shape of  -CD molecule (Lit.[92]).  
Table 1: Some characteristics of -,  - and  -CD (Lit. [1]) and (Lit. [4]). 
Parameters  -CD -CD -CD 
Number of glucose units 6 7 8 
MW [g/mol] 972 1135 1297 
Solubility in water at room temperature [g/100 ml] 14.5 1.85 23.2 
[a]D at 25°C [°C] 150±0.5 162±0.5 177.4±0.5 
Cavity diameter [pm] 470-530 600-680 750-830 
Height of torus [pm] 790±10 790±10 790±10 
Diameter of outer periphery [pm] 1460±40 1540±40 1750±40 
Approximate volume of cavity (106 pm3) 174 262 427 
Approximate cavity volume in mol of cyclodextrin 104 1257 256 
Approximate cavity volume in 1 g of cyclodextrin 0.1 0.14 0.2 
pKa (by potentiometry) at 25°C 12.332 12.202 12.081 
Hydrolysis by A. oryzea -amylase Negligible Low Rapid 
Enthalpy of solution, DH° [kJ mol-1] 32.1 34.8 32.4 
Entropy of solution, DS° [J K-1 mol-1] 57.8 49 61.5 
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4.2 Cyclodextrin-Guest Complexation 
The various cyclodextrins can be considered as an empty cavity of molecular size. When the 
cavity is filled with a molecule of another substrate, it is called an inclusion complex11.  
Inclusion complexes are systems that consist of two or more molecules, in which one of the 
molecules, the host, includes entirely or partially the guest molecule. The molecules in the 
inclusion complex are only in contact by physical forces and without covalent binding (Lit. 
[1]- Lit. [5]). 
Moreover, the dissociation-association equilibrium is probably the most characteristic feature 
of the host-guest association (Lit. [1]).   
4.2.1 Overall Inclusion Complex Stability Constant 
The equilibrium between the guest and cyclodextrin is fundamental in the measurement of the 
inclusion complex stability constant. The general equation can be expressed as:  
n[Guest] + m[CD]  [GuestnCDm]  
where n and m are the number of mole for the guest molecule and cyclodextrin, respectively. 
The equilibrium constant K or inclusion complex stability constant for the process can be 
defined as:  
K= [GuestnCDm]/(Guest]n[CD]m)  
where n and m are the number of mole for the guest molecule and cyclodextrin, respectively.  
The simplest formation of a complex between the cyclodextrin and a guest molecule is a 
stoichiometric proportions of 1:1. Cyclodextrin complexes with two guest molecules per 
cyclodextrin or vice-versa are also quite common [Lit.1].   
4.2.2 Mechanism of Inclusion Constant 
Since the cavity of cyclodextrins is hydrophobic, the inclusion of a molecule in the 
cyclodextrin cavity is basically a substitution of the water inside the cavity with a less polar 
substance. The substitution of water from the cavity with a more non-polar guest is 
energetically favourable for both the cyclodextrin and the guest, which is illustrated in figure 
10.  
                                                          
 
11  Since no covalent bond is established between the host and guest, the expression inclusion complex has been 
used to describe the process. 
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Figure 10: Schematic illustration of inclusion complexation of p-xylene by a 
cyclodextrin. The small circles represent the water molecules (Lit. [1]).   
The 3D structure of the parent CD provides a cavity (Figure 11) that is hydrophobic relative 
to an aqueous environment. The sequestration of hydrophobic drugs inside the cavity of the 
CD can improve the drug's solubility and stability in water, the rate and extent of dissolution 
of the drug:CD complex, and the bioavailability of the drug when dissolution and solubility 
are limiting the delivery. These properties of the CDs enable the creation of formulations for 
insoluble drugs typically difficult to formulate and deliver with more traditional excipients.   
Figure 11: Complexation of drugs inside the hydrophobic cavity of CDs (Lit. [6]).  
CDs form inclusion complexes with hydrophobic drugs through an equilibrium process 
(Figure 11), quantitatively described in Equation 1 by an association or stability constant (K 
a:b),    
Ka:b= [Druga CDb]/(Drugt]a[CD]b)  
where a and b represent the molar ratio of the sequestered drug molecule to the CD. The 
magnitude of this associate constant can be used to compare the binding effectiveness of 
different CDs. Various complexes with different ratios of drug-to-CD molecules can be 
formed, depending on the type of CD used and the size and physicochemical characteristics of 
the drug molecule. In dilute solutions and/or if the drug fits entirely into the CD cavity, a 1:1 
complex results.  
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Figure 12: Equilibrium process describing the interaction between a CD and an 
insoluble drug molecule to form a soluble or insoluble complex. (Modified from (Lit. 
[6]).   
However, if the cavity is large enough, two drug molecules may be accommodated, resulting 
in the formation of a 2:1 complex. Conversely, if the drug is very large, then several CD 
molecules might enclose the drug for the formation of 1:2 or higher order complexes. 
Although each complex has a finite stoichiometry, more than one complex may be formed in 
a given system. Depending on the method used to determine the association constant, it is 
possible to obtain a description of the stoichiometry of the complex (a:b).  
Figure 13: Examples for CD-complexes: the same CD with different guests, and the 
same guest with different CDs. Toluene/ CD (A), diphenylamine/ CD (B), long-
chain fatty acid/CD (C), short chain fatty acid + diethyl ether ternary CD complex 
(D), prostaglandin E2/ CD (E), prostaglandin E2/ CD complex (F), prostaglandin 
E2/ CD (G) (Lit. [1]).
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Figure 14: Schematic representation of the production of a CD complex (Lit. [1]).  
The driving force in the complexation is not fully understood, but it seems to be a 
combination of different effects depending on the specific guest and cyclodextrin.  
These effects can be hydrophobic interaction, van der Waals interaction, hydrogen bonding, 
dipoledipole interaction, and release of enthalpy-rich water (Lit. [1]-Lit. [5]).    
a) Hydrophobic Interaction  
Hydrophobic interaction occurs when non-polar molecules tend to cluster together in an 
aqueous environment due to removal of apolar surfaces from contact with water. The 
structure of the surrounding water is a critical factor in classical hydrophobic interaction. 
The interaction results in a slightly positive H° and a large positive S° at low temperature, 
and its thereby said to be entropy driven (Lit. [7], Lit. [8] and Lit. [9]). The fact that the 
entropy change is positive, even though the molecules are clustering together, shows that 
there must be a contribution to the entropy from the solvent and that solvent molecules must 
be more free to move once the solute molecules have herded into small aggregates (Lit. [10]). 
Since the majority of the cyclodextrin complexation is enthalpy driven , it seems obvious 
that hydrophobic interactions are of minor contribution compared to the other driving forces 
and therefore several authors have reported that hydrophobic interactions do not need to be 
taken into consideration (Lit. [7], Lit. [8] and Lit. [9]). However, cyclodextrin is a semi-
polar molecule where semi-polar means a cavity more hydrophobic than water but less 
hydrophobic than n-octanol base on the dielectric constant of toluidinyl groups after 
inclusion, which provides an environment suitable for interaction with hydrophobic guests 
(Lit. [1]). If hydrophobic interactions occur, there should be no expectation that the 
classical system is applicable in the cyclodextrin system (Lit. [9]).  
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A model describing a non-classical hydrophobic interaction between semi-polar molecules 
seems to be relevant to the cyclodextrin complexation where molecules may have either a 
negative DH° or DS°. In this model, the driving forces for complexation can be either a 
favourable enthalpy or entropy change that relies on the magnitude and sign of DH° and DS° 
(Lit. [7- Lit. [9]). However, this model cannot solely be applied to predict the complexation 
between cyclodextrin and guest, since the complexation is a combination of different effects 
as mentioned above.   
b) Van der Waals Interaction  
When two molecules are brought close together, they both attract and repel each other 
depending on the distance that separates them. The attraction force of the molecules is caused 
by instantaneous and short-lived imbalance in the electron distribution of an atom that 
generates a temporary dipole. These short-living induced dipoles result in an induction 
electron distribution of the neighbouring atom that generates a temporary polarization. This 
polarisation minimizes the electron-electron repulsion between the atoms also known as 
induced dipole-induced dipole interaction or London dispersions forces. Other forces 
involved are dipole-induced dipole and permanent dipole. Common for all these repulsive and 
attractive forces, known as van der Waals forces, are that they neither are non covalent nor 
non ionic (Lit. [11]- Lit. [12]). 
These forces are usually weak for all kind of interactions, but are likely to be numerous in the 
cyclodextrin cavity and thereby have to be taken into consideration (Lit. [1]- Lit. [7]).   
c) Hydrogen Bonding Interaction  
If hydrogen is close to an atom that is very good at attracting electrons (like N, O, or F) the 
hydrogen end of the bond becomes very positively charged and the other atom becomes 
negatively charged (i.e., polar). Hydrogen is the smallest atom in the periodic table, which 
makes it possible for hydrogen atom and the other atom to get very close together. The 
combination of high polarity and close approach result in the interaction being particularly 
strong due to the force of attraction between two opposite charges. This is proportional to the 
magnitude of their charges divided by the square of the distance between them. In fact, the 
interaction is so strong that it dwarfs all other dipole-dipole attractions (Lit. [13]). 
The hydrogen bonding is considered to play an important role in the stability of the 
cyclodextrin complexes in aqueous solution. It may, furthermore, contribute to a 
conformational change either in the cyclodextrin, the guest, or both, which results in a more 
stable complex (Lit. [9]).         
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d) Release of Enthalpy-rich Water  
When water is substituted from the cavity of the cyclodextrin a decrease in energy occurs. 
This is caused due to an increase in solvent-solvent interaction, since the surface contact 
between solvent and cyclodextrin cavity, as well as between solvent and guest molecule, are 
reduced. Furthermore, water inside the cyclodextrin cavity cannot possess its tetrahedral 
hydrogen bonding capacity compared to those in the surrounding solvent, and it is therefore 
often reported as high energy water or enthalpy rich water. One of the main driving 
forces for complexation could, therefore, be the release of this high energy water from the 
cyclodextrin cavity, which, allowing them to form their full compliment of hydrogen, bonds 
with the surrounding water (Lit. [1], Lit. [7] and Lit. [8]).  
4.3 Evaluating Complex Formation 
One of the most common methods of determining association constants and stoichiometry is 
the phase solubility technique (Lit. [27]). The technique involves adding an equal weight (in 
considerable excess of its normal solubility) of the compound to be complexed into each of 
several vials or ampoules. A constant volume of solvent is added to each container. 
Successively increasing portions of the complexing agent are then added to the vessels. The 
vessels are then closed and the contents brought to solubility equilibrium by prolonged 
agitation at constant temperature. The solution phases are then analyzed for total solute 
content. A phase diagram is constructed by plotting the molar concentration of dissolved 
solute, found on the vertical axis, against the concentration of complexing agent added on the 
horizontal axis.  
Two general types of phase solubility profiles are generated: Type A where soluble complexes 
are formed and Type B where complexes of limited solubility are formed. 
The A-type diagrams are defined by the absence of any form of precipitation of the inclusion 
complexes after equilibrium has been attained and by an increase in solubility of the drug as a 
result of complexation with cyclodextrin. The B-type solubility diagrams on the other hand 
indicate precipitation of a drug-cyclodextrin complex at a certain concentration of the 
cyclodextrin.   
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Figure 15: The A-type phase-solubility diagrams of the sodium salts of ibuprofen ( ) 
and diflunisal ( ) in 2-HP- -CD containing pH 6.0 aqueous 0.1 M phosphate buffer 
solution at ambient temperature (Lit. [87]).   
Figure 16: The B-type phase solubility diagrams of 3 heterocyclic steroids 
compounds 1, 3 and 4 in water ethanol system, in the presence of -CD (Lit. 
[88]).12  
In Type A diagrams, an increase in solubility of the compound occurs as the amount of 
complexing agent increases. Soluble complexes are formed between the compound and the 
complexing agent, thereby increasing the total amount of compound in solution. Depending 
                                                          
12  I-stigmasteryl-5 -nitrobenzo[b]-thiophen-2 -carboxylate; III- citosteryl-5 -nitrobenzo[b]-thiophensulphone-2 -
carboxilate (3); IV-cholesteryl-6-bromobenzothiazolyl carbamate.  
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on the nature of the complexes formed, the diagram can be linear, AL, or show curvature in a 
positive, AP, or negative, AN, fashion (Figure 16). Linear diagrams are formed when each 
complex contains only one molecule of complexing agent. When more than one molecule of 
complexing agent is found in the complex, an AP-type diagram is formed. AN diagrams are 
uncommon but may result if self-association is present or high concentrations of complexing 
agent cause alterations in the nature of the solvent.  
Figure 17: Possible types of phase solubility diagrams.  
Type B diagrams are observed when complexes of limited solubility are formed. In Figure 16, 
the segment xy in curve BS shows the formation of a complex that increases the total 
solubility of the compound. This is similar to a Type A diagram. At a certain point, however, 
the solubility of the complex is reached and as additional compound goes into solution, some 
solid complex precipitates. Then, the entire excess solid compound added to the vials has 
been consumed by this process. Further addition of complexing agent beyond this point 
results in depletion of the compound from solution by complex formation. Curve BI is 
interpreted in a similar manner except that the complex formed is so insoluble that no increase 
in solubility is observed.  
The stoichiometry of the complexes can often be determined from the ascending and 
descending portions of these diagrams if certain assumptions can be made (Lit. [27]). If a 1:1 
complex is formed, the association constant Ka:b can be determined from the slope of the 
initial linear portion of the phase solubility curve, and the intrinsic solubility of the 
compound, S0, using  the following equation:  
K1:1 = [Slope]/[So (1-Slope)]  
Additional methods are available to determine these association or stability constants 
including spectroscopy (UV, fluorescence, NMR, and ORD-CD), potentiometry, 
microcalorimetry, surface tension, membrane permeation, electrophoresis and freezing point 
depression. Chromatographic methods include HPLC and TLC techniques. 
When cyclodextrins are used to solubilise water insoluble drugs, it is generally assumed that 
the solubilization proceeds through inclusion complex formation, e.g. that the lipophilic 
water-insoluble drug molecules, or some lipophilic moieties of the drug molecule, are taken 
into the hydrophobic central cavity of the water-soluble cyclodextrin molecules. 
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Linear phase-solubility diagrams (i.e. Figure 16, plots drug solubility versus cyclodextrin 
concentration) are usually assumed to indicate formation of 1:1 drug/cyclodextrin inclusion 
complexes or at least complexes that are first order with respect to cyclodextrin. Positive 
deviation from linearity is thought to indicate higher-order inclusion complexes such as 
formation of 1:2 drug/cyclodextrin complexes at higher cyclodextrin concentrations (Lit. 
[77] Lit. [79]). Such higher order systems are characterized by stepwise binding constants, 
e.g. that 1:2 complex is formed by association of the 1:1 complex with one additional 
cyclodextrin molecule. Frequently, the stoichiometry is obtained by simply fitting the phase 
solubility diagrams to the appropriate equation without any further verification. In some 
cases, proposed stoichiometry and structure of a given drug/cyclodextrin complex is verified 
through nuclear magnetic resonance (NMR) investigations (Lit. [79]).  
However, these are usually performed in dilute solutions whereas the phase-solubility studies 
are based on investigations of saturated drug solutions. Other methods for stoichiometry 
verifications are based on theoretical gas-phase computer modelling of complexes that do not 
describe well the actual conditions in saturated aqueous solutions (Lit. [80]). Thus, the 
conventional descriptions of 1:1 drug/cyclodextrin complexes, as well as of those containing 
different stoichiometry, are not as unambiguous as one might think. 
Cyclodextrins are all known to self-associate and to form complexes with various types of 
compounds (Lit. [81]-Lit.[84]). It is also well known that many drugs are surface active and 
that these drugs form micelles, which are stabilized by water-soluble polymers in a similar 
way as micelles (Lit. [85]-Lit. [86]). Cyclodextrin complexes are also known to self-associate 
to form water-soluble aggregates or micelles. These cyclodextrin aggregates and micelles, and 
their effects on drug solubilization, are not accounted for in the current complexation models 
(Lit. [87]-Lit. [89]).  
The stoichiometry of drug/cyclodextrin complexes cannot be derived exclusively from simple 
phase solubility studies. Self-association of surface active drugs, lipophilic drug molecules, 
and drug/cyclodextrin complexes, as well as drug solubilization through non-inclusion 
interactions with drug/cyclodextrin complexes, will influence both the shapes and 
mathematical interpretation of the phase-solubility diagrams. 
In summary, drug/cyclodextrin complexes can self-associate to form water-soluble aggregates 
of several drug/cyclodextrin complexes.               
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4.4 Self-association of cyclodextrin complexes  
Aqueous cyclodextrin solutions have been regarded as true solutions where individual 
cyclodextrin molecules as well as cyclodextrin complexes form a homogeneous molecular 
dispersion in a continuous system of water molecules.  
In recent years it has been shown that cyclodextrins and cyclodextrin complexes self-associate 
to form aggregates or micelle-like structures (Lit). Furthermore, it has been shown that water-
soluble polymers do interact with such systems and that the aggregates can solubilise drugs 
through non-inclusion complex formation (Lit). Various techniques can be applied to enhance 
the water-solubility of drug/cyclodextrin complex aggregates. For example, addition of small 
amount of water-soluble polymers to aqueous complexation media increases the solubility of 
the aggregates. Likewise, addition of various salts, such as sodium acetate, can increase the 
solubility of drug/cyclodextrin complexes.  
Formation of drug/cyclodextrin complexes depends on the chemical structure and the 
physicochemical properties of both the drug and the cyclodextrin. For an inclusion complex to 
be formed some lipophilic moiety of the drug molecule has to fit into the hydrophobic 
cyclodextrin cavity. Also, low aqueous solubility is not always due to lipophilicity of the drug 
molecules.  
The effects of the molecular structure and physicochemical properties of both the drug and the 
cyclodextrin on the formation of drug/cyclodextrin complexes are:  
Size of the cyclodextrin cavity: the size of the cyclodextrin cavity will 
influence the complex formation. For instance, the -cyclodextrin cavity is too 
small for naphthalene and only the -cyclodextrin cavity can accommodate 
anthracene. -Cyclodextrin can be used for small molecules or side-chains of 
larger molecules (e.g., prostaglandins), -cyclodextrin is very useful for 
complexing molecules containing a phenyl group, a group encompassing many 
drugs, and -cyclodextrin can be used for complexation of larger molecules 
such as macrolide antibiotics;  
Molar substitution (or degree of substitution) of the cyclodextrin molecule:  
chemically modified cyclodextrins of lower degree substitution are frequently 
better complexing agents than the same derivatives with higher molar 
substitution;  
The intrinsic solubility of the drug: the lower the intrinsic drug solubility, the 
greater is the relative solubility enhancement obtained via cyclodextrin 
complexation. Drugs that possess aqueous solubility in the µg/ml range 
generally demonstrate much greater relative enhancement than drugs possessing 
solubility in the mg/ml range;  
Hydrophilic drugs possessing low intrinsic solubility in water: zwitter ionic 
drugs, and other polar drugs of limited aqueous solubility, generally 
demonstrate low complexing abilities. The basis for such poor enhanced 
solubility is that the low aqueous solubility of the drug is frequently due to high 
crystal energy rather than their lipophilicity. Once in solution, the hydrated drug 
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molecules often have little tendency to be included into the hydrophobic 
cyclodextrin cavity. However, many ionisable drugs are capable of forming 
cyclodextrin complexes and although the ionized form tends to form complexes 
less avidly than the unionized form, it is frequently possible to enhance aqueous 
solubilization of ionisable drugs by appropriate pH adjustments;  
 
Ion pairing: compared to neutral cyclodextrins, enhanced complexation is 
frequently observed when the drug and cyclodextrin molecules have opposite 
charge while decreased complexation is observed when the drug and 
cyclodextrin carry same type of charge.  
It might also be mentioned that various vehicle additives commonly used in pharmaceutical 
preparations, such as sodium chloride, buffer salts, surfactants, preservatives and organic 
solvents, often attenuate the ability of cyclodextrins to solubilise drugs. Thus, solubility 
studies should be completed a) using the intended formulation and b) under normal 
production conditions. In general, the complexation efficiency of cyclodextrins is rather low, 
and thus relatively large amounts of cyclodextrins are needed to complex small amounts of a 
drug. 
Due to toxicological considerations, formulation and production costs, it is important to use as 
little cyclodextrin as possible in pharmaceutical preparations. The complexation efficiency is 
equal to the intrinsic solubility of the drug times the stability constant of the drug cyclodextrin 
complex. Enhanced complexation efficiency can be obtained by increasing the apparent 
intrinsic solubility of the drug, by increasing the apparent stability constant of the 
drug/cyclodextrin complex or by increasing both simultaneously. Some methods that can be 
applied to enhance the complexation efficiency are:  
Drug ionization: Unionized drugs do usually form more stable complexes than 
their ionic counterparts. However, ionization of a drug increases its apparent 
intrinsic solubility resulting in enhanced complexation;  
Salt formation: it is sometimes possible to enhance the apparent intrinsic 
solubility of a drug through salt formation;  
Complex-in-complex: in some cases the apparent intrinsic solubility of a drug 
can be increased through formation of metal complexes;  
The acid/base ternary complexes: It has been shown that certain organic 
hydroxy acids (such as citric acid) and certain organic bases are able to enhance 
the complexation efficiency by formation of ternary drug/cyclodextrin/acid or 
base complexes.  
Polymer complexes: water-soluble polymers form a ternary complex with 
drug/cyclodextrin complexes increasing the observed stability constant of the 
drug/cyclodextrin complex. This again increases the complexation efficiency;  
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Solubilization of cyclodextrin aggregates: organic cations and anions are 
known to solubilise uncharged drug/cyclodextrin complexes that have limited 
aqueous solubility. This will enhance the complexation efficiency during 
preparation of, for example, solid drug/cyclodextrin complex powder;  
Combination of two or more methods: frequently, the complexation 
efficiency can be enhanced even further my combining two or more of the 
above mentioned methods. For example drug ionization and the polymer 
method, or solubilization of the cyclodextrin aggregates by adding both 
polymers and cations or anions to the aqueous complexation medium.   
4.5 Pharmacokinetics of the Drug/Cyclodextrin Complexes 
Complexation of molecules to cyclodextrins occurs, with some exceptions, through a non-
covalent interaction between the molecule and the cyclodextrin cavity. This is a dynamic 
process whereby be the guest molecule continuously associates and dissociates from the host 
cyclodextrin. Although most complexation schemes depict the complex as a single entity, the 
complex is more realistically composed of a family of species with the depicted complex 
representing some average. It probably represents the specie with the longest lifetime.  
For example, in a 1:1 complexation, the association is usually described as in Scheme 1. Two 
important parameters can be defined for the inclusion process. First, is the complexation 
strength or constant (K) defined by Scheme 1 and Eq. (1), where [CD] and [D] are the 
concentrations of free cyclodextrin and free drug molecule, respectively. 
Second, is the lifetime (t) of the complex, also defined in Scheme 1 and Eq. (2), measured 
when the equilibrium is disturbed. The constants kf and kr are the forward and reverse rate 
constants, respectively, and kobs  is the observed rate constant for the reestablishment of the 
equilibrium after it is perturbed. 
If the complex is diluted such that dissociation of the complex is complete, the half-life will 
be that associated with kr.13  
K=kf/kr=[DCyD]/[Df][CyDf] 
Kobs=l/ = kf(CyDf) + [Df][ + K
 
Df + CyDf <=> DCyD  
Scheme 1: The interaction of drug, D, with a cyclodextrin, CyD, to form an inclusion 
complex, DCyD, with a binding constant of K, where K=kf /kr. According to (Lit. 
[76]).  
Several factors can have influence the dissociation of the drug from the cyclodextrins 
complexes. For example:  
                                                          
13  Taking in consideration that kf is a second order rate constant while kr is a first order rate constant. 
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4.5.1 Competitive displacement 
Competitive displacement of drugs from their cyclodextrin complexes can have a significant 
influence in vivo. As an example of the competitive displacement of a drug from its 
cyclodextrin complex is the work of Tokumura et al on the water insoluble drug cinnarizine 
(Lit. [73]-Lit. [74]). A -cyclodextrin complex of the water insoluble drug, cinnarizine, was 
more soluble than cinnarizine alone. After oral administration of the complex, improvement 
in cinnarizine availability were less than expected based on in vitro dissolution experiments. It 
was suggested that cinnarizine was too strongly bound to the cyclodextrin such that complex 
dissociation was limiting oral availability. 
Co-administration of phenylalanine, a displacing agent, improved the availability of 
cinnarizine from the complex but not from conventional tablets of cinnarizine. 
When cinnarizine was administered to dogs as HP -CD or (SBE) -CD aqueous solutions 
of pH 4.5, or as a (SBE) -CD/ cinnarizine complex in capsules, oral availability was 
essentially complete without the need for a displacing agent (Lit. [75]). In other words, 
dissociation of cinnarizine from these two cyclodextrins was not limiting.  
4.5.2 Dilution 
The effect of the dilution on the drug release from the cyclodextrin complex depends on the 
route of administration. For example, dilution is minimal when a complex is administered 
ophthalmically or pulmonary. However, after oral drug administration, some dilution is likely 
to occur but again, dilution alone is probably insufficient to account for the relative good 
absorption of drugs administered as cyclodextrin complexes. Unlike, ophthalmic delivery, 
residence time in the GI tract is longer, allowing time for other factors to contribute to 
complex dissociation.  
4.5.3 Protein binding 
Scheme 2 shows a possible three equilibrium processes that can occur following the 
administration of a drug/cyclodextrin complex.    
D1,f + CyDf  
 
D1CyD   
+  +  
P  D2,f   
  
D1P  D2CyD  
Scheme 2: Protein binding and displacement equilibrium competing with drug/ 
cyclodextrin inclusion complexation. According to ([76]).  
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The scheme represents the binding of drug (D) to a cyclodextrin (CyD), binding of drug to a 
protein (P) and the binding of a competing agent (D) to the cyclodextrin. K1, K2 and Kp are 
the binding constants for 1:1 drug/ cyclodextrin complexation, 1:1 competing agent / 
cyclodextrin complexation and drug/ protein binding, respectively. 
As one can see, the protein binding does have an effect on facilitating drug dissociation from 
cyclodextrin complexes. However, the level of influence of the protein binding on the drug 
dissociation from the cyclodextrin complexes needs to be determined for each of the 
drug/cyclodextrin complexes.  
4.5.4 Drug uptake into tissue 
A potential contributing mechanism for drug release from cyclodextrin is preferential drug 
uptake by tissues. Scheme 3 illustrates this point: if the drug is lipophilic and has access to 
tissue not available to the cyclodextrin or the complex, the tissue then acts as a sink causing 
dissociation of the complex based on simple mass action principles. This mechanism may 
become more relevant for highly bound drugs or when the complex is administered at a site 
where dilution is minimal, e.g., after ocular, nasal, sublingual, pulmonary, dermal or rectal 
administration.  
Scheme 3: Selective tissue uptake facilitates complex dissociation. According to (Lit. 
[76]).  
Upon administration, drugs appear to be rapidly and quantitatively released from cyclodextrin 
complexes. Dissociation due to dilution appears to be the major release mechanism although 
other factors such as competitive displacement of the drug from the complex, drug binding to 
plasma and tissue components, uptake of the drug by tissues not available to the complex or 
cyclodextrin and cyclodextrin elimination may also contribute for more strongly bound drugs.  
In conclusion, the association and dissociation of molecules to and from cyclodextrins are 
dynamic processes. The reactions occur at very rapid rates for both strong and weak 
complexes with the average lifetime of the molecules in the host cavity being in the milli- to 
micro-second time range or shorter.  
With these processes occurring at such rates, the kinetics of release of a drug molecule from 
cyclodextrin cavity should not be a limiting factor. 
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4.6 Benefits of Complexation 
4.6.1 Improvement in solubility, dissolution and bioavailability 
One of the most important applications of cyclodextrins in the pharmaceutical field is to 
enhance aqueous solubility of drugs through inclusion complexation. 
The solubility of a guest compound can be changed upon complexation with a cyclodextrin 
either to increase or to decrease the solubility. When a guest compound is complexed by a 
cyclodextrin, the guest in the cavity of the cyclodextrin is essentially surrounded by the 
molecule of cyclodextrin. The hydrophobic groups of the guest that would be in contact with 
the solvent in the free state interact with the atoms of the cavity of the cyclodextrin instead. 
The outer surface of the cyclodextrin interacts with the solvent. As a result, this outer surface 
of the cyclodextrin contributes to the solubility of the complex and not the portion of the guest 
interacting with the cavity of the cyclodextrin.  
4.6.2 Reduction of Unpleasant Side Effects and Bitter Taste  
Improvements in the rate and extent of dissolution of a drug can improve the rate of 
absorption of the drug. Reducing the contact time between the drug and the tissue mucosa can 
help minimize tissue irritation produced by drugs. Nonsteroidal anti-inflammatory drugs 
cause a high incidence of gastrointestinal ulcerative lesions that are a result of both local 
irritation from the drug and systemic inhibition of prostaglandin synthesis by the drug. CD 
formulations of naproxen cause fewer gastric lesions associated with the acute local tissue 
irritation than produced by the drug alone (Lit. [15]).  
Complexation with CDs can also have the effect of reducing the amount of contact with taste 
receptors. This can be of great benefit in the preparation of oral solutions. Not only are the 
drugs masked from the receptors by inclusion in the CD cavity, but the increased 
hydrophilicity enables the easier removal of the bitter substance from the receptor surface as 
well. The apparent concentration of the uncomplexed bitter drug is a function of the 
complexation constant, the amount of free CD, and the water solubility of the drug (Lit. [16]). 
Complexation has been used to mask the unpleasant bitter taste of a number of drugs such as 
acetaminophen (Lit. [16]).  
4.6.3 Improvements in Drug Stability  
CDs are normally thought of as stabilizing agents in pharmaceutical formulations (Lit. [17]-
Lit. [18]). They have been shown to stabilize drugs to hydrolysis Lit. [19] and hydrolytic 
dehalogenation, oxidation, decarboxylation and isomerization, both in solution and in the 
solid state(Lit. [20-23]). The nature of the stabilization or destabilization depends on the CD 
used (parent and functional groups of any derivative) and on the position of the guest 
molecule inside the CD. If the molecule is positioned such that the area of instability is 
located outside the CD, no effect on stability may be observed. When the position allows 
interaction of the CD hydroxyls (or derivative functional groups) with a hydrolytically prone 
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site, decreased stability may be observed but if the site is located fully within the CD, 
enhanced stability usually results. 
Stabilization is not limited to small compounds, since larger molecules such as peptides and 
proteins can also form complexes that result in enhanced chemical and physical stability 
(Lit.[23]). The CDs will typically interact with functional groups present on exposed surfaces 
of the macromolecules and often form multiple complexes (several CDs per molecule).   
4.6.4 Reduction in Volatility  
Inclusion complexes have been prepared with a number of volatile substances (Lit. [24]-
Lit.[25]) including spices, flavours, essential oils, and several drugs. CD complexation has 
been shown to reduce the volatility and improve the stability of many compounds. Examples 
include lemon oil and other flavouring agents (Lit. [25]- Lit. [26]).  
4.7 Use of Cyclodextrins as Drug Carriers 
As mentioned previously, CDs are cyclic nonreducing oligosaccharides containing 6, 7, or 8 
glucopyranose units ( -, -, or -CD, respectively).  
The CD exterior, containing hydroxyl groups, is hydrophilic, whereas the central cavity is 
relatively lipophilic (Lit. [28-30]). The selection of CDs is also based on structural 
modifications to reduce toxicity. Some of these modifications are discussed below.  
Sustained Drug Release  
For pulmonary administration of the drug, CD makes it possible to protect the drug from 
enzymatic degradation, to release the drug in a sustained pattern, and, as a result, to reduce the 
number of administrations required and prevent the high peak concentrations frequently 
encountered following single-dose administration.  
Bioavailability Enhancer  
CDs have the ability to increase drug bioavailability by enhancing drug permeation through 
biological membranes. The preferred explanation for this phenomenon is that CDs increase 
the aqueous solubility of water-insoluble drugs. But the situation is actually more 
complicated, because CDs are also known to decrease drug bioavailability. This is, therefore, 
not solely a question of increased aqueous drug solubility (Lit. [28]).        
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4.8 Toxicological Considerations 
-CD permeates lipophilic membranes with considerable difficulty and, thus, is virtually non-
toxic when used in oral or topical formulations. The acute toxicity of -CD, administered by 
the oral route, was studied in rats and dogs and did not reveal any toxicity. Therefore, even if 
they are swallowed during or after pulmonary administration, CD will not be toxic. 
Nevertheless, CD exerted a relatively mild and reversible effect on the ciliary beat frequency 
of both chicken embryo trachea and human nasal adenoid tissue in vitro in a concentration-
dependent manner. (Lit. [31]-Lit. [32]). Consequently, CD appears to be non-toxic for both 
the upper and lower airways. 
Even though some of the cyclodextrins are not suitable for parenteral use, because of its 
toxicity, they can still be used in other kinds of formulation. 
Table 2 include the cyclodextrins with potential interest as drug carrier and how they can be 
used.  
Table 2: Description of  cyclodextrins with potential interest as drug carriers. 
Derivatives Examples Characteristic Possible use 
(dosage form) 
Hydrophilic 
Methylated  -CD 
Methylated- -CD
 
Soluble in cold water and in 
organic solvents, surface 
active, haemolytic 
Oral, dermal, 
mucosal14 
 
DIMEB   
TRIMEB   
Hydroxyalkylated-  
-CD 
Hydroxyalkylated  
-CD 
Amorphous mixture with 
different degrees of 
substitution, highly water 
soluble, low toxicity 
Oral, dermal, 
mucosal, 
parenteral(i.v.) 
2-HP-b-CD   
Branched- -CD Highly water soluble, low 
toxicity 
Oral, mucosal, 
parenteral (i.v.) 
G-  -CD   
M-  -CD   
Ionisable Anionic  
-CD 
Anionic  -CD Highly water soluble, low 
toxicity 
Oral, mucosal, 
parenteral (i.v.) 
      
                                                          
14  Mucosal: nasal, sublingual, ophthalmic, pulmonary, rectal, vaginal, etc.  
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4.9 Pulmonary Administration of Cyclodextrins 
Insulin 
The relative effectiveness of CD and derivatives as pulmonary insulin absorption enhancers 
was investigated in rats (Lit.[33]). There was an improved hypoglycaemic response when 
insulin was administered intratracheally in the presence of CD. The relative effectiveness of 
CD in enhancing pulmonary insulin absorption as measured by pharmacodynamic relative 
efficacy followed the rank order of DM- -CD > -CD > -CD> -CD > HP- -CD. 
Pharmacokinetic analysis also revealed near complete insulin uptake from the pulmonary sacs 
upon co administration with 5% DM- -CD. However, an absolute bioavailability of only 22% 
was obtained in the presence of 5% HP- -CD. Relatively low acute mucotoxicity was 
observed. The absolute bioavailabilities following pulmonary insulin administration with CD 
revealed that the thinner epithelial cell layer of the respiratory mucosa in comparison with the 
intestinal mucosa offered less resistance to CD-promoted insulin uptake (Lit. [33]).   
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5 MATERIALS AND METHODS 
5.1 Materials 
The following materials were used in this work:  
Table 1: List of materials used 
Substance Synonym Charge/Lot 
Number 
Supplier 
Ascorbic acid Vitamin C 99K29GN-
703239 
Bufa B.V. Pharmaceuticals 
products, Uitgeest, Holland
  
32043334 Merck GmbH, Darmstad, 
Germany 
Aspartame  433698/1 Fluka AG, Buchs, 
Switzerland 
Azithromycin  410150 Hande Industry & Trade 
Holdings Limited, China 
Calcium chloride-Dihydrate TAG 
43081012 
Merck GmbH, Darmstad, 
Germany 
Chitosan  4040701 Pfannenschmidt GmbH, 
Germany 
Cyclosporin A  FPO 1472 C Fährhaus Pharma GmbH, 
Hamburg, Germany 
Citric acid monohydrate  00125HH-
155795 
Bufa B.V. Pharmaceuticals 
products, Uitgeest, Holland
Cyclodextrin Cavamax W6 ( -
CD) 
60P301 Wacker Chemie GmbH, 
Munich, Germany 
Cyclodextrin Cavamax W7 (ß-
CD) 
70P225 Wacker Chemie GmbH, 
Munich, Germany 
Cyclodextrin Cavamax W8 ( -
CD) 
80P200 Wacker Chemie GmbH, 
Munich, Germany 
Cyclodextrin Cavasol W8 HP 
(2-
Hydroxypropyl-ß-
cyclodextrin) 
83B003 Wacker Chemie GmbH, 
Munich, Germany 
Cyclodextrin Heptakis (2,6-Di-
O-Methyl)-ß-
Cyclodextrin 
043K0717 Sigma-Aldrich Chemie 
GmbH, Munich, Germany 
Cyclodextrin (2-
Hydroxypropyl-ß-
cyclodextrin 
447841/1 Fluka AG, Buchs, 
Switzerland 
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Cyclodextrin (2-
Hydroxypropyl)-
ß-cyclodextrin 
454270/1 Fluka AG, Buchs, 
Switzerland 
Cyclodextrin Hydroxypropyl-ß-
Cyclodextrin 
04909TA-483 Fluka AG, Buchs, 
Switzerland 
Cyclodextrin Kleptose HP 
(Hydroxypropyl-
ß-cyclodextrin) 
E2004 Roquette Inc., Lestrem, 
France 
Cyclodextrin Kleptose HPB (2-
Hydroxypropyl-ß-
cyclodextrin) 
E0018 Roquette Inc., Lestrem, 
France 
Cyclodextrin Kleptose HPB (2-
Hydroxypropyl-ß-
cyclodextrin) 
E0020 Roquette Inc., Lestrem, 
France 
Cyclodextrin maltosyl- -CD-
Mixture 
97135 Dexy Pearl / Ensuiko sugar 
refining CO.,LTD, Japan 
Cyclodextrin Trappsol( 6-0-
Maltosyl- -CD) 
804712 Cyclodextrin Technologies 
Development Inc., Florida, 
USA 
Cyclodextrin Trappsol(Hydroxy
propyl- -CD) 
060474T005 Cyclodextrin Technologies 
Development Inc., Florida, 
USA 
Cyclodextrin Trappsol 
(Hydroxypropyl-
-CD) 
090174B008 Cyclodextrin Technologies 
Development Inc., Florida, 
USA 
Cyclodextrin Heptakis(2,6-Di-
O-Methyl)-ß-
Cyclodextrin 
043 K 0717 Sigma-Aldrich Chemie 
GmbH, Munich, Germany 
Cyclodextrin (2-
Hydroxypropyl)-
ß-cyclodextrin 
447841/1 Fluka AG, Buchs, 
Switzerland 
Cyclodextrin Hydroxypropyl-ß-
Cyclodextrin 
04909TA-483 Sigma-Aldrich Chemie 
GmbH, Munich, Germany 
Cyclodextrin Trappsol 
(Hydroxypropyl 
-CD) 
1203109J2 Cyclodextrin Technologies 
Development Inc., Florida, 
USA 
Cyclodextrin Ethylated-ß-
cyclodextrin 
CYL-292 CycloLab, Budapest, 
Hungary 
Cyclodextrin Trappsol 
(Hydroxypropyl 
-CD) 
090174B008 Cyclodextrin Technologies 
Development Inc., Florida, 
USA 
Cyclodextrin Trappsol 
(Maltosyl Alpha 
CD Mixture) 
91203 Cyclodextrin Technologies 
Development Inc., Florida, 
USA 
Cyclodextrin Trappsol 
(Maltosyl -CD 
Mixture) 
91203 Cyclodextrin Technologies 
Development Inc., Florida, 
USA 
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Glucose Monohydrate  K28721342 Merck GmbH, Darmstad, 
Germany 
  
K31253942 Merck GmbH, Darmstad, 
Germany 
Hydroxypropyl-
methylcellulose  
390367/1 
33301 
Fluka AG, Buchs, 
Switzerland 
Lipoid S 100 Soja lecithin 790260-1 Lipoid GmbH, 
Ludwigshafen, Germany 
Lipoid S 100 Soja lecithin 790474-4/27 Lipoid GmbH, 
Ludwigshafen, Germany 
Lipoid S 100 Soja lecithin 790501-4 / 23 Lipoid GmbH, 
Ludwigshafen, Germany 
Lipoid S 100 Soja lecithin 790509-2/22 Lipoid GmbH, 
Ludwigshafen, Germany 
LysineMonohydrat  K27386233 Merck GmbH, Darmstad, 
Germany 
Magnesiumsulfat 
Hexahydrat  
431328/1 Fluka AG, Buchs, 
Switzerland 
Pentoxifylline  0010102-S LKT Labs, Minnesota, USA
23924705 LKT Labs, Minnesota, USA
Pluronic F 68  X02316P Bioconcept, Allschwil, 
Switzerland 
Y07018P Bioconcept, Allschwil, 
Switzerland 
Polyvinyl-pyrrolidon K25  368948/12319
8 
Fluka AG, Buchs, 
Switzerland 
Polyvinyl-pyrrolidon K30   375755/14179
8 
Fluka AG, Buchs, 
Switzerland 
Sodium acetate  032K0177 Sigma-Aldrich Chemie 
GmbH, Munich, Germany 
Sodium ascorbate  43457025 Merck GmbH, Darmstad, 
Germany 
32960244 Merck GmbH, Darmstad, 
Germany 
43457025 Merck GmbH, Darmstad, 
Germany 
Trehalose  S4112361 Merck GmbH, Darmstad, 
Germany 
Tween 80  40762194 Merck GmbH, Darmstad, 
Germany 
083K0588 Sigma-Aldrich Chemie 
GmbH, Munich, Germany 
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Tyloxapol  083K0588 Sigma-Aldrich Chemie 
GmbH, Munich, Germany 
Vitamine E acetate alpha-Tocopherol-
acetate 
2450412 Merck GmbH, Darmstad, 
Germany 
The other chemicals were of pharmaceutical or reagent grade and were used without further 
purification.  
5.2 Physicochemical Properties of the Drugs Substances 
5.2.1 Cyclosporin A 
Cyclosporin is a cyclic oligopeptide produced by the fungus Tolypocladium inflatum Gams, 
or Cylindrocapron lucidum Booth. 
It is a hydrophobic cyclic peptide built from nonmammalian amino acids with low oral 
bioavailability Lit [34]. Cyclosporin A (CSA) is one of several biologically active 
cyclosporins produced by these fungi (Lit. [35]).  
Figure 1: Structure of Cyclosporin A.  
It is a first line immunosuppressive drug used to prevent transplant rejection and to threat 
autoimmune diseases. CSA causes selective suppression of cell mediated immunity by 
inhibition of T cells Lit.[35]. 
Cyclosporin A is a potent immunosuppressive agent extensively employed to avert graft 
rejection in kidney, liver and bone marrow transplant patients and to delay or prevent disease 
progression in patients with autoimmune disease and inflammation (Lit. [36-39]). The 
immunosuppressive effect of CSA is due to a selective and reversible inhibition of T-
lymphocytes (Lit. [40-41]). CSA selectively inhibits interleukin-2 (IL-2) driven proliferation 
of activated T-lymphocytes.   
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In spite of the great clinical importance of the drug, their extended usage has often been 
limited by several disadvantages including low bioavailability, narrow therapeutic window, 
nephrotoxicity and hepatotoxicity (Lit. [42-43]). 
Nephrotoxicity may appear acutely, associated with reversible hemodynamic changes, or as a 
result of interstitial fibrosis after chronic dosing (Lit. [44]- Lit. [45]) It has also, been reported 
that Cremophor EL®, a solubilizing agent, present in the commercially available intravenous 
dosage form of cyclosporin A, is nephrotoxic and haemolytic (Lit. [46-47]).  
5.2.1.1 Physicochemical properties of cyclosporin A 
Cyclosporin A occurs as white prismatic crystals from acetone. It is insoluble in water and n-
hexane and very soluble in all other organic solvents such as methanol, ethanol, acetone, 
ether, and chloroform. Cyclosporin A has a melting point of 148-151 °C (natural) and 149-
150 °C (synthetic). It is stable in solution at temperatures below 30 °C but is sensitive to light, 
cold and oxidization. When heated to decomposition, cyclosporin A emits toxic fumes of 
nitrogen oxides (NOx).  
5.2.2 Azithromycin 
Azithromycin is a macrolide antibiotic belonging to the azalide group. It has in vitro activity 
against many gram-positive and gram-negative aerobic and anaerobic bacteria. It also has 
greater stability than erythromycin in the presence of an acid. 
Azithromycin binds to the 50S ribosomal subunit of the 70S ribosome of susceptible 
organisms, thereby inhibiting RNA-dependent protein synthesis.  
5.2.2.1 Physicochemical properties of azithromycin 
Azithromycin, as the dihydrate, is a white crystalline powder with a molecular formula of 
C38H72N2O12·2H2O. It is not water soluble but it is soluble in Acetone, Chloroform, Methyl 
Chrolide, Ethyl Acetate, Ethanol, Methanol and Dimethyl Formamide. It has a pH between 9-
11 and a molecular weight of 785.0. 
 
Figure 2: Structure of Azithromycin. 
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5.2.3 Pentoxifylline 
Pentoxifylline (PTX) is a xanthine derivative that has generated widespread interest in the 
field of oncology based on its reported potential ability to ameliorate radiation- and 
chemotherapy-induced toxicity. 
The radiosensitivity of the lung tissue limits the dose of radiation which can be delivered to 
tumours in the thoracic region. Radiation-induced lung damage may arise depending on the 
total dose of radiation, the fractionation schedule, the volume of lung tissue irradiated, the 
existence of prior lung disease and the use of chemotherapeutic drugs in the treatment of the 
disease (Lit. [48-50]). Damage to endothelial or epithelial cells is assumed to be the initial 
step leading to radiation pneumonitis and ultimately to pulmonary fibrosis.  
However, the process of injury and repair initiated by irradiation is also a function of 
activation of cells to produce important biological mediators, such as cytokines, which 
modulate diverse aspects of the inflammatory and fibrogenic response. 
Therefore, the pathophysiological tissue response after lung irradiation implies the induction 
of numerous cytokines which form the basis for the multicellular interactions of the 
inflammatory and fibrogenic process associated with radiation injury (Lit. [51-57]). The 
relative role of cytokine dysregulation versus direct tissue injury from irradiation for the 
pathogenesis of radiation pneumonitis/fibrosis remains elusive. 
Tumor necrosis factor-  (TNF- ) is thought to be a key mediator for the pathogenesis of 
radiation pneumonitis, because it shows a varied spectrum of biological activities. TNF- 
exerts in particular proinflammatory effects by inducing the expression of adhesion molecules 
that recruit leukocytes into the sites of tissue damage, by priming leukocytes for oxidant 
production, and by inducing production of prostaglandins and other mediators of 
inflammation. TNF- inhibits anticoagulatory mechanisms and therefore promotes thrombotic 
processes (Lit. [58]). In addition, TNF- exerts fibrogenic effects by stimulating the growth of 
fibroblasts and increasing the collagen deposition (Lit. [59]). Therefore, a pharmacological 
regulation of the TNF-  production at the initial stage could possibly halt the progression of 
radiation-induced injury. A drug which suppresses the production of TNF- but lacks the 
many side effects of glucocorticoids might be useful as an anti-inflammatory agent. 
In addition, PTX down-regulates the production of proinflammatory cytokines, particularly 
TNF- , in response to noxious stimuli and inhibits granulocyte-mediated cytotoxicity after 
TNF-  exposure and may, therefore, provide protection against radiation-induced, cytokine-
mediated cellular damage (Lit. [60-63]). PTX is able to inhibit the synthesis of messenger 
RNA (mRNA) for TNF- in mouse peritoneal macrophages at the transcriptional level (Lit. 
[63-64]). Also in humans, PXT is able to reduce the release of TNF- by peripheral blood 
monocytes (PBM) (Lit. [66]). Compared with other new agents, PTX is relatively inexpensive 
and has few side effects. A recent study suggests that patients with progressive sarcoidosis 
respond to PXT treatment (Lit. [67]). This beneficial clinical effect may be due to the 
interference of the drug with TNF- production from alveolar macrophages (AM), because 
these cells frequently release increased amounts of TNF- in patients with sarcoidosis 
(Lit.[68-70]). 
In Lit. [71] it is referred the use of PTX for the treatment of bronchopulmonary dysplasia 
(BPD). The treatment of bronchopulmonary dysplasia  with steroids still remains 
controversial. For this reason, a new approach was investigated using nebulised pentoxifylline 
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in the successful treatment of five premature neonates with bronchopulmonary dysplasia. 
PTX has a strong anti-inflammatory effect, mainly through its inhibitory influence on 
neutrophils, macrophages and monocytes. Cytokines produced by those cells may prolong 
inflammation and impair healing of the immature lung. PTX also inhibits synthesis of ICAM-
1 and plasma soluble intercellular adhesion molecule, the concentration of the latter correlates 
with the risk of BPD development (Lit. [72]). Moreover, PTX as a methylxanthine derivative 
has a bronchodilator, diuretic and respiratory muscles stimulant effect.  
The route of PTX administration was established by a pilot trial which showed that in the 
nebulised form, the drug exerted a significantly greater effect than when given by intravenous 
infusion. One possible explanation for this may be the diminished penetration of PTX from 
blood to the foci of lung tissue inflammation and destruction.  
5.2.3.1 Physicochemical properties of pentoxifylline 
Pentoxifylline is a white or almost white crystalline powder with a molecular weight of 278.3. 
It is soluble in water and sparingly soluble in alcohol. It is also freely soluble in chloroform,  
methyl alcohol and slightly soluble in ether.  
 
Figure 3: Structure of pentoxiphylline  
5.2.4 Budesonide 
Budesonide is a potent nonhalogenated synthetic glucocorticosteroid with strong topical and 
weak systemic effects.  
Budesonide has a high topical anti-inflammatory potency and it is rapidly biotransformed in 
the liver. This favourable separation between topical anti-inflammatory activity and systemic 
effect is due to strong glucocorticosteroid receptor affinity and an effective first pass 
metabolism with a short half-life.  
5.2.4.1 Physicochemical properties of budesonide 
Budesonide is a white or almost white, crystalline powder. It is practically insoluble in water; 
sparingly soluble in alcohol; freely soluble in dichloromethane. The molecular weight 
(C25H34O6) is 430.5.    
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Figure 5: Structure of budesonide.  
5.3 Methods 
5.3.1 Analytical Methods 
5.3.1.1 Particle size and zeta potential determination 
The mean diameter, size distribution and zeta potential of the cyclosporin A/( )-cyclodextrin 
and the azithromycin/( )-cyclodextrin nanospheres were determined by laser diffraction using 
a Malvern Zetasizer (Model Zetasizer 3000 HAS, Malvern Instruments GmbH, Herrenberg, 
Germany).   
Underlying principle 
The particle size and zeta potential analysis were performed using Photon Correlation 
Spectroscopy (PCS). It is applicable to particles suspended in a liquid, which are in a state of 
random movement due to Brownian Motion (i.e. particles generally of 2 -3 µm diameter and 
smaller). The pace of the movement is inversely proportional to particle size (the smaller the 
particles are, the faster they move, or diffuse), and the pace can be detected by analyzing the 
time dependency of the light intensity fluctuations scattered from the particles when they are 
illuminated with a laser beam. On the other hand, the measurement of the zeta potential is 
usually done in three stages. The first stage involves checking instrument settings. The 
voltage sensed is checked against the voltage applied for the capillary cell. If the drop is too 
great, there may be a bubble in the system and therefore the measurement is aborted. . If the 
voltage is different, then this suggests polarisation, normally caused by bubbles at the 
electrode.  
The second stage calculates the apparent mobility when no field is applied. This corrects for 
particle motion due purely to Brownian motion. The third stage is the measurement itself. The 
field is applied in short burst to prevent heating of the sample. The frequency is recorded and 
converted to electrophoretic nobilities and zeta potential. 
In order to fit the measurement parameters, the samples were diluted using water as the 
solvent. In the case of the particle size analysis, each sample was measured in three sets (each 
containing 10 measurements points) and average values along with the polydispersity index 
were then obtained. For the zeta potential analysis, a 5 ml sample volume was used. 
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5.3.1.2 Scanning electron microscopy 
The assessment of the form and shape of the cyclosporin A and azithromycin nanospheres 
was determined by scanning electron microscopy.  
Underlying principle 
 
In light microscopy, a specimen is viewed through a series of lenses that magnify the visible-
light image. However, the scanning electron microscope (SEM) does not actually view a true 
image of the specimen, but rather produces an electronic map of the specimen that is 
displayed on a cathode ray tube (CRT). Electrons from a filament in an electron gun are 
beamed at the specimen in a vacuum chamber. The beam forms a line that continuously 
sweeps across the specimen at high speed. This beam irradiates the specimen which in turn 
produces a signal in the form of either x-ray fluorescence, secondary or backscattered 
electrons. 
By changing the width (w) of the electron beam, the magnification (M) can be changed where   
M = W/w 
and W is the width of the CRT. Since W is constant, the magnification can be increased by 
decreasing w. 
The specimens examined by SEM must be able to withstand the strong electric currents 
produced by the electron beam. Samples that do not conduct electricity can be damaged by 
the charges, which can be built up. Non-conductive specimens must first be coated with a thin 
layer of conductive material. Since most biological samples are non-conductive, they must be 
coated. The coating produces a nanometre thickness of conductive material on the surface 
through a cold plasma process that retains the contours of the specimen. 
However, many of these samples also need additional treatment prior to sputter coating to 
prevent the cells from collapsing under the intense electron beam. The types of treatments 
vary according to the specimens. This usually involves a process that fixes the components of 
the specimen. 
Once the specimen is fixed, it is then glued to a sample holder. The sample holder is placed 
into the sputter coater until a thin layer of gold is applied to the surface. The specimen is then 
placed in the SEM vacuum chamber and the electron gun is switched on. 
Morphological examination of the suspensions and particle size analysis were carried out 
using a scanning electron microscope (Jeol JSM-5510 LV, Eching, Germany) after gold 
coating the samples using a Cressington 108auto (Elektronen-Optik-Service GmbH, 
Germany). 
The normal operation procedure involved:  
Preparation of the sample: to a glass slide, one droplet of the sample was 
added. After allowing the sample droplet to dry, the sample was then gold 
coated in order to enable it to be electrically conductive;   
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Mounting of the sample into the specimen chamber;  
Sample analysis: an image will appear automatically when the vacuum is ready 
after a specimen is set in the specimen chamber. The operation conditions are 
automatically optimized when a standard recipe or a customized recipe is 
selected. The automatic functions include auto focus, auto stigmator, and auto 
contrast and brightness make the total operation simple and easy. Nevertheless, 
manual adjustments are also possible in order to optimize the quality of the 
image. All the samples were analysed following the previous operations 
procedures;   
Every sample was analysed following the previous procedure. Several images were taken out, 
at different magnifications, as way of having a more detailed description of the shape and size 
of the nanospheres.   
5.3.1.3 Determination of the Cyclosporin, Azithromycin, Budesonide and Pentoxifylline 
content 
The content of the several drugs investigated in this work was determined by High 
Performance Liquid Chromatography (HPLC).  
Underlying principle 
The fundamental basis for HPLC consists in passing a sample (analyte mixture) in a high 
pressure solvent (called the mobile phase) through a steel tube (called a column) packed with 
sorbents (called the stationary phase). 
As the analytes pass through the column they interact between the two phases (mobile and 
stationary) at different rates. The difference in rates is primarily due to different polarities for 
the analytes. The analytes that have the least amount of interaction with the stationary phase 
or the most amount of interaction with the mobile phase will exit the column faster. Repeated 
interactions along the length of the column effect a separation of the analytes. Various 
mixtures of analytes can be analyzed by changing the polarities of the stationary phase and 
the mobile phase. 
As the analytes exit the column, they can be detected by various means. Refractive index, 
electrochemical, or ultraviolet-absorbance changes in the mobile phase can indicate the 
presence of an analyte. The amount of analyte leaving the column will determine the intensity 
of the signal produced in the detector. The detector measures a signal peak as each analyte 
leaves the column. By comparing the time it takes for the peak to show up (called the 
retention time) with the retention times for a mixture of known compounds, the components 
of unknown sample mixtures can be identified. By measuring the signal intensity (response) 
and comparing it to the response of a known amount of that particular analyte, the amount of 
analyte in the mixture is then determined 
The specifications of the HPLC methods used in the determination of the drug content are 
described below:  
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Cyclosporin content was determined by using a HPLC method with a 
spectrophotometer detector set at 220 nm. The chromatography analysis was 
performed under the following conditions: column, Waters Sunfire C18 (3.5 
µm, 125*3 mm); mobile phase, 0.01% TFA (Trifluoroacetic acid): Acetonitrile 
(including 0.01% TFA): Iso-Propanol; gradient mode; flow rate, 0.90 ml/min;  
Azithromycin content was determined by using a HPLC method with a 
spectrophotometer detector set at 215 nm. The chromatography analysis was 
performed under the following conditions: column, phenomenex GeminiC18; 
5µm; 110A; 150 x 4.6 mm (L*ID); precolumn, phenomenex GeminiC18; 4 x 
3.0 mm; mobile phase, H2B3O3 Buffer (pH=10.5): Acetonitrile (35%:65%); 
gradient mode; flow rate, 1.8 ml/min;  
Budesonide content was determined by isocratic reversed phase liquid 
chromatography using a HPLC method with a spectrophotometer detector set at 
245 nm. The chromatography analysis was performed under the following 
conditions: column, Merck LiChrospher 60, RP Select B; 5µm; 125 x 3mm; 
precolumn, Merck LiChrospher 60, RP Select B; 5µm; 5 x 4mm; mobile phase, 
Methanol/Water (63%:37%); isocratic mode; flow rate, 1.0 ml/min;  
Pentoxifylline content was determined by using a HPLC method with a 
spectrophotometric detector set at 273 nm. The chromatography analysis was 
performed under the following conditions: column, Waters, Symmetry C18; 
5µm; 150 x 3.9 mm (L*ID); mobile phase, 600 ml Water pH=3.0/Methanol 
(60%:40%); isocratic mode; flow rate, 0.8 ml/min.  
5.3.1.4 Viscosity determination 
The viscosities of the several formulations were determined using a Rheostress 1 from Haake, 
Karlsruhe, Germany.   
Underlying principle 
The assessment of the dynamic viscosity is based on the measurement of the cone s rotation 
speed upon initiation of a given and constant torque. The dynamic viscosity is calculated 
taking in consideration the shear stress and shear rate values. 
The assessment of the dynamic viscosity is based on the measurement of the cone s rotation 
speed upon initiation of a given and constant torque. The dynamic viscosity is calculated 
taking in consideration the shear stress and shear rate values. 
The rheometer specifications are described in table 2.    
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 Table 2: Rheometer specifications (Lit. [1]) 
Parameters Values 
Angular resolution (µ rad)  0.3 
Rotational speed CR-mode (min-1) 0.025  1200 
Rotational speed CS-mode (min-1) 0.001  1200 
Torque (mNm) 0.1  50 (1) 0.0005  100 
Oscillation frequency (Hz) 0.0001  100 (1) 
Multiwave (Hz)  0.01  10 
Torsional movement (°)  360 
Bearing mechanical  air bearing 
Motor type micror drag cup motor 
Optional high shear 0.025  3200 rpm 
(1) The highest torque is not reached at the highest oscillation frequency.  
The determination of the dynamic viscosity was performed under the following conditions:  
Flow Curve with C60-1 Ti ; 
Shear Rate: 100 to 1000 1/s; 
Temperature: 19.5°C (stabilizing time: 50 seconds); 
Regression model: Newtonian; 
Sample volume: approx. 1 ml;  
5.3.1.5 Surface tension determination  
The surface tension of the several formulations was determined using Sitaonline t60 from 
Sita, Dresden, Germany.  
Underlying principle 
The measurement of the dynamic surface tension is based on the bubble-pressure method. In 
this case, air bubbles are injected into the test sample (liquid) by means of a capillary tube 
fixed at the measuring head of the tensiometer. The pressure required for this operation is 
assessed and can be transformed into the dynamic surface tension of the liquid test sample 
using the Young-Laplace formula taking into account the capillary diameter. At the same 
time, the bubble frequency, their standing time and the temperature of the solution are 
measured and stored by the tensiometer. 
The determination of the dynamic viscosity was performed in the following conditions:  
Sample temperature: 20°C±1°C 
Sample volume: Approx. 10 ml 
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Software parameters15:   
Control: Liftime  
Factor: 1.10  
Auto clr data: Off  
Auto save: Off  
Before the beginning of every the measurement set, the surface tension value of water was 
determined as a reference.   
5.3.1.6 Water content determination 
The water content in the cyclosporin A and azithromycin lyophilizates was determined by 
using the Karl Fischer method.  
Underlying principle 
Karl Fischer method is a widely used analytical method for quantifying water content in a 
variety of products. It is based on the following reaction: 
Water and iodine are consumed in a 1:1 ratio in the above reaction. Once all of the water 
present is consumed, the presence of excess iodine is detected voltametrically by the titrator s 
indicator electrode. Consequently, that signals the end-point of the titration. 
The amount of water present in the sample is calculated based on the concentration of iodine 
in the Karl Fischer titrating reagent and the amount of Karl Fischer Reagent consumed in the 
titration. 
The water content was determined by using a 756 KF Coulometer from Metrohm AG, 
Herisau, Switzerland. The parameters and reagents used for the measurement were:  
a) Rule Parameters 
Rule range:100 mV; 
Max. rate:1500 µg/min; 
Min. rate:15 µg/min; 
Stop criteria: Relative drift; 
Relative Drift:15 µg/min.       
                                                          
15  The software will allow the recording of data points over the bubble lifetime range of 1-60 secs. 
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b) Titration Parameters 
Pause: 15 s; 
Extraction time: 30 secs; 
Start drift: 10 µg/min; 
Temperature: 20 °C; 
Time interval: 2 secs; 
Max. tritation: OFF.  
c) Reagents 
Trethylamin; 
Hydranal-Coulomat AG; 
Ethanol, denatured.  
The determination of the water content was performed by weighting between 50-100 mg for 
both lyophilizates. The amount of sample used was based on the anticipated water content in 
the lyophilizates in order to obtain a suitable degree of accuracy. 
The measurement was repeated two times in both cases and the obtained average value was 
then used.  
5.3.1.7 Lyophilization  
Underlying principle 
Lyophilization is the term given to the process whereby water is sublimed from frozen 
solutions, generally under reduced pressure, leaving a dry porous mass of approximately the 
same size and shape as the original frozen mass. A typical freeze-drying cycle essentially 
consists of three stages: 
a) Freezing; 
b) Primary drying; 
c) Secondary drying; 
Since freeze-drying takes place at a lower temperature than spray-drying it is normally 
considered to be less destructive, especially to protein products (Lit. [2]). 
In the first stage, the material is cooled until it is completely frozen. This has the effect, at 
least in part, of separating the water from the solutes. The second stage, usually performed 
under vacuum and by supplying heat to the product, involves removal of most of the water by 
sublimation of the ice in the product. The last stage involves the removal of sorbed water and 
is normally carried out at elevated product temperature to achieve efficient water removal. 
Lyophilization of the samples was performed with a Christ Epsilon 2-6D, Osterode am Harz, 
Germany. The lyophilization parameters are described in the following table.   
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Table 3: Lyophilization parameters of the cyclosporin A and azithromycin samples. 
Process Phase
 
Time 
(min) 
Temp. 
(°C) 
Vacuum 
(mbar) 
Si. Pressure 
(mbar) 
Start value 0 0 OFF OFF 
Freezing 1 -38 OFF OFF 
Freezing 44 -38 OFF OFF 
Preparation 15 -38 OFF OFF 
Main drying 1 -38 0.08 OFF 
Main drying 15 -25 0.08 0.140 
Main drying 704 -25 0.08 0.140 
After drying 1 -25 0.08 0.140 
After drying 300 15 0.08 0.140 
After drying 719 15 0.08 0.140 
To the lyophilization vials, it was added 1 ml of the cyclosporin A and azithromycin 
solutions. At the end of the lyophilization process, the vials were then sealed and kept at 2-
8°C.  
5.3.1.8 Nebulisation parameters determination 
The nebulisation performance was investigated using a novel electronic nebuliser, eFlow® 
(PARI GmbH, Starnberg, Germany). Droplet sizes of the aerosols were measured by laser 
diffraction (MasterSizer X, Malvern Instruments, Herrenberg, Germany).  
Underlying principle 
Laser diffraction is a preferred method for particle size analysis of nebulized aerosols. The 
method is well established and relies on the fact that particles scatter light at angles in inverse 
proportion to their size. Laser diffraction systems can measure over a wide dynamic range and 
have the flexibility to accommodate a variety of sample formats, including liquids, slurries, 
dry powders and sprays. 
The determination of droplet size distribution laser diffraction measurements were performed 
according to the PARI SOPs:   
Environmental conditions (T = 23 ± 1°C, r.h. = 50 ± 5 %) were controlled and 
monitored. Test formulation for the characterization of the function of the 
eFlow® nebulizer heads was an aqueous 0.9% NaCl solution. The droplet size 
distributions of the formulation were assessed after the eFlow® nebulizer heads 
have been characterized with 0.9% NaCl solution.  
After the characterisation of the eFlow® nebulizer heads, the sample volume (2 
ml) was nebulised for two minutes by using the eflow® under the same 
environmental conditions previously described. 
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 At the end, the following parameters determined:  
TOR  
MMD  
GSD  
Percentage of droplets < 5µm  
Percentage of droplets < 2µm              
Figure 1: Schematic view of the nebulisation test section.  
For a complete view of the test section, please see Figure 2-3.:  
Figure 2: View of the nebulisation test section.    
L a s e r 
lig h t 
d e te c to r
L a s e r 
F ilte r c o m b in a tio n  
N e b u lize r 
P A R I s ta n d a rd f it t in g & 
m o u th p ie c e  
A ir v e n t.
1 c m
1 c m 
2 .5 c m
N e b u lis e r c h a m b e r 
Materials and Methods 
92 
 
Figure 3: Detailed view of the nebulisation chamber containing the eflow .   
5.3.1.9 Taste masking determination 
The taste of the formulations were analysed by nebulising and inhaling the formulations or by 
tasting it with the tongue. The tests were performed with a group of five persons. Although, 
we could ascertain the taste masking ability of the cyclodextrins regarding the different drug 
formulations with this method, we can consider it as a subjective test.  
5.3.2 Preparation Methods 
5.3.2.1 Preparation methods for the azithromycin formulations 
5.3.2.1.1 Initial preparation method the azithromycin/CD formulations  
In the first set of experiments, the following preparation method was used:  
Preparation of the cyclodextrin solution by dissolving of 2-HP-( )-CD in water. 
Afterwards, the suspension is put under sonification until a clear solution is 
obtained; 
Next, 1 ml of the previous solution was added to each of the vials. Then, an 
excess of azithromycin is added to the vials. Finally, the vials are continuously 
stirred at room temperature for 2 hours; 
After 2 hours of stirring, the excipients are added to the vials in accordance to 
the factorial design; 
Then, the pH of the vials is adjusted to 6.7-7.0. Afterwards, the vials are 
continuously stirred at room temperature; 
After 3 days, equilibrium time, azithromycin concentration is determined by 
HPLC.   
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5.3.2.1.2 Final preparation method for the azithromycin/CD formulations 
The following preparation method was used to prepare azithromycin formulations with a 
superior taste masking ability:  
The azithromycin is weighted  into an aqueous solution. The resulting 
suspension is then stirred; 
Afterwards, HCl (1M) is added until all the azithromycin is solubilized; 
The 2-HP- -CD is added to the previous solution. Then, the flask is 
continuously stirred at room temperature; 
 Afterwards, NaOH (1M) is added quickly until the pH is between 8.85-9.0; 
Centrifugation at 6000 rpm for 1 min or filtration using a 0.45 µm filter follows; 
To the resulting clear solution, 2-HP- -CD is added. It is stirred until a clear 
solution is obtained. 
Finally, the pH is adjusted to 7.5; 
Determination of the azithromycin concentration by HPLC follows.  
5.3.2.2 Preparation method for the ethylated- -cyclodextrin nanospheres 
In the case of the ethylated- -cyclodextrin nanospheres loaded with cyclosporin A, the 
following experimental procedure was performed:  
The ethylated- -cyclodextrin is added into an organic solvent (ethanol). 
Sonification is applied until a clear solution was obtained; 
A specific amount of cyclosporin A is added to the previous solution. In this 
case, sonification is also applied to obtain a clear solution; 
The ethylated- -cyclosporin A/cyclodextrin solution was then added to a 10 ml 
aqueous solution containing 0.88% of Pluronic F68®; 
 Consequently, the nanospheres precipitated spontaneously forming an 
ethylated- -cyclosporin A/cyclodextrin suspension; 
The organic solvent was then removed by evaporation under vacuum16; 
A 1.2 µm filter was used to eliminate the large aggregates.    
5.3.2.3 Preparation method for the - -cyclodextrin nanospheres loaded with cyclosporin A 
In the case of the -cyclodextrin nanospheres loaded with cyclosporin A, the following 
experimental procedure was also performed:  
A specific amount of cyclosporin A was added to a flask containing 25ml or 
50ml of ethanol, depending on the set experiment. Sonification was applied 
until a clear solution was obtained; 
Afterwards, the -cyclodextrin (c.a. 50 mg or 100 mg) was added to the 
previous solution. In this case, sonification was also applied; 
                                                          
16The equipment used was the Laborata 4003-digital from Heidolph, at a pressure of 150 mbar. 
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The -cyclosporin A/cyclodextrin solution was then added to a certain volume 
(25 ml or 50 ml) of an aqueous solution containing the following surfactant 
combinations:  
0.88% of Pluronic F68®   
0.5% Pluronic F68®    
0.53% Pluronic F68® and 0.31% of Tween 80®  
Consequently, the nanospheres precipitated spontaneously forming a -
cyclosporin A/cyclodextrin suspension; 
The ethanol was then removed by evaporation under vacuum; 
A 1.2 µm filter was used to eliminate the large aggregates.  
5.3.2.4 Optimisation of preparation method for the -cyclodextrin nanospheres loaded with 
cyclosporin A 
The method of preparation was:  
The -CD was added to 25 ml flask. Then, the ethanol is added until the mark 
was reached. Sonification was applied for 10 minutes; 
Afterwards, the excess of -CD was removed by using a 0.22 µm filter; 
To the last solution, a specific amount of cyclosporin A is added. After volume 
correction, the flask was sonificated until a clear solution is obtained; 
To this last solution, 25 ml of an aqueous solution containing 10 mg/ml of 
Pluronics F68® is added; 
After evaporation of the ethanol, c.a. 18 ml of the -CD/cyclosporin A is 
obtained17; 
Then, the suspension was diluted to 50 ml using a volumetric flask. NaCl was 
used as a solvent.  
5.3.2.5 Preparation method for the -cyclodextrin nanospheres loaded with azithromycin 
For the case of the -cyclodextrin nanospheres loaded with azithromycin, the following 
experimental procedure was also performed:  
A specific amount of azithromycin was added to a flask containing 50ml of 
ethanol. Sonification was applied until a clear solution was obtained; 
Afterwards, the -cyclodextrin (c.a. 50 mg) was added to the previous solution. 
In this case, sonification was also applied; 
The -cyclodextrin/azithromycin solution was then added to a 50 ml of an 
aqueous solution containing 0.8% of Pluronic F68®; 
Consequently, the nanospheres precipitated spontaneously forming a -
cyclodextrin/azithromycin suspension; 
                                                          
17  In addition to the evaporation of the ethanol, also a part of the water was removed. 
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The ethanol was then separate from the aqueous solution containing the 
nanospheres by centrifugation (3000 rpm for 2 min.); 
A 1.2 µm filter was used to eliminate the large aggregates.   
5.3.2.6 Preparation method for the Pentoxifylline formulations 
The preparation method of the pentoxifylline formulations involves:  
Preparation of a 50 mg/ml aqueous solution of pentoxifylline. Sonification is 
applied until a clear solution was obtained;  
To the previous solution, specific amount of 2-HP- -CD is added in order to 
obtain the desired concentration of cyclodextrin. Sonification is applied until a 
clear solution is obtained;  
Finally, the vials are stirred at room temperature for a defined period of time.    
5.3.2.7 Preparation method for the Budesonide formulations 
The method of preparation was similar to the one performed for cyclosporin A with the 
difference that for the budesonide/cyclodextrin system, the equilibrium time and pH were, 
respectively, 1 day and 4.5. The method consists of:  
Preparation of cyclodextrin aqueous solutions containing different 
concentrations (for example, between 1-40%); 
To each of the vials containing the cyclodextrin solutions, an excess budesonide 
is added; 
Afterwards, sodium ascorbate was added to the vials;  
The pH was then corrected to 4.5; 
Then, the vials are stirred at room temperatures for one day; 
Finally, the solutions are filtered (0.45µm and 0.22µm) and analysed by UV-
spectrophotometer.  
Subchapter references 
[1]  https://www.thermo.com 
[2]  Pikal, M.J., Freeze drying of proteins. Part I: Process design , BioPharm. (1990):18 27.  
[3]  Higuchi, T., Connors, K.A. Phase-Solubility Techniques, Advances in Analytical Chemistry and 
Instrumentation , Reilly, C.,N., John Wiley & Sons, Inc., New York, (1965): 117 212.  
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6 RESULTS 
6.1 Determination of the nebulisation parameters of the eflow 
In the study performed, a Tween 80® (0.001-0.5% w/v) and glucose (5-40% w/v) aqueous 
solutions were prepared in order to investigate the effects of solutions with defined viscosities 
and surface tensions on Mass Median Diameter (MMD) and total output rate (TOR) in the 
eflow® to predict optimal viscosity and surface tension ranges. The nebulisation performance 
was investigated in accordance to the 5.3.1.8. analytical method. 
The results allowed to obtain the following conclusions:  
An increase of viscosity to about 2.6 mPas causes:   
 
Decrease in MMDs with an increase in the respirable fraction from 59% to 
68%.  
Decrease in total output rates from 350 to about 200 mg/min when the viscosity 
rose by 1.5 mPas.   
An decrease in surface tension to about 55 mN/m causes:  
Practically no effect in total output rates.  
In order to confirm the previous conclusions, a pentoxifylline formulation was also analysed 
in terms of the relationship between Viscosity/Surface tension and the MMD/TOR.   
Table 1: Physicochemical properties of 5 different pentoxifylline formulations 
Formulation composition  Viscosity 
(mPa s) 
Surface Tension 
(mN/m) 
MMD (µm) TOR 
(mg/ml) 
50 mg/ml Pentoxifylline+ 
10 mg/ml 2-HP- -CD 
1.24 55.10 3.36 490 
50 mg/ml Pentoxifylline+ 
25 mg/ml 2-HP- -CD 
1.28 55.81 3.30 476 
50 mg/ml Pentoxifylline+ 
50 mg/ml 2-HP- -CD 
1.38 56.59 3.25 485 
50 mg/ml Pentoxifylline+ 
75 mg/ml 2-HP- -CD 
1.51 56.81 3.21 454 
50 mg/ml Pentoxifylline+ 
100 mg/ml 2-HP- -CD 
1.64 57.12 3.05 400 
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Figure 1: Fitting a linear model to describe the relationship between MMD and 
Viscosity. The units of viscosity mPa s and MMD are in mPa s and µm, respectively    
Table 2: Fitting a linear model to describe the relationship between MMD and 
Viscosity. The units of viscosity and MMD are in mPa s and µm, respectively. 
Parameter Estimate Error Statistic P-Value 
Intercept  4.25762 0.123929 34.3554 0.0001 
Slope -0.721715 0.0874121 -8.25647 0.0037 
 
Table 3: Analysis of Variance of the linear model to describe the relationship 
between MMD and Viscosity. 
Source  
Sum of 
Squares Df 
Mean 
Square F-Ratio P-Value 
Model 0.0570877 1 0.0570877 68.17 0.0037 
Residual  0.00251232 3 0.000837439 --- --- 
Total 
(Corr.) 0.0596 4 --- --- --- 
Correlation Coefficient = -0.978697 
R-squared = 95.7847 percent 
R-squared (adjusted for d.f.) = 94.3796 percent 
Standard Error of Est. = 0.0289385 
Mean absolute error = 0.0168686 
Durbin-Watson statistic = 2.92116 (P=0.0088) 
Lag 1 residual autocorrelation = -0.576708  
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The output shows the results of fitting a linear model to describe the relationship between 
MMD and Viscosity. The equation of the fitted model is:  
MMD = 4.25762  0.721715*Viscosity  
Since the P-value in the ANOVA table is less than 0.01, there is a statistically significant 
relationship between MMD and Viscosity at the 99% confidence level.  
The R-Squared statistic indicates that the model as fitted explains 95.7847% of the variability 
in MMD. The correlation coefficient equals -0.978697, indicating a relatively strong 
relationship between the variables. The standard error of the estimate shows the standard 
deviation of the residuals to be 0.0289385.  
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Figure 2: Fitting a linear model to describe the relationship between TOR and 
Viscosity. The units of viscosity and TOR are in mPa s and mg/ml respectively    
Table 4: Fitting a linear model to describe the relationship between TOR and 
Viscosity. The units of viscosity and TOR are in mPa s and mg/ml, respectively. 
Parameter Estimate Error Statistic P-Value 
Intercept  748.275 72.6115 10.3052 0.0019 
Slope -203.741 51.2159 -3.97808 0.0284 
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Table 5: Analysis of Variance of the linear model to describe the relationship 
between TOR and Viscosity. 
Source  Sum of 
Squares 
Df Mean 
Square 
F-Ratio P-Value 
Model 4549.53 1 4549.53 15,83 0,0284 
Residual  862.466 3 287.489 --- --- 
Total (Corr.) 5412 4 --- --- --- 
Correlation Coefficient = -0.916863 
R-squared = 84.0638 % 
R-squared (adjusted for d.f.) = 78.7518 % 
Standard Error of Est. = 16.9555 
Mean absolute error = 12.5047 
Durbin-Watson statistic = 1.94146 (P=0.1683) 
Lag 1 residual autocorrelation = -0.105047  
The output shows the results of fitting a linear model to describe the relationship between 
TOR and Viscosity.  The equation of the fitted model is  
TOR = 748.275  203.741*Viscosity  
Since the P-value in the ANOVA table is less than 0.05, there is a statistically significant 
relationship between TOR and Viscosity at the 95% confidence level. 
The R-Squared statistic indicates that the model as fitted explains 84.0638% of the variability 
in TOR. The correlation coefficient equals -0.916863, indicating a relatively strong 
relationship between the variables.  The standard error of the estimate shows the standard 
deviation of the residuals to be 16.9555.  
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Figure 3: Fitting a linear model to describe the relationship between MMD and 
Surface Tension. The units of Surface Tension and MMD are in mN/m and µm, 
respectively. 
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Table 6: Fitting a linear model to describe the relationship between MMD and 
Surface Tension. The units of Surface Tension and MMD are in mN/m and µm, 
respectively. 
Parameter Estimate Error Statistic P-Value 
Intercept 10.6795 2.21368 4.8243 0.017 
Slope -0.132172 0.0393528
 
-3.36096 0.0437 
 
Table 7: Analysis of Variance of the linear model to describe the relationship 
between Surface Tension and MMD. 
Source  Sum of 
Squares 
Df Mean 
Square 
F-Ratio P-Value 
Model 0.0470931 1 0.0470931 11.3 0.0437 
Residual  0.0125069 3 0.00416898 --- --- 
Total 
(Corr.) 0.0596 4 --- --- --- 
Correlation Coefficient = -0.888905 
R-squared = 79.0152 % 
R-squared (adjusted for d.f.) = 72.0203 % 
Standard Error of Est. = 0.0645677 
Mean absolute error = 0.0466099 
Durbin-Watson statistic = 1.51083 (P=0.0555) 
Lag 1 residual autocorrelation = -0.063802   
The output shows the results of fitting a linear model to describe the relationship between 
MMD and Surface Tension. The equation of the fitted model is:  
MMD = 10.6795  0.132172*Surface Tension  
Since the P-value in the ANOVA table is less than 0.05, there is a statistically significant 
relationship between MMD and Surface Tension at the 95% confidence level.  
The R-Squared statistic indicates that the model as fitted explains 79.0152% of the variability 
in MMD. The correlation coefficient equals -0.888905, indicating a moderately strong 
relationship between the variables. The standard error of the estimate shows the standard, 
deviation of the residuals to be 0.0645677. 
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Figure 4: Fitting a linear model to describe the relationship between TOR and 
Surface Tension. The units of Surface Tension and TOR are in mN/m and mg/ml, 
respectively.   
Table 8: Fitting a linear model to describe the relationship between TOR and 
Surface Tension. The units of Surface Tension and MMD are in mN/m and mg/ml, 
respectively. 
Parameter Estimate Error Statistic P-Value 
Intercept     2317.71 987.364 24433 0.1008 
Slope -32.9337 17.5404 -1.87759 0.1571 
 
Table 9: Analysis of Variance of the linear model to describe the relationship 
between Surface Tension and TOR. 
Source  Sum of 
Squares 
Df Mean 
Square 
F-Ratio P-Value 
Model 2923.85 1 2923.85 3.53 0.1571 
Residual  2488.15 3 829. 382 --- --- 
Total 
(Corr.) 5412.0 4 --- --- --- 
Correlation Coefficient = -0.735019 
R-squared = 54.0254 5 
R-squared (adjusted for d.f.) = 38.7005 % 
Standard Error of Est. = 28.799 
Mean absolute error = 17.7076 
Durbin-Watson statistic = 1.51647 (P=0.0566) 
Lag 1 residual autocorrelation = -0.00453906 
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The output shows the results of fitting a linear model to describe the relationship between 
TOR and Surface Tension.  The equation of the fitted model is  
TOR = 2314.71  32.9337*Surface Tension  
Since the P-value in the ANOVA table is greater or equal to 0.10, there is not a statistically 
significant relationship between TOR and Surface Tension at the 90% or higher confidence 
level.  
The R-Squared statistic indicates that the model as fitted explains 54.0254% of the variability 
in TOR. The correlation coefficient equals -0.735019, indicating a moderately strong 
relationship between the variables. The standard error of the estimate shows the standard 
deviation of the residuals to be 28.799.  
Subchapter conclusion 
Since excipients and drugs can affect viscosity and surface tension, the physicochemical 
properties and also the concentration of each formulation component can have an influence on 
the final viscosity and surface tension values.  
Based on this study,  recommend values for viscosity and surface tension for formulations can 
be defined, making it possible to develop optimized formulations for the e-Flow nebuliser18.                        
                                                          
 
18  The measurements were performed using an equipment (eflow®) that was still under development. For this 
reason, slight changes in the values obtained can be expected when using the final version of the device.  
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6.2 Solutions 
6.2.1 Cyclosporin A Cyclodextrin Formulations 
6.2.1.1 Introduction 
In order to improve the solubility of cyclosporin A (CSA) in an aqueous solution, the 
possibility of using cyclodextrins as solubility enhancers was investigated. 
From previous work, it is known that the smaller cavities of the -CD molecules are more 
appropriate for the nonpolar aliphatic parts of the CSA molecule to be held in and, 
consequently more suitable for the complex formation (Lit. [14]). 
As a starting point, the water solubility of CSA was determined at 2 different temperatures:    
Water solubility of Cyclosporin A at 23°C: 10.41µg/ml 
Water solubility of Cyclosporin A at 36°C: 12.1µg/ml  
Although, the smaller cavity from the -CD is more suitable for the inclusion complex 
formation, it is known that cyclodextrins and cyclodextrin complexes self-associate to form 
aggregates or micelle-like structures. Furthermore, it has been shown that the use of other 
excipients, like water soluble polymers, can interact with such systems and that these 
aggregates can solubilise drugs through non-inclusion complex formation. 
For the reasons mentioned above, it was decided to investigate the possibility of increasing 
the water solubility of CSA not only by the formation of inclusion complexes but also through 
non-inclusion complex formation (aggregates or micelle-like structures). 
Initially, the ability of several cyclodextrins to increase the solubility of CSA was investigated 
using the Higuchi/Connors method (Lit. [15]).  
However, due to toxicological and costs issues, the amount and also the type of cyclodextrin 
that can be used to enhance the water solubility/stability of a drug is limited. Consequently, in 
order to reduce the amount of cyclodextrin necessary to obtain the desired drug 
solubilizing/stabilizing effect, it is important to maximize the complexing ability of the 
cyclodextrins without recurring to an increase of the cyclodextrin concentration. 
As previous mentioned, cyclodextrins and cyclodextrins complexes are known to self-
associate to form aggregates or micelle-like structures consisting of two to several hundred 
cyclodextrin molecules and/or cyclodextrins complexes (Lit. [16]). In addition, the 
drug/cyclodextrin complexes self-association forms water soluble aggregates (or 
microaggregates) of several drug/cyclodextrin complex units and these aggregates can 
solubilise lipophilic water insoluble drugs through non-inclusion complexation (Lit.[17]-Lit. 
18]). For these reasons, the standard description of drug/cyclodextrin complexes in aqueous 
solutions is more complex as it might seem.  
With this purpose in mind, several classes of substances were investigated, through the use of 
a factorial design, for their ability to improve the solubility/stability effect of the 
cyclodextrins.  
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6.2.1.2 Methods 
The following methods were used for the preparation of the cyclosporin A formulations 
6.2.1.2.1 The Higuchi Connors method and its variants 
The initial preparation method for the cyclosporin A formulations was based on the 
Higuchi/Connors method (Lit. [3]). It consists of:  
1) Preparation of aqueous solutions of cyclodextrin containing different 
concentrations (for example, between 1-40%); 
2) To each of the vials containing the cyclodextrin aqueous solutions, an 
excess cyclosporin A is added; 
3) Afterwards, the vials are stirred at different temperatures and for defined 
periods of time; 
4) Then, the solutions are filtered, using 0.45 µm filters, or centrifuged; 
5) Finally, the content of CSA is analysed by UV-spectrophotometer.   
A variation of this method consisted in adding the several auxiliary substances used between 
steps 2 and 3.  
One other variation involves adding the defined amounts of the CSA/Lecithin system at step 2 
instead of an excess of CSA.  
6.2.1.2.2 Preparation method of the CSA/CD lyophilizate 
 
The 2-HP-( )-CD was dissolved in an aqueous solution. Sonification was 
applied until a clear solution was obtained19;  
In parallel, the CSA/Lecithin was dissolved in an ethanolic solution. 
Sonification was applied until a clear solution was obtained; 
While stirring the CD solution, the sodium ascorbate was added. Sonification 
was applied until a clear solution was obtained;  
Afterwards, to the CD/Sodium ascorbate solution, the ethanolic CSA/Lecithin 
solution was added;  
Sonification was applied for 15 minutes. At the end, trehalose was added to the 
final solution as a cryoprotector. 
The pH was then corrected to 4.5. 
To the Lyophilization vials, 1 ml of the CSA/CD solution was added. The 
lyophilization program chosen was 13c GSH_2. A detailed description of the 
lyophilization parameters is present on table 3.  
                                                          
19
 The equipment used was the Sonorex Super RK 1028 from Bandelin electronics; Sonification was applied for 15 minutes. 
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6.2.1.3 Results  
6.2.1.3.1 Phase solubility tests between CSA and several cyclodextrins 
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Figure 1: Phase solubility diagram in aqueous heptakis (2, 3, 6-O-tri-Acetyl)- -CD 
solutions at ambient temperature.  
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Figure 2: Phase solubility diagram in aqueous 2-HP- -CD solutions at ambient 
temperature.  
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Figure 3: Phase solubility diagram in aqueous heptakis (2, 6-O-di-Methyl)- -CD 
solutions at ambient temperature.  
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Figure 4: Phase solubility diagram in aqueous heptakis 6-O-Maltosyl- -CD solutions 
at ambient temperature.  
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Figure 5: Phase solubility diagram in aqueous heptakis 6-O-Maltosyl- -CD solutions 
at ambient temperature. 
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From the results obtained, it was possible to classify the different cyclodextrins in terms of 
their solubility profile with cyclosporin A.:  
2-HP- -CD, Heptakis (2, 6-O-di-Metyl)- -CD, 6-O-Maltosyl- -CD and Heptakis 6-O-
Maltosyl- -CD: Type A diagram (subtype Ap) where an increase in solubility of the 
compound occurs as the amount of complexing agent increases.  
Heptakis (2, 3, 6-O-tri-Acetyl)- -CD: Type B diagrams (subtype Bs) where complexes of 
limited solubility are formed. The curve BS shows the formation of a complex that increases 
the total solubility of the compound.  
6.2.1.4 Influence of the cavity size on the solubility of Cyclosporin A 
In order to study the influence of the cyclodextrin cavity size on the complex formation, a 
Heptakis 6-O-Maltosyl- -CD/Cyclosporin A formulation was prepared.   
Table 1: Influence of the cavity size (indirectly determined by CD-type) on the 
cyclosporin A solubility in aqueous maltosyl- -CD and maltosyl- -CD solutions at 
ambient temperature. 
Cyclodextrin 
Type (  or )  and concentration 
Conc. Cyclosporin 
A 
(µg/ml) 
25 mg/ml Maltosyl- -CD 157.2 
50 mg/ml Maltosyl- -CD 192.3 
100 mg/ml Maltosyl- -CD 345.7 
200 mg/ml Maltosyl- -CD 670.3 
400 mg/ml Maltosyl- -CD 1413.8 
25 mg/ml Maltosyl- -CD 72.5 
50 mg/ml Maltosyl- -CD 93.3 
100 mg/ml Maltosyl- -CD 167.6 
200 mg/ml Maltosyl- -CD 314.1 
400 mg/ml Maltosyl- -CD 1033.7 
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Figure 6: Influence of the cavity size on the cyclosporin A solubility in aqueous 
maltosyl- -CD and maltosyl- -CD solutions at ambient temperature.   
From the results obtained, we can ascertain that the cavity size from the maltosyl- -CD is 
more suitable for the formation of inclusion complexes rather than the bigger cavity of 
maltosyl- -CD. This is due to the fact that the cavity size of the -CD molecules are more 
appropriate for the nonpolar aliphatic parts of the CSA to be held in.   
6.2.1.4.1 Influence of several excipients on the complexing ability of cyclodextrins 
As mentioned before, it is known that cyclodextrins and cyclodextrin complexes self-
associate to form aggregates or micelle-like structures. It has also been showed that the use of 
other excipients, like water soluble polymers, can interact with such systems and that these 
aggregates can solubilise drugs through non-inclusion complex formation. 
With this purpose in mind, 3 different types of water soluble polymers were used to 
investigate the possibility of increasing the solubility of cyclosporin A through the formation 
of non-inclusion complexes.               
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Table 2: Effect of polymers on the solubilisation of cyclosporin A in aqueous 
cyclodextrins solutions at ambient temperature and with 2 days of equilibrium 
time.20 
Cyclodextrin  Polymer  S1 
(µg/ml) 
S2 
(µg/ml) 
SR  
200 mg/ml Maltosyl- -CD 1.1 mg/ml HPMC 314.1 324.0 1.03
200 mg/ml Maltosyl- -CD 2.0 mg/ml HPMC 314.1 371.6 1.18
200 mg/ml Maltosyl- -CD 2.6 mg/ml HPMC 314.1 344.3 1.10
200 mg/ml Maltosyl- -CD 1.2 mg/ml PVP K25 314.1 250.1 0.80
200 mg/ml Maltosyl- -CD 2.0 mg/ml PVP K25 314.1 341.4 1.09
200 mg/ml Maltosyl- -CD 2.6 mg/ml PVP K25 314.1 271.8 0.87
200 mg/ml Maltosyl- -CD 1.2 mg/ml PVP K30 314.1 333.7 1.06
200 mg/ml Maltosyl- -CD 2.0 mg/ml PVP K30 314.1 357.0 1.14
200 mg/ml Maltosyl- -CD 2.5 mg/ml PVP K30 314.1 430.1 1.37
S1 Solubility in aqueous (200 mg/ml) cyclodextrin solutions. S2 Solubility in 
aqueous solutions containing different concentrations of a given polymer and 200 
mg/ml cyclodextrin. SR Solubility ratio.   
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Figure 7: Influence of the HPMC concentration on the cyclosporin A solubility in 
aqueous maltosyl- -CD solutions at ambient temperature.  
                                                          
20  Autoclavation parameters: 120°C for 20 minutes. 
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Figure 8: Influence of the PVP concentration on the cyclosporin A solubility in 
aqueous maltosyl- -CD solutions at ambient temperature.  
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Figure 9: Influence of PVP K30 concentration on the cyclosporin A solubility in 
aqueous maltosyl- -CD solutions at ambient temperature.  
When the polymer and cyclodextrin are mixed together, it is possible to achieve a larger 
solubilization enhancement than when the polymer and cyclodextrin are used separately. The 
solubilization increase is mostly due to a synergistic process rather than a simple additive 
process.  
The optimum amount of the HPMC polymer in the aqueous cyclodextrins solutions appeared 
to be 2.0 mg/ml. In the case of PVP and PVP K30 polymers, the optimum amount appears to 
be 2.0 mg/ml and 2.5 mg/ml, respectively. 
With the HPMC and PVP polymers, the 2.0 mg/ml polymer concentration seems to be the 
most appropriate since higher concentrations lead to some decrease on drug solubility. 
Figures 8 and 9 shows the effect of increasing the polymer concentration on the solubility of 
cyclosporin A. The solubility increases with the maximum solubility at 2.0 mg/ml and then 
decreases slowly again. 
In the case of the PVP K30 polymer, the solubility of cyclosporin A increases steadily until 
2.5 mg/ml of the PVP K30 polymer. However, it is possible that the cyclosporin A solubility 
can be increased even more by using larger amounts of the PVP K30 polymer. 
The driving force for the drug-cyclodextrin formation is the release of enthalpy rich water 
molecules from the cyclodextrin cavity. These are promptly replaced by better suitable guest 
molecules which are less polar than water. The expulsion of the water molecules from the 
cyclodextrin cavity results in a negative enthalpy. The large negative H° outweighed the 
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unfavourable negative S° value. The addition of polymers to the aqueous complexation 
system results in an increase negative enthalpy change, together with an increase negative 
entropy change. However, the unfavourable S° changes are outweighed by the larger H° 
values. 
Consequently, the complexation is increased upon the addition of polymers to the 
complexation system. 
However, in the case of HPMC and PVP polymers, an increase in the concentration over 2.0 
mg/ml seems to result in a decrease of the negative H° value which can lead to a decrease of 
the cyclosporin solubility. 
Nevertheless, a further improvement of the cyclosporin solubility through the use of polymers 
is possible by changing such parameters as autoclavation time or complexation equilibrium 
time. 
In the next set of experiments the equilibrium and also the autoclavation time were changed in 
order to study the effect on the solubility of CSA.   
Table 3: Effect of HPMC and PVP concentrations on the solubility of cyclosporin A 
in aqueous cyclodextrins solutions at ambient temperature and with 3 days of 
equilibrium time.21 
Cyclodextrin  Polymer  S1 
(mg/ml) 
S2 
(mg/ml) 
SR  
200 mg/ml Maltosyl- -CD 2.0 mg/ml HPMC 314 569.9 1.81 
200 mg/ml Maltosyl- -CD 2.0 mg/ml PVP 314 399.6 1.27 
S1 Solubility in aqueous (200 mg/ml) cyclodextrin solutions. S2 Solubility in aqueous 
solutions containing different concentrations of a given polymer and 200 mg/ml 
cyclodextrin. SR Solubility ratio.  
The results show that altering both the equilibrium and also the autoclavation time, it is 
possible to obtain an even larger increase in the solubility of CSA.  
Table 4: Factorial design used to investigate the influence of several classes of 
excipients on the solubility of CSA. 
Vial 
Number 
Amino acids Vitamins Metal ions
1 + + + 
2 + - + 
3 + + - 
4 + - - 
5 - + + 
6 - - + 
7 - + - 
8 - - - 
                                                          
21  Autoclavation parameters: 120°C for 15 minutes.  
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For the next set of experiments 2-Hydroxyproply- -cyclodextrin (2-HP- -CD) was used 
because it is the most accepted representative of the hydroxyalkylated -cyclodextrin 
derivatives, due to its high water solubility and solubilizing power, low cost and low 
toxicology.   
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Figure 10: Phase solubility diagram of cyclosporin A in aqueous 2-HP- -CD 
solutions at ambient temperature.  
6.2.1.4.2 Influence of temperature on the solubility of CSA 
An investigation was performed to ascertain the influence of the temperature on the solubility 
of cyclosporin A. The conditions are described bellow  
a) First set of experiments: 
Systems containing only cyclosporin A/cyclodextrin were stirred at 70°C22 for 1 day. 
The additives were then added and the system was stirred at room temperature for 3 days.  
                                                          
22  It was decided to increase the temperature of the cyclosporin A/ cyclodextrin system to 70°C for specific 
period of time before adding the auxiliary substances.  
This was based on the fact that the viscosity of the cyclosporin A/ lecithin system at room temperature is 
relatively high. Increasing the temperature resulted in a decrease of the viscosity of the cyclosporin A/lecithin 
system and, consequently, in an increase in the formation of inclusion and non-inclusion complexes.  
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Table 5: Phase solubility table of cyclosporin A in aqueous 2-HP- -CD solutions. 
One day equilibrium time at 70°C with cyclodextrin/cyclosporin A. Afterwards, the 
additives were and the systems were left under stirring at room temperature for 3 
days. 
Formulation  
Composition 
Conc. 
Cyclosporin A 
(µg/ml) 
200 mg/ml 2-HP- -CD  
+ 0.51 mg/ml Lysine monohydrate + 0.05 mg/ml  CaCl2.2H2O 
+ 0.076 mg/ml MgSO4.6H2O + 0.35 mg/ml Ascorbic acid 
192 
200 mg/ml 2-HP- -CD + 0.51 mg/ml Lysine monohydrate 
 + 0.05 mg/ml  CaCl2.2H2O + 0.076 mg/ml MgSO4.6H2O 
222 
200 mg/ml 2-HP- -CD + 0.51 mg/ml Lysine monohydrate  
+  0.35 mg/ml Ascorbic acid 
249 
200 mg/ml 2-HP- -CD + 0.51 mg/ml Lysine monohydrate 389 
200 mg/ml 2-HP- -CD + 0.05 mg/ml CaCl2.2H2O  
+ 0.076 mg/ml MgSO4.6H2O + 0.35 mg/ml Ascorbic acid 
a 
200 mg/ml 2-HP- -CD + 0.05 mg/ml CaCl2.2H2O  
+ 0.076 mg/ml MgSO4.6H2O 
464 
200 mg/ml 2-HP- -CD + 0.35 mg/ml Ascorbic acid 857 
200 mg/ml 2-HP- -CD 562 
a The HPLC measurement of the vial was not possible due to experimental reasons.    
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Figure 11: Phase solubility diagram of cyclosporin A in aqueous 2-HP- -CD 
solutions. One day equilibrium time at 70°C with cyclodextrin/cyclosporin A. 
Afterwards, the additives were and the systems were left under stirring at room 
temperature for 3 days.                    
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b) Second set of experiments:  
Systems containing only cyclosporin A/cyclodextrin were stirred at 70°C for 5 hours 
The additives were then added and the system was stirred at room temperature for 3 days.  
Table 6: Phase solubility table of cyclosporin A in aqueous 2-HP- -CD solutions. 
Five hours equilibrium time at 70°C with the cyclosporin A/cyclodextrin system. 
Afterwards, the additives were and the systems were left under stirring at room 
temperature for 3 days. 
Formulation  
Composition 
Conc. 
Cyclosporin A
(µg/ml) 
200 mg/ml 2-HP- -CD + 0.4 mg/ml Lysine 
monohydrate + 0.05 mg/ml  CaCl2.2H2O + 0.076 
mg/ml MgSO4.6H2O + 0.35 mg/ml Ascorbic acid 
1845 
200 mg/ml 2-HP- -CD + 0.4 mg/ml Lysine 
monohydrate + 0.05 mg/ml  CaCl2.2H2O + 0.076 
mg/ml MgSO4.6H2O 
56 
200 mg/ml 2-HP- -CD + 0.4 mg/ml Lysine 
monohydrate +  0.35 mg/ml Ascorbic acid 
51 
200 mg/ml 2-HP- -CD + 0.4 mg/ml Lysine 
monohydrate 
69 
200 mg/ml 2-HP- -CD + 0.05 mg/ml  CaCl2.2H2O + 
0.076 mg/ml MgSO4.6H2O + 0.35 mg/ml Ascorbic 
acid 
898 
200 mg/ml 2-HP- -CD + 0.05 mg/ml CaCl2. 2H2O + 
0.076 mg/ml MgSO4. 6H2O 
2246 
200 mg/ml 2-HP- -CD + 0.35 mg/ml Ascorbic acid 289 
200 mg/ml 2-HP- -CD 275 
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Figure 12: Phase solubility diagram of cyclosporin A  in aqueous 2-HP- -CD 
solutions. Five hours equilibrium time at 70°C with cyclosporin A/cyclodextrin. 
Afterwards, the additives were and the systems were left under stirring at room 
temperature for 3 days.  
Based on these results, we could see that the temperature has a very important influence on 
the solubility of cyclosporin A. It was noticed that shorter equilibrium times at 70°C were 
more suitable for the increase of the cyclosporin A solubility, contrary to longer times at 70°C 
or at room temperature. In addition, it was also possible to ascertain that one of the best 
combinations were the ones containing the metal ions and the ascorbic acid as auxiliary 
substances. 
For this reason, the experiment was repeated for the best combinations changing the 
preparations conditions due to stability purposes. The parameters were:  
a) First set of experiments: 
Systems containing only cyclosporin A/cyclodextrin at 70°C for 2 hours. 
The additives were added and the system was put under stirring at room temperature for 4 
days.       
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Table 7: Phase solubility table of cyclosporin A in aqueous 2-HP- -CD solutions. 
Two hours equilibrium time at 70°C with cyclosporin A/cyclodextrin. Afterwards, 
the additives were added and the systems were left under stirring at room 
temperature for 4 days.  
Formulation composition Conc. 
Cyclosporin A (µg/ml) 
200 mg/ml 2-HP- -CD + 0.05 mg/ml  
CaCl2.2H2O + 0.076 mg/ml MgSO4.6H2O 
+ 0.35 mg/ml Ascorbic acid 
4136  
200 mg/ml 2-HP- -CD + 0.35 mg/ml 
Ascorbic acid 
7485 
b) Second set of experiments:  
Systems containing only cyclosporin A/cyclodextrin at 70°C for 30 minutes. 
The additives were added and the system was put under stirring at room temperature for 4 
days.     
Table 8: Phase solubility table of cyclosporin A in aqueous 2-HP- -CD solutions. 30 
minutes equilibrium time at 70°C with cyclodextrin/cyclosporin A. Afterwards, the 
additives were added and the systems were left under stirring at room temperature 
for 4 days.  
Formulation composition  Conc. Cyclosporin A 
(µg/ml) 
200 mg/ml 2-HP- -CD + 9.6 mg/ml Ascorbic acid  12904.5 
200 mg/ml 2-HP- -CD + 41.4 mg/ml Ascorbic acid  13076.8 
200 mg/ml 2-HP- -CD + 74.9 mg/ml Ascorbic acid  12825.3 
200 mg/ml 2-HP- -CD + 100 mg/ml Ascorbic acid  10998.6 
200 mg/ml 2-HP- -CD + 119.9 mg/ml Ascorbic acid  6940.4 
200 mg/ml 2-HP- -CD + 136.4 mg/ml Ascorbic acid  9370.3 
200 mg/ml 2-HP- -CD + 150.1 mg/ml Ascorbic acid  9401.0 
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Figure 13: Phase solubility diagram of cyclosporin A in aqueous 2-HP- -CD 
solutions. 30 minutes equilibrium time at 70°C with cyclosporin A/cyclodextrin. 
Afterwards, the additives were added and the systems were left under stirring at 
room temperature for 4 days.   
From the results obtained from the different set of experiments, it was possible to ascertain 
that temperature plays a very important role on the complex formation and, consequently, on 
the solubility of CSA. This is mainly due to an increase in the intrinsic solubility and mobility 
of the lecithin/cyclosporin A system that allows an increase in the formation of inclusion and 
non-inclusion complexes.                    
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6.2.1.4.3 Influence of pH on the solubility of CSA 
From the results previously obtained, we could see that in presence of ascorbic acid the 
solubility of CSA is greatly improved. For this reason and also to ascertain the effect of the 
pH on the solubility, the following experiments were performed using ascorbic as the 
auxiliary substance.  
Table 9: Influence of the pH on the solubility of in aqueous 2-HP- -CD solutions. 
One day equilibrium time at room temperature with cyclosporin A/cyclodextrin 
system. Afterwards, the additive was added and the system was stirred at room 
temperature for 4 days.  
Formulation  
Composition  
Conc. 
Cyclosporin A 
(µg/ml) 
200 mg/ml 2-HP- -CD  
+ 1.44 mg/ml Ascorbic acid (pH 4.5) 
864 
200 mg/ml 2-HP- -CD  
+ 3.35 mg/ml Ascorbic acid (pH 4.5) 
1083 
200 mg/ml 2-HP- -CD  
+ 6.66 mg/ml Ascorbic acid (pH 4.5) 
2063 
200 mg/ml 2-HP- -CD  
+ 9.6 mg/ml Ascorbic acid (pH 4.5) 
1840 
200 mg/ml 2-HP- -CD  
+ 1.44 mg/ml Ascorbic acid (pH 8.0) 
280 
200 mg/ml 2-HP- -CD  
+ 3.35 mg/ml Ascorbic acid (pH 8.0) 
249 
200 mg/ml 2-HP- -CD  
+ 6.66 mg/ml Ascorbic acid (pH 8.0) 
191 
200 mg/ml 2-HP- -CD  
+ 9.6 mg/ml Ascorbic acid (pH 8.0) 
186 
From the results we can see that the pH does have an influence on the formation cyclosporin 
A and 2-HP- -CD. In the presence of ascorbic acid, the complex formation is favoured by an 
acidic environment.        
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6.2.1.4.4 Influence of sodium acetate on the solubility of CSA 
The influence of sodium acetate on the solubility of CSA was also investigated. For this 
purpose, it was added to several vials containing 200 mg/ml 2-HP- -CD aqueous solution 
increasing amounts of sodium acetate.  
Table 10: Influence of sodium acetate on the solubility of CSA in aqueous 2-HP- -
CD solutions. Thirty minutes equilibrium time at 70°C with cyclosporin 
A/cyclodextrin system. Afterwards, the additive was added and the system was 
stirred at room temperature for 2 days. 
Formulation  
Composition  
Conc. 
Cyclosporin A 
(µg/ml) 
200 mg/ml 2-HP- -CD  
+ 9.6 mg/ml Sodium acetate   
1306 
200 mg/ml 2-HP- -CD 
+ 18.5 mg/ml Sodium acetate   
1210 
200 mg/ml 2-HP- -CD 
+ 22.6 mg/ml Sodium acetate   
544 
200 mg/ml 2-HP- -CD 
+ 26.5 mg/ml Sodium acetate   
1455 
200 mg/ml 2-HP- -CD 
+ 33.9 mg/ml Sodium acetate   
2405 
  
0
500
1000
1500
2000
2500
3000
200 mg/ml 2-
HP-Beta-CD 
+ 9.6 mg/ml
Sodium
acetate  
200 mg/ml 2-
HP-Beta-CD 
+ 18.5 mg/ml
Sodium
acetate  
200 mg/ml 2-
HP-Beta-CD 
+ 22.6 mg/ml
Sodium
acetate  
200 mg/ml 2-
HP-Beta-CD 
+ 26.5 mg/ml
Sodium
acetate  
200 mg/ml 2-
HP-Beta-CD 
+ 33.9 mg/ml
Sodium
acetate  
Co
n
c.
 
Cy
cl
o
sp
o
rin
e 
A
 
(µg
/m
l)
Figure 14: Influence of sodium acetate on the solubility of CSA in aqueous 2-HP- -
CD solutions. Thirty minutes equilibrium time at 70°C with cyclosporin 
A/cyclodextrin system. Afterwards, the additive was added and the system was 
stirred at room temperature for 2 days. 
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In the case of sodium acetate, the optimum amount that maximizes the complex formation 
and, consequently, the solubility of CSA is 33.9 mg/ml. 
Figure 14 shows the effect of increasing the sodium acetate concentration on the solubility of 
cyclosporin A. The solubility decreases with the minimum solubility at 22.6 mg/ml and then 
increases rapidly.  
Table 11: Influence of sodium acetate on the solubility of CSA in aqueous 2-HP- -
CD solutions. Thirty minutes equilibrium time at 70°C with cyclosporin 
A/cyclodextrin system. Afterwards, the additive was added and the system was 
stirred at room temperature for 3 days. 
Formulation 
Composition  
Conc. 
Cyclosporine A 
(µg/ml) 
200 mg/ml 2-HP- -CD 
+ 18.2 mg/ml Sodium acetate   
1200 
200 mg/ml 2-HP- -CD 
+ 29.2 mg/ml Sodium acetate   
747 
200 mg/ml 2-HP- -CD 
+ 33.5 mg/ml Sodium acetate   
1633 
200 mg/ml 2-HP- -CD 
+ 40.2 mg/ml Sodium acetate   
1092 
200 mg/ml 2-HP- -CD 
+ 46.3 mg/ml Sodium acetate   
3697 
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Figure 15: Influence of sodium acetate on the solubility of CSA in aqueous 2-HP- -
CD solutions. Thirty minutes equilibrium time at 70°C with cyclosporin 
A/cyclodextrin system. Afterwards, the additive was added and the system was 
stirred at room temperature for 3 days. 
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The aqueous solubility of cyclosporin A at 25°C is 10.4 µg/ml. In the presence of 46.3 mg/ml 
of sodium acetate and 200 mg/ml of 2-HP- -CD, the solubility is increased to 3697 mg/ml. 
The acetate ions are able solubilized the cyclosporin A/cyclodextrin microagregates formed in 
the aqueous solutions increasing, consequently, the solubility of cyclosporin A.   
6.2.1.4.5 Influence of several parameters on the ascorbic acid complexation 
From the previous results we could ascertain that ascorbic acid is the best auxiliary substance 
for the complex formation. However, as previously showed, the complex formation and, 
therefore, the solubility of cyclosporin A are also influenced by temperature and equilibrium 
time.   
In the next experiment, the system containing only cyclosporin A and cyclodextrin was stirred 
for 30 minutes at 70°C. Afterwards, the system continued under stirring at room temperature. 
One day after, the ascorbic acid was added and was stirred at room temperature for 2 more 
days. At the end, the equilibrium time was 3 days.  
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Figure 16: Influence of ascorbic acid on the solubility of CSA in aqueous 2-HP- -CD 
solutions. Thirty minutes of equilibrium time at 70°C with cyclosporin 
A/cyclodextrin system. Afterwards, the additive was added and the system was 
stirred at room temperature for 2 days.  
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Figure 17:  Influence of ascorbic acid on the solubility of CSA in aqueous 2-HP- -
CD solutions. Thirty minutes of equilibrium time at 70°C with cyclosporin 
A/cyclodextrin system. Afterwards, the additive was added and the system was 
stirred at room temperature for 2 days.  
In addition to the temperature and equilibrium time, also the relationship between the amount 
of cyclosporin A and the lecithin was investigated.   
In the next experiment, the system containing only cyclosporin A and cyclodextrin was stirred 
for 30 minutes at 70°C. Afterwards, the system continued under stirring at room temperature. 
One day after, the ascorbic acid was added and was stirred at room temperature for 2 days. At 
the end, the equilibrium time was 3 days.                  
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For a 4.0g lecithin/0.375g of cyclosporin A relationship:  
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Figure 18: Influence of the relationship between the amount of cyclosporin A and 
the lecithin on the solubility of CSA in aqueous 2-HP- -CD solutions. Thirty minutes 
of equilibrium time at 70°C with cyclosporin A/cyclodextrin system. Afterwards, the 
additive was added and the system was stirred at room temperature for 2 days.   
For a 4.0g lecithin/0.75g of cyclosporin A relationship:  
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Figure 19: Influence of the relationship between the amount of cyclosporin A and 
the lecithin on the solubility of CSA in aqueous 2-HP- -CD solutions. Thirty minutes 
of equilibrium time at 70°C with cyclosporin A/cyclodextrin system. Afterwards, the 
additive was added and the system was stirred at room temperature for 2 days.    
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For a 4.0g lecithin/1.125g of cyclosporin A relationship:  
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Figure 20: Influence of the relationship between the amount of cyclosporin A and 
the lecithin on the solubility of CSA in aqueous 2-HP- -CD solutions. Thirty minutes 
of equilibrium time at 70°C with cyclosporin A/cyclodextrin system. Afterwards, the 
additive was added and the system was stirred at room temperature for 2 days.  
In order to study the effect of the equilibrium time on the complex formation, the previous 
experiment was repeated but with an equilibrium time of 7 days.  
For a 4.0g lecithin/0.375g of cyclosporin A relationship:   
0
5000
10000
15000
20000
200 mg/ml 2-
HP-Beta-CD 
+ 9.6 mg/ml
Ascorbic acid 
200 mg/ml 2-
HP-Beta-CD 
+  41.5 mg/ml
Ascorbic acid 
200 mg/ml 2-
HP-Beta-CD 
+  75.2 mg/ml
Ascorbic acid 
200 mg/ml 2-
HP-Beta-CD 
+  100.3
mg/ml
Ascorbic acid 
200 mg/ml 2-
HP-Beta-CD 
+  120.3
mg/ml
Ascorbic acid 
200 mg/ml 2-
HP-Beta-CD 
+  136.8
mg/ml
Ascorbic acid 
200 mg/ml 2-
HP-Beta-CD 
+  150.5
mg/ml
Ascorbic acid 
Co
n
c
.
 
Cy
c
lo
s
po
rin
e 
A
 
(µg
/m
l)
Figure 21: Influence of the relationship between the amount of cyclosporin A and 
the lecithin on the solubility of CSA in aqueous 2-HP- -CD solutions. Thirty minutes 
of equilibrium time at 70°C with cyclosporin A/cyclodextrin system. Afterwards, the 
additive was added and the system was stirred at room temperature for 7 days.     
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For a 4.0g lecithin/0.75g of cyclosporin A relationship:  
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Figure 22: Influence of the relationship between the amount of cyclosporin A and 
the lecithin on the solubility of CSA in aqueous 2-HP- -CD solutions. Thirty minutes 
of equilibrium time at 70°C with cyclosporin A/cyclodextrin system. Afterwards, the 
additive was added and the system was stirred at room temperature for 7 days.   
For a 4.0g lecithin/1.125g of cyclosporin A relationship:  
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Figure 23: Influence of the relationship between the amount of cyclosporin A and 
the lecithin on the solubility of CSA in aqueous 2-HP- -CD solutions. Thirty minutes 
of equilibrium time at 70°C with cyclosporin A/cyclodextrin system. Afterwards, the 
additive was added and the system was stirred at room temperature for 7 days.  
The results show that an increase of the amount of cyclosporin A in the cyclosporin A/lecithin 
relationship is directly related to an increase of the cyclosporin solubility.      
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Based on the previous results, it was decided that the best parameters for the complex 
formation are:  
Equilibrium time: between 3-5 days (in total). 
Time and temperature for the cyclosporin A/cyclodextrin system: 70°C for 
30 minutes. 
Auxiliary substance: ascorbic acid.  
Due to toxicological and also cost issues, the amount of cyclodextrin that can be used is 
limited. Consequently, the next set of experiments focus on the influence of the amount of 
cyclodextrin used on the solubility of cyclosporin A.    
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Figure 24: Influence of the 2-HP- -CD concentration on the cyclosporin A solubility 
in aqueous 2-HP- -CD solutions. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.                  
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Another combination of cyclosporin A/cyclodextrin was also used:  
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Figure 25: Influence of the 2-HP- -CD concentration on the cyclosporin A solubility 
in aqueous 2-HP- -CD solutions. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
The relationship between the amount of lecithin and cyclosporin A but also the amounts of 
this system added to the complexing media have a very important influence on the solubility 
of cyclosporin A. 
For this reason, the influence of the amount of lecithin/cyclosporin A added to the system was 
investigated.  
Adding 0.125 ml of Lecithin/Cyclosporin A :  
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Figure 26: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.125 ml of lecithin/cyclosporin A to a aqueous solution 
containing 25 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
Adding 0.250 ml of Lecithin/Cyclosporin A to an aqueous solution containing 
25 mg/ml of 2-HP- -CD:  
0
500
1000
1500
2000
2500
3000
25 mg/ml 2-HP-Beta-
CD  + 10 mg/ml
Ascorbic acid 
25 mg/ml 2-HP-Beta-
CD  + 50 mg/ml
Ascorbic acid 
25 mg/ml 2-HP-Beta-
CD  + 100 mg/ml
Ascorbic acid 
Co
n
c.
 
Cy
cl
o
sp
o
rin
e 
A
 
(µg
/m
l)
Figure 27: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.25 ml of lecithin/cyclosporin A to an aqueous solution 
containing 25 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
Adding 0.5 ml of Lecithin/Cyclosporin A to an aqueous solution containing 25 
mg/ml of 2-HP- -CD:  
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Figure 28: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.5 ml of lecithin/cyclosporin A to a aqueous solution 
containing 25 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
Adding 0.250 ml of Lecithin/Cyclosporin A to an aqueous solution containing 
50 mg/ml of 2-HP- -CD:  
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Figure 29: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.25 ml of lecithin/cyclosporin A to an aqueous solution 
containing 50 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.   
Adding 0.50 ml of Lecithin/Cyclosporin A to an aqueous solution containing 50 
mg/ml of 2-HP- -CD:  
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Figure 30: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.5 ml of lecithin/cyclosporin A to an aqueous solution 
containing 50 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
Adding 0.75 ml of Lecithin/Cyclosporin A to an aqueous solution containing 50 
mg/ml of 2-HP- -CD:  
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Figure 31: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.75 ml of lecithin/cyclosporin A to a aqueous solution 
containing 50 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C with 
cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
Adding 0.5 ml of Lecithin/Cyclosporin A to an aqueous solution containing 100 
mg/ml of 2-HP- -CD:  
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Figure 32: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.5 ml of lecithin/cyclosporin A to a aqueous solution 
containing 100 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C 
with cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
Adding 0.75 ml of Lecithin/Cyclosporin A to an aqueous solution containing 
100 mg/ml of 2-HP- -CD:  
0
2000
4000
6000
8000
10000
12000
14000
100 mg/ml 2-HP-
Beta-CD  + 10
mg/ml Ascorbic acid 
100 mg/ml 2-HP-
Beta-CD  + 50
mg/ml Ascorbic acid 
100 mg/ml 2-HP-
Beta-CD  + 100
mg/ml Ascorbic acid 
Co
n
c.
 
Cy
cl
o
sp
o
rin
e 
A
 
(µg
/m
l)
Figure 33: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 0.75 ml of lecithin/cyclosporin A to an aqueous solution 
containing 100 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C 
with cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.   
Adding 1.0 ml of Lecithin/Cyclosporin A to an aqueous solution containing 100 
mg/ml of 2-HP- -CD:  
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Figure 34: Influence on the solubility of cyclosporin A in aqueous 2-HP- -CD 
solutions after adding 1.0 ml of lecithin/cyclosporin A to an aqueous solution 
containing 100 mg/ml of 2-HP- -CD. Thirty minutes of equilibrium time at 70°C 
with cyclosporin A/cyclodextrin system. Afterwards, the additive was added and the 
system was stirred at room temperature for 3 days.  
After analysing the results, it was possible to ascertain that there is a direct relation between 
the amount of lecithin/cyclosporin A added to the complexing media and the solubility of 
cyclosporin A. 
In all 3 different concentrations of 2-HP- -CD used, an increase of the amount of 
lecithin/cyclosporin A added to the complexing media results in a improvement in the 
solubility of cyclosporin A. 
In order to determine which formulation is the most suitable to be nebulized with the eflow 
(for example, in terms of viscosity and surface tension), it was also taken in consideration the 
physicochemical characteristics of each of the formulations.  
6.2.1.4.6 Physicochemical properties of the cyclosporin A/cyclodextrin formulations 
As a starting point, the physicochemical properties of five 2-HP- -CD formulations 
containing different concentrations were investigated in order to differentiate the influence of 
the cyclodextrins from the final physicochemical properties of the cyclosporin A/cyclodextrin 
formulations. 
The results were:  
Table 12: Physicochemical properties of five aqueous 2-HP- -CD formulations 
containing different concentrations. 
Formulation  
Composition 
Surface Tension 
(mN/m) 
Osmolarity 
(osmol/kg) 
Viscosity 
(mPa s) 
pH 
50 mg/ml 2-HP-Beta-CD 59.23±0.14 0.031±0.002 1.23±0.05 6.36
100 mg/ml 2-HP-Beta-CD 62.67±0.08 0.077±0.001 1.48±0.03 5.86
200 mg/ml 2-HP-Beta-CD 56.73±0.09 0.266±0.08 2.43±0.03 5.93
400 mg/ml 2-HP-Beta-CD 55.01±0.10 1.28±0.09 9.24±0.24 5.96
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The influence of the amount of lecithin/cyclosporin A added to the system on the 
physicochemical properties of the cyclosporin A/cyclodextrin formulations was also 
investigated.  
Table 13: Physicochemical properties of a cyclosporin A/cyclodextrin formulation in 
an aqueous solution containing 25 mg/ml of 2-HP- -CD, after adding 2 different 
amounts of lecithin/cyclosporin A to the complexing media. 
Formulation  
composition 
Surface Tension 
(N/m) 
Osmolarity 
(osmol/kg) 
Viscosity 
(mPa s) 
pH 
25 mg/ml 2-HP-Beta-CD + 
50 mg/ml Ascorbic acidA 
33.58±0.35 0.348±0.003 1.32±0.03 2.26
 
25 mg/ml 2-HP-Beta-CD + 
50 mg/ml Ascorbic acidB 
33.31±0.26 0.435±0.001 1.52±0.04 2.27
A: After adding 0. 125 ml of Lecithin/Cyclosporin A to a aqueous solution 
containing 25 mg/ml of 2-HP- -CD 
B: After adding 0. 50 ml of Lecithin/Cyclosporin A to a aqueous solution containing 
25 mg/ml of 2-HP- -CD  
Table 14: Physicochemical properties of a cyclosporin A/cyclodextrin formulation in 
an aqueous solution containing 50 mg/ml of 2-HP- -CD, after adding 2 different 
amounts of lecithin/cyclosporin A to the complexing media. 
Formulation composition  Surface 
Tension 
(mN/m) 
Osmolarity 
(osmol/kg) 
Viscosity 
(mPa s) 
pH 
50 mg/ml 2-HP-Beta-CD + 
50 mg/ml Ascorbic acidA  
33.33±0.7 0.415±0.004 1.46±0.004 2.25 
50 mg/ml 2-HP-Beta-CD + 
50 mg/ml Ascorbic acidB 
33.46±0.65 0.443±0.004 1.72±0.04 2.3 
A: After adding 0. 25 ml of lecithin/cyclosporin A to a aqueous solution containing 
50 mg/ml of 2-HP- -CD 
B: After adding 0. 50 ml of lecithin/cyclosporin A to a aqueous solution containing 
50 mg/ml of 2-HP- -CD       
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Table 15: Physicochemical properties of a cyclosporin A/cyclodextrin formulation in 
an aqueous solution containing 100 mg/ml of 2-HP- -CD, after adding 2 different 
amounts of lecithin/cyclosporin A to the complexing media. 
Formulation composition    Surface 
Tension 
(mN/m)  
Osmolarity 
(mosmol/kg)   
Viscosity 
(mPa s)   
pH    
100 mg/ml 2-HP-Beta-CD  + 
50 mg/ml Ascorbic acidA 
33.37±0.59 0.466±0.004 1.72±0.03 2.26 
100 mg/ml 2-HP-Beta-CD  + 
50 mg/ml Ascorbic acidB 
33.72±0.91 0.492±0.005 2.04±0.04 2.29 
A: After adding 0.5 ml of Lecithin/Cyclosporin A to a aqueous solution containing 
100 mg/ml of 2-HP- -CD 
B: After adding 0. 75 ml of Lecithin/Cyclosporin A to a aqueous solution containing 
100 mg/ml of 2-HP- -CD   
Table 16: Comparison of the physicochemical properties of 2 cyclosporin 
A/cyclodextrin formulations in an aqueous solution containing 25 mg/ml and 50 
mg/ml of 2-HP- -CD. Two different amounts of lecithin/cyclosporin A were added 
to the complexing media. 
Formulation composition   Surface 
Tension 
(mN/m)  
Osmolarity
(osmol/kg)   
Viscosity 
(mPa s)   
pH    
25 mg/ml 2-HP-Beta-CD  + 10 mg/ml 
Ascorbic acid A 
33.25±0.24 0.145±0.004 0.87±0.04 2.64 
50 mg/ml 2-HP-Beta-CD  + 10 mg/ml 
Sodium ascorbateB 
33.26±1.73 0.359±0.003 1.22±0.09 6.26 
A: After adding 0.25 ml of lecithin/cyclosporin A to a aqueous solution containing 
25 mg/ml of 2-HP- -CD 
B: After adding 1.0 ml of lecithin/cyclosporin A to a aqueous solution containing 50 
mg/ml of 2-HP- -CD   
From the results, it was possible to ascertain the following facts:  
1. Surface Tension: in all formulations there was a decrease in the surface 
tension values in comparison to the cyclodextrins formulations. However, 
the addition of increasing amounts of lecithin/cyclosporin A to the 
complexing media does not have a significant influence on the value of the 
surface tension on the different formulations.    
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2. Viscosity: regarding the viscosity, all formulations presented an increase in 
the viscosity values in comparison to the cyclodextrin solutions due to the 
addition cyclosporin A and the other excipients. Also, the addition of 
increasing amounts of lecithin/cyclosporin A to the complexing media 
results in an increase of the value of the viscosity on the different 
formulations.  
3. Osmolarity: the osmolarity values were greater as the ones of the 
cyclodextrin solutions due to the addition cyclosporin A and the other 
excipients to the cyclodextrins solutions. Furthermore, the addition of 
increasing amounts of lecithin/cyclosporin A to the complexing media 
results in an increase of the value of the osmolarity on the different 
formulations.  
4. pH: the cyclodextrins solutions have a pH value between 6.0-6.5 while the 
cyclosporin A/cyclodextrin formulations have a value between 2.25-2.64. 
The difference can be explained by the presence of the ascorbic acid in the 
formulations. However, one of the cyclosporin A/cyclodextrin formulations 
has a value of 6.26 because the ascorbic acid was substituted with sodium 
ascorbate as excipient.  
6.2.1.4.7  Determination of the humidity content of the lyophilizate 
The humidity content was determined (Karl-Fischer method), as a way of quantifying the 
residual water of the product obtained right after the lyophilization process. In the case of the 
lyophilized amphotericin B microemulsion, the content was just 0.75±0.03% (water content 
of the lyophilized product should be less than 3%) which is low enough to avoid the 
hydrolysis reaction by the lecithin phosphatide groups and, therefore, protect the system from 
any decomposition phenomena related to such processes23.  
As an example, AmBisome® for injection is a sterile, non-pyrogenic lyophilized product for 
intravenous infusion and it has stability of 36 months at 25°C. 24 
Taking in consideration the previous information, it was decided to lyophilizate the 
cyclosporin A/cyclodextrin formulation in order to avoid the hydrolysis reaction by the 
lecithin phosphatide groups and, consequently to obtain a more stable formulation.   
                                                          
 
23  For a more detailed explanation see appendix 2. 
24  AmBisome® is a market product containing amphotericin B as active substance. AmBisome® for injection is 
a sterile, non-pyrogenic lyophilized product for intravenous infusion. Each vial contains 50 mg of 
amphotericin B, USP, intercalated into a liposomal membrane consisting of approximately 213 mg 
hydrogenated soy phosphatidylcholine; 52 mg cholesterol, NF; 84 mg distearoylphosphatidylglycerol; 0.64 mg 
alpha tocopherol, USP; together with 900 mg sucrose, NF; and 27 mg disodium succinate hexahydrate as 
buffer. Following reconstitution with sterile water for injection, USP, the resulting pH of the suspension is 
between 5.0-6.0.   
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6.2.1.4.8 Lyophilization of the Cyclosporin A/Cyclodextrin Formulation 
With the purpose of protecting the cyclosporin A/cyclodextrin(CSA/CD) system from any 
decomposition phenomena related to the hydrolysis reaction by the lecithin phosphatide 
groups, one cyclosporin A/cyclodextrin formulation was prepared and lyophilized. 
The formulation had the following composition:  
Table 17: Composition of a lyophilized CSA/CD formulation. 
Formulation  
Composition 
Conc. 
(mg/ml) 
Cyclosporin A 1825 
Lecithin 205.9 
2-HP- -CD 100 
Sodium ascorbate 10 
The vials were filled with 1 ml of the CSA/CD formulation each and placed inside the 
lyophilizer chamber. Lyophilization of the samples was performed with a Christ Epsilon 2-6D 
equipment. Conditions of the entire process are shown in Table 23.  
Table 18:  Lyophilization conditions of a CSA/CD Formulation 
Process Phase Time 
(min) 
Temp. 
(°C) 
Vacuum 
(mbar) 
Si. Pressure 
(mbar) 
Start value 0 0 OFF OFF 
Freezing 1 -38 OFF OFF 
Freezing 44 -38 OFF OFF 
Preparation 15 -38 OFF OFF 
Main drying 1 -38 0.08 OFF 
Main drying 15 -25 0.08 0.140 
Main drying 704 -25 0.08 0.140 
After drying 1 -25 0.08 0.140 
After drying 300 15 0.08 0.140 
After drying 719 15 0.08 0.140 
At the end of the process, the lyophilized obtained was a light yellow coloured product 
(please see Figure 35). 
                                                          
25  Value obtained from the delivery dose. The lyophilizate was reconstituted with 3 ml of water and the 
nebulisation parameters were: nebulisation time of 7.56 min and a 10 l/min flow. 
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Figure 35: Image of a lyophilizate of a CSA/CD formulation. Image taken 6 days 
after lyophilization.   
The reconstituted lyophilizate of the CSA/CD formulation was a homogeneous, white 
coloured product (please see Figure 36 and Figure 37).   
Figure 36: Image of a reconstituted lyophilizate of a CSA/CD formulation. 
Reconstitution was made by adding 3 ml and manually shaking the vial. Image 
taken 6 days after lyophilization.   
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Figure 37: Reconstituted lyophilizate of a CSA/CD formulation. Reconstitution was 
performed by adding 3 ml and manually shaking the vial. Image taken 1.5 months 
after lyophilization.  
6.2.1.4.9 Physicochemical properties and nebulisation parameters of 
cyclosporin/cyclodextrin lyophilizates  
Table 20: Physicochemical properties of a CSA/CD formulation in an aqueous 
solution containing 100 mg/ml of 2-HP- -CD. 
Formulation  
composition 
Surface Tension 
(mN/m) 
Viscosity 
(mPa s) 
100 mg/ml 2-HP-Beta-CD + 
10 mg/ml Sodium ascorbate 
35.16±0.44 2.4±0.35 
 
Table 21: Nebulization properties of a CSA/CD  lyophilizate using eflow ® (Pari 
GmbH, Germany) as nebuliser .26 
MMD 
(µm)  
GSD   TOR 
(mg/ml) 
Percent. 
Particles <5 µm  
Percent. 
Particles <2 µm  
3.07 1.62 320 83.79 18.12 
                                                          
26  MMD (NaCl) =3.44 µm; Measured at a Malvern Zetasizer (Model Zetasizer 3000 HAS, Germany). The 
nebulisation trial was performed using a electronic nebulizer, eflow® (Pari GmbH, Germany) 
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Table 22: Nebulization properties of a CSA/CD lyophilizate using eflow® (Pari 
GmbH, Germany) as nebuliser .27 
MMD 
(µm) 
GSD  TOR 
(mg/ml) 
Percent. 
Particles <5 µm 
Percent. 
Particles <2 µm 
3.6 1.58 438 77.44 9.08 
  
6.2.1.4.10 Stability trials   
In order to ascertain the stability of the formulation, a new CSA/CD formulation was 
prepared. The Lyophilization was performed under the conditions describe on table 27.  
To the CSA/CD system also trehalose was added as a cryoprotectant in order to prevent any 
degradation caused by the lyophilization process.  
The formulation composition of both formulations is described in the following tables:  
Table 23: Composition of a lyophilized CSA/CD formulation. 
Formulation  
Composition 
Conc. 
(mg/ml) 
Cyclosporin A 2.8528 
Lecithin 29.8 
2-HP- -CD 101.8 
Trehalose 2.1 
Table 24: Nebulization properties of a CSA/CD lyophilizate using ® (Pari GmbH, 
Germany) as nebuliser .29 
MMD 
(µm) 
GSD  TOR 
(mg/ml) 
Percent. 
Particles <5 µm 
Percent. 
Particles <2 µm 
3.58 1.55 415 77.22 8.94 
In accordance with the ICH Steering Committee s recommendations, the samples were kept at 
25°C and 60% relative humidity for a period of 5 months (Lit. [13]). 
Samples were withdrawn in duplicate at 0, 1and 5 months, and assessed for their:  
                                                          
27  MMD (NaCl) =4.2 µm; Measured at a Malvern Zetasizer (Model Zetasizer 3000 HAS, Germany). The 
nebulisation trial was performed using a electronic nebulizer, eflow® (Pari GmbH, Germany) 
28  Value obtained from the delivery dose. The lyophilizate was reconstituted with 2 ml of water and the 
nebulisation parameters were: nebulisation time of 6.06min and a 10 l/min flow. 
29  MMD (NaCl) =3.93 µm; TOR (NaCl) =608 mg/ ml. Measured at a Malvern Zetasizer (Model Zetasizer 3000 
HAS, Germany). The nebulisation trial was performed using an electronic nebulizer, eflow® (Pari GmbH, 
Germany). 
 Results   
141 
1) Chemical stability: expressed as cyclosporin content, determined by 
HPLC. Samples were deemed to be stable if presented a cyclosporin A 
content between 95 105% of the amount declared at the beginning of the 
study.  
2) Physical stability: Water content of the lyophilized product should be less 
than 3%; organoleptic properties of the lyophilized product should be white 
coloured; macroscopic appearance of the reconstituted lyophilizate should 
have a homogeneous and with milky appearance.   
Figure 38: Image of a lyophilizate of a CSA/CD formulation. Image taken 1 day 
after lyophilization  
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Figure 39: Image of a reconstituted lyophilizate of a CSA/CD formulation. 
Reconstituted by adding 2 ml and manual shaking. Image taken 1 day after 
lyophilization.   
Table 25: Nebulization properties of reconstituted lyophilizate of a CSA/CD 
formulation. Reconstitution was made by adding 3 ml and manually shaking the 
vial30.  
MMD 
(µm) 
GSD TOR 
(mg/ml) 
Percent. 
Particles <5 µm
Percent. 
Particles <2 µm 
3.58 1.55 415 77.22 8.94 
 
The water content of the cyclosporin A lyophilizate was also determined. The results are 
described on table 27.  
Table 26: Water content of a CSA/CD lyophilizate. 
Formulation  Water content (%) 
Cyclosporin A 2.8 
 
                                                          
30  MMD (NaCl): 4.2 µm; TOR (NaCl): 610 mg/ m. Measured at a Malvern Zetasizer (Model Zetasizer 3000 
HAS, Germany). The nebulisation trial was performed using a electronic nebulizer, eflow® (Pari GmbH, 
Germany) 
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6.2.1.4.10.1  Stability trial of a lyophilized cyclosporin A/cyclodextrin formulation
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Figure 40: Stability of a lyophilized CSA/CD formulation kept at 25°C and 60% 
relative humidity.  
From the results of the stability trial, we can ascertain that the lyophilized cyclosporin 
A/cyclodextrin formulation kept at 25°C and 60% relative humidity is stable for at least 5 
months.  
Subchapter conclusions 
Cyclosporin A is a potent immunosuppressive agent widely employed to prevent graft 
rejection in kidney, liver and bone marrow transplant patients and to delay or prevent disease 
progression in patients with autoimmune disease and inflammation. 
The immunosuppressive effect of CSA is due to a selective and reversible inhibition of T-
lymphocytes interleukin-2 driven proliferation of activated T-lymphocytes. Although taking 
in consideration the important clinical value of the cyclosporin A, its extended use has been 
often limited by several disadvantages such as low bioavailability, narrow therapeutic 
window, nephrotoxicity and hepatotoxicity (Lit. [20]- Lit. [21]). It has also been reported that 
Cremophor EL®, which is a solubilizing agent present in the commercially available 
intravenous dosage form of CSA, has a risk of anaphylactic shock and nephrotoxicity (Lit. 
[22]- Lit. [23]). Due to the disadvantages previously mentioned, it is fundamental to develop 
alternative dosage forms.  
Pulmonary delivery can provide an alternative a non-invasive method of delivering drugs that 
currently can only be delivered orally or intravenously. It is a unique and innovative delivery 
alternative for therapies that can only be administered by injection (i.v., i.m., s.c.) or by oral 
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delivery which causes adverse effects or is poorly absorbed. In fact, the main advantage of a 
therapy via the lungs is the potentially improved therapeutic index, that is, the ratio of 
therapeutic benefit to adverse effects. This applies mainly to the therapy of pulmonary 
diseases, but may also be applicable to systemic diseases due to reduced first-pass metabolism 
that may be associated with hepatocellular injury. One other advantage lies on the very rapid 
onset of action similar to the i.v. route and quicker than can be achieved with either oral 
delivery or subcutaneous injections.   
However, cyclosporin A is a water insoluble drug which can constitute a problem in terms of 
delivering it to the lungs due to its poor solubility. For this reason, cyclodextrins were studied 
as a mean of improving not only the solubility but also the stability of CSA. Cyclodextrins are 
potential candidates for these functions because of their ability to alter physical, chemical and 
biological properties of guest molecules through the formation of inclusion and non-inclusion 
complexes.  
The first experiments performed showed that the cavity size of the -CD molecule is more 
suitable for the complex formation and, therefore, for the increase in the solubility of CSA. 
Nevertheless, due to toxicological and costs issues, it was decided to use 2-HP- -CD instead 
of -CD, or derivatives therefore, because of its high water solubility, high solubilizing 
power, low cost and low toxicology. 
In addition, it is known that cyclodextrin and drug/cyclodextrin complexes self-associate to 
form water soluble aggregates (or microaggregates) of several drug/cyclodextrin complex 
units and these aggregates can solubilise lipophilic water insoluble drugs through non-
inclusion complexation. 
Furthermore, the addition of suitable auxiliary substances can significantly increase the 
cyclodextrin solubilizing and complexing abilities by multicomponent complex formation.  
With this purpose in mind, several classes of substances were investigated, through the use of 
a factorial design, for their ability to improve the solubility/stability effect of the 
cyclodextrins.  
The first results using 2-HP- -CD and cyclosporin A in the presence of several auxiliary 
substances showed that the use of auxiliary substances did not increase the solubilizing ability 
of the cyclodextrin molecules. This was probably due to the fact that the cyclosporin A 
molecule was not able to interact with the molecules of the several auxiliary substances added 
to the complexing system. 
Consequently, the major factor in the cyclosporin A/cyclodextrin complexation formation is 
the cavity size of the cyclodextrin molecule and the cavity size the -CD molecule is the most 
appropriate for the nonpolar aliphatic parts of the Cyclosporin A molecules to be held. 
Taking in consideration the physical chemical properties of the cyclosporin A molecule, it 
was decided to investigate the possibility inserting the cyclosporin A in another molecule as 
way of overtaking the natural properties of the cyclosporin A molecule. 
Thus, it was decided to use lecithin as the carrier molecule for cyclosporin A. It is made 
from biological phospholipids that are biodegradable, lacking imunogenicity and they exhibit 
low intrinsic toxicity. In addition, the presence of suitable functional groups in the molecular 
structure of the lecithin molecules permits the interaction between the several auxiliary 
substances and the cyclodextrin, allowing this way the formation and stabilization of non-
inclusion complexes. 
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From the auxiliary substances used, we could ascertain that sodium ascorbate is the best 
auxiliary substance for the complex formation and the best parameters for the complex 
formation are:   
Equilibrium time: between 3-5 days (in total). 
Time and temperature for the cyclosporin A/cyclodextrin system: 70°C for 
30 minutes. 
Auxiliary substance: sodium ascorbate.  
Nevertheless, in order to determine if a formulation is suitable to be nebulized with the 
eflow® (for example, in terms of viscosity and surface tension), we also investigated the 
physicochemical characteristics of the formulations. 
The results showed that formulations containing 25 mg/ml to 100 mg/ml of aqueous 2-HP- -
CD solutions with 5 mg/ml of sodium ascorbate provide the best results in terms of the 
nebulisation properties. 
With the purpose of protecting the CSA/CD system from any decomposition phenomena 
related to the hydrolysis reaction by the lecithin phosphatide groups, it was decided to prepare 
a lyophilizate of the formulation. The results obtained from the stability trials showed that the 
lyophilized cyclosporin A/cyclodextrin formulation kept at 25°C and 60% relative humidity is 
stable for at least 5 months.  
As summary, it was possible to obtain a stable formulation of cyclosporin A through the use 
of cyclodextrin that can be nebulized which, consequently, constitutes a valid option for the 
prevention and treatment of graft rejection in the lungs. 
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6.2.2 Azithromycin/Cyclodextrin Formulations 
Azithromycin is a macrolide antibiotic belonging to the azalide group. It is a water insoluble 
drug and for this reason, cyclodextrins were investigated as a mean of improving the 
solubility and stability of azithromycin. Cyclodextrins are potential candidates for this 
function because of their ability to alter physical, chemical and biological properties of guest 
molecules through formation of inclusion and non-inclusion complexes. 
Based on the previous work performed with cyclosporin A and cyclodextrins, it was decided 
to proceed taking in account this previous experience.  
To determine which group of additives can be used to form and stabilize non-inclusion 
complexes of drug-cyclodextrin and, therefore, enhance the solubility azithromycin, several 
additives were added to the azithromycin-cyclodextrin complex solutions.    
6.2.2.1 Influence of several excipients on the solubility of azithromycin 
The tests were performed according to the following factorial design:   
Table 1: Factorial design. 
Vial 
Number 
Amino acids
 
Metal 
ions 
Vitamins
1 + + + 
2 + + - 
3 + - + 
4 + - - 
5 - + + 
6 - + - 
7 - - + 
8 - - - 
 
To prepare the following formulations, the preparation method from chapter 5.3.2.1.1 was 
used.  
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Table 2: Phase solubility table of azithromycin  in aqueous 2-HP- -CD solutions in 
the presence of several excipients. Performed at pH 6.5-7.0, with 3 days of 
equilibrium time at room temperature.  
Formulation  
Composition  
CODE Azithromycin 
Conc. (mg/ml) 
200 mg/ml 2-HP- -CD + 
3.5mg/ml Lysine monohydrate + 3. 5 mg/ml Ascorbic Acid 
+ 0.75 mg/ml MgSO4 6.H2O+ 0.5 mg/ml CaCl2.2H2O 
BCD L A M C 8.5 
200 mg/ml 2-HP- -CD + 3. 5mg/ml Lysine monohydrate  
+ 0.75 mg/ml MgSO4 6.H2O+ 0.5 mg/ml CaCl2.2H2O 
BCD L     M C 7.0 
200 mg/ml 2-HP- -CD + 3.5mg/ml Lysine monohydrate  
+ 3.5 mg/ml Ascorbic Acid 
BCD L A 8.7 
200 mg/ml 2-HP- -CD + 3.5mg/ml Lysine monohydrate BCD L 7.2 
200 mg/ml 2-HP- -CD + 3.5 mg/ml Ascorbic Acid 
+ 0.75 mg/ml MgSO4 6.H2O+ 0.5 mg/ml CaCl2.2H2O 
BCD     A M C 8.2 
200 mg/ml 2-HP- -CD + 0.75 mg/ml MgSO4 6.H2O 
+ 0.5 mg/ml CaCl2.2H2O 
BCD         M C 4.3 
200 mg/ml 2-HP-  -CD + 3.5 mg/ml Ascorbic Acid BCD     A 8.5 
200 mg/ml 2-HP- -CD BCD 6.1 
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Figure 1: Phase solubility diagram of azithromycin in aqueous 2-HP- -CD solutions 
in the presence of several excipients. Performed at pH 6.5-7.0, with 3 days of 
equilibrium time at room temperature.   
From the results, it can be ascertain that in general the combine use of CDs and auxiliary 
substances can help improve the solubility of azithromycin. The level to which this increase 
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can be achieved depends on the type and concentration of the auxiliary substances along with 
the concentration of CDs. Nevertheless, other parameters such as temperature and pH also 
have a very important influence on the solubility increase of azithromycin.   
6.2.2.2 Influence of sodium acetate and citric acid on the solubility of azithromycin 
The capacity of sodium acetate and citric acid to form non-inclusion complexes was also 
investigated. The preparation of each of the formulations was the same as the one performed 
for the factorial design (c.f. 6.2.2.1).  
Table 3: Phase solubility table of azithromycin in aqueous 2-HP- -CD solutions in 
presence of increasing concentrations of sodium acetate. Performed at pH 6.5-7.0, 
with 3 days of equilibrium time at room temperature. 
Formulation Composition Azithromycin 
Conc. (mg/ml) 
200 mg/ml 2-HP- -CD + 2% Sodium Acetate 7.7 
200 mg/ml 2-HP- -CD + 3% Sodium Acetate 6.5 
200 mg/ml 2-HP- -CD + 4% Sodium Acetate 7.4 
  
0
1
2
3
4
5
6
7
8
9
200 mg/ml 2-HP-Beta-CD +
2% Sodium Acetate 
200 mg/ml 2-HP-Beta-CD +
3% Sodium Acetate 
200 mg/ml 2-HP-Beta-CD +
4% Sodium Acetate 
A
zi
th
ro
m
yc
in
 
Co
n
c.
 
(m
g/
m
l)
Figure 3: Phase solubility diagram of azithromycin in aqueous 2-HP- -CD solutions 
in presence of increasing concentrations of sodium acetate. Performed at pH 6.5-7.0, 
with 3 days of equilibrium time at room temperature. 
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Table 4: Phase solubility table of azithromycin  in aqueous 2-HP- -CD solutions in 
presence of increasing concentrations of citric acid. Performed at pH 6.5-7.0, with 3 
days of equilibrium time at room temperature. 
Formulation Composition Azithromycin 
Conc. (mg/ml) 
200 mg/ml 2-HP- CD + 6.67 mg/ml Citric Acid  6.7 
200 mg/ml 2-HP- CD + 13.3 mg/ml Citric Acid 8.1 
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Figure 3: Phase solubility diagram of azithromycin in aqueous 2-HP- -CD solutions 
in presence of increasing concentrations of citric acid. Performed at pH 6.5-7.0, with 
3 days of equilibrium time at room temperature.  
After analysing the results, it can be concluded that for the case of sodium acetate, a 
maximum solubility of azithromycin can be achieved with 2% sodium acetate. On the other 
hand, a concentration of 13.3 mg/ml of citric acid allows a higher increase of the 
azithromycin solubility in comparison with 6.6 mg/ml citric acid.  
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6.2.2.3 Influence of pH on the solubility of azithromycin 
In order to ascertain the effect of pH on the azithromycin solubility, 3 formulations were 
chosen based on their improved solubility. In this experiment, the pH was adjusted to 4.5-5.5 
and 6.5-7.0 respectively.  
Table 5: Phase solubility table of azithromycin in 200 mg/ml 2-HP- -CD aqueous 
solution in presence of citric acid at 2 different pH values. Performed at pH 4.5-5.5 
and pH 6.5-7.0, with 3 days of equilibrium time at room temperature. 
Formulation Composition Azithromycin 
Conc. (mg/ml) 
200 mg/ml 2-HP- -CD + 6.67mg/ml Citric acid (pH 4.5-5.5) 8.94 
200 mg/ml 2-HP- -CD + 6.67mg/ml Citric acid (pH 6.5-7.0) 6.80 
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Figure 4: Phase solubility diagram of azithromycin in 200 mg/ml 2-HP- -CD 
aqueous solution in presence of citric acid, at 2 different pH values. Performed at 
pH 4.5-5.5 and pH 6.5-7.0, with 3 days of equilibrium time at room temperature.   
Table 6: Phase solubility table of azithromycin in 200 mg/ml 2-HP- -CD aqueous 
solution in presence of ascorbic acid, at 2 different pH values. Performed at pH 4.5-
5.5 and pH 6.5-7.0, with 3 days of equilibrium time at room temperature. 
Formulation Composition Azithromycin 
Conc. (mg/ml) 
200 mg/ml 2-HP- -CD + 3.5 mg/ml Ascorbic Acid (pH 4.5-5.5) 7.0 
200 mg/ml 2-HP- CD + 3.5 mg/ml Ascorbic Acid (pH 6.5-7.0) 8.5 
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Figure 5: Phase solubility diagram of azithromycin in 200 mg/ml 2-HP- -CD 
aqueous solution in presence of ascorbic acid at 2 different pH values. Performed at 
pH 4.5-5.5 and pH 6.5-7.0, with 3 days of equilibrium time at room temperature.    
Table 7: Phase solubility table of azithromycin in 200 mg/ml 2-HP- -CD aqueous 
solution in presence of sodium acetate at 2 different pH values. Performed at pH 4.5-
5.5 and pH 6.5-7.0, with 3 days of equilibrium time at room temperature. 
Formulation Composition Azithromycin 
Conc. (mg/ml) 
200 mg/ml 2-HP-  CD + 2% Sodium Acetate (pH 4.5-5.5) 5.77 
200 mg/ml 2-HP-  CD + 2% Sodium Acetate (pH 6.5-7.0) 7.73 
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Figure 6: Phase solubility diagram of azithromycin in 200 mg/ml 2-HP- -CD 
aqueous solution in presence of sodium acetate, at 2 different pH values. Performed 
at pH 4.5-5.5 and pH 6.5-7.0, with 3 days of equilibrium time at room temperature.  
For each of the excipients used, there is a pH range in which the solubility of azithromycin 
can reach its maximum. For example, in the case of citric acid, a pH range between 4.5-5.5 is 
more suitable than a pH range between 6.5-7.0. Contrary, in the case of sodium acetate and 
ascorbic acid, a pH range 6.5-7.0 produces a higher solubility increase than a pH range 4.5-
5.5. This is due to the fact that at a specific pH range, the complex formation between the 
several components of the formulation is promoted.  
6.2.2.4 Influence of lactic acid, nicotine amide and vitamin E acetate on the solubility of 
azithromycin 
In addition, three more excipients were tested in order to determine their ability to solubilise 
the azithromycin.  
For the next set of experiments it was decided to present the results in terms of the percentage 
of azithromycin recovered as way of comparing the complexing ability of the several 
auxiliary substances used.  This way it was easier to compare the effects of each of the 
excipients on the solubility of azithromycin.  
The experiment was performed at pH 4.5-5.0, with 1 day of equilibrium time at room 
temperature.      
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Table 8: Percentage of azithromycin recovered in the presence of different lactic 
acid concentrations. Performed at pH 4.5-5.0, with 1 day of equilibrium time at 
room temperature. 
Formulation Composition Azithromycin 
Recovered (%) 
200 mg/ml 2-HP- -CD + 10 mg/ml Lactic Acid 92.1 
200 mg/ml 2-HP- -CD + 50 mg/ml Lactic Acid 70.5 
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Figure 7: Percentage of azithromycin recovered in the presence of different lactic 
acid concentrations. Performed at pH 4.5-5.0, with 1 day of equilibrium time at 
room temperature.  
Table 9: Percentage of azithromycin recovered in the presence of different nicotine 
amide concentrations. Performed at pH 4.5-5.0, with 1 day of equilibrium time at 
room temperature. 
Formulation Composition Azithromycin recovered (%) 
200 mg/ml 2-HP- -CD + 10 mg/ml Nicotine Amide 82 
200 mg/ml 2-HP- -CD + 50 mg/ml Nicotine Amide 78 
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Figure 8: Percentage of azithromycin recovered in the presence of different Nicotine 
amide concentrations. Performed at pH 4.5-5.0, with 1 day of equilibrium time at 
room temperature.  
Table 10: Percentage of azithromycin recovered in the presence of different Vitamin 
E acetate concentrations. Performed at pH 4.5-5.0, with 1 day of equilibrium time at 
room temperature. 
Formulation Composition Azithromycin recovered (%) 
200 mg/ml 2-HP- -CD + 10 mg/ml Vitamin E acetate 66 
200 mg/ml 2-HP- -CD + 50 mg/ml Vitamin E acetate 58 
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Figure 9: Percentage of azithromycin recovered in the presence of different Vitamin 
E acetate concentrations. Performed at pH 4.5-5.0, with 1 day of equilibrium time at 
room temperature.  
From the results it was possible to ascertain that there is a relationship between the 
concentration of each of the excipients and the solubility of azithromycin. 
For example, in the case of vitamin E acetate, the increase of the concentration had a negative 
effect on the solubility of azithromycin.  
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6.2.2.5 Influence on the solubility of azithromycin of a formulation containing ascorbic acid, 
2-HP- -cyclodextrin 
With the purpose of finding the best relationship between the concentration of ascorbic acid, 
2-HP- -cyclodextrin and azithromycin, the following experiments were performed. The 
experimental procedure for this experiment was similar to the previous experiments but in this 
case, the equilibrium time was 1 day.  
Table 11: Percentage of recovered azithromycin in the presence different 
concentrations of 2-HP- -Cyclodextrin, ascorbic acid and azithromycin. Performed 
at pH 6.5-7.0, with 1 day of equilibrium time at room temperature. 
Formulation Composition Azithromycin recovered (%) 
200 mg/ml 2-HP- -CD + 10 mg/ml Ascorbic Acid 84 
200 mg/ml 2-HP- -CD + 50 mg/ml Ascorbic Acid 93 
200 mg/ml 2-HP- -CD + 100 mg/ml Ascorbic Acid 92 
100 mg/ml 2-HP- -CD + 10 mg/ml Ascorbic Acid 99 
100 mg/ml 2-HP- -CD + 50 mg/ml Ascorbic Acid 95 
100 mg/ml 2-HP- -CD + 100 mg/ml Ascorbic Acid 93 
50 mg/ml 2-HP- -CD + 10 mg/ml Ascorbic Acid 100 
50 mg/ml 2-HP- -CD + 50 mg/ml Ascorbic Acid 97 
50 mg/ml 2-HP- -CD + 100 mg/ml Ascorbic Acid 98 
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Figure 10: Percentage of recovered azithromycin in the presence of different 
concentrations of 2-HP- -Cyclodextrin, ascorbic acid and azithromycin. Performed 
at pH 6.5-7.0, with 1 day of equilibrium time at room temperature.    
For each of the 2-HP- -CD concentrations, there is a specific concentration of ascorbic acid 
that maximizes the solubility of azithromycin:  
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1. 200 mg/ml 2-HP- -CD  50 mg/ml Ascorbic Acid 
2. 100 mg/ml 2-HP- -CD  10 mg/ml Ascorbic Acid 
3. 50 mg/ml 2-HP- -CD  10 mg/ml Ascorbic Acid  
Based on these results, it is possible to improve the solubility of azithromycin by optimising 
other parameters. 
In the next set of experiments, the effect of the temperature, the pH and the equilibrium time 
was analysed.   
6.2.2.5.1 Influence of equilibrium time on the solubility of azithromycin 
In this of experiment, the effect of the equilibrium time was analysed. Regarding the 
equilibrium time, it was observed:  
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Figure 11: Comparison of the percentage of azithromycin recovered based on the 
equilibrium time, at a pH of 6.5-7.0.   
From the results, it could be ascertained that the equilibrium time has an influence on the 
solubility of azithromycin. In the formulation with the higher concentration of 2-HP- -CD, 
the maximum solubility of azithromycin was obtained at 2 days equilibrium time. This can be 
explained based on the fact that the complex formation process requires more time due to the 
higher amount of 2-HP- -CD present in the formulation. 
On the other hand, the formulations containing 50 mg/ml and 100mg/ml 2-HP- -CD require 
only 1 day equilibrium time to achieve the maximum solubility of azithromycin.  
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6.2.2.5.2 Influence of temperature on the solubility of azithromycin 
To analyse the effect of the temperature, two identical formulations were prepared using two 
different temperatures. One of the formulations was continuously stirred at room temperature, 
while the other was stirred for 30 minutes at 70°C. Afterwards, the vial containing the 
formulation was continuously stirred at room temperature. The equilibrium time in this 
experiment was 1 day.  
Table 12: Percentage of azithromycin recovered based on the temperature effect. 
Performed at pH 6.5-7.0, with 1 day of equilibrium time at room temperature. 
Formulation Composition Azithromycin 
Recovered (%) 
50 mg/ml 2-HP- -CD + 10 mg/ml Ascorbic Acid (RT) 100 
50 mg/ml 2-HP- -CD + 10 mg/ml Ascorbic Acid  
(t=70°C, for 30 min) 
100 
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Figure 12: Percentage of azithromycin recovered based on the temperature effect. 
Performed at pH 6.5-7.0, with 1 day of equilibrium time at room temperature.  
Based on the results, it can be concluded that the temperature has no influence in increasing 
the solubility of azithromycin. 
6.2.2.5.3 Influence of pH on the solubility of azithromycin 
To ascertain the pH effect, two identical formulations were prepared and the pH from these 
formulations was adjusted at two different values: 6.5-7.0 and 4.5-5.5. The equilibrium time 
in this experiment was 1 day, at room temperature.  
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Table 13: Percentage of azithromycin recovered based on the pH effect. Performed 
at pH 4.5-5.5 and pH 6.5-7.0, with 1 day of equilibrium time at room temperature. 
Formulation Composition Azithromycin 
recovered (%) 
50 mg/ml 2-HP- -CD + 10 mg/ml Ascorbic Acid  
(pH 6.5-7.0) 
100 
50 mg/ml 2-HP- -CD + 10 mg/ml Ascorbic Acid 
(pH 4.5-5.5) 
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Figure 13: Percentage of Azithromycin recovered based on the pH effect. Performed 
at pH 4.5-5.5 and pH 6.5-7.0, with 1 day of equilibrium time at room temperature.  
After analysing the results, it was possible to ascertain that the pH plays a very important role 
on the solubility of azithromycin. The pH range 6.5-7.0 is the most suitable for the solubility 
increase of azithromycin.    
6.2.2.5.4 Influence of 2-HP- -CD concentrations on the solubility of azithromycin 
To study the effect of the 2-HP- -CD concentrations on the solublization of azithromycin, 
two formulations were prepared. In this experiment, two concentrations were used: 25 mg/ml 
and 50 mg/ml. As excipient, ascorbic acid was also used. This experiment was performed at 
pH 6.5-7.0, with 2 days of equilibrium time at room temperature.  
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Table 14: Percentage of azithromycin recovered in the presence of different 2-HP- -
CD concentrations. Performed at pH 6.5.7.0, with 2 days of equilibrium time at 
room temperature. 
Formulation Composition Azithromycin 
recovered (%) 
50 mg/ml 2-HP-B-CD + 50 mg/ml Ascorbic Acid 91 
25 mg/ml 2-HP-B-CD + 50 mg/ml Ascorbic Acid 89 
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Figure 14: Percentage of azithromycin recovered in the presence of different 2-HP-
-CD concentrations. Performed at pH 6.5.7.0, with 2 days of equilibrium time at 
room temperature.  
From the results, it can be concluded that increasing the concentration of 2-HP- -CD has a 
very small effect on the solubility of azithromycin. Based in terms of toxicology and cost 
issues, it is advisable to use smaller concentrations of 2-HP- -CD.   
6.2.2.5.5 Influence of sodium ascorbate concentrations on the solubility of azithromycin 
In the next set of experiments, it was investigated the solubility effect of sodium ascorbate. 
The reason of using this excipient was mainly based on its better stability and also on its 
similar molecular structure to ascorbic acid.  
This experiment was performed at pH 6.5-7.0, with 2 days of equilibrium time at room 
temperature. 
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Table 15: Percentage of azithromycin recovered in the presence of Sodium 
Ascorbate. Performed at pH 6.5.7.0, with 2 days of equilibrium time at room 
temperature. 
Formulation Composition Azithromycin 
recovered (%) 
200 mg/ml 2-HP-B-CD + 10mg/ml Sodium Ascorbate 96 
100 mg/ml 2-HP-B-CD + 10 mg/ml Sodium Ascorbate 98 
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Figure 15: Percentage of azithromycin recovered in the presence of sodium 
ascorbate. Performed at pH 6.5-7.0, with 2 days of equilibrium time at room 
temperature.  
Based on the results, increasing the 2-HP- -CD concentration has little influence on the 
solubility of azithromycin, as previously explained.  
One of the reasons for using cyclodextrins is their ability to improve the solubility and 
stability of azithromycin. On the other hand, taste masking is another important feature to take 
in consideration; especially in the case of azithromycin molecules due to their very bitter 
taste. If a patient, particularly  young patients, do not like the taste, it is more difficult to 
persuade them to continue with the therapy. Consequently, taste masking is an important 
factor in patient compliance. 
From the work performed, we could increase the solubility of azithromycin in aqueous 
solutions, but the taste of the formulations was still bitter. This is mainly due to the presence 
of azithromycin outside of the cyclodextrin cavity, in non-inclusion complexes. 
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With the objective of improving the solubility and also the taste of the azithromycin 
formulation, a new approach was developed. It involves increasing the intrinsic solubility of 
azithromycin with the help of pH adjustments in order to maximize the solubilization capacity 
of the cyclodextrins without the formation of non-inclusion complexes.   
The resulting formulation showed an improvement in the taste masking although the bitter 
was not entirely removed. However, the taste of the formulation was tolerable for inhalation. 
The concentration of azithromycin of the last formulation was 17 mg/ml.  
From the previous data, it was possible to ascertain that the pH plays a very important role in 
the solubilization of azithromycin. In addition, the concentration of the 2-HP- -Cyclodextrin 
also influences the solubility of azithromycin. Finally, the type and also the concentration of 
the excipients used can also play a part in the solubilization of azithromycin. 
However, the effect of the pH is the most important parameter in the solubilization of 
azithromycin.   
6.2.2.6 Nebulization trials 
In order to test nebulisation characteristics of the azithromycin/cyclodextrin formulations, 
three different formulations were analysed, in terms of MMD, TOR, percentage of particles 
below 5% and 2%.  
Table 16: Nebulization trials using 3 different 2-HP- -CD aqueous solutions in the 
presence of sodium ascorbate. 
Formulation  
Composition 
MMD 
NaCl 
(µm) 
MMD 
Formulation 
(µm) 
GSD   TOR 
(mg/min)  
%<5 µm
 
%< 2µm
200 mg/ml 2-HP-Beta-CD 
+ 10mg/ml Sodium ascorbate 
4.2 2.97 1.6 252 84.5 17.6 
100 mg/ml 2-HP-Beta-CD 
+ 10 mg/ml Sodium ascorbate 
4.2 3.21 1.6 335 81.03 16 
25 mg/ml 2-HP-Beta-CD 
+ 50 mg/ml Ascorbic acid 
4.2 3.28 1.63 380 79.95 15.1 
The results show that it is possible to obtain particle sizes (2.5-3.5 µm) suitable for the 
pulmonary administration of azitromycin by nebulising the azithromycin/cyclodextrin 
formulations with the eflow device.       
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6.2.2.7 Lyophilization of the Azithromycin/Cyclodextrin Formulation  
With the purpose of protecting the azithromycin/cyclodextrin system from any decomposition 
phenomena related to hydrolysis reactions, an azithromycin/cyclodextrin formulation was 
prepared and lyophilizated. 
The formulation had the following composition:  
Table 17: Composition of a lyophilized azithromycin/cyclodextrin formulation 
Formulation Composition Conc. (mg/ml) 
Azithromycin 4.331 
2-HP- -CD 51.5 
 
The vials were filled with 1 ml of the azithromycin/cyclodextrin formulation each and placed 
inside the lyophilizer chamber. Lyophilization of the samples was performed with a Christ 
Epsilon 2-6D (Germany) equipment. Conditions of the entire process are shown in Table 18  
Table 18: Lyophilization conditions of an azithromycin/cyclodextrin formulation. 
Process Phase Time 
(min) 
Temp. 
(°C) 
Vacuum 
(mbar) 
Si. Pressure 
(mbar) 
Start value 0 0 OFF OFF 
Freezing 1 -38 OFF OFF 
Freezing 44 -38 OFF OFF 
Preparation 15 -38 OFF OFF 
Main drying 1 -38 0.08 OFF 
Main drying 15 -25 0.08 0.140 
Main drying 704 -25 0.08 0.140 
After drying 1 -25 0.08 0.140 
After drying 300 15 0.08 0.140 
After drying 719 15 0.08 0.140 
At the end of the process, the lyophilized obtained was a white coloured product (see Figure 
16). 
                                                          
31  Amount present in 19mg of the lyophilizate. 
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Figure 16: Image of a lyophilizate of an azithromycin/cyclodextrin formulation. 
Image taken 1 day after lyophilization.  
Figure 17: Image of a reconstituted lyophilizate of an azithromycin/cyclodextrin 
formulation. Reconstitution was made by adding 3 ml and manually shaking the 
vial. Image taken 1 day after lyophilization.  
The determination of the nebulisation properties was investigated using the eflow® device 
(Pari GmbH, Germany) as nebuliser. 
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Table 19: Nebulization characteristics reconstituted lyophilizate of an 
azithromycin/cyclodextrin formulation. Reconstitution was made by adding 3 ml 
and manually shaking the vial4.  
MMD 
(µm) 
GSD
 
TOR 
(mg/ml) 
Percent. 
Particles <5 µm
Percent. 
Particles <2 µm
3.75 1.55 583 74.3 8.3 
 
The water content present in the lyophilizate was also determined:  
Table 20: Water content of a lyophilizate of azithromycin/cyclodextrin 
Formulation Water content (%) 
Azithromycin 4.08 
The low water content of the formulation allows for a more stable formulation because it 
reduces of possibility from any decomposition phenomena related to hydrolysis reactions to 
occur.  
6.2.2.8 Stability Batches 
It is known from literature (Lit. [24]) that azithromycin can degrade in aqueous solutions, 
especially in the presence of acids.  
In order to investigate the stability of the azithromycin formulation, six stability batches 
(STB), five solutions and one lyophilizate were prepared:  
STB 1: 3.5g azithromycin and 10g 2-HP- -CD were stirred in 100ml water; pH 
was continuously observed. 85% phosphoric acid, in quantities of 10 µl, was 
added when pH was above 7.5. After 18h in total, 320µl H3PO4 were 
needed to obtain a clear solution with a pH of 7.4. 
STB 2: 3.5g azithromycin and 10g 2-HP- -CD were solubilized in 50ml 
methanol. After stirring over night, methanol was removed using a rotary 
evaporator at 30°C to a final pressure of 52 mbar in about 60 minutes. 
Reconstitution in 120 ml water resulted, surprisingly, in a stable suspension. 
STB 3: 3g azithromycin were solubilized in 100ml water and 470µl 85% 
H3PO4. Then 8g of 2-HP- -CD were added. After 15 minutes stirring, 
9.5ml 1M NaOH were added to pH 8.8 causing precipitation. Suspension 
was filtrated (0.45µm); pH of the clear solution was adjusted to 7.8 with 
H3PO4. 
STB 4: 2.5g azithromycin were added to 100 ml water and solubilized by 
adding approx. 4ml 1M HCl. 8g of 2-HP- -CD were added and solution was 
stirred for 30 minutes. 1M NaOH was quickly added till pH reached 8.9. 
Resulting suspension was centrifuged twice at 6000 Rpm for one minute. 
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STB 5: 3g azithromycin were solubilized in 100 ml water containing 450µl 
85% H3PO4, resulting in a clear solution with pH 6.2. This preparation 
served as reference solution. 
STB 6: 3g azithromycin, 10g 2-HP- -CD and 350µl H3PO4 were solubilized 
similarly to batch STB 1 in 60 ml water. 2 ml were pipetted into vials and 
freeze dried according to following program 1  
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Figure 18: Stability batches of 6 different azithromycin formulations.   
Table 21: Percentage of recovered azithromycin in 6 different azithromycin 
formulations stability batches. 
Storage 
Conditions
STB 1 
4 
weeks(%) 
STB 2 
4 
weeks(%) 
STB 3 
4 weeks 
(%) 
STB 4 
4 weeks 
(%) 
STB 5 
4 weeks (%)
STB 6 
6 weeks (%)
STB 6 
16 weeks 
(%) 
4°C 100.1 101.4 99.4 100.4 100.6 100.0 102.1 
25°C 91.8 95.4 86.3 95.2 99.6 100.0 101.3 
30° / 
cycling 
78.7 95.0 66.7 93.2 96.5 100.5 100.8 
40°C 65.3 92.1 48.8 87.7 92.6 99.8 91.8 
 
From the results we could ascertain that all aqueous formulations were unstable. It seems to 
appear that cyclodextrins could have an influence in accelerating the drug degradation, as 
STB 5, consisting only of drug and acid, was the most stable among the solutions. 
However, the lyophilizate showed no significant degradation after 6 weeks, even at 40°C / 
75% r.h. storage conditions. Only after 16 weeks under 40°C / 75% r.h. storage conditions it 
was possible to see some degradation. Although the difference between the 6 weeks and 16 
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weeks value is above the analytical error (8%), it is not possible to conclude that the 
difference is statistic significant due to low number of data points   
Subchapter conclusion 
It was decided to use cyclodextrins as mean of improving not only the solubility/stability 
properties of the azithromycin but also to taste mask its bitter taste. 
From the results obtained, we could ascertain that the pH plays a very important role in the 
solubility of azithromycin. However, this increase in the solubility of azithromycin was not 
accompanied by an improvement of the taste of the formulations. This was due to the 
formation of not only inclusion complexes between the azithromycin and the cyclodextrins, 
but also due to the formation of non-inclusion complexes.  
With the objective of improving the solubility and also the taste of the azithromycin 
formulation, a new approach was developed. It involved increasing the intrinsic solubility of 
azithromycin with the help of pH adjustments in order to maximize the solubilization capacity 
of the cyclodextrins without the formation of non-inclusion complexes. Consequently, the 
resulting formulation showed an improvement in the taste masking although the bitter was not 
entirely removed. However, the taste of the formulation was tolerable for inhalation.  
Based on the  results, we can ascertain that the best excipients which promote the formation 
of non-inclusion complexes and, consequently, increase the solubility azithromycin solubility 
are ascorbic acid and citric acid.  
With the purpose of obtaining a stable azithromycin formulation it was investigated the 
stability five solutions and one lyophilizate.  
From the results we could ascertain that all aqueous formulations were unstable. However, the 
lyophilizate showed no significant degradation after 16 weeks. Only after 16 weeks under 
40°C / 75% r.h. storage conditions we could see some degradation although not very 
significant, taking in consideration the storage conditions.   
In conclusion, it was possible to obtain a stable formulation of azithromycin with a taste 
suitable to inhalation purposes.         
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6.2.3 Pentoxifylline 
Pentoxifylline is a water soluble drug32 used in the field of oncology due its reported potential 
ability to ameliorate radiation- and chemotherapy-induced toxicity. However, it possesses a 
very bitter taste which has a very important influence in patient compliance, especially in 
young patients. For this reason, it was decided to use cyclodextrins as a mean of taste masking 
the bitter taste of the pentoxifylline formulations. 
To five vials containing 50 mg/ml of pentoxifylline, different concentrations of 2-HP- -CD 
were added.   
Table 1: Formulation composition of 5 different pentoxifylline formulations. 
Formulation composition Code 
50 mg/ml Pentoxifylline+ 10 mg/ml 2-HP-Beta-CD P10 
50 mg/ml Pentoxifylline+ 25 mg/ml 2-HP-Beta-CD P25 
50 mg/ml Pentoxifylline+ 50 mg/ml 2-HP-Beta-CD P50 
50 mg/ml Pentoxifylline+ 75 mg/ml 2-HP-Beta-CD P75 
50 mg/ml Pentoxifylline+ 100 mg/ml 2-HP-Beta-CD P100 
These 5 formulations were then analysed not only in terms of their physicochemical 
properties but also for their nebulisation parameters.   
Table 2: Physicochemical properties of 5 different pentoxifylline formulations. 
Formulation  
Comde 
pH Osmolarity 
(osmol/Kg) 
Viscosity 
(mPa s) 
Surface Tension 
(mN/m) 
P10 2.52 0.114±0.002 1.24±0.05 55.1±0.17 
P25 2.7 0.118±0.003 1.28±0.03 55.81±0.19 
P50 3.23 0.129±0.002 1.38±0.03 56.59±0.28 
P75 3.44 0.142±0.004 1.51±0.03 56.81±0.12 
P100 3.46 0.161±0.001 1.64±0.04 57.12±0.1 
         
                                                          
32  The water solubility of pentoxifylline is > 43 mg/ml.  
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Table 3: Nebulization parameters of 5 different pentoxifylline formulations33 
Formulation  
code 
MMD 
(µm) 
GSD  TOR 
(mg/ml) 
Particles 
<5 µm (%) 
Particles 
<2 µm (%)
 
P10 2.08 1.64 151 95.4 46.5 
P25 2.13 1.66 157 98.4 44.1 
P50 2.31 1.76 142 98.7 49.5 
P75 2.01 1.7 125 98.1 49.62 
P100 2.25 1.69 110 81.7 40.2 
 
Table 4: Nebulization properties of 5 different pentoxifylline formulations34 
Formulation  
Composition 
MMD 
(µm) 
GSD TOR 
(mg/ml) 
Particles 
<5 µm (%) 
Particles 
<2 µm (%) 
P10 3.36 1.58 490 80.22 12.48 
P25 3.33 1.57 476 80.8 12.64 
P50 3.25 1.58 485 81.82 13.52 
P75 3.21 1.57 454 82.38 13.63 
P100 3.05 1.55 400 85.47 15.1 
The nebulisation of the formulations produced particle size droplets suitable for inhalation. 
For example, using a nebulizer head of 2.75 µm it was possible to produce droplets size 
between 2.08-2.25 µm. With this particle size it possible to reach 45-55% deposition in the 
alveolar region. However, the output rate was low, between 110-150 mg/ml, which means 
longer nebulisation times (table3). 
On the other, using a nebulizer head of 3.8 µm, it is possible to obtain a higher output rate 
(between 400-490 mg/ml) and, consequently, lower nebulisation times. In addition, a droplet 
size between 3.05-3.36 µm also allows a 45-55% deposition in the alveolar region (table 4). 
The taste masking ability of the cyclodextrin in the different pentoxifylline formulations was 
also investigated.  
In order to ascertain the taste of formulations, all five formulations were nebulized (after pH 
and osmolarity correction) using the electronic nebuliser eflow. All formulations showed a 
neutral to a slight sweet taste which indicates that cyclodextrins were able to taste mask the 
bitter taste of the pentoxifylline35.     
                                                          
33  MMD (NaCl) = 2.75 µm; Measured at a Malvern Zetasizer (Model Zetasizer 3000 HAS, Germany). The 
nebulisation trial was performed using an electronic nebulizer, eflow® (Pari GmbH, Germany). 
34  MMD (NaCl) = 3.8 µm; Measured at a Malvern Zetasizer (Model Zetasizer 3000 HAS, Germany). The 
nebulisation trial was performed using an electronic nebulizer, eflow® (Pari GmbH, Germany). 
35
 The taste of all formulations was evaluated subjectively by a group of 5 persons. 
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Table 5: Taste description of 5 different pentoxifylline formulations. 
Formulation composition Taste 
Description 
50 mg/ml Pentoxifylline+ 10 mg/ml 2-HP- -CD Neutral 
50 mg/ml Pentoxifylline+ 25 mg/ml 2-HP- -CD Neutral 
50 mg/ml Pentoxifylline+ 50 mg/ml 2-HP- -CD Neutral 
50 mg/ml Pentoxifylline+ 75 mg/ml 2-HP- -CD Neutral to Sweet 
50 mg/ml Pentoxifylline+ 100 mg/ml 2-HP- -CD Neutral to Sweet 
 
Thus, the use of cyclodextrins can help improve the patient compliance in treatments were 
pentoxifylline plays a major role.   
Subchapter conclusion 
Pentoxifylline is a xanthine derivate that has been used in the field of oncology based on its 
reported potential ability to ameliorate radiation- and chemotherapy-induced toxicity. 
It is a water soluble molecule which, however, possesses a very bitter taste. In order to 
improve patient compliance, it was decided to use cyclodextrins as a mean of taste masking 
the bitter taste of the Pentoxifylline molecules. 
The results obtained show that it is possible to prepare a pentoxifylline formulation with a 
taste suitable for pulmonary administration. In addition, the formulations can be also 
efficiently nebulized through the use of eflow®.                    
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6.2.4 Budesonide 
Budesonide is a corticosteroid used for the treatment of asthma, non-infectious rhinitis 
(including hay fever and other allergies) and for the treatment and prevention of nasal 
polyposis. However, budesonide is water insoluble drug which constitutes a challenge not 
only in terms of increasing its solubility but also its stability. 
Based on the previous work devolved for cyclosporin A and azithromycin, it was decided to 
investigate the possibility of using cyclodextrins as a way of increasing the solubility and 
stability of budesonide.  
The purpose behind this approach was to investigate the plausibility of using a common 
platform to increase to solubility of water insoluble drugs. 
Consequently, taking in consideration the previous work preformed with cyclosporin 
A/azithromycin and cyclodextrin and also the physicochemical properties of budesonide, it 
was decide to prepare a budesonide/2-HP- -CD formulation.  
The method of preparation was similar to the one performed for cyclosporin A with the 
difference that for the budesonide/cyclodextrin system, the equilibrium time and pH were, 
respectively, 1 day and 4.536. The formulation composition and the results obtained are as 
follows:  
Table 1: Formulation composition of a budesonide/cyclodextrin formulation. 
Formulation composition Conc. Budesonide (µg/ml) 
100 mg/ml 2-HP-Beta-CD 
+ 5.0 mg/ml sodium ascorbate   
1008 
  
Table 2: Physicochemical properties of a budesonide/cyclodextrin formulation. 
Property value 
Surface Tension ( ) [mN/m] 59.05±0.12 
Osmolarity [osmol/kg] 0.169±0.001 
pH  4.59 
Viscosity [mPa s] 1.4±0.04 
                                                          
36
 A complete description of the preparation method is on point 5.3.2.7 of the method chapter.  
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Table 3: Nebulization properties of a budesonide/cyclodextrin formulation.37 
MMD 
(µm) 
GSD TOR 
(mg/ml) 
Percent. 
Particles <5 µm 
Percent. 
Particles <2 µm 
3.00 1.58 330 85.24 17.47 
In addition to the previous formulation, the influence of the amount cyclodextrin in the 
solubility of budesonide was also investigated.  
Table 4: Formulation composition of a budesonide/cyclodextrin formulation. 
Formulation  
composition 
Conc. 
Budesonide (µg/ml) 
50 mg/ml 2-HP-Beta-CD 
+ 5.0 mg/ml Sodium ascorbate 
584 
From the results obtained, we could ascertain that the solubility of budesonide is also directly 
dependent from the amount of cyclodextrin used.   
It is known that budesonide can degrade in aqueous solutions. For this reason, a 
budesonide/cyclodextrin formulation was prepared in order to investigate the stability of 
budesonide in aqueous solutions at 2 different temperatures.   
65
70
75
80
85
90
95
100
105
110 
4 w eeks 4 w eeks 12 w eeks 12 w eeks
5°C Stability 40°C Stabiliby 5°C Stability 40°C Stabiliby
Re
l. 
Dr
u
g 
As
sa
y 
[%
]  5°C Stability  4 weeks
40°C Stabiliby 
4 weeks
5°C Stability 
12 weeks
40°C Stabiliby
12 weeks
Figure 1: Stability test of a budesonide/cyclodextrin formulation.  
                                                          
37  MMD (NaCl) =3.44 µm; Measured at a Malvern Zetasizer (Model Zetasizer 3000 HAS, Germany). The 
nebulisation trial was performed using an electronic nebulizer, eflow® (Pari GmbH, Germany). 
Results 
172 
Budesonide, total impurities
0.96
1.04
1.24
1.01
1.11
0.50
0.75
1.00
1.25
1.50
1.75
2.00
0 1 2 3 4 5 6 7
Storage time  [month]
To
ta
l i
m
pu
rit
ie
s 
 
[A
re
a 
%
]
5°C +- 3°C 40°C / 75%r.h. 
Figure 2: Stability test of a budesonide/cyclodextrin.  
The results showed that the budesonide/cyclodextrin formulation is stable in aqueous 
solutions. 
In addition, if required the budesonide/cyclodextrin formulation can be sterilised. For this 
reason and only as an example, the influence of filtration on the solubility of budesonide was 
investigated. Two different filters, 0.45 µm and 0.22 µm, were used.  
Table 5: Comparison of the budesonide solubility between unfiltered and filtered 
aqueous solutions of budesonide. 
Formulation  
composition 
Conc. Budesonide 
(µg/ml) 
100 mg/ml 2-HP-Beta-CD + 5.0 mg/ml Sodium 
Ascorbate (unfiltered)   
299.7 
100 mg/ml 2-HP-Beta-CD + 5.0 mg/ml Sodium 
ascorbate (0.45 µm filtered)   
299.5 
100 mg/ml 2-HP-Beta-CD + 5.0 mg/ml Sodium 
Ascorbate (0.22 µm filtered)   
299.5 
 
The results proved that the filtration has no influence in the solubility of budesonide and that, 
consequently, it is possible to obtain a sterile solution without affecting the solubility of 
budesonide.  
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Subchapter conclusion 
Taking in consideration the work previously done with cyclosporin A and azithromycin, it 
was decide to prepare a budesonide/2-HP- -CD formulation using a method of preparation 
similar to the one performed for cyclosporin A.  
The results show that it is possible to apply the preparation method used for cyclosporin A to 
other water insoluble drugs. 
As a conclusion, the use of cyclodextrins allows the preparation of a sterile and stable 
aqueous solution of budesonide.   
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6.3 SUSPENSIONS 
The preparation of water insoluble/cyclodextrin solutions and the possibility of using 
suspensions as a way of increasing the solubility of water insoluble drug, such as cyclosporin 
A and azithromycin were investigated.  
However, it was decided to try a new approach using cyclodextrin in the preparation of the 
suspensions.  
Amphiphilic and hydrophobic esters of cyclodextrins have been used to prepare colloidal 
suspensions of nanospheres which can be used as carriers for hydrophobic drugs. The method 
currently used to prepare these nanospheres suspensions is called nanoprecipitation Lit [1]. 
It is based on the spontaneous assembling of the cyclodextrin molecules previously dissolved 
in a water-miscible organic solvent when it is added into an aqueous phase. Normally, the 
hydrophobic drug is added to the organic phase of the formulation. 
Another type of method, called emulsification solvent evaporation, is usually used to 
encapsulate hydrophobic drugs in polymeric matrices. It requires the emulsification of water-
immiscible organic solutions of preformed polymers in aqueous phases containing soluble 
surfactants Lit [2]. This method has been widely applied to prepare biodegradable 
microspheres (Lit. [ 3], Lit. [4] and Lit. [5]).  
Nevertheless, to obtain submicronic particles it is necessary to make modifications on the 
emulsification procedure, such as the salting-out process, high-pressure emulsification, or 
emulsification solvent diffusion (Lit. [6-11]).    
In this work, we first investigated the feasibility of preparing nanospheres from hydrophobic 
cyclodextrins, instead of using amphiphilic cyclodextrins, with the nanoprecipitation method. 
However, several other cyclodextrins with different water solubility values can also be used, 
although different results can be expected. As an example, -cyclodextrin and -cyclodextrin 
are more water soluble molecules as the -cyclodextrin but it is also possible to prepare 
nanosuspensions from the  and  cyclodextrins. Nonetheless, the method of preparation is 
different from the more hydrophobic cyclodextrins. Thus, it was decided to use hydrophobic 
cyclodextrins mainly due to availability and experimental reasons although the list of 
cyclodextrins that can be used is quite large.  
The influence of the cyclodextrin concentration on the loading capacity of a hydrophobic drug 
was also investigated. Finally, it was also studied the feasibility nebulisation of these 
formulations using a novel electronic nebuliser , the eFlow® (PARI GmbH, Starnberg, 
Germany).The eFlow® uses a vibrating perforated membrane to generate aerosols of a well 
defined droplet size distribution. 
Cyclosporin A and azithromycin were used in this study as hydrophobic model drugs.  
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6.3.1 Methods of preparation 
6.3.1.1 Preparation of cyclodextrin nanospheres loaded with insoluble drugs 
The preparation method of the cyclodextrin nanospheres consists in dissolving the 
cyclodextrin in an organic solvent miscible in water (acetone or ethanol) and adding this 
solution in an aqueous phase, with or without the presence of a surfactant, under stirring at 
room temperature. Consequently, the nanospheres precipitate spontaneously. Afterwards, the 
organic solvent, and also a part of the water, are removed by evaporation under vacuum. 
The preparation of drug-loaded nanospheres can be obtained by following the previous 
procedure, with water soluble or water insoluble drugs dissolved in the aqueous phase or the 
organic solvent, respectively. 
Nanospheres of cyclodextrin can also be prepared by using the emulsion solvent evaporation 
method [Lit12]. 
For the preparation of the cyclodextrin nanospheres, two types of cyclodextrin were used:  
 
-Cyclodextrin; 
Ethylated- -Cyclodextrin.  
As model drugs, two  water-insoluble drugs were chosen:  
Cyclosporin A; 
Azithromycin.   
6.3.1.1.1 Cyclosporin A/Cyclodextrin and Azithromycin/Cyclodextrin suspensions 
The preparation methods of the cyclosporin A/cyclodextrin and azithromycin/cyclodextrin 
nanosuspensions are described in detail in chapter 3.2.2. .   
6.3.1.2 Cyclosporin A Suspensions 
In this work, we first evaluated the feasibility of producing hydrophobic cyclodextrin 
nanospheres by the nanoprecipitation method. It is based on the spontaneous assembling of 
the cyclodextrin molecules previously dissolved in a water-miscible organic solvent (with the 
hydrophobic drug present) when it is added into an aqueous phase. 
With this purpose in mind, a cyclosporin A suspension containing 20.2 mg/ml of ethylated- -
cyclodextrin and 8.86 mg/ml Pluronic F68® in an aqueous system was prepared. 
As we can see from Figure 1, it was possible to produce ethylated- -cyclosporin 
A/cyclodextrin nanospheres. The content of cyclosporin A present in the suspension was 0.51 
mg/ml. 
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Table 1: Formulation composition of an ethylated- -cyclosporin A/cyclodextrin 
nanospheres suspension. 
Formulation  
composition 
Conc. 
(mg/ml) 
Cyclosporin A 0.51 
Ethylated- -cyclodextrin 20.2 
Pluronic F68® 8.86 
 
Figure 1: Magnified view of a cyclosporin A suspension containing 20.2 mg/ml of 
ethylated- -cyclodextrin, 0.51 mg/ml of cyclosporin A and 8.86 mg/ml Pluronic 
F68® in an aqueous system. Magnified x8000.  
After ascertaining the feasibility of forming hydrophobic cyclodextrin nanospheres, one other 
type of hydrophobic cyclodextrin was investigated for its ability on forming nanospheres, -
cyclodextrin. 
Also in his case, it was possible to form a -cyclosporin A/cyclodextrin nanospheres 
suspension (see Figure 2 to Figure 6).  
Table 2: Formulation composition of a -cyclosporin A/cyclodextrin nanospheres 
suspension. 
Formulation composition Conc. 
(mg/ml) 
-cyclodextrin 2.34 
Pluronic F68® 8.86 
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Figure 2: Overall view of a cyclosporin A suspension containing 2.3 mg/ml of -
cyclodextrin and 8.86 mg/ml Pluronic F68® in an aqueous system. Magnified x1000.   
 
Figure 3: Overall view of a cyclosporin A suspension containing 2.3 mg/ml of -
cyclodextrin and 8.86 mg/ml Pluronic F68® in an aqueous system. Magnified x2500.   
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Figure 4: Overall view of a cyclosporin A suspension containing 2.3 mg/ml of -
cyclodextrin and 8.86 mg/ml Pluronic F68® in an aqueous system. Magnified x4300.   
Figure 5: Magnified view of a cyclosporin A suspension containing 2.3 mg/ml of -
cyclodextrin and 8.86 mg/ml Pluronic F68® in an aqueous system. Magnified 
x10000.  
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Figure 6: Detail view of a cyclosporin A suspension containing 2.3 mg/ml of -
cyclodextrin and 8.86 mg/ml Pluronic F68® in an aqueous system. Magnified x17000 
and x25000.  
After confirming the feasibility of producing -cyclosporin A/cyclodextrin nanospheres, a 
new suspension was prepared (see Figure 7 and Figure 8). The composition of the formulation 
is described in Table 3.  
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Table 3: Formulation composition of a -cyclodextrin /cyclosporin A nanospheres 
suspension. 
Formulation composition Conc. 
(mg/ml) 
Cyclosporin A 1.7 
-Cyclodextrin 1.13 
Pluronic F68® 1.02 
The particle size of this suspension was also determined. The results are shown in table 4.  
Table 4: Particle size of a cyclosporin A/ -cyclodextrin suspension. 
Formulation composition Size 
(nm) 
PI 
1.7 mg/ml of cyclosporin A 
+ 1.13 mg/ml of -cyclodextrin 
+ 1.02 mg/ml Pluronic F68®  
341 0.102 
(PI: Polydispersity index)  
Figure 7: Overall view of a cyclosporin A suspension containing 1.7 mg/ml of 
cyclosporin A, 1.13 mg/ml of -cyclodextrin and 1.02 mg/ml Pluronic F68® in an 
aqueous system. Magnified x5500.  
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Figure 8: Magnified view of a cyclosporin A suspension containing 1.7 mg/ml of 
cyclosporin A, 1.13 mg/ml of -cyclodextrin and 1.02 mg/ml Pluronic F68® in an 
aqueous system.  Magnified x20000.   
A new -cyclosporin A/cyclodextrin suspension was prepared with the purpose of investigate 
its nebulisation characteristics and also to ascertain the feasibility of increasing the 
cyclosporin A concentration by increasing the amount of -cyclodextrin used (see Figure 9 to 
Figure 12).  
Table 5: Nebulization properties of a -cyclosporin A/cyclodextrin nanospheres 
suspension containing 4 mg/ml of cyclosporin A, 2.08mg/ml of -cyclodextrin, 5.3 
mg/ml Pluronic F68® and 3.08 mg/ml of Tween 80®.38 
Formulation  
Composition  
MMD 
(µm)  
GSD
 
TOR 
(mg/ml)  
Percent. 
Particles 
<5 µm 
Percent. 
Particles 
<2 µm 
4 mg/ml of cyclosporin A  
+ 2.08 mg/ml of -cyclodextrin 
+ 5.3 mg/ml Pluronic F68®  
+ 3.08 mg/ml of Tween 80® 
2.81 1.49 281 91.5 18.3 
The particle size of this suspension was also determined. The results are shown in Table 6.  
                                                          
38  MMD (NaCl) =4.36 µm; TOR (NaCl) =319 mg/ ml. Measured at a Malvern Zetasizer (Model Zetasizer 3000 
HAS, Germany). The nebulisation trial was performed using an electronic nebulizer, eflow® (Pari GmbH, 
Germany). 
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Table 6: Characteristics of the -cyclosporin A/cyclodextrin nanospheres in a 
suspension containing 4 mg/ml of cyclosporin A, 2.08mg/ml of -cyclodextrin, 5.3 
mg/ml Pluronic F68® and 3.08 mg/ml of Tween 80®. 
Formulation composition   Size 
(nm)  
PI   Zeta 
Potential (mV) 
4 mg/ml of cyclosporin A 
+ 2.08 mg/ml of -cyclodextrin 
+ 5.3 mg/ml Pluronic F68® + 
3.08 mg/ml Tween 80® 
249 0.33 - 2,8 
(PI: Polydispersity index)    
Figure 9: Overall view of a cyclosporin A suspension containing 4 mg/ml of 
cyclosporin A, 2.08 mg/ml of -cyclodextrin, 5.3 mg/ml Pluronic F68 and 3.08 mg/ml 
of Tween 80® in an aqueous system. Magnified x2000.   
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Figure 10: Overall view of a cyclosporin A suspension containing 4 mg/ml of 
cyclosporin A, 2.08 mg/ml of -cyclodextrin, 5.3 mg/ml Pluronic F68® and 3.08 
mg/ml of Tween 80® in an aqueous system Magnified x1300.   
Figure 11: Magnified view of a cyclosporin A suspension containing 4 mg/ml of 
cyclosporin A, 2.08 mg/ml of -cyclodextrin, 5.3 mg/ml Pluronic F68® and 3.08 
mg/ml of Tween 80® in an aqueous system. Magnified x3700.    
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Figure 12: Magnified view of a cyclosporin A suspension containing 4 mg/ml of 
cyclosporin A, 2.08 mg/ml of -cyclodextrin, 5.3 mg/ml Pluronic F68® and 3.08 
mg/ml of Tween 80® in an aqueous system. Magnified x10000.  
From the previous experiments, it was noticed that the solubility of -CD in ethanol may have 
an important influence on the particle size of the formulation. The presence of unsolubilized 
-CD can affect the particle size due to the formation of uncomplexed -CD aggregates. 
For this reason, in the following experiment, an ethanolic solution containing -CD was 
filtrated using a 0.22 µm filter in order to assure that all the -CD present in the ethanolic 
solution is solubilized.   
The method of preparation was:  
The -CD was added to 25 ml flask. Afterwards, the ethanol was added until the 
mark was reached. Sonification was applied for 10 min; 
After that operation was concluded, the excess of -CD was removed by using a 
0.22µm filter; 
To the last solution, 98.38 mg of cyclosporin A were added. After volume 
correction, the flask was sonificated until a clear solution was obtained; 
To this last solution, 25 ml of an aqueous solution containing 10 mg/ml of 
Pluronics F68® were added; 
 
After evaporation of the ethanol, c.a. 18 ml of the -CD/cyclosporin A were 
obtained39; 
Then, the suspension was diluted to 50 ml using a volumetric flask. As NaCl 
was used as a solvent.  
At end, the particle size of the formulation was 207.2 nm with a polydispersity index of 0.24. 
                                                          
39  In addition to the evaporation of the ethanol, also a part of the water was removed. 
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Figure 13: View of a cyclosporin A suspension containing 1.4 mg/ml of cyclosporin A 
and 10 mg/ml Pluronic F68® in an aqueous system.  
Table 7: Physicochemical properties of cyclosporin A suspension. 
Parameter Unit Value 
pH value (22.0°C) - 6.09 
Osmolarity mOsmol/kg 432  3 
Dyn. viscosity mPas 1.18  0.03 
Surface tension mN/m 38.41  0.520 
 
Table 8: Nebulization properties of a cyclosporin A/cyclodextrin nanospheres 
suspension containing 1.4 mg/ml of cyclosporin A and 10 mg/ml Pluronic F68® in an 
aqueous system. 40 
MD 
(µm) 
GSD TOR 
(mg/ml)
Percent. 
Particles 
<5 µm 
Percent. 
Particles 
<2 µm 
3.86 1.58 587 71.44 8.13 
                                                          
40 MMD (NaCl) =4.13 µm; TOR (NaCl) =754 mg/ ml. Measured at a Malvern Zetasizer (Model Zetasizer 3000 
HAS, Germany). The nebulisation trial was performed using a electronic nebulizer, eflow® (Pari GmbH, 
Germany)  
 Results   
187 
6.3.1.3 Azithromycin Suspensions 
The main purpose of this experiment was to investigate the feasibility of producing 
azithromycin/ -cyclodextrin nanospheres in comparison with the cyclosporin A suspensions. 
From the results obtained (see Figures 14 through 18), we could confirm that it is also feasible 
to manufacture azithromycin/ -cyclodextrin nanospheres. The formulation composition is 
described in table 7.  
Table 9: Formulation composition of a -cyclodextrin/azithromycin nanospheres 
suspension. 
Formulation composition Conc. (mg/ml) 
Azithromycin 7.0 
-cyclodextrin 1.11 
Pluronic F68® 7.94 
 
Figure 14: Overall view of an azithromycin suspension containing 7.0 mg/ml of 
azithromycin, 1.11 mg/ml of -cyclodextrin and 7.94 mg/ml Pluronic F68® in an 
aqueous system. Magnified x2000.  
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Figure 15: Overall view of an azithromycin suspension containing 7.0 mg/ml of 
azithromycin, 1.11 mg/ml of -cyclodextrin and 7.94 mg/ml Pluronic F68® in an 
aqueous system. Magnified x2500.   
Figure 16: Magnified view of an azithromycin suspension containing 7.0 mg/ml of 
azithromycin, 1.11 mg/ml of -cyclodextrin and 7.94 mg/ml Pluronic F68® in an 
aqueous system. Magnified x4000.   
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Figure 17: Magnified view of an azithromycin suspension containing 7.0 mg/ml of 
azithromycin, 1.11 mg/ml of -cyclodextrin and 7.94 mg/ml Pluronic F68® in an 
aqueous system. Magnified x9000.   
Figure 18: Detail view of a particle in of an azithromycin suspension containing 7.0 
mg/ml of azithromycin, 1.11 mg/ml of -cyclodextrin and 7.94 mg/ml Pluronic F68® 
in an aqueous system. Magnified x9000.  
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Chapter conclusion 
The main purpose of this part of the study was to investigate the possibility of preparing 
suspensions of water insoluble drugs through the use of cyclodextrins. The results show that it 
is possible to prepare nanosuspensions of water insoluble drugs such as cyclosporin A and 
azithromycin using the nanoprecititation method.  
In addition, the results also show that the nanosuspensions are capable of being efficiently 
nebulized through the use of the eflow®. The droplet size permits an efficient delivery of the 
active substances into the deep lung. Nevertheless, the stability of the nanosuspensions also 
needs to be taken into consideration due to the high surface area of the nanospheres. For this 
reason, the use of surfactants and also of substances that alter the zeta potential of the 
nanosuspensions, such as chitosan, needs to be studied in more detail in order to obtain a 
more stable suspension41. Furthermore, it would be advisable to use substances that provide a 
positive zeta potential such as chitosan opposing to substances that can generate negative 
charges such as sodium glycolcholate. This is due to the higher bioavailability of the CSA/CD 
nanospheres. 
Although the preparation of stable nanosuspensions of insoluble drugs was always an 
objective, a detail study of the use of such substances on the stability of the nanosuspensions 
was not a fucral part of this work. However, the stability of this cyclodextrin nanospheres can 
be further improved by the use more suitable surfactants (or combination of surfactants) and 
also through the use of substances that can alter the zeta potential of the particles with the 
purpose of obtaining a more stable nanosuspensions. 
As a conclusion, the use cyclodextrins through the application of the nanoprecititation method 
allows the preparation of nanosuspensions that are able to be efficiently nebulized into the 
deep lungs.  
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7 SYSTEMATIC FORMULATION DEVELOPMENT 
7.1 Theoretical approach 
In the development process, it is necessary to take into account various topics: from the API's 
properties, over excipient interactions, application device to the desired product; just to 
mention a few. Figure 1 describes a standard formulation development process divided into its 
tasks and subtasks.   
However, the development of pharmaceutical products suffers lack of well-established 
theories that describe interactions and relationships between excipients and drug formulation. 
The formulator may routinely access databases on previous formulations as well as make use 
of mathematical models. During the formulation process, specific tests may need to be 
performed to evaluate the properties of the proposed formulation and an analysis of 
unexpected results may result in an adjustment of the excipients and/or their levels. 
This is the reason why human experience is still very important for the optimal formulation 
search, but in order to speed up the formulation process and to increase efficacy, computer-
aiding systems can be applied. They provide assistance in understanding the complicated and 
non-linear relationships influenced by many key-factors in the pharmaceutical formulation 
development. These systems would operate under human supervision and their role would be 
associated to the decision supporting rather than taking over the whole process.  
Consequently, empirical modelling seems to be a logical alternative or addition. Among 
various tools for empirical modelling, expert systems are can be regarded to be one of the 
most common and effective.  
  
Figure 1: General operations usually performed during the (pre)formulation 
development process in the order from left to right.  
 Systematic Formulation Development   
193 
An expert system is a knowledge-based system that emulates the knowledge of human experts 
to solve significant problems in a particular area of expertise, such as pharmaceutical 
formulation development.  
Expert systems are basically computer programs that either recommend or make decisions for 
people, based on knowledge collected from experts in the field. They are mostly rule-based 
systems. 
At its basic configuration, an expert system comprises three main components:  
A user interface system that allows a two-way communication between the user 
and the system. 
A knowledge base where all the knowledge related to the subject is stored.  
An inference engine where the knowledge is extracted and applied to solve a 
specific problem.  
In a rule-based system, the knowledge needs to be highly structured42. It is often represented 
as production rules, expressing the relationship between several pieces of information. These 
are conditional statements that specify actions to be taken or advice to be followed, and have 
the form If (condition), Then (action), 43Unless (exception) and Because (reason). More 
elements can be added by having several clauses joined by operators such as And or Or or by 
nesting conditional clauses. Mathematical formulae and algorithms can also be included.  
The use of expert systems as an aid tool for the pharmaceutical formulation development 
process has several advantages. For example:   
1 Knowledge protection 
and availability 
The existence of a coherent and constant knowledge base 
which is not affected by staff turnover. 
2 Consistency It introduces robust formulations with an increased level of 
certainty and consistency. This is a particularly important 
benefit in terms of regulatory issues. 
3 Training aid It can be used to provide training for both novice and 
experienced formulators. 
4 Speed of development It allows the reduction of time in the development formulation 
process. 
5 Cost savings Cost savings can be achieved not only by reducing the 
development time but also by a more effective use of materials.
6 Freeing experts from 
trivial tasks 
The implementation of expert systems in the product 
formulation process allows expert formulators to dedicate more 
for other tasks. 
7 Improved 
communication 
Provides a common platform from which to discuss and 
manage changes in the working practice and also to identify 
those critical areas requiring research.  
                                                          
42  The InSilico-MAX software system does necessarily require that the knowledge is presented in a highly 
structured manner. 
43
   The Unless (exception) and Because (reason) terms are not so often used Seite: 3 
in the development process.  
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In this work, the InSilico-MAX software system was used to build up the expert system. It is 
tree like based structure that permits not only the processing of commands but also 
calculations at each step.   
In order for the software system to give an possible formulation, it is necessary to describe in 
detail the API properties and also the desired product profile. In addition, the device specific 
properties also have to be taken in consideration. 
As an example, the following tables show the typical API properties and product profile.    
 
Sample API properties  
Table 1: Sample API properties 
Property Value and unit 
Name  Cyclosporine A 
Solubility (pH7) Soluble in methanol, ethanol, ether, chloroform 
and methylene chloride. It is practically insoluble 
in water and saturated hydrocarbons. 
mr 148-151°C 
Incompatibilities The plasticiser diethylhexyl phthalate, which is a 
possible carcinogen, was leached from PVC 
containers by cyclosporin preparations containing 
polyethoxylated castor oil.  Such preparations 
should not be given through PVC tubing nor 
stored in PVC containers. Polysorbate 80, which 
is an excipient in other cyclosporin preparations, 
also leached plasticiser from PVC, and similar 
precautions would apply to preparations so 
formulated. 
Requires light protection Yes 
Hygroscopic No 
Stable in aqueous solution No 
Stable in buffered solution No 
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Sample product profile  
Table 2: Sample product profile 
Properties (limited by 
customer) 
Value and unit 
Name eflow® 
Type of device Nebuliser 
Max. Volume for formulation 4 ml 
Viscosity 1 to 2.5 mPa s 
Surface tension < 73 mN/m 
pH 4.5-8.0 
Suitable for suspensions Yes 
By choosing a device in the previous list, a number of device specific properties 
(requirements) are attached to the product profile list. A sample list listed:  
Table 3: Sample product profile list.  
Properties (limited by 
device) 
Value and unit 
Device Name Eflow 
Max. applicable volume 4 ml 
Surface tension < 73 mNm 
Viscosity < 2.5 mPa 
PH 4.5-8.0 
     
7.1.1 Measures (Excipients and Procedures) 
In the database, several excipients and procedures can be employed in order to resolve the 
possible formulation development problems. A description of the formulation development 
problems is showed on table 1. The excipients and also the procedures required to solve the 
development problems are presented in table 2 to table 16. However, the substances and the 
procedures described serve as reference. Nevertheless, further substances and procedures can 
be added to the system.      
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Table 4: Description of the possible development problems. 
Development Problem
 
Development Step Measures
Solubility Solubility 
enhancement 
Yes 
Viscosity Viscosity correction  Yes 
Surface Tension Surface tension 
correction  
Yes 
Osmolarity Osmolarity correction Yes 
Total Output Rate Total Output Rate 
correction 
Yes 
Particle size Particle size 
correction  
Yes 
pH pH correction  Yes 
Volume Volume correction  Yes 
Taste Taste Masking Yes 
Self Life Stability Stability Yes 
 
Table 5: Hydrophilic Cyclodextrins 
Name   Function   Company  Group 
Number
Acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
2,3,6-Tri-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
2,3,6-Tri-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
2,3,6-Tri-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
2,6-Di-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Randomly methylated- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Randomly methylated- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Randomly methylated- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
2-Hydroxyproply- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
2-Hydroxyproply- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
2-Hydroxyproply- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
sulfobutylether- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
6-O-maltosyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
6-O-maltosyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Carboxymethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
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Carboxymethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Carboxymethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Succinyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Succinyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Succinyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Succinyl- -Hydroxypropyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Succinyl-2-Hydroxypropyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
Succinyl-2-Hydroxypropyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 1 
 
Table 6: Hydrophobic Cyclodextrins 
Name  Function   Company  Group 
Number
2,3,6-Tri-O-acetyl-1-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
2,3,6-Tri-O-acetyl-2-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
2,3,6-Tri-O-acetyl-3-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
Ethyl-1-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
Ethyl-2-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
Ethyl-3-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
2,6-Di-O-ethyl-2-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
2,6-Di-O-ethyl-3-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
2,3,6-Tri-O-ethyl-2-cyclodextrin Solubilisation Sigma Aldrich, Germany 2 
Table 7: List of the solubility enhancement additives. 
Name  Function   Company  Group 
Number
HPMC Solubilisation Enhancement Fluka, Germany 3 
PVP K30 Solubilisation Enhancement Fluka, Germany 3 
Ascorbic Acid Solubilisation Enhancement Fluka, Germany 3 
Sodium Ascorbate Solubilisation Enhancement Fluka, Germany 3 
Nicotine amide Solubilisation Enhancement Fluka, Germany 3 
CMC Solubilisation Enhancement Fluka, Germany 3 
Lysine Monohydrate Solubilisation Enhancement Fluka, Germany 3 
Sodium acetate Solubilisation Enhancement Fluka, Germany 3 
Sodium citrate Solubilisation Enhancement Fluka, Germany 3 
Lactic acid Solubilisation Enhancement Fluka, Germany 3 
Citric Acid Solubilisation Enhancement Fluka, Germany 3 
Systematic Formulation Development 
198 
MgSO4.6H20 Solubilisation Enhancement Fluka, Germany 3 
CaCl2.2H2O Solubilisation Enhancement Fluka, Germany 3 
Vitamin E  Solubilisation Enhancement Fluka, Germany 3 
Vitamin E acetate Solubilisation Enhancement Fluka, Germany 3 
  
Table 7: Alpha Type Hydrophilic Cyclodextrins 
Name  Function   Company  Group 
Number
Acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 4 
2,3,6-Tri-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 4 
Randomly methylated- -cyclodextrin Solubilisation Sigma Aldrich, Germany 4 
2-Hydroxyproply- -cyclodextrin Solubilisation Sigma Aldrich, Germany 4 
6-O-maltosyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 4 
Carboxymethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 4 
Succinyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 4 
Table 8: Beta Type Hydrophilic Cyclodextrins 
Name  Function   Company  Group 
Number
Acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
2,3,6-Tri-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
2,6-Di-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
Randomly methylated- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
2-Hydroxyproply- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
Sulfobutylether- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
6-O-maltosyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
Carboxymethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
Succinyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
Succinyl-2-Hydroxypropyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 5 
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Table 9: Gamma Type Hydrophilic Cyclodextrins 
Name  Function   Company  Group 
Number
Acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 6 
2,3,6-Tri-O-methyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 6 
Randomly methylated- -cyclodextrin Solubilisation Sigma Aldrich, Germany 6 
2-Hydroxyproply- -cyclodextrin Solubilisation Sigma Aldrich, Germany 6 
Carboxymethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 6 
Succinyl-2-Hydroxypropyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 6 
 
Table 10: Alpha Type Hydrophobic Cyclodextrins 
Name  Function  Company  Group 
Number
2,3,6-Tri-O-acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 7 
Ethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 7 
Table 11: Beta Type Hydrophobic Cyclodextrins 
Name  Function  Company  Group 
Number
2,3,6-Tri-O-acetyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 8 
Ethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 8 
2,6-Di-O-ethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 8 
2,3,6-Tri-O-ethyl- -cyclodextrin Solubilisation Sigma Aldrich, Germany 8 
Table 12: Gamma Type Hydrophobic Cyclodextrins 
Name  Function  Company  Group 
Number
2,3,6-Tri-O-acetyl-3-cyclodextrin Solubilisation Sigma Aldrich, Germany 9 
2,6-Di-O-ethyl-3-cyclodextrin Solubilisation Sigma Aldrich, Germany 9 
      
Systematic Formulation Development 
200 
Table 13: List of excipients for the surface tension correctors. 
Name  Function  Company  Group 
Number
 
Tyloxapol Surface tension adjustment  Sigma Aldrich, Germany 10 
Polysorbate Surface tension adjustment   Merck, Germany 10 
Sorbitan 
monooleate 
Surface tension adjustment   Merck, Germany 10 
    
Table 14: List of excipients for the taste masking. 
Name  Function   Company  Group 
Number
Macrogolglycerol-
hydroxystearate 
Taste Masking Sigma Aldrich, Germany 11 
Sodium Citrate Taste Masking Caelo, Germany 11 
Lysine monohydrate Taste Masking Sigma-Aldrich 11 
Sodium Chloride Taste Masking Caelo, Germany 11 
Table 15: List of excipients for the taste masking. 
Name  Function   Company  Group 
Number
Glucose Taste Masking Sigma Aldrich, Germany 12 
Fructose Taste Masking Sigma Aldrich, Germany 12 
Saccharin Taste Masking Sigma Aldrich, Germany 12 
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7.1.2 Monographs 
See appendix 3.  
7.1.3 Rules 
7.1.3.1.1 Rules for the Solubility problem 
The solubility of the water insoluble drugs needs to be increased as much as possible. For this 
reason, several excipients can be used. 
However, if the solubility can not be increased through the use of the several different actions, 
other approaches can be investigated. As an example, the increase of the intrinsic solubility of 
the drug through the use of specific solvent or solvents combinations.   
Rule 1:  
IF  Desired Release Profile: Immediate Release  
THEN  System Decision: Choose from Hydrophilic CD (Group 1)   
Rule 2:  
IF  Desired Release Profile: Sustained Release  
THEN  System Decision: Choose from Hydrophobic CD (Group 2)   
Rule 3:  
IF  Result Test A44= Type CD AND  Desired Release Profile: Immediate 
Release  
THEN  System Decision: System Decision: Choose from Hydrophilic- -CD (Group 4)   
Rule 4:  
IF  Result Test A= Type CD AND  Desired Release Profile: Immediate 
Release  
THEN  System Decision: Choose from Hydrophilic- -CD (Group 5)    
                                                          
44
 Test A: see appendix 3 for a detailed description. 
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Rule 5:  
IF  Result Test A= Type CD 
 
AND  Desired Release Profile: Immediate 
Release  
THEN  System Decision: Choose from Hydrophilic- -CD (Group 6)   
Rule 6:  
IF  Result Test A= Type CD AND  Desired Release Profile: Sustained 
Release  
THEN  System Decision: Choose from Hydrophobic- -CD (Group 7)   
Rule 7:  
IF  Result Test A= Type CD AND  Desired Release Profile: Sustained 
Release  
THEN  System Decision: Choose from Hydrophobic- -CD (Group 8)   
Rule 8:  
IF  Result Test A= Type CD AND  Desired Release Profile: Sustained 
Release  
THEN  System Decision: Choose from Hydrophobic- -CD (Group 9)   
Rule 9:  
IF  Solubility increase <5%  AND  Cyclodextrin concentration >100 mg/ml  
THEN  System Decision: Choose from Additives from Group 3   
Rule 10:  
IF  Solubility increase <5%  AND  Cyclodextrin concentration >100 mg/ml 
OR Additives concentration >5%   
THEN  System Decision: Change Cyclodextrin Derivative   
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7.1.3.1.2 Rules for the Viscosity problem 
The viscosity of the formulation plays a very important role in the in the drug delivery 
performance. It has not only an important influence on the droplet size but also on the total 
output rate of the nebulizer. For this reason, the viscosity value must be located between a 
determined range. In order to achieve this goal, the possible actions that can be taken are 
described in the following rules.   
Rule 1:  
IF  Viscosity of formulation <2.5 mPa s  
THEN  System Decision: No Action required.  
Rule 2:  
IF  Viscosity of formulation > 2.5 mPa s    
THEN  System Decision: decrease the concentration of the cyclodextrin derivative   
Rule 3:  
IF  Viscosity of formulation > 2.5 mPa s   AND concentration of the 
cyclodextrin derivative <1%  
THEN  System Decision: decrease the concentration of the additive    
7.1.3.1.3 Rules for the Surface Tension problem 
The surface tension of the formulation has influence on the droplet size and consequently, in 
the drug delivery performance. For this reason, the surface tension of the formulations must 
be below a specific value. In order to achieve this goal, the possible actions that can be taken 
are described in the following rules.   
Rule 1:  
IF  Surface Tension of formulation <73 mN/m  
THEN  System Decision: No Action required.  
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Rule 2:  
IF  Surface Tension of formulation >73 mN/m  
THEN  System Decision: Choose Additive from Group 10   
7.1.3.1.4 Rules for the Osmolarity problem 
The osmolarity value of the formulations has to be located within the physiological values 
that can be tolerated by the lungs cells. Consequently, several actions have to be taken if the 
osmolarity value of the formulation is not located within the allowed value range.   
Rule 1:  
IF  Osmolarity of formulation 286<Ohm<600 mosmol/kg  
THEN  System Decision: No Action required.   
Rule 2:  
IF  Osmolarity of formulation <286 mosmol/kg  
THEN  System Decision: Add NaCl to the formulation   
Rule 3:  
IF  Osmolarity of formulation >600 mosmol/kg  
THEN  System Decision: decrease concentration of additives   
7.1.3.1.5 Rules for the Total Output Rate problem 
The total output rate of the nebuliser is closely related to the patient compliance. Longer 
nebulisation time usually exert a negative effect on the treatment compliance by the patients, 
in particular with younger patients. For this reason, it is important to have a high total output 
rate in order improve the patient compliance.    
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Rule 1:  
IF  Total Output Rate of formulation 200 mg/min  
THEN  System Decision: No Action required.   
Rule 2:  
IF  Total Output Rate of formulation <200 mg/min  
THEN  System Decision: decrease viscosity of formulation   
7.1.3.1.6 Rules for the Particle Size problem 
For optimal lung delivery, it is important to have the correct aerosol particle size. 
Consequently, particles should range from 1 to 3.5 µm in diameter for optimal deposition 
efficiency. The following rules can be applied in order to obtain the correct particle size.  
Rule 1:  
IF  Particle Size of Formulation 1 µm<PS<3.5 µm  
THEN  System Decision: No Action required.   
Rule 2:  
IF  Particle Size of Formulation >3.5 µm  
THEN  System Decision: Decrease size of nebulising head   
Rule 3:  
IF  Particle Size of Formulation <1 µm  
THEN  System Decision: Increase size of nebulising head   
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7.1.3.1.7 Rules for the pH problem 
The pH value of the formulations has to be located within the physiological values that can be 
tolerated by the lungs cells. The pH adjustment of the formulations can be obtained by 
performing the following actions.  
Rule 1:  
IF  pH of formulation 4.5>pH<8.0  
THEN  System Decision: No Action required.   
Rule 2:  
IF  pH of formulation 4.5<pH> 8.0  
THEN  System Decision: Add acid or Base   
7.1.3.1.8 Rules for the Volume problem 
In order to have an uniform drug dose delivery, the volume that can be used has to be located 
between specific values. If not, the following actions have to be taken.  
Rule 1:  
IF  Volume of formulation Product-profile.volume-lowlimit >Vol. <4.0 ml  
THEN  System Decision: No Action required.   
Rule 2:  
IF  Volume of formulation Vol.>4 ml  
THEN  System Decision: Doses reduction   
Rule 3:  
IF  Volume of formulation Vol. <0.5 ml  
THEN  System Decision: Add isotonic solution   
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7.1.3.1.9 Rules for the Taste problem 
The taste of the formulations has a very important influence in patient compliance, especially 
in the case of young patients. Consequently, the following actions have to be taken in order to 
obtain a formulations that is suitable for inhalation in terms of its taste.  
Rule 1:  
IF  Taste of Formulation is Neutral OR Tolerable  
THEN  System Decision: No Action required.   
Rule 2:  
IF NOT  Taste of Formulation is Neutral OR Tolerable  
THEN  System Decision: Increase Cyclodextrin Concentration   
Rule 3:  
IF NOT  Taste of Formulation is Neutral OR Tolerable AND Cyclodextrin 
concentration > 100 mg/ml   
THEN  System Decision: Decrease Drug Concentration   
Rule 4:  
IF NOT  Taste of Formulation is Neutral OR Tolerable AND Cyclodextrin 
concentration > 100 mg/ml AND Drug concentration too Low  
THEN  System Decision: Choose Additives from Group 11 and 12  
7.1.3.1.10 Rules for the Stability problem 
To have a stable formulation it is also an important objective to achieve. Consequently, the 
following approaches can be taken.  
Rule 1:  
IF   Stability of Formulation >4 weeks  
THEN  System Decision: No Action required.  
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Rule 2:  
IF  Stability of Formulation <4 weeks  
THEN  System Decision: Lyophilization   
Rule 3:  
IF  Stability of Formulation <4 weeks  
THEN  System Decision: N2 Degassing  
7.1.3.1.11 Rules for the back steps 
The return to a previous development step occurs when the system has no pre-determined 
action available for a specific problem in the development process. Consequently, a system 
should offer specific back steps prepared for these situations. The back steps that can be 
applied by the system are described in table 15. 
However, with the InSilico-MAX software system, it is possible to step back to any specific 
development step when wanted. No special structuring is required. The back steps described 
in table 15 serve only as guidance.  
Table 16: Description of the back steps present in the system. 
From Development Step
 
To Development Step
Viscosity Solubility 
Surface Tension Solubility 
Osmolarity Solubility 
Taste Masking Solubility 
Stability Solubility 
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7.1.3.1.12 Rules for the prognosis of formulation properties 
The rules applied by system for the formulation prognosis are described on table 17.   
Table 17: Rules for the formulation prognosis 
Property Action Step Formula 
Particle size (MMD) Nebulisation MMD=4.25-0.72*Viscosity 
Particle size (MMD) Nebulisation MMD=10,67-0.013*Surface Tension 
Total Output Rate (TOR) Nebulisation TOR=748.2-204*Viscosity 
Surface tension Nebulisation Predicted by Neural Network 
Surface tension is predicted by applying a neural network with 3 nodes in a hidden layer. 
Viscosity is included in the network for comparison only since the expert system will use a 
conventional formula for the predictions.  
Figure 2: Structure of the applied neural network   
The quality of the predicted values is shown in the following figures:  
   
Figure 4: Correlation and relative deviation between real and predicted values of 
surface tension and viscosity  
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7.1.3.1.13 Rules for the quantity of excipients 
Concentrations or amounts will be calculated based on previous knowledge. However, the 
quantity of each excipient that can be added will also depend on its toxicology. 
The amount of excipients added to the formulation will be determined based on the following 
formulas:  
Table 18: Rules for the quantification of the amount of excipients 
Action Group  Formula/Amount (per ml)45 
Solubility improvement  
with CD/ immediate release 
mCD= (100-mDS)/S0 [mg] 
Solubility improvement  
with CD/ sustained release 
mCD= (10-mDS)/S0 [mg] 
Solubility enhancement additives mEA=mCD/10 [mg] 
Surface tension improvement  Rule of thumb (mST=mCD/100 
[mg]) or based on functional 
connection /Neural Net 
 
7.2 Implementation 
The development of a new formulation starts with an API and should result in a formulation, 
which has to meet a certain profile (several requirements like dose, applicable volume etc.). 
API as well as the profile can be characterised by properties and their values. These are stored 
in variables. The assigned variable names for API and profile are listed in the following two 
tables.  
Notes how to read the tables: 
variables, which characterise an excipient, device etc. but not relevant for program 
execution are printed on grey background for these and the following tables in this 
chapter. 
The last column contains information about where this data comes from: 
D: stored in a knowledge base data file 
S: generated during system execution  
Table 19: Properties of an API represented by variables 
Variable Remark origin 
Name D 
Shortname D 
Mass Quantity of substance expressed in g S 
                                                          
45
 CD: Cyclodextrins; TM: taste masking;ST: Surface tension;EA: Enhancement additives: S0: Intrinsic solubility 
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Solubility  D 
Taste  D 
Conc Concentration expressed in g/ml S 
Fvisc  D 
Ovisc  D 
Liso LIso value required for calculation of osmolarity D 
DT Freezing point depression of a 1% solution [°C] D 
Size Geometrical molecule size [nm]. Used to see whether molecule fits into 
CD cavity 
D 
MW Molecular weight D 
Mol Quantity of substance expressed in mol S 
PH PH value of 5% dispersion in water at RT D 
CDequivalents The number of CD molecules needed to complex one API molecule (=1 
for smal molecules, 2 or more for larger API molecules) 
S 
Hydrolip$ Whether API is hydrophilic or lipophilic D 
Oxprob Is API sensitive to oxidation? D 
Lightprob Does the API require light protection? D 
Hygroscopic Wheter the API is hygroscopic D 
Aqstable Whether the API is stable in aqueous solution D 
Buffstable Whether the API is stable in a buffered solution D 
Incomp$ The API's known incompatibilitites D 
Table 20: Properties of a product profile 
Variable Remark Origin 
Name D 
Shortname D 
Type$ immediate  
Dose  D 
Mintaste  D 
Device$  D 
Release$ Immediate or sustained release D 
MinpH Minimally tolerable pH D 
MaxpH Maximally tolerable pH D 
OptpH Optimum pH D 
Some important properties regarding volume, the type of dosage form (suspension/solution), 
viscosity etc. seem to be missing in the above table. Instead the device is a part of the product 
profile and the device's properties are stored in a separate file. It makes sense to split the 
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formulation into two parts, because device specific properties stay constant for a certain 
device while dosing or the acceptance criteria for taste might differ from product to product. 
Nevertheless, the device specific properties must be regarded as a part of the formulation. 
They are listed in the next table.  
Table 21: Properties of a device 
Variable Remark Origin 
Name 
 
D 
Shortname D 
Suspsol$ Whether the device can handle suspensions, solutions or both D 
Maxviscosity The maximum viscosity for a solution to be nebulised by the device D 
Optvolume optimum volume that the device should be filled with D 
Maxvolume maximum capacity of formulation that the device can hold D 
Maxsurf Maximum surface tension D 
holediameter The diameter of the nebuliser membrane's holes  D 
Maxpartsize Maximum size of particles D 
Based on the API data, the profile and the device characteristics, the system is supposed to 
guide the user in the selection of appropriate ecxipients in order to generate a formulation. 
Ihis formulation again exhibits some characteristics; mainly regarding actual volume, actual 
taste, pH, viscosity, surface tension etc. The formuletion's properties are listed in the 
following table:  
Table 22: Formulation properties 
Variable Remark Origin 
Name$ (S) 
Shortname$ (S) 
Type$ Whether it is a solution or a suspension S 
Volume The total volume of the final formulation S 
Viscosity The actual viscosity S 
PH The formulation's pH S 
Surftens The surface tension of the formulation S 
Osmol Its osmolariry S 
MMD The size of the drops generated by the nebuliser when the formulation is 
nebulised 
S 
TOR Total output ratio S 
The excipients needed to transfer the API into the final formulation can be grouped into the 
following categories:   
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Table 23: Excipient categories 
Category Names used by the 
system 
Comment 
Solubility 
enhancers 
Solenhancers For poorly soluble drugs, solubility enhancers can be used to 
keep the drug in solution. The main solubility enhancers used 
and investigated in this thesis are cyclodextrins (CD), especially 
-cyclodextrinderivates  
Additional 
solubility 
enhancers 
Additional To incorporate a drug in the center of the CD and to fill out the 
CD-cavity perfectly, some additional excipients might be used. 
Surfactants Surfactant Used to decrease surface tension 
PH agents Phcorrect Used to correct the pH of the formulation to tolerable levels. PH 
agents are split into two groups: acids and bases 
Isotonants Isotonant Used to correct the osmolarity of the formulation to tolerable 
levels 
 
Each group of excipients can be characterised by specific properties as listed in the following 
tables:  
Table 24: properties of solubility enhancer 
Variable Remark Origin 
Name D 
Shortname D 
MW The molecular mass D 
Glucunits The number of glucose units D 
PKa PKa at 25°C D 
Enthalpy of 
solution 
D 
Entropy of 
solution 
D 
Hydrolysis  Semiquantitative evaluation of hydrolysisby a. oryzea -amylase D 
Type Whether it's a Cyclodextrin (CD) or other D 
Hydrolip Whether CD is hydrophilic or lipophilic D 
Cavdiam Diameter of the cavity D 
Torusheight Height of the torus D 
Solubility The enhancer's solubility in Water at 25°C (not to be messed up with the 
solubilising potential of the solubility enhancer) 
D 
Fvisc  D 
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Ovisc  D 
Liso LIso value required for calculation of osmolarity D 
Mass Quantity of substance expressed in g S 
Conc Concentration expressed in g/ml S 
DT Freezing point depression of a 1% solution [°C] D 
Mol Quantity of substance expressed in mol S 
Surftens  D 
 
Table 25: properties of additional solubility anhancers 
Variable Remark Origin 
Name D 
Shortname D 
Fvisc  D 
Ovisc  D 
Liso LIso value required for calculation of osmolarity D 
Mass Quantity of substance expressed in g S 
Conc Concentration expressed in g/ml S 
DT Freezing point depression of a 1% solution [°C] D 
Table 26: properties of taste masking excipients 
Variable Remark Origin 
Name D 
Shortname D 
Liso LIso value required for calculation of osmolarity D 
Mass Quantity of substance expressed in g S 
Conc Concentration expressed in g/ml S 
DT Freezing point depression of a 1% solution [°C] D 
Tasteimp Tasteimprovement in ranks D 
Usualconc Usual concentration in g/ml D 
Table 27: surfactant properties 
Variable Remark Origin 
Name D 
Shortname D 
Fsurf  D 
Liso LIso value required for calculation of osmolarity D 
Mass Quantity of substance expressed in g S 
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Conc Concentration expressed in g/ml S 
DT Freezing point depression of a 1% solution [°C] S 
Table 28: properties of pH agents (acids, bases, buffers) 
Variable Remark Origin 
Name D 
Shortname D 
Type Whether the pH-agent is a buffer, acid or base D 
Subtype "Strong" or "weak" (applies only to acids and bases and is used to calculate 
the resulting pH correctly) 
D 
PH The resulting pH (applies only to buffers since resulting pH is mainly 
independent of the buffer concentration) 
D 
PKa The pka is necessary to calculate the D 
Liso LIso value required for calculation of osmolarity D 
Volume  S 
Mass Quantity of substance expressed in g S 
Conc Concentration expressed in g/ml S 
MW Molecular weight D 
DT Freezing point depression of a 1% solution [°C] D 
Usualconc The usual concentration in which a buffer is applied D 
Val  D 
Table 29: isotonant properties 
Variable Remark Origin 
Name D 
Shortname D 
Liso LIso value required for calculation of osmolarity D 
Mass Quantity of substance expressed in g S 
Conc Concentration expressed in g/ml S 
DT Freezing point depression of a 1% solution [°C] D 
Table 30: medium properties 
Variable Remark Origin 
Name D 
Shortname D 
mass Quantity of substance expressed in g S 
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Table 31: Specific non-continuous, attributive values for some variables 
Variable Values 
aqstable 0: no 
1: yes = is stable in aqueous solution 
buffstable 0: no 
1: yes = is stable in buffered solution 
hydrolipo$ Hydrophilic 
Lipophilic 
Hydrolysis 0: none 
1: negligible 
2: low 
3: rapid 
hygroscopic 0: no 
1: yes = is hygroscopic 
lightprob 0: no 
1: yes = shows sensitivity to light 
oxprob 0: no 
1: yes = shows oxidative problems 
release$ Immediate 
Sustained 
subtype Weak 
Strong 
suspsol$ Suspension (which means suitable for suspensions and solutions) 
Solution (for solutions only; device not suitable for suspensions) 
taste 1: excellent / no taste 
2: slightly noticable taste 
3: noticable bad taste (slightly bitter) 
4: just tolerable (bitter) 
5: intolerable (very bitter) 
6: disgusting 
Type$ CD for cyclodextrins 
Acid for acids 
Base for bases 
Buffer for buffers 
 
Provided all necessary data concerning API, excipients and devices are given and a profile is 
specified, the system can start formulation development. The following problems are handled:  
Solubility / dispersion type (cell 20) 
Based on the API's solubility, the program checks whether a true solution can be 
accomplished. 
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If this is not the case, either solubility enhancers must be used or a suspension can be 
formulated. 
For solutions (cell 11), the necessary amount of CD is calculated on molar basis while the 
API size is also taken into account. 
If the device can't handle suspensions, the solubility enhancer pathway (cell 18) must be used.  
Taste masking (cell 11) 
If the profile requires a taste better than the API's taste, taste masking has to take place.  
If a CD is already used for solubility issues, the CD's taste masking properties can be 
exploited. Otherwise one of the taste masking agents ("masker") has to be used.  
Additional solubility enhancers (cell 11) 
In most of the cases when a CD is used as the main excipient, the API won't perfectly fit into 
the cavity. Therefore additional excipients, the so called additional solubility enhancers 
("additional") are used. They are selected in dependence of the mismatch between CD cavity 
size and API molecule size. 
The amount of additional is set to 1/10th of the solubility enhancer's mass.  
PH (cell 14) 
The pH is influenced by the API first. All APIs are regarded to be weak acids/bases46 and 
their strength is represented by their pKa values. 
PH calculation is based on the formula 
clogpKa
2
1pH
with c being the API concentration.  
A pH deviation from the profile's optimum pH has to be corrected using acidic or basic pH 
agents (pHcorrect). They cause a change in osmolarity in return, however. 
The necessary amount or pHcorrect is calculated by applying the titration formula for weak 
acids with strong bases: 
1logpKapH  
in its delogarithmed form: 
base
base
a
c
ccK)H(c
 
which results in 
110
c
c pHpKabase
cbase represents the concentration of a onebasic (val = 1) base. This is transformed to the bases 
mass by 
mbase = cbase  M  V  val  
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where M is the bases molecular weight and V the formulation's volume. Val contains the 
number of OH- equivalents per mole of base.  
Surface tension (cell 13) 
Surfactants may be used to correct the formulation's surface tension. The use of surfactants 
also influences osmolarity.  
Osmolarity (cell 15) 
Since osmolarity should be within the range specified in the product profile, either isotonants 
have to be added or the formulation must be diluted  
Viscosity (cell 12) 
The viscosity of the final formulation is not changed by any means but must be calculated 
since it's a necessary parameter for the calculation of derived formulation properties as MMD 
and TOR.  
When using the suspension pathway (cell 18), the program performs the same actions except 
for unnecessary calculations concerning the API like pH, surface tension etc. Also a different 
output template is used since manufacturing of a suspension differs from the manufacturing 
procedure of a solution, of course. Therefore the following excerpt of the knowledge base 
concentrates on the formulation development of solutions.  
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7.2.1 Knowledge base 
The complete knowledge base and the appropriate datafiles are available via internet and will 
be updated from time to time. The latest version is accessible via 
http://www.jmbnet.de/thesis/raposo/index.html. An excerpt of the knowledge based is 
presented here:  
------------------------------------------------------------ 
No:    1 
Root:  0  
Question: 
Would you like to start a formulation or view the instructions?  
Comment: 
keytext "start formulation\view instructions"  
Branches: 
Key: s branch to cell nr.  3 
Key: i branch to cell nr.  2  
------------------------------------------------------------ 
No:    2 
Root:  1  
Question: 
Would you like to read the system manual or instructions how to add new APIs, 
devices and excipients?  
Comment: 
keytext "system manual", "instructions"  
Branches: 
Key: s branch to cell nr.  4 
Key: i branch to cell nr.  5  
------------------------------------------------------------ 
No:    3 
Root:  1  
Question: 
choose: existing or new api   
Commandfile: 
tablechoosefrom "API", "api.txt", "api", a$, b$, n 
'loadincomps "incomp.txt", "known" 
'clearincomps  
if b$ = "newdrug" then 
 gotocell 9 
else 
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 concat sect$, b$, ":api" 
 tablereadvariables "api.txt", sect$ 
 'addtoincomps api.excipient$, api.backbone$, api.incomp$ 
 gotocell 10 
endif 
------------------------------------------------------------ 
No:    4 
Root:  2  
Question: 
system manual   
Branches: 
Key: n branch to cell nr.  6  
Commandfile: 
rtfload "system_manual.rtf" 
rtfview 
gotocell 6 
------------------------------------------------------------ 
No:    5 
Root:  2  
Question: 
Would you like to add new properties to existing APis/Devices/Excipients or add 
completely new API/Device/Excipient entities?  
Comment: 
keytext "new properties\new entities"  
Branches: 
Key: p branch to cell nr.  7 
Key: e branch to cell nr.  8  
------------------------------------------------------------ 
No:    6 
Root:  4  
Answer: 
Resume from start   
Commandfile: 
gotocell 1 
------------------------------------------------------------ 
No:    7 
Root:  5  
Answer: 
Instructions: enter new properties   
Commandfile: 
rtfload "new_properties.rtf" 
rtfview 
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gotocell 6 
------------------------------------------------------------ 
No:    8 
Root:  5  
Answer: 
instructions: enter new entities   
Commandfile: 
rtfload "new_entities.rtf" 
rtfview 
gotocell 6 
------------------------------------------------------------ 
No:    9 
Root:  3  
Answer: 
Ask for relevant API data   
Commandfile: 
askfor "API Name", "Name of API", api.name$ 
askfor "API shortname", "Name of API", api.short$ 
askfor "API", "molecular mass", api.mw 
askfor "API solubility", "solubility", api.solubility 
askfor "API taste", "API taste", api.taste 
askfor "API", "viscosity slope", api.fvisc 
askfor "API", "viscosity offset", api.ovisc 
askfor "API", "L Iso", api.Liso 
askfor "API", "oxidation", api.oxproblem 
askfor "API", "sensitivity to light", api.lightproblem  
askfor "API", "hygroscopicity", api.hygroscopic 
askfor "API", "stability in water", api.aqstable 
askfor "API", "stability in buffer", api.buffstable 
askfor "API", "Name of API", api.name$ 
askfor "API", "known incompatibilities", api.incomp$ 
askfor "API", "alkaline / acid reaction", api.acidbase$ 
askfor "API", "pKa", api.pKa  
gotocell 10 
------------------------------------------------------------ 
No:    10 
Root:  3      
Question: 
choose or enter product profile  
Comment: 
branch to solutions or suspension afterwards   
Commandfile: 
'***** Product profile ***** 
tablechoosefrom "Product profile", "profile.txt", "profile", a$, b$, n 
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concat b$, b$, ":profile" 
tablereadvariables "profile.txt", b$  
if api.dose = 0 then 
 askfor "Dose", "Dose in mg", profile.dose 
endif  
if profil.sname$ = "newprofile" then 
 'not implemented yet 
 'ask for all the relevant properties here 
 gotocell 19 
endif  
gotocell 20 
------------------------------------------------------------ 
No:    11 
Root:  20  
Question: 
solutions   
Branches: 
Key: n branch to cell nr.  12  
Commandfile:  
'*** solutions *** 
chooseenhancer = 0 
solenhancer.name$ = "(not required)" 
solenhancer.mass = 0 
masker.mass = 0 
masker.name$ = "(not required)" 
isotonant.mass = 0 
isotonant.name$ = "(not required)" 
additional.mass = 0 
additional.name$= "(not required)" 
surfactant.mass = 0 
surfactant.name$ = "(not required)" 
explanation$ = "" 
formulation.volume = device.optvolume 
formulation.name$ = profile.name$ 
api.mass = profile.dose 
formulation.taste = api.taste 
required.solubility = api.mass / formulation.volume  
'use water as medium 
 tablereadvariables "medium.txt", "H2O:medium"   
'if solubility or taste is too bad, CD complexation has to be chosen 
if api.solubility < required.solubility then 
 Message "Solubility", "API solubility is too poor. A solubility enhancer is needed." 
 concat explanation$, explanation$, "API solubility is too poor; therefore a solubility 
enhancer is used. " 
 chooseenhancer = 1 
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endif  
if api.taste > profile.mintaste then 
 if chooseenhancer = 0 then 
  'no extra taste masking needed when CD is used 
  message "Taste masking", "API taste is inacceptable. Tastemasking is required." 
  tablechoosefrom "taste masker", "masker.txt", "masker", a$, b$, n 
  concat b$, b$, ":masker" 
  tablereadvariables "masker.txt", b$ 
  formulation.taste = formulation.taste - masker.tasteimp   
  concat explanation$, explanation$, "Poor API taste requires tastemasking 
([masker.name$]). " 
  masker.mass = masker.usualconc * formulation.volume 
  masker.conc = masker.mass / formulation.volume 
  showvariables 
 endif 
endif  
'there's no better taste than "excellent" 
if formulation.taste < 1 then 
 formulation.taste = 1 
endif  
if chooseenhancer = 1 then 
 'choose a solubility enhancer here 
 if profile.release$ = "immediate" then 
  tablechoosefrom "hydrophilic solubility enhancer", "solenhancer.txt", "solenhancer", 
a$, b$, n 
  concat explanation$, explanation$, "For immediate release a hydrophilic solubility 
enhancer ([solenhancer.name$]) is chosen. "  
 else 
  tablechoosefrom "lipophilic solubility enhancer", "solenhancer.txt", "solenhancer", a$, 
b$, n 
   concat explanation$, explanation$, "for sustained release a hydrophobic solubility 
enhancer  ([solenhancer.name$]) is chosen. "    
 endif 
 concat b$, b$, ":solenhancer" 
 tablereadvariables "solenhancer.txt", b$ 
 api.conc = api.mass / formulation.volume 
 api.mol = api.mass / api.mw 
 'use an excess of 50% CD to complex API 
 concat explanation$, explanation$, "A 50% (mol/mol) excess of solubility enhancer is 
used to complex [api.name$]. " 
 solenhancer.mol = api.mol * 1.5 
 solenhancer.mass = solenhancer.mw * solenhancer.mol 
 solenhancer.conc = solenhancer.mass / formulation.volume 
   
 if solenhancer.type$ = "CD" then 
  concat explanation$, explanation$, "The use of a cyclodextrin also improves taste for 
up to [solenhancer.tasteimp] units. " 
  formulation.taste = api.taste - solenhancer.tasteimp 
  'check for cavity size 
  cavsizemismatch = solenhancer.cavsize / api.size  
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  if ( cavsizemismatch < 0.9 ) 
   message "Cavity size", "CD cavity size doesn't mach api size"  
   'choose an additional excipient 
   tablechoosefrom "Additional enhancer", "additional.txt", "additional", a$, b$, n 
   concat b$, b$, ":additional" 
   tablereadvariables "additional.txt", b$ 
   concat explanation$, explanation$, "Since API size ([api.size] pm) doesn't match CD 
cavity ([solenhancer.cavdiam] pm), an additional enhancer ([additional.name$]) is 
required. It's mass is set to one tenth of the CD's mass. "  
   additional.mass = solenhancer.mass / 10 
   additional.conc = additional.mass / formulation.volume 
  endif 
 endif 
endif   
'calculate those properties here, which are needed afterwards 
formulation.surftens = medium.surftens 
additional.conc = additional.mass / formulation.volume 
solenhancer.conc = solenhancer.mass / formulation.volume 
api.conc = api.mass / formulation.volume 
formulation.viscosity = solenhancer.fvisc * solenhancer.conc + solenhancer.ovisc   
formulation.pH = api.pH   
'surface tension is calculated by a neural net 
'formulation.surftens = 53.386 + solenhancer.ksurf * solenhancer.conc ^ .33 
nnload "surftensNET.ann" 
nnclearinputs 
sec = solenhancer.conc * 100 
apic = api.conc * 100 
nnsetinput "cHPCD", sec 
nnsetinput "cAPI", apic 
nngetoutput "surftens", formulation.surftens 
message "surface tension", formulation.surftens 
formulation.osmol = solenhancer.fosm * solenhancer.conc + additional.fosm * 
additional.conc  
------------------------------------------------------------ 
No:    12 
Root:  11  
Question: 
viscosity   
Branches: 
Key: n branch to cell nr.  13  
Commandfile: 
'viscosity 
if formulation.viscosity > device.maxviscosity then 
 'decrease CD concentration 
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 solenhancer.conc 
 solenhancer.mass = solenhancer.conc * form.volume  
 'eventually decrease concentration of additive 
 additional.mass = solenhancer.mass / 10 
 additional.conc = additional.mass / form.volume  
endif 
------------------------------------------------------------ 
No:    13 
Root:  12  
Question: 
surface tension   
Branches: 
Key: n branch to cell nr.  14  
Commandfile: 
'surface tension 
if formulation.surftens > device.maxsurf then 
 tablechoosefrom "Surfactant", "surfactant.txt", "surfactant", a$, b$, n 
 concat b$, b$, ":surfactant" 
 tablereadvariables "surfactant.txt", b$ 
 surfactant.conc = ( formulation.surftens - device.maxsurf )  / surfactant.fsurf * 10  
surfactant.mass = surfactant.conc * formulation.volume 
 formulation.surftens = medium.surftens - sqr( solenhancer.ksurf * solenhancer.conc ) - 
( surfactant.mass * surfactant.fsurf * 10 )  
showvariables 
endif 
------------------------------------------------------------ 
No:    14 
Root:  13  
Question: 
pH   
Branches: 
Key: n branch to cell nr.  15  
Commandfile: 
'until now, formulation's pH depends mainly on the API's acidity  
api.mconc = api.conc / api.mw 
message "api.mconc", api.mconc 
if api.acidbase$ = "neutral" then 
 formulation.pH = 7 
endif  
if api.acidbase$ = "acid" then  
formulation.pH = 0.5 * ( api.pKa - log( api.mconc ) ) 
endif 
if api.acidbase$ = "base" then  
formulation.pH = 14 - 0.5 * ( log( api.mconc ) + 14 - api.pKa ) 
endif  
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'adjust pH  
if formulation.pH < profile.minpH then 
 'add base 
 tablechoosefrom "pH Adjustment", "bases.txt", "pHcorrect", a$, b$, n 
 concat b$, b$, ":phcorrect" 
 tablereadvariables "bases.txt", b$ 
 'calculate necessary amount. Distinguish between buffers and bases 
 if bases.type$ = "buffer" then 
  phcorrect.mass = phcorrect.usualconc * device.optvol 
 else 
  'for strong bases 
  'ca is concentration of weak acid (api) 
  ca = api.mconc 
  valconc = ca / ( 10 ^ ( api.pKa - profile.optpH ) + 1 ) 
  phcorrect.mass = valconc * phcorrect.mw * formulation.volume / phcorrect.val   
  formulation.pH = api.pKa - log( ( ca - valconc ) / valconc )  
 endif  
endif  
if formulation.pH > profile.maxph then 
 'add acid 
 tablechoosefrom "pH Adjustment", "acids.txt", "pHcorrect", a$, b$, n 
 concat b$, b$, ":phcorrect" 
 tablereadvariables "bases.txt", b$ 
 'calculate necessary amount. Distinguish between buffers and acids 
 if bases.type$ = "buffer" then 
  phcorrect.mass = phcorrect.usualconc * device.optvol 
 else 
  'for strong acids 
  conc = 10 ^ profile.optpH 
  phcorrect.mass = conc * device.optvolume 
 endif     
endif 
------------------------------------------------------------ 
No:    15 
Root:  14  
Question: 
osmolarity   
Branches: 
Key: n branch to cell nr.  16  
Commandfile: 
'osmolarity 
osmoldtfactor = 1000 / medium.cryoconst 
profile.optdt = profile.optosmol / osmoldtfactor 
profile.maxdt = profile.maxosmol / osmoldtfactor   
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formulation.dT = ( api.mass * api.dT + solenhancer.mass * solenhancer.dT + 
additional.mass * additional.dT + pHcorrect.mass * pHcorrect.dT + surfactant.mass * 
surfactant.dT ) / formulation.volume  
if formulation.dT > profile.optdT then 
 message "Dilution required", "solution is hyperosmotic and needs to be diluted" 
 isotonant.mass = 0 
 'cf is correction factor 
 cf = formulation.dt / profile.maxdT  
 api.mass = api.mass / cf 
 solenhancer.mass = solenhancer.mass / cf 
 additional.mass = additional.mass / cf 
 pHcorrect.mass = pHcorrect.mass / cf 
 surfactant.mass = surfactant.mass / cf  
else 
 'add isotonant 
 tablechoosefrom "Osmolarity", "isotonant.txt", "isotonant", a$, b$, n 
 concat b$, b$, ":isotonant" 
 tablereadvariables "isotonant.txt", b$ 
 isotonant.mass = ( profile.optdT - formulation.dT ) * formulation.volume / isotonant.dT   
endif  
formulation.dT = ( api.mass * api.dT + solenhancer.mass * solenhancer.dT + 
additional.mass * additional.dT + pHcorrect.mass * pHcorrect.dT + surfactant.mass * 
surfactant.dT + isotonant.mass * isotonant.dT ) / formulation.volume 
formulation.osmol = formulation.dt * osmoldtfactor 
------------------------------------------------------------ 
No:    16 
Root:  15  
Question: 
TOR, volume, droplet size   
Branches: 
Key: n branch to cell nr.  17  
Commandfile:  
'final calculations 
formulation.ingredientmass = api.mass + solenhancer.mass + additional.mass + 
pHcorrect.mass + surfactant.mass + isotonant.mass  
'medium mass is calculated assuming a density of 1g/cm³ 
medium.mass = formulation.volume - form.ingredients 
formulation.mass = formulation.ingredientmass + medium.mass  
api.conc = api.mass / formulation.volume 
solenhancer.conc = solenhancer.mass / formulation.volume 
additional.conc = additional.mass / formulation.volume 
pHcorrect.conc = pHcorrect.mass / formulation.volume 
surfactant.conc = surfactant.mass / formulation.volume 
isotonant.conc = isotonant.mass / formulation.volume   
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'showvariables  
'********** 
'formulation.surftens = medium.surftens (step 11) 
if chooseenhancer = 1 then 
 formulation.viscosity = solenhancer.fvisc * solenhancer.conc + solenhancer.ovisc 
else 
 formulation.viscosity = medium.viscosity 
endif    
formulation.MMD = 4.25 - 0.7217 * formulation.viscosity 
formulation.TOR = 748.27 - 203.74 * formulation.viscosity  
'TOR (Total output rate) 
if formulation.tor < 200 then 
 'decrease viscosity 
 reductionfactor = 1 
 'reductionfactor = put_formula_here  
 api.mass = api.mass / reductionfactor  
 isotonant.mass = isotonant.mass / reductionfactor 
 'formulation.tor = recalculate_tor_here 
endif  
if api.stabilityproblem = 1 then 
 concat comment$ , comment$, "Due to stability issues during preformulation tests, 
Nitrogen gassing or lyophilisation are suggested. " 
endif  
if api.lightproblem = 1 then 
 concat comment$, comment$, "API's light sensitivity requires light protection during 
prosessing and for primary packaging. " 
endif  
if ( api.aqstable = 0 ) and ( api.hygroscopic = 0 ) then 
 concat comment$, comment$, "Since the API exhibits a poor stability in aqueous 
solution, it is recommended to produce a lyophilised dosage form that has to be 
reconstituted prior usage. " 
endif  
if ( api.aqstable = 0 ) and ( api.hygroscopic = 1 ) then 
 concat comment$, comment$, "API shows poor stability in aqeuous solution AND 
hygroscopicity. Either pH optimisation, reduction of shelf life or lyophilisation with 
terminal nitrogen flooding is suggested. " 
endif  
if api.oxproblem = 1 then 
 concat comment$, comment$, "Terminal nitrogen flooding is required due to oxidation 
issues. " 
endif   
'MMD (mean mass diameter = droplet size) 
if formulation.MMD > device.holediameter  then 
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 'change size of nebulising head 
 message "Droplet size too large", "Please change nebulising head's holesize" 
endif  
if formulation.MMD < 1.0 then 
 'change size of nebulising head 
 message "Droplet size too small", "Please change nebulizing head's holesize" 
endif 
------------------------------------------------------------ 
No:    17 
Root:  16  
Answer: 
output    
Commandfile: 
rtfload "formulation_solution.rtf" 
' first of all, replace all variables 
rtfvarreplace 
' second: replace variablenames within the replaces variable values (especially 
required for explanation$) 
rtfvarreplace 
rtfview 
------------------------------------------------------------ 
No:    18 
Root:  10  
Answer: 
suspension   
Commandfile: 
(not shown here) 
------------------------------------------------------------ 
No:    19 
Root:  10     
Question: 
New profile   
Commandfile: 
(not shown here) 
------------------------------------------------------------ 
No:    20 
Root:  10  
Question: 
Choose dispersion type   
Branches: 
Key: n branch to cell nr.  11  
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Commandfile: 
'***** Dispersion type *****   
'If no device is specified in the profile, then choose one from list 
if profile.device$ = "" then 
 tablechoosefrom "Inhalation device", "device.txt", "device", device.name$, 
device.shortname$, n 
else 
 device.shortname$ = profile.device$ 
endif 
'Now load the data that describes the device precisely 
concat sect$, device.shortname$, ":device" 
tablereadvariables "device.txt", sect$  
if device.suspsol$ = "solution" then 
 message "Dispersion type", "Device requires the formulation of a solution" 
 gotocell 18 
else 
 'usual volume is 4ml 
 formulation.estvolume = 4 
 required.totalsolubility = api.mass / formulation.estvolume 
 required.partialsolubility = required.totalsolubility / 10 
 if api.solubility > required.totalsolubility then 
  message "Solubility", "API solubility is sufficient for solution development." 
 else 
  if api.solubility > partialsolubility then  
   message "Solubility", "Poor API solubility might be enhanced in order to develop a 
solution." 
  else 
   message "Solubility", "API solubility is too low. The development of a suspension is 
suggested." 
  endif 
 endif 
 tablechoosefrom "Dispersion type", "extra.txt", "suspsol", disp.type$, disp.shortype$, n  
 if disp.type$ = "solution" then 
  gotocell 11 
 else 
  gotocell 18 
 endif 
endif 
------------------------------------------------------------   
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7.2.2 Output  
The system will provide a possible formulation in terms of the excipients and the amounts 
that can be used. The layout as well as the contents can be freely composed by means of a 
template file meet personal preferences or company requirements. A sample output looks like 
this:  
May 4th 2006
Testformulation 1   
Composition 
# Function name quantity   
1 active ingredient API P-034025-2006 7.22 mg 
2 solubility enhancer alphaCD 23.08 mg 
3 taste masking (not required) 0 mg 
4 additional excipient citric acid 2.308 mg 
5 surfactant (not required) 0 mg 
6 pH adjustment sodiumhydroxide .609 mg 
7 isotonant (not required) 0 mg  
Total  33.22 mg   
Medium Water ad 3 ml  
Device  
Device PARI eFlow  
optimal volume 3 ml  
maximum volume 4 ml  
holesize 3.5 µm  
maximum viscosity 2.5 mPas  
max. surface tension 70 mN/m    
Manufacturing 
Disperse CD in approx. 90% of water, add API, stirr at RT, add additional excipient, wait 
3-5 days,  filtrate, remove excess, add taste masking agent and surfactant, correct pH and 
add isotonant. Then fill up with rest of water         
1 of 2  
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May 4th 2006
Testformulation 1  
Properties 
Property predicted demanded unit 
TOR 748 - mg/min 
Freezing p. depress. .73 0.558 (<=0.558) K 
Osmolarity 390 300 (<=390) mosmol/kg 
pH 7.4  6.2 - 8.2 - 
surface tension 54.8 <=70 mN/m 
final volume 3 3 (<=4) ml 
taste ranking 1 <= 3 - 
viscosity  2 <=2.5 mPas 
MMD 4.3 - µm  
Footnotes 
Taste ranking 
1 = excellent / no taste 
2 = slight bad taste 
3 = noticable bad taste 
4 = just tolerable 
5 = intolerable 
6 = disgusting  
Notes 
The formulation doesn't meet the desired dose of 25mg in the given volume without being 
hyperosmotic. Therefore the developer reduced the dose to obtain a isotonic solution. 
API's light sensitivity requires light protection during prosessing and for primary 
packaging. Terminal nitrogen flooding is required due to oxidation issues.   
Incompatibilities 
No incompatibilities were detected between the ingredients of this formulation.  
Explanations 
API solubility is too poor; therefore a solubility enhancer is used. For immediate release a 
hydrophilic solubility enhancer (alphaCD) is chosen. A 50% (mol/mol) excess of 
solubility enhancer is used to complex Test API. The use of a cyclodextrin also improves 
taste for up to 4 units. Since API size (432 pm) doesn't match CD cavity (500 pm), an 
additional enhancer (citric acid) is required. Its mass is set to one tenth of the CD's mass.    
2 of 2  
Subchapter conclusion 
The ability to rapidly assess the potential for a new molecule in a manner consistent with 
speed of the market is a key step in the development of new drugs. 
The elaboration of a database system for the development of formulations constitutes a very 
important aid tool. It allows not only the reduction of time during the development 
formulation process but also the decrease costs by a more effective management of time and 
materials.   
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8 DISCUSSION 
This work had as its main objective the development of systematic approach for water 
insoluble and water soluble drug formulations suitable for nebulisation using a specific 
nebulisation device - the eflow. 
It constituted a new and interesting approach which, however, presented additional (and 
difficult) challenges. Apart from the common difficulties present in the development of a 
water insoluble drug formulation, such as the physicochemical properties of the drugs itself, 
the operation requirements of the nebulisation device (e.g., viscosity limits) also had to be 
taken into account. This meant that the link between the drug formulation and the nebulisation 
device was an ever present concern during the entire development process and constituted one 
of the pillars of this work. 
In order to achieve the above-mentioned objectives, the solubility/stability enhancement of 
three water insoluble drugs was investigated by using cyclodextrins in two different forms: 
solutions and suspensions.   
One of the drugs studied was cyclosporin A, a water insoluble drug used as an 
immunosuppressive to prevent transplant rejection and to treat autoimmune diseases. 
Cyclodextrins were investigated as a means of improving the water solubility and stability of 
cyclosporin A. 
With respect to solutions, the first results obtained showed that the cavity size of the -CDs 
was the most suitable for the complex formation between the cyclosporin A and the CD. 
However, due to toxicological/cost issues and also the project objectives previously set out 
(e.g. required concentration of CSA in the deep lung), the amount and also the type of 
cyclodextrin that could be used to enhance the water solubility/stability of CSA was limited. 
Amongst the group of possible CD available for use in the work, the 2-HP- -CD was chosen 
because it is the most widely accepted representative of the hydroxyalkylated -cyclodextrin 
derivatives, due to its high water solubility, solubilizing power, low cost and low toxicology. 
Nevertheless, results did not show the same increase in the solubility when compared with the 
-CDs. For this reason, it was decided to add auxiliary substances, such as amino acids, in 
order to allow for the formation of non-inclusion complexes between cyclosporin A and the 
cyclodextrin complexes. 
From the results obtained, it could be ascertained that the use of auxiliary substances did not 
increase the solubility aptitude of the cyclodextrin molecules. This was probably due to the 
fact that the CSA molecule was not able to interact with the molecules of the several auxiliary 
substances added to the complexing system. 
Consequently, the critical factor in the CSA/CD complexation formation was the cavity size 
of the cyclodextrin. 
Taking in consideration the physical chemical properties of the CSA molecule, it was decided 
to investigate the possibility of inserting the CSA in another molecule as a means of 
overtaking the natural properties of the CSA molecule. 
Thus, lecithin was used as the carrier molecule for cyclosporin A, which is made from 
biological phospholipids that are biodegradable, lacking imunogenicity and exhibit low 
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intrinsic toxicity. In addition, the presence of suitable functional groups in the molecular 
structure of the lecithin molecules permits the interaction between the several auxiliary 
substances and the cyclodextrin, allowing this way the formation and stabilization of non-
inclusion complexes. 
From the several auxiliary substances investigated in combination with the lecithin/CSA 
system, ascorbic acid proved to be the best in terms of the improvement of the water 
solubility of CSA. However, due to stability problems of the ascorbic acid in aqueous 
solutions, it was decided to use sodium ascorbate instead. 
An investigation of the influence of temperature, pH and equilibrium time on the solubility 
and stability of CSA was also performed with the purpose of determining the values of these 
parameters, which allow for a maximum of solubility/stability of CSA. 
Finally, in order to obtain a stable formulation, it was prepared a lyophilizate of the CSA/CD 
formulation. This was mainly due to the hydrolysis of the lecithin molecules and also the 
oxidation of unsaturated fatty acid residues in the lecithin molecules.  
The results of the stability tests show that the lyophilised cyclosporin A/cyclodextrin 
formulation kept at 25°C and 60% relative humidity is stable for at least 5 months. 
In parallel, it was also analyzed the nebulisation properties of each of the prepared 
formulations aimed at achieving not only the best formulations in terms of solubility/stability 
but also the most suitable formulation to be efficiently nebulised by the eflow. The results 
showed that it was possible to develop a CSA formulation that can be efficiently delivered to 
the deep lungs using the eflow. 
A new approach aimed at improving the water solubility of CSA through the 
nanoprecipitation method was also attempted using hydrophobic cyclodextrins. This, in turn, 
posed different problems and challenges in the development process in comparison with the 
solution approach such as the influence of the amount and type of the cyclodextrin used on 
the particle size. Nevertheless, with this approach, it was also possible to improve the water 
solubility of CSA and the developed formulations allowed for an efficient nebulisation with 
the eflow.  
Azithromycin was one of the other model drugs investigated. Although, it is also a water 
insoluble drug, like CSA, the issue of the taste of the formulation was pivotal. 
By means of a factorial design, it was possible to ascertain which CD and auxiliary substances 
could be used to improve the solubility and stability of azithromycin Consequently, the 
formulation prepared using this new method had not only improved the water solubility of 
azithromycin but it had also produced a suitable taste for inhalation. 
Based on the stability tests, we could ascertain that the azithromycin was not stable in 
aqueous solutions, which led us to lyophilizate the azithromycin/CD formulations. The results 
show that the lyophilizate presented no significant degradation after 6 weeks, even at 40°C / 
75% r.h. storage conditions. Only after 16 weeks under 40°C / 75% r.h. storage conditions 
could we witness some degradation although not worth mentioning. 
The use of the nanoprecipitation method (like in the case of CSA), improved the solubility of 
azithromycin.  
Budesonide was another water insoluble drug studied in this work. The objectives were not 
only to improve its water solubility/stability but also to obtain a formulation that posed no 
problems in term of its taste. In fact, budesonide represented the common ground between 
cyclosporin A and azithromycin, as it shared the same development objectives as cyclosporin 
A and azithromycin. 
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Based on previous experiences with CSA and azithromycin, it was possible to prepare, 
through the use of CD, a sterile and stable aqueous solution of budesonide that could be 
efficiently delivered into the deep lung.   
On the other hand, pentoxifylline presented a different challenge in comparison with the 
previously described drugs. It is a water soluble drug, which meant that the taste masking of 
the formulation constituted the main objective in the development of the formulation. In the 
end, it was possible to obtain a formulation that could be efficiently delivered into the deep 
lung and presented a suitable taste for inhalation.  
The elaboration of a knowledge based system for the development of formulations suitable 
for nebulisation constitutes a very important aid tool.  
This system is able not only to reduce the time in the development formulation process but 
also decrease costs by reducing development time as well as by a more effective use of 
materials.   
The interdependency link between the development process of the drug formulation and the 
nebulisation device was at the centre of the entire development process and represented the 
cornerstone upon which this work was build. 
It constituted an interesting but difficult challenge which, nevertheless, yield the systematic 
preparation of formulations that can be efficiently nebulised and delivered into the deep lungs.   
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9 CONCLUSION 
Despite the long-term use of inhalation technologies for therapeutic purposes, there still is 
room for improvement in a number of areas such as deposition efficiency and targeting. The 
inhalation route, primarily employed for drugs acting in the respiratory tract, is now being 
extended for systemic macromolecule delivery. These challenges can be achieved in part by 
formulation development and device engineering for inhalation delivery.  
This work had as main objectives not only the development of formulations suitable for 
nebulisation but it also investigated and customised the formulations for a specific 
nebulisation device, the eflow. This new approach represented an interesting challenge during 
the formulation development due the physicochemical properties of the drugs itself but also to 
the required operating parameters of the device. It was a valid approach because having a 
suitable formulation nebulisation does not necessary mean that it will be efficiently delivered 
into the deep lungs. In fact, the device has to have also the ability to nebulise the formulation 
in an efficient way, for example in terms of droplet size and delivery rate and breath pattern. 
This work demonstrated that the use of CD can contribute new possibilities and advantages to 
the preparation of new nebulised formulations for both: water insoluble and water soluble 
drugs. The use of CD permitted an increase in stability and solubility of water insoluble dugs 
by the formation of Drug:CD complexes. In addition, the taste or local irritation of a drug can 
also be reduced through the use of CD. Furthermore, this work also showed that the 
development of formulations in association with the inhalation device allows the drug to be 
more efficiently delivered into the lungs.  
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10 OUTLOOK 
As further steps of research, the influence of other auxiliary substances on the solubility and 
stability enhancement provided by the cyclodextrins could be investigated in closer detail.  
The type and amount of auxiliary substances used can be studied in order to maximize the 
solubility and stability of the water insoluble drugs. As an example, the use of different amino 
acids or metals ions can be investigated in order to ascertain the possibility of increasing even 
more the solubility and stability of the water insoluble drugs.  
Furthermore, the type and amount of CD used can also be closer investigated as a way of 
improving the solubility/stability of the model drugs. This can be applied for both the 
solutions and suspensions. Nevertheless, in the case of the suspensions, the type and the 
amount of surfactants used and also the use of substances that can alter the zeta potential of 
the nanospheres could be subject to further investigations in order to obtain more stable 
suspensions.  
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11 GLOSSARY 
BPD (Bronchopulmonary Dysplasia) 
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of babies, which develops most 
commonly in the first 4 weeks after birth. It mostly occurs in babies who are born more than 4 
weeks before their due dates, though sometimes the babies are full term.  
Bronchiolitis 
Is a common illness of the respiratory tract caused by a respiratory infection that affects the 
tiny airways, called the bronchioles, which lead to the lungs. As these airways become 
inflamed, they swell and fill with mucus, making it difficult for a child to breathe.  
CF (Cystic fibrosis) 
Cystic fibrosis is a genetic disease affecting approximately 30,000 children and adults in the 
United States. A defective gene causes the body to produce abnormally thick, sticky mucus 
that clogs the lungs and leads to life-threatening lung infections. These thick secretions also 
obstruct the pancreas, preventing digestive enzymes from reaching the intestines to help break 
down and absorb food. The mucus also can block the bile duct in the liver, eventually causing 
permanent liver damage in approximately six percent of people with CF.    
COPD (Chronic Obstructive Pulmonary Disease) 
Chronic obstructive pulmonary disease (COPD) is a lung disease in which the lung is 
damaged, making it hard to breathe. In COPD, the airways-the tubes that carry air in and out 
of your lungs-are partly obstructed, making it difficult to get air in and out.  
DD (Delivered Dose) 
Dose that reaches the patient and it is not eliminated during exhalation.   
DPI (Dry Powder Inhaler) 
A dry powder inhaler (DPI) is similar to a metered dose inhaler. Both are handheld devices 
that deliver a precisely measured dose of drug. into the lungs. In a dry powder inhaler, drug 
comes in a dry powder form - inside a small capsule, a disk or a compartment inside the 
inhaler.  
GI (Gastrointestinal) 
The digestive or gastrointestinal (GI) tract includes the esophagus, stomach, small intestine, 
large intestine or colon, rectum and anus.  
GSD (Geometric Standard Deviation) 
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Corresponds to the ratio of the diameters of particles from aerosols corresponding to 84% and 
50% on the cumulative distribution curve of the weights of particles. The use of a geometric 
standard deviation to describe the particle size distribution requires that particle sizes are log-
normally distributed. If, as is frequently the case, particles are not log-normally distributed, 
the geometrical standard deviation is meaningless and a misleading representation of the 
distribution. Heterogeneous aerosols have, by definition, a GSD of greater than or equal to 
1.22.  
MDI (Metered Dose Inhaler) 
Metered dose inhalers (MDI) are pharmaceutical delivery systems designed for oral or nasal 
use, which deliver discrete doses of aerosolized medicament to the respiratory tract.  
MMAD (Mass Median Aerodynamic Diameter) 
Makes it possible to define the granulometry of aerosol particles by taking into account their 
geometrical diameter, shape, and density: MMAD= MMD × Density.  
MMD (Mass Median Diameter) 
Corresponds to the diameter of the particles for which 50% w/w of particles have a lower 
diameter and 50% w/w have a higher diameter.  
Parkinson Disease 
Parkinson's disease is a slowly progressive neurodegenerative illness characterized by: 
tremor, stiffness, (rigidity), slowness of movement (bradykinesia) and difficulty with balance 
(postural instability). The symptoms appear when there is not enough dopamine in the brain.  
RDS (Respiratory Distress Syndrome): 
Acute Respiratory Distress Syndrome is inflammatory disease of the lung characterized by the 
sudden onset of pulmonary edema and respiratory failure, usually in the setting of other acute 
medical conditions resulting from local (e.g. pneumonia) or distant (e.g. multiple trauma) 
injury.  
TOR (Total Output Rate) 
Corresponds to the rate of aerosol delivery (mg/ml).   
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12 SYMBOLS AND ABBREVIATION (ALPHABETIC ORDER) 
Å: 
 
Ångstrøm (1 Å = 0.0001 µm) 
AM: Alveolar Macrophages 
BDP: Bronchopulmonary Dysplasia  
CD: Cyclodextrin 
CF: Cystic Fibrosis 
COPD: Chronic Obstructive Pulmonary Disease 
CSA: Cyclosporin A 
DPI: Dry Powder Inhaler 
DPPC: Dipalmitoyl phosphatidylcholine 
e.g.: Exempli gratia or for example 
Eq.: Equation 
et al. : Et alii or and others 
FDA: U.S. Food and Drug Administration 
G.I.: Gastro intestinal tract 
HP: Hydroxypropyl 
HPLC: High Pressure Liquid Chromatography 
i.e.: Id est or that is 
i.m.: Intramusculous 
i.v.: Intravenous 
IL-2: Interleukin-2 
K: Inclusion complex stability constant 
MDI: Metered-Dose Inhaler 
MW: Molecular weight 
M- -CD: Maltosyl- -Cyclodextrin 
OH : Hydroxyl 
PI: Polydispersity index 
PTX: Pentoxifylline 
r.h.: Relative humidity 
RDS: Respiratory Distress Syndrome 
s.c.: Subcutaneous 
SOP: Standart operation procedure 
T: Temperature 
TNF- : Tumor Necrosis Factor alpha 
UV: Ultra violet 
-CD: Alpha-Cyclodextrin (six glucose units) 
-CD: Beta-Cyclodextrin (seven glucose units) 
-CD: Gamma-Cyclodextrin (Eight glucose units)    
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13 APPENDIX  
13.1 Appendix 1 (The problem with propellants) 
It is known that CFCs could lead to the depletion of stratospheric ozone. For this reason, the 
pharmaceutical industry has been working since 1987 to find alternative propellants with 
which to replace the CFCs used in MDIs.  
The research for propellants with low or zero ozone depletion potential has contributed to the 
identification of a number of potential compounds. Several chemical industry research groups 
were created to investigate the acute toxicity of the most promising candidates under The 
Programme for Alternative Fluorocarbon Toxicity Testing (PAFTT).  
The use of hydrofluorocarbons (HCFC) has been taken in consideration, although they still 
have a significant effect on the ozone depletion. For example, the HCFC 22 could be a 
suitable replacement for CFC 12. However, revisions to the Montreal Protocol in 1990 require 
the phase-out of HCFCs by the year 2020.  
The odour and flammability of hydrocarbons such as isobutane has prevented their use in 
medical aerosols although purer grades, which are odourless, are now available.  
Dimethylether (DME) is also a possibility because it combines low ozone depletion with a 
superior solvency for various active components and appreciable miscibility with water. 
Nevertheless, the high flammability of both the hydrocarbons and DME would require 
expensive modifications of facilities for the manufacture, storage, and transportation of MDIs.   
In addition, the use of both hydrocarbons and DME as propellants in a suspension MDI 
formulation, is  their low density, compared with most drug substances. This could generate a 
poor suspension stability and, consequently, to the potential for inconsistent dose delivery.  
Another alternative identified, was the hydrofluoroalkanes (HFAs) or HFCs. Within this class, 
134a and 227ea were adopted for inhalation toxicity testing by two consortia of 
pharmaceutical companies: IPACT 1 for 134a and IPACT 2 for 227ea (IPACT: International 
Pharmaceutical Aerosol Consortium for Toxicity Testing).    
13.2 Appendix 2: Lecithin (properties and experimental data) 
13.2.1 Physical and Chemical Properties of Lecithin   
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Lecithin is usually used as synonym for phosphatidylcholine (PC), which is the major 
component of a phosphatide fraction which is frequently isolated from either egg yolk or soya 
beans and is commercially available in high purity. PC is a mixture of differently substituted 
sn-glycerol-3-phosphatidylcholine backbones.   
 
Figure 1: Molecular structure of PC and their natural occurrence in egg yolk 
lecithin (mol/mol). Values according to (Lit. [1]).  
From Figure 35, the structure of PC is variable and dependent on fatty acid substitution. In the 
sn-1-position (R1), saturated acyl-groups, and in sn-2-position (R2), unsaturated species are 
more common (Lit. [1]). By dietetic means the fatty acid substitution of egg phospholipids 
can be altered in the sn-2-position (Lit [2]). Fatty acids of mainly 16-20 C in chain length 
dominate in egg PC. The sn-1-chain typically shows an average of 16 C, whereas the sn-2-
chain shows an average of 18 C. Naturally occurring unsaturated fatty acids are almost 
entirely of all-cis-conformation (Lit [3]).   
Palmitoyl/Oleoyl [16:0/18:1]-PC (POPC) 
38.2% in Egg PC 
Palmitoyl/Linoleoyl [16:0/18:2]-PC (PLPC) 
21.8% in Egg PC 
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Stearoyl/Linoleoyl [18:0/18:2]-PC (SLPC) 
11.22% in Egg PC 
Stearoyl/Oleoyl [18:0/18:1]-PC (SOPC) 9.3% 
in Egg PC 
Stearoyl/Arachidoyl [18:0/20:4]-PC (SAPC) 
3.36% in Egg PC 
Di-Palmitoyl [16:0/16:0]-PC (DPPC) 0.72% 
in Egg PC  
Figure 2: Different species of PC and their natural occurrence in egg yolk lecithin 
(mol/mol). Values according to Lit.1.   
Lecithin is commonly regarded as safe to use for parenteral administration because lecithin 
can be totally biodegraded and metabolised, since it is an integral part of biological 
membranes, making it virtually non-toxic. 
For this reason, lecithin is regarded as a well tolerated and non-toxic compound (which is also 
expressed by its GRAS-status [ Generally Recognised As Safe ] approved by the FDA), 
making it suitable for long-term and large-dose infusion, for example.   
13.2.2 Stability and Degradation of Lecithin  
Possible chemical degradation includes oxidation of unsaturated fatty acid residues in the 
lecithin molecules (Lit [4]) and also hydrolysis (Lit. [5]).  
According to (Lit. [6]), a possible mechanism for the oxidation of unsaturated fatty acid 
residues in the lecithin involves the oxidation of the double bonds within the lecithin. 
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On the other hand, the hydrolysis of phospholipids leads to formation of free fatty acids, lyso-
phospholipids and glycerophosphorylic compounds (please see Figure 3).  
Hydrolysis products need to be minimised since lyso-phospholipids exhibit haemolytic effects 
in vitro and have, therefore, to be regarded as toxic Lit [7]. Based on the Lit [8] and Lit [9], 
several hydrolysis rates of PC and PE in aqueous media at various temperatures and at pH 6.5 
were determined. The degradation products were more water-soluble than the original 
phospholipids, which promote further degradation as they cause lowering of pH (Lit. [10] and 
Lit [11]).   
 
Figure 3: Pathways of phospholipids hydrolysis.   
With the purpose of avoiding hydrolysis reactions of lecithin phosphatide groups, 
lyophilization can be used. 
As an example, a microemulsion of amphotericin B containing 10% (w/w) of lecithin was 
lyophilized in order to prevent hydrolysis reactions of lecithin (Lit. [13]).        
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Table 1: Composition (% w/w) of an amphotericin B microemulsion 
Composition Percentage 
(w/w) 
Amphotericin B 0.2 
Isopropyl myristate 10 
Dist. Water 59.8 
Polysorbate 80 20 
Soybean lecithin 10 
Due to the fluid nature of most the excipients, 5 % (w/v) of mannitol was added to the 
external phase of the formulation as a bulky agent. Conditions of the lyophilization process 
are described in Table 1.   
Table 2: Lyophilization conditions of an amphotericin B microemulsion. Values 
according to (Lit. [12]). 
Step in process Duration Product: Final 
temperature 
Condenser: Final 
temperature 
Pressure in 
chamber 
Freezing 2 hours Approx. -40°C Approx. 19°C Atmospheric 
1ry Dessication 24 hours Approx. -36°C Approx. -50°C 30 microns 
2ry Dessication 40 hours Approx. 30°C Approx. -50°C 30 microns 
The lyophilized amphotericin B microemulsion was characterised in terms of macroscopically 
appearance, water content and reconstitution. It was also compared with a non lyophilized 
microemulsion. The results are presented table 3 and table 4.   
Table 3: Results from the stability evaluation of a non lyophilized amphotericin B 
microemulsion. Values according to (Lit. [12]). 
Time (days) 0 7 14 21 
Reconstituted microemulsion 
appearance 
As 
specifieda 
Amphotericin B 
precipitated 
Phase 
separationb 
Phase 
separationb 
pH 8.97±0.03 8.20±0.11 --- --- 
Amphotericin B content (%) 8.97±0.03 8.97±0.9 --- --- 
a Stable amphotericin B microemulsion macroscopical characteristics. 
b After phase separation systems were no longer consider as microemulsions.     
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Table 4: Results from the stability evaluation of a lyophilized amphotericin B 
microemulsion. Values according to (Lit. [12]). 
Time (months) 0 1 2 6 
Lyophilized products 
appearance 
As specifieda As specifieda As specifieda As specifieda 
Humidity content (%) 0.75±0.08 0.52±0.01 0.57±0.04 0.47±0.02 
Reconstituted microemulsions 
appearance 
As specifiedb As specifiedb As specifiedb As specifiedb 
pH 9.12±0.08 9.2±0.02 8.96±0.07 8.98±0.06 
Amphotericin B content (%) 95.6±1.5 99.2±2.2 96.5±1.4 97.6±1.0 
a Stable lyophilized product amphotericin B microemulsion macroscopical 
characteristics.  
b Stable reconstituted amphotericin B microemulsion macroscopical characteristics.   
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13.3 Appendix 3: Description of Test A 
13.3.1 Description of Test A  
The Test A is used to determine which type of CDs ( ,  or ) is more suitable for the 
complex formation between the drug substance and the CDs. It consists of:  
Preparation of aqueous solutions of cyclodextrin containing a specific 
concentration (for example, between 10%); 
To each of the vials containing the cyclodextrin aqueous solutions, an excess of 
the drug substance is added; 
Afterwards, the vials are stirred at a specific temperature and for defined period 
of time; 
Then, the solutions are filtered, using 0.45 µm filters, or centrifuged; 
Finally, the drug content is determined.   
The type of CD in which the most solubility increase of the drug substance was obtained will 
be chosen for the further formulation development process.                      
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13.4 Appendix 4: Properties of used substances  
Ascorbic Acid  
Nonproprietary Names  
BP: Ascorbic acid 
JP: Ascorbic acid 
PhEur: Acidum ascorbicum 
USP: Ascorbic acid   
Synonyms  
C-97; cevitamic acid; 2,3-didehydro-L-threo-hexono-1,4-lactone; E300; 3-oxo-L-gulofuranolactone, 
enol form; vitamin C.  
Molecular Formula and Molecular Weight  
C6H8O6 
Mw=176.13 g/mol  
Structural Formula  
   
Functional Category  
Antioxidant; therapeutic agent.   
Description  
Ascorbic acid occurs as a white to light yellow colored, nonhygroscopic, odorless, crystalline powder 
or colourless crystals with a sharp, acidic taste. It gradually darkens in colour upon.              
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Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for ascorbic 
acid. 
Test JP 2001
PhEur 
2002 
(suppl. 4.3)
USP 26 
Identification + + + 
Characters + 
Specific 
rotation 
+ 20.5° to + 20.5° to + 20.5° to 
(10% w/v 
solution) 
+ 21.5° + 21.5° + 21.5° 
Residue on 
ignition 
0.1 % 0.1 % 
pH 2.2 2.5 2.1 2.6 
Sulfated ash 0.1% 
Copper 5 ppm 
Heavy 
metals 
20 ppm 10 ppm 0.002% 
Loss on 
drying 
0.2% 
Iron 2 ppm 
Appearance 
of Solution 
+ + 
Oxalic acid + 
Organic 
volatile 
impurities 
+ 
Assay 99.0% 99.0
100.5% 
99.0
100.5% 
Typical Properties  
Acidity/alkalinity 
pH = 2.1 2.6 (5% w/v aqueous solution)  
Density (bulk)  
0.7 0.9 g/cm3 for crystalline material 
0.5 0.7 g/cm3 for powder 
Density (particle)  
1.65 g/cm3  
Density (tapped)  
1.0 1.2 g/cm3 for crystalline material 
0.9 1.1 g/cm3 for powder 
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Density (true)  
1.688 g/cm3  
Dissociation constant  
pKa1 = 4.17 
pKa2 = 11.57  
Melting point  
190°C (with decomposition)  
Moisture content  
0.1% w/w   
Solubility  
Table 2: Solubility of ascorbic acid. 
Solvent Solubility at 20°C 
Chloroform Practically insoluble 
Ethanol 1 in 50 
Ethanol 
(95%) 
1 in 25 
Ether Practically insoluble 
Fixed oils Practically insoluble 
Glycerin 1 in 1000 
Propylene 
glycol 
1 in 20 
Water 1 in 3.5 
  
Stability and Storage Conditions  
In powder form, ascorbic acid is relatively stable in air. In the absence of oxygen and other oxidizing 
agents it is also heat stable. Ascorbic acid is unstable in solution, especially alkaline solution, readily 
undergoing oxidation on exposure to the air. The oxidation process is accelerated by light and heat and 
is catalyzed by traces of copper and iron. Ascorbic acid solutions exhibit maximum stability at about 
pH 5.4. Solutions may be sterilized by filtration. 
The bulk material should be stored in a well-closed non-metallic container, protected from light, in a 
cool, dry place.   
Incompatibilities  
Incompatible with alkalis, heavy metal ions, especially copper and iron, oxidizing materials, 
methenamine, phenylephrine hydrochloride, pyrilamine maleate, salicylamide, sodium nitrite, sodium 
salicylate, the obromine salicylate, and picotamide. Additionally, ascorbic acid has been found to 
interfere with certain colorimetric assays by reducing the intensity of the colour produced.     
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Safety  
Ascorbic acid is an essential part of the human diet, with 40 mg being the recommended daily dose in 
the UK and 60 mg in the US. However, these figures are controversial, with some advocating doses of 
150 or 250 mg daily. Mega doses of 10 g daily have also been suggested to prevent illness. 
The body can absorb about 500 mg of ascorbic acid daily with any excess immediately excreted by the 
kidneys. Large doses may cause diarrhea or other gastrointestinal disturbances. Damage to the teeth 
has also been reported. However, no adverse effects have been reported at the levels employed as an 
antioxidant in foods and pharmaceuticals. The WHO has set an acceptable daily intake of ascorbic 
acid, potassium ascorbate, and sodium ascorbate, as antioxidants in food, at up to 15 mg/kg body-
weight in addition to that naturally present in food.  
LD50 (mouse, IV): 0.52 g/kg 
LD50 (mouse, oral): 3.37 g/kg 
LD50 (rat, oral): 11.9 g/kg   
Handling Precautions  
Ascorbic acid may be harmful if ingested in large quantities and may be irritating to the eyes. Observe 
normal precautions appropriate to the circumstances and quantity of material handled. Eye protection 
and rubber or plastic gloves are recommended.   
Regulatory Status  
GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Guide 
(inhalations, injections, oral capsules, suspensions, tablets, topical preparations, and suppositories). 
Included in medicines licensed in the UK.   
Related Substances 
Ascorbyl palmitate; sodium ascorbate.    
Sodium Ascorbate  
Non-proprietary Names  
PhEur: Natrii ascorbas 
USP: Sodium ascorbate  
Synonyms  
L-Ascorbic acid monosodium salt; E301; 3-oxo-L-gulofuranolactone sodium enolate; SA-99; vitamin 
C sodium.  
Chemical Name   
Monosodium L-(+)-ascorbate   
Molecular Formula and Molecular Weight  
C6H7NaO6 
Mw= 198.11 g/mol  
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Structural Formula  
   
Functional Category  
Antioxidant; therapeutic agent.  
Description  
Sodium ascorbate occurs as a white or slightly yellow-colored, practically odorless, crystalline powder 
with a pleasant saline taste.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for sodium 
ascorbate. 
Test PhEur 2002 USP 26 
Identification + + 
Characters + 
Appearance 
of solution 
+ 
pH 7.0 8.0 7.0 8.0 
Specific 
optical 
rotation (10% 
w/v aqueous 
solution) 
+103° to +108° +103° to 
+108° 
Oxalic acid 0.30% 
Benzene 2 ppm 
Sulfates 150 ppm 
Copper 5 ppm 
Iron 2 ppm 
Nickel 1 ppm 
Heavy metals 10 ppm 0.002% 
Loss on 
drying 
0.25% 0.25% 
Organic 
volatile 
impurities 
+ 
Assay (dried 
basis) 
99.0 101.0% 99.0
101.0% 
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Typical Properties  
Acidity/alkalinity  
pH = 7 8 (10% w/v aqueous solution)  
Density (tapped)  
0.6 1.1 g/cm3 for fine powder 
0.8 1.1 g/cm3 for fine granular grade  
Density (true)  
1.826 g/cm3  
Hygroscopicity  
Not hygroscopic. Sodium ascorbate adsorbs practically no water up to 80% relative humidity at 20°C 
and less than 1% w/w of water at 90% relative humidity.  
Melting point  
218°C (with decomposition)  
Particle size distribution  
Various grades of sodium ascorbate with different particle-size distributions are commercially 
available, e.g., approximately 98% passes through a 149 m mesh for a fine powder grade (Takeda 
Europe GmbH), and approximately 95% passes through a 840 m mesh for a standard grade (Takeda).
 
Solubility  
Table 2: Solubility of sodium ascorbate. 
Solvent Solubility at 20°C
Chloroform Practically 
insoluble 
Ethanol 
(95%) 
Very slightly 
soluble 
Ether Practically 
insoluble 
Water 1 in 1.6 
1 in 1.3 at 75°C 
Stability and Storage Conditions  
Sodium ascorbate is relatively stable in air, although it gradually darkens on exposure to light. 
Aqueous solutions are unstable and subject to rapid oxidation in air at pH > 6.0. 
The bulk material should be stored in a well-closed non-metallic container, protected from light, in a 
cool, dry place. 
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Incompatibilities  
Incompatible with oxidizing agents, heavy metal ions, especially copper and iron, methenamine, 
sodium nitrite, sodium salicylate, and the obromine salicylate. The aqueous solution is reported to be 
incompatible with stainless steel filters.  
Safety  
The parenteral administration of between 0.25 and 1.00 g of sodium ascorbate, given daily in divided 
doses, is recommended in the treatment of vitamin C deficiencies. Various adverse reactions have 
been reported following the administration of 1 g or more of sodium ascorbate, although ascorbic acid 
and sodium ascorbate are usually well tolerated. There have been no reports of adverse effects 
associated with the much lower concentrations of sodium ascorbate and ascorbic acid, which are 
employed as antioxidants. 
The WHO has set an acceptable daily intake of ascorbic acid, potassium ascorbate, and sodium 
ascorbate, as antioxidants in food, at up to 15 mg/kg body-weight in addition to that naturally present 
in food.  
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. 
Sodium ascorbate may be irritant to the eyes. Eye protection and rubber or plastic gloves are 
recommended.  
Regulatory Status  
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients 
Guide (IV preparations; oral tablets). Included in nonparenteral and parenteral medicines licensed in 
the UK.  
Related Substances  
Ascorbic acid; ascorbyl palmitate; calcium ascorbate.   
Sodium citrate  
Non-proprietary Names  
BP: Sodium citrate 
JP: Sodium citrate 
PhEur: Natrii citras 
USP: Sodium citrate  
Synonyms  
Citric acid trisodium salt; E331; sodium citrate tertiary; trisodium citrate.  
Chemical Name   
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate dihydrate      
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Molecular Formula and Molecular Weight  
C6H5Na3O7 2H2O 
Mw = 294.10 g/mol  
Structural Formula  
 
Functional Category  
Alkalizing agent; buffering agent; emulsifier; sequestering agent.   
Description  
Sodium citrate dihydrate consists of odorless, colourless, monoclinic crystals, or a white crystalline 
powder with a cooling, saline taste. It is slightly deliquescent in moist air, and in warm dry air it is 
efflorescent. Although most pharmacopoeias specify that sodium citrate is the dihydrate, the USP 26 
states that sodium citrate may be either the dihydrate or anhydrous material.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for sodium 
citrate dihydrate. 
Test JP 2001 PhEur 2002 USP 26 
Identification + + + 
Characters + 
pH 7.5 8.5 
Appearance 
of solution 
+ + 
Acidity or 
alkalinity 
+ + + 
Loss on 
drying 
10.0
13.0% 
Water 11.0
13.0% 
10.0
13.0% 
Oxalate + 300 ppm 
Sulphate 0.048% 150 ppm 
Heavy 
metals 
10 ppm 10 ppm 0.001% 
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Arsenic 2 ppm 
 
Chloride 0.015% 50 ppm 
Tartrate + + 
Readily 
carbonizable 
substances 
+ + 
Pyrogens +(a) 
Assay 
(anhydrous 
basis) 
99.0% 99.0
101.0% 
99.0
100.5% 
Typical Properties  
Acidity/alkalinity  
pH = 7.0 9.0 (5% w/v aqueous solution)  
Density (bulk)  
1.12 g/cm3  
Density (tapped)  
0.99 g/cm3  
Density (true)  
1.19 g/cm3  
Melting point  
Converts to the anhydrous form at 150°C.  
Osmolarity  
A 3.02% w/v aqueous solution is iso-osmotic with serum.  
Particle size distribution  
Various grades of sodium citrate dihydrate with different particle sizes are commercially available.  
Solubility  
Soluble 1 in 1.5 of water, 1 in 0.6 of boiling water; practically insoluble in ethanol (95%). 
Stability and Storage Conditions   
Incompatibilities 
Aqueous solutions are slightly alkaline and will react with acidic substances. Alkaloidal salts may be 
precipitated from their aqueous or hydro-alcohol solutions. Calcium and strontium salts will cause 
precipitation of the corresponding citrates. Other incompatibilities include bases, reducing agents, and 
oxidizing agents.  
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Safety  
After ingestion, sodium citrate is absorbed and metabolized to bicarbonate. Although it is generally 
regarded as a non-toxic and non-irritant excipient, excessive consumption may cause gastrointestinal 
discomfort or diarrhea. Therapeutically, in adults, up to 15 g daily of sodium citrate dihydrate may be 
administered orally, in divided doses, as an aqueous solution to relieve the painful irritation caused by 
cystitis. 
Citrates and citric acid enhance intestinal aluminium absorption in renal patients, which may lead to 
increased, harmful serum aluminium levels. It has therefore been suggested that patients with renal 
failure taking aluminium compounds to control phosphate absorption should not be prescribed citrate- 
or citric acid-containing products.  
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. 
Sodium citrate dihydrate dust may be irritant to the eyes and respiratory tract. Eye protection and 
gloves are recommended. Sodium citrate should be handled in a well-ventilated environment or a dust 
mask should be worn.  
Regulatory Status  
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients 
Guide (inhalations, injections, ophthalmic products, oral solutions, suspensions, syrups and tablets, 
nasal, otic, rectal, topical, transdermal, and vaginal preparations). Included in nonparenteral and 
parenteral medicines licensed in the UK.   
Related Substances  
Anhydrous sodium citrate; citric acid monohydrate.   
Sodium Acetate   
Non-proprietary Names  
BP: Sodium acetate 
JP: Sodium acetate 
PhEur: Natrii acetas trihydricus 
USP: Sodium acetate  
Synonyms  
E262; acetic acid, sodium acetate trihydrate; sodium ethanoate; sodium ethanoate trihydrate; sodium 
salt.  
Chemical Name   
Sodium acetate anhydrous [127-09-3] 
Sodium acetate trihydrate [6131-90-4]     
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Molecular Formula and Molecular Weight  
C2H3NaO2  
Mw=  82.0 (for anhydrous)  
C2H3NaO2 3H2O  
Mw=  136.1 (for trihydrate)  
The PhEur 2002 contains a monograph for sodium acetate; however, in Supplement 4.3 this was 
replaced with a monograph for sodium acetate trihydrate, where it is defined as sodium ethanoate 
trihydrate.  
Structural Formula  
    
Functional Category  
Antimicrobial preservative; buffering agent; flavouring agent, stabilizing agent.  
Description  
Sodium acetate occurs as colourless, transparent crystals or a granular crystalline powder with a slight 
acetic acid door.   
Pharmacopeial Specifications  
The PhEur 2002 (Suppl. 4.3) and JP 2001 refer to sodium acetate trihydrate, whereas the USP 26 
refers to the anhydrous material.  
Table 1: Pharmacopeial specifications for sodium acetate. 
Test JP 2001 
PhEur 
2002 
(Suppl. 
4.3) 
USP 26 
Identification + + + 
Description + 
Characters + 
Appearance 
of solution 
+ + 
Acid or 
alkali 
+ 
pH 7.5 9.0 7.5 9.2 
Insoluble 
matter 
0.05% 
 Appendix   
259 
Chloride 0.011% 200 ppm 0.035% 
Sulphate 0.017% 200 ppm 0.005% 
Heavy 
metals 
10 ppm 10 ppm 10 ppm 
Calcium and 
magnesium 
+ 50 ppm + 
Potassium + 
Arsenic 2 ppm 2 ppm 
Iron 10 ppm 
Reducing 
substances 
+ + 
Aluminium 0.2 ppm 0.2 g/g
Loss on 
drying 
39.0
40.5% 
39.0
40.5% 
1.0% 
Organic 
volatile 
impurities 
+ 
Assay 99.5% 99.0
101.0% 
99.0
101.0% 
  
Typical Properties  
Acidity/alkalinity  
pH = 7.5 9.0 (5% w/v aqueous solution)  
Hygroscopicity  
The anhydrous and trihydrate sodium acetate are hygroscopic.  
Melting point  
58°C for trihydrate; 324°C for anhydrous  
Solubility  
Soluble 1 in 0.8 in water, 1 in 20 in ethanol.  
Stability and Storage Conditions  
Sodium acetate should be stored in airtight containers.  
Incompatibilities  
Sodium acetate reacts with acidic and basic components. It will react violently with fluorine, 
potassium nitrate, and diketene.  
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Safety  
Sodium acetate is widely used in cosmetics, foods, and pharmaceutical formulations and is generally 
regarded as a non-toxic and non-irritant material. 
A short-term feeding study in chickens with a diet supplemented with 5.44% sodium acetate showed 
reduced growth rates that were attributed to the sodium content. Sodium acetate is poisonous if 
injected intravenously, is moderately toxic by ingestion, and is an irritant to the skin and eyes.  
LD50 (rat, oral): 3.530 g/kg 
LD50 (mouse, IV): 0.380 g/kg 
LD50 (mouse, SC): 8.0 g/kg   
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. 
Sodium acetate is a mild skin and eye irritant; gloves and eye protection are recommended. On 
exposure, wash eyes and skin with large amounts of water. Inhalation of dust may cause pulmonary 
tract problems. When heated to decomposition, sodium acetate emits toxic fumes of NaO2.  
Regulatory Status  
GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Guide 
(injections, nasal, otic, ophthalmic, and oral preparations).  
Related Substances 
Acetic acid, glacial.   
Lactic Acid  
Non-proprietary Names  
BP: Lactic acid 
JP: Lactic acid 
PhEur: Acidum lacticum 
USP: Lactic acid  
Synonyms  
E270; Eco-Lac; 2-hydroxypropanoic acid; -hydroxypropionic acid; L18; DL-lactic acid; milk acid; 
racemic lactic acid.  
Chemical Name   
2-Hydroxypropionic acid 
 (R)-( )-2-Hydroxypropionic acid  
 (S)-(+)-2-Hydroxypropionic acid  
(RS)-(±)-2-Hydroxypropionic acid   
Molecular Formula and Molecular Weight  
C3H6O3  
Mw= 90.08 g/mol   
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Structural Formula  
 
Functional Category  
Acidifying agent; acidulant.  
Description  
Lactic acid consists of a mixture of 2-hydroxypropionic acid, its condensation products, such as 
lactoyllactic acid and other polylactic acids, and water. It is usually in the form of the racemate, (RS)-
lactic acid, but in some cases the (S)-(+)-isomer is predominant. 
Lactic acid is a practically odorless, colourless or slightly yellow-colored, viscous, hygroscopic, 
nonvolatile liquid.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for lactic acid. 
Test JP 2001 
PhEur 
2002 
(Suppl 4.1)
USP 26 
Identification + + + 
Appearance 
of solution 
+ 
Specific 
rotation 
0.05° to 
+0.05° 
Calcium 200 ppm 
Heavy metals 10 ppm 10 ppm 0.001% 
Iron 5 ppm 
Sulphate 0.01% 200 ppm + 
Chloride 0.036% + 
Citric, oxalic, 
phosphoric, 
and tartaric 
acids 
+ + + 
Ether-
insoluble 
substances 
+ 
Cyanide + 
Sugars and 
other 
reducing 
substances 
+ + + 
Glycerin and 
mannitol 
+ 
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Methanol and 
methyl esters 
 
50 ppm 
Reducing 
substances 
+ 
Readily 
carbonizable 
substances 
+ + 
Bacterial 
endotoxins 
5 IU/g 
Volatile fatty 
acids 
+ + 
Residue on 
ignition 
0.1% 0.1% 3.0 mg 
Sulfated ash 0.1% 0.05% 
Assay + 88.0
92.0% 
88.0
92.0% 
 
Typical Properties  
Boiling point  
122°C at 2 kPa (15 mmHg)  
Dissociation constant  
pKa = 4.14 at 22.5°C  
Melting point  
17°C  
Osmolarity  
a 2.3% w/v aqueous solution is isoosmotic with serum.  
Specific gravit  
1.21  
Viscosity (dynamic)  
28.5 mPa s (28.5 cP) for 85% aqueous solution at 25°C.   
Solubility  
Miscible with ethanol (95%), ether, and water; practically insoluble in chloroform.      
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Stability and Storage Conditions  
Lactic acid is hygroscopic and will form condensation products such as polylactic acids on contact 
with water. The equilibrium between the polylactic acids and lactic acid is dependent on concentration 
and temperature. At elevated temperatures lactic acid will form lactide, which is readily hydrolyzed 
back to lactic acid. 
Lactic acid should be stored in a well-closed container in a cool, dry place.  
Incompatibilities  
Incompatible with oxidizing agents, iodides, and albumin. Reacts violently with hydrofluoric acid and 
nitric acid.  
Safety  
Lactic acid occurs in appreciable quantities in the body as an end product of the anaerobic metabolism 
of carbohydrates and, while harmful in the concentrated form, can be considered non-toxic at the 
levels at which it is used as an excipient. A 1% v/v solution, for example, is harmless when applied to 
the skin. 
There is evidence that neonates have difficulty in metabolizing (R)-lactic acid and this isomer and the 
racemate should therefore not be used in foods intended for infants aged less than 3 months old. 
There is no evidence that lactic acid is carcinogenic, teratogenic, or mutagenic. 
LD50 (guinea pig, oral): 1.81 g/kg 
LD50 (mouse, oral): 4.88 g/kg 
LD50 (mouse, SC): 4.5 g/kg 
LD50 (rat, oral): 3.73 g/kg   
Handling Precautions  
Lactic acid is caustic in concentrated form and can cause burns on contact with the skin and eyes. It is 
harmful if swallowed, inhaled, or absorbed through the skin. Observe precautions appropriate to the 
circumstances and quantity of material handled. Eye protection, rubber gloves, and respirator are 
recommended. It is advisable to handle the compound in a chemical fume hood and to avoid repeated 
or prolonged exposure. Spillages should be diluted with copious quantities of water. In case of 
excessive inhalation, remove the patient to a well-ventilated environment and seek medical attention. 
Lactic acid presents no fire or explosion hazard but emits acrid smoke and fumes when heated to 
decomposition.  
Regulatory Status  
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients 
Guide (IM, IV, and SC injections, oral syrups and tablets, topical and vaginal preparations). Included 
in medicines licensed in the UK.  
Related Substances  
Aliphatic polyesters.       
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Citric Acid  
Non-proprietary Names  
BP: Citric acid monohydrate 
JP: Citric acid 
PhEur: Acidum citricum monohydricum 
USP: Citric acid  
Synonyms  
E330; 2-hydroxypropane-1,2,3-tricarboxylic acid monohydrate.  
Chemical Name   
2-Hydroxy-1,2,3-propanetricarboxylic acid monohydrate   
Molecular Formula and Molecular Weight  
C6H8O7 H2O  
Mw= 210.14 g/mol  
Structural Formula 
   
Functional Category  
Acidifying agent; antioxidant; buffering agent; chelating agent; flavour enhancer.  
Description  
Citric acid monohydrate occurs as colourless or translucent crystals, or as a white crystalline, 
efflorescent powder. It is odorless and has a strong acidic taste. The crystal structure is orthorhombic.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for citric acid monohydrate (and 
anhydrous). 
Test JP 2001 PhEur 2002 USP 26(a) 
Identification + + + 
Characters + 
Appearance 
of solution 
+ 
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Water    
(hydrous 
form) 
7.5 9.0% 8.8% 
(anhydrous 
form) 
0.5% 1.0% 0.5% 
Bacterial 
endotoxins 
+ 
Residue on 
ignition 
0.1% 0.05% 
Sulfated ash 0.1% 
Calcium + 
Aluminium 0.2 ppm 
Oxalate + + 
Oxalic acid 350 ppm 
Sulphate 0.048% 150 ppm + 
Arsenic 1 ppm 3 ppm 
Heavy metals 10 ppm 10 ppm 0.001% 
Related 
substances 
+ 
Readily 
carbonizable 
substances 
+ + + 
Polycyclic 
aromatic 
hydrocarbon 
+ 
Organic 
volatile 
impurities 
+ 
Assay 
(anhydrous 
basis) 
99.5% 99.5
101.0% 
99.5
100.5% 
 
Typical Properties  
Acidity/alkalinity  
pH = 2.2 (1% w/v aqueous solution)  
Density  
1.542 g/cm3   
Hygroscopicity  
At relative humidities less than about 65%, citric acid monohydrate effloresces at 25°C, the anhydrous 
acid being formed at relative humidities less than about 40%. At relative humidities between about 
65% and 75%, citric acid monohydrate absorbs insignificant amounts of moisture, but under more 
humid conditions substantial amounts of water are absorbed.  
Melting point  
100°C (softens at 75°C) 
Particle size distribution 
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Various grades of citric acid monohydrate with different particle sizes are commercially available.  
Solubility  
Soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than 1 part of water; sparingly soluble in ether.  
Viscosity (dynamic)  
6.5 mPa s (6.5 cP) for a 50% w/v aqueous solution at 25°C.   
Stability and Storage Conditions  
Citric acid monohydrate loses water of crystallization in dry air or when heated to about 40°C. It is 
slightly deliquescent in moist air. Dilute aqueous solutions of citric acid may ferment on standing. 
The bulk monohydrate or anhydrous material should be stored in airtight containers in a cool, dry 
place. 
Incompatibilities 
Citric acid is incompatible with potassium tartrate, alkali and alkaline earth carbonates and 
bicarbonates, acetates, and sulfides. Incompatibilities also include oxidizing agents, bases, reducing 
agents, and nitrates. It is potentially explosive in combination with metal nitrates. On storage, sucrose 
may crystallize from syrups in the presence of citric acid.   
Safety  
Citric acid is found naturally in the body, mainly in the bones, and is commonly consumed as part of a 
normal diet. Orally ingested citric acid is absorbed and is generally regarded as a non-toxic material 
when used as an excipient. However, excessive or frequent consumption of citric acid has been 
associated with erosion of the teeth. 
Citric acid and citrates also enhance intestinal aluminium absorption in renal patients, which may lead 
to increased, harmful serum aluminium levels. It has therefore been suggested that patients with renal 
failure taking aluminium compounds to control phosphate absorption should not be prescribed citric 
acid or citrate-containing products.  
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye 
protection and gloves are recommended. Direct contact with eyes can cause serious damage. Citric 
acid should be handled in a well-ventilated environment or a dust mask should be worn.  
Regulatory Status  
GRAS listed. The anhydrous form is accepted for use as a food additive in Europe. Included in the 
FDA Inactive Ingredients Guide (inhalations; IM, IV, and other injections; ophthalmic preparations; 
oral capsules, solutions, suspensions and tablets; topical and vaginal preparations). Included in 
nonparenteral and parenteral medicines licensed in Japan and the UK.  
Related Substances  
Anhydrous citric acid; fumaric acid; malic acid; sodium citrate dihydrate; tartaric acid.     
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Vitamin E  
Non-proprietary Names  
BP: Alpha tocopherol 
JP: Tocopherol 
PhEur: -Tocopherolum 
USP: Vitamin E  
Synonyms  
Copherol F1300; (±)-3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-
ol; E307; synthetic alpha tocopherol; all-rac- -tocopherol; dl- -tocopherol; 5,7,8-trimethyltocol.   
Chemical Name   
(±)-(2RS,4 RS,8 RS)-2,5,7,8-Tetramethyl-2-(4 ,8 ,12 -trimethyltridecyl)-6-chromanol  
Note that alpha tocopherol has three chiral centres, giving rise to eight isomeric forms. The naturally 
occurring form is known as d-alpha tocopherol or (2R,4 R,8 R)-alpha-tocopherol. The synthetic form, 
dl-alpha tocopherol or simply alpha tocopherol, occurs as a racemic mixture containing equimolar 
quantities of all the isomers. 
Similar considerations apply to beta, delta, and gamma tocopherol and tocopherol esters.  
Molecular Formula and Molecular Weight  
C29H50O2  
Mw= 430.72 g/mol   
Structural Formula  
 
Alpha tocopherol:  R1 = R2 = R3 = CH3 
Beta tocopherol:  R1 = R3 = CH3; R2 = H 
Delta tocopherol:  R1 = CH3; R2 = R3 = H 
Gamma tocopherol:  R1 = R2 = CH3; R3 = H 
Indicates chiral centers.  
Functional Category  
Antioxidant; therapeutic agent.  
Description  
Alpha tocopherol is a natural product. Therefore, it is available either as a practically odorless, clear, 
colourless, yellow, yellowish-brown, or greenish-yellow viscous oil.  
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Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for alpha tocopherol. 
Test JP 2001 PhEur 2002 USP 26 
Identification + + + 
Acidity 
 
+ 
Acid value 2 
Optical 
rotation 
0.01° to 
+0.01° 
+ 
Heavy metals 20 ppm 20 ppm 
Sulfated ash 0.1% 
Organic 
volatile 
impurities 
+ 
Absorbance + + 
at 255 nm 6.0 8.0 
at 292 nm 72.0 76.0 
Refractive 
index 
1.503 1.507 
Specific 
gravity 
0.947 0.955 
Clarity and 
colour 
of solution 
+ 
Assay 96.0 102.0% 96.0
102.0% 
96.0
102.0% 
 
Note that the USP 26 describes vitamin E as comprising d- or dl-alpha tocopherol, d- or dl-alpha 
tocopheryl acetate, or d- or dl-alpha tocopheryl acid succinate. However, the PhEur 2002 describes 
alpha tocopherol and alpha tocopheryl acetate in separate monographs. 
The diversity of the tocopherols described in the various pharmacopeial monographs makes the 
comparison of specifications more complicated..   
Typical Properties  
Boiling point  
235°C   
Density 
0.947 0.951 g/cm3  
Refractive index  
n20D = 1.503 1.507 
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Solubility  
Practically insoluble in water; freely soluble in acetone, ethanol, ether, and vegetable oils. 
Stability and Storage Conditions 
Tocopherols are oxidized slowly by atmospheric oxygen and rapidly by ferric and silver salts. 
Oxidation products include tocopheroxide, tocopherylquinone, and tocopherylhydroquinone, as well 
as dimers and trimers. Tocopherol esters are more stable to oxidation than the free tocopherols but 
are in consequence less effective antioxidants. 
Tocopherols should be stored under an inert gas, in an airtight container in a cool, dry place and 
protected from light.   
Incompatibilities  
Tocopherols are incompatible with peroxides and metal ions, especially iron, copper, and silver. 
Tocopherols may be absorbed into plastic.   
Safety  
Tocopherols (vitamin E) occur in many food substances that are consumed as part of the normal diet. 
The daily nutritional requirement has not been clearly defined but is estimated to be 3.0 20.0 mg. 
Absorption from the gastrointestinal tract is dependent upon normal pancreatic function and the 
presence of bile. Tocopherols are widely distributed throughout the body, with some ingested 
tocopherol metabolized in the liver; excretion of metabolites is via the urine or bile. Individuals with 
vitamin E deficiency are usually treated by oral administration of tocopherols, although intramuscular 
and intravenous administration may sometimes be used. 
Tocopherols are well tolerated, although excessive oral intake may cause headache, fatigue, weakness, 
digestive disturbance, and nausea. Prolonged and intensive skin contact may lead to erythema and 
contact dermatitis. 
The use of tocopherols as antioxidants in pharmaceuticals and food products is unlikely to pose any 
hazard to human health since the daily intake from such uses is small compared to the intake of 
naturally occurring tocopherols in the diet. 
The WHO has set an acceptable daily intake of tocopherol used as an antioxidant at 0.15 2.0 mg/kg 
body-weight.   
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. Gloves 
and eye protection are recommended.   
Regulatory Status  
GRAS listed. Accepted in Europe as a food additive. Included in the FDA Inactive Ingredients Guide 
(oral capsules, tablets, and topical preparations). Included in nonparenteral medicines licensed in the 
UK.   
Related Substances  
d-Alpha tocopherol; d-alpha tocopheryl acetate; dl-alpha tocopheryl acetate; d-alpha tocopheryl acid 
succinate; dl-alpha tocopheryl acid succinate; beta tocopherol; delta tocopherol; gamma tocopherol; 
tocopherols excipient. 
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Calcium Carbonate  
Non-proprietary Names  
BP: Calcium carbonate 
JP: Precipitated calcium carbonate 
PhEur: Calcii carbonas 
USP: Calcium carbonate  
Synonyms  
Barcroft; Cal-Carb; CalciPure; calcium carbonate (1 : 1); creta preparada; Destab; E170; MagGran 
CC; Millicarb; Pharma-Carb; Precarb; precipitated carbonate of lime; precipitated chalk; Sturcal; 
Vivapress Ca.  
Chemical Name   
Carbonic acid, calcium salt (1 : 1)   
Molecular Formula and Molecular Weight  
CaCO3  
Mw= 100.09 g/mol  
Functional Category  
Tablet and capsule diluents; therapeutic agent.  
Description  
Calcium carbonate occurs as an odorless and tasteless white powder or crystals.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for calcium carbonate. 
Test JP 2001 PhEur 2002 USP 26 
Identification + + + 
Characters 
 
+ 
Loss on 
drying 
1.0% 2.0% 2.0% 
Substances 
insoluble in 
acetic acid 
0.2% 0.2% 0.2% 
Fluoride 0.005% 
Arsenic 5 ppm 4 ppm 3 ppm 
Barium + + + 
Chlorides 330 ppm 
Lead 3 ppm 
Iron 200 ppm 0.1% 
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Heavy metals 20 ppm 20 ppm 0.002% 
Magnesium 
and alkali 
(metals) salts 
0.5% 1.5% 1.0% 
Sulfates 0.25% 
Mercury 0.5 g/g
Organic 
volatile 
impurities 
+ 
Assay (dried 
basis)  
98.5% 98.5%
100.5% 
98.0%
100.5% 
 
Typical Properties  
Acidity/alkalinity  
pH = 9.0 (10% w/v aqueous dispersion)  
Density (bulk)  
0.8 g/cm3  
Density (tapped)  
1.2 g/cm3  
Melting point  
Decomposes at 825°C.  
Solubility  
Practically insoluble in ethanol (95%) and water. Solubility in water is increased by the presence of 
ammonium salts or carbon dioxide. The presence of alkali hydroxides reduces solubility.   
Stability and Storage Conditions  
Calcium carbonate is stable and should be stored in a well-closed container in a cool, dry place.   
Incompatibilities  
Incompatible with acids and ammonium salts.   
Safety  
Calcium carbonate is mainly used in oral pharmaceutical formulations and is generally regarded as a 
non-toxic material. However, calcium carbonate administered orally may cause constipation and 
flatulence. Consumption of large quantities (4 60 g daily) may also result in hypercalcemia or renal 
impairment. Therapeutically, oral doses of up to about 1.5 g are employed as an antacid. In the 
treatment of hyperphosphatemia in patients with chronic renal failure, oral daily doses of 2.5 17 g 
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have been used. Calcium carbonate may interfere with the absorption of other drugs from the 
gastrointestinal tract if administered concomitantly. 
LD50 (rat: oral) 6.45 g/kg   
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. 
Calcium carbonate may be irritant to the eyes and on inhalation. Eye protection, gloves, and a dust 
mask are recommended. Calcium carbonate should be handled in a well-ventilated environment. In the 
UK, the long-term (8-hour TWA) occupational exposure limit for calcium carbonate is 10 mg/m3 for 
total inhalable dust and 4 mg/m3 for respirable dust.   
Regulatory Status  
GRAS listed. Accepted for use as a food additive in Europe. Included in FDA Inactive Ingredients 
Guide (oral capsules and tablets; otic solutions). Included in nonparenteral medicines licensed in the 
UK.    
Hydroxyethylmethyl Cellulose  
Non-proprietary Names  
BP: Hydroxyethylmethylcellulose 
PhEur: Methylhydroxyethylcellulosum  
Synonyms  
Cellulose, 2-hydroxyethyl methyl ester; Culminal MHEC; HEMC; hydroxyethyl methylcellulose; 
hymetellose; MHEC; methylhydroxyethylcellulose; Tylopur MH; Tylopur MHB; Tylose MB; Tylose 
MH; Tylose MHB.  
Chemical Name   
Hydroxyethylmethylcellulose   
Molecular Formula and Molecular Weight  
The PhEur 2002 describes hydroxyethylmethyl cellulose as a partly O-methylated and O-(2-
hydroxyethylated) cellulose. Various different grades are available, which are distinguished by 
appending a number indicative of the apparent viscosity in millipascal seconds (mPa s) of a 2% w/v 
solution measured at 20°C.   
Description  
A white, yellowish-white or greyish-white powder or granules, hygroscopic after drying.  
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications 
for hydroxyethylmethyl cellulose. 
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Test PhEur 2002
Identification + 
Appearance of 
solution 
+ 
pH 5.5 8.0 
Apparent viscosity + 
Chlorides 0.5% 
Heavy metals 20 ppm 
Loss on drying 10.0% 
Sulfated ash 1.0% 
Typical Properties  
Acidity/alkalinity  
pH = 5.5 8.0 (2% w/v aqueous solution)  
Moisture content  
10%  
Solubility  
Hydroxyethylmethyl cellulose is practically insoluble in hot water (above 60°C), acetone, ethanol, 
ether, and toluene. It dissolves in cold water to form a colloidal solution.  
Viscosity (dynamic)  
22 30 mPa s (22 30 cP) for a 2% w/v aqueous solution at 20°C.   
Stability and Storage Conditions  
Hydroxyethylmethyl cellulose is hygroscopic and should therefore be stored under dry conditions 
away from heat.   
Incompatibilities  
None   
Safety  
Hydroxyethylmethyl cellulose is used as an excipient in various oral and topical pharmaceutical 
preparations and is generally regarded as an essentially non-toxic and non-irritant material.   
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of the material handled. 
Eye protection and gloves are recommended.  
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Regulatory Status  
GRAS listed. Included in nonparenteral medicines licensed in Europe (oral suspensions, tablets, and 
topical preparations).   
Related Substances  
Ethylcellulose; hydroxyethyl cellulose; hypromellose; methylcellulose.     
Carboxymethylcellulose Sodium  
Non-proprietary Names  
BP: Carmellose sodium 
JP: Carmellose sodium 
PhEur: Carmellosum natricum 
USP: Carboxymethylcellulose sodium   
Synonyms  
Akucell; Aquasorb; Blanose; cellulose gum; CMC sodium; E466; Finnfix; Nymcel; SCMC; sodium 
carboxymethylcellulose; sodium cellulose glycolate; sodium CMC; Tylose CB.   
Chemical Name   
Cellulose, carboxymethyl ether, sodium salt.    
Molecular Weight  
The USP 26 describes carboxymethylcellulose sodium as the sodium salt of a polycarboxymethyl 
ether of cellulose. Typical molecular weight is 90 000 700 000.   
Structural Formula  
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Functional Category  
Coating agent; tablet and capsule disintegrate; tablet binder; stabilizing agent; suspending agent; 
viscosity-increasing agent; water-absorbing agent.   
Description  
Carboxymethylcellulose sodium occurs as a white to almost white, odorless, granular powder.         
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for carboxymethylcellulose 
sodium. 
Test JP 2001 PhEur 2002 USP 26 
Identification + + + 
Characters + 
pH (1% w/v 
solution) 
6.0 8.0 6.0 8.0 6.5 8.5 
Appearance of 
solution 
+ + 
Viscosity + + + 
Loss on drying 10.0% 10.0% 10.0% 
Heavy metals 20 ppm 20 ppm 20 g/g
Chloride 0.64% 0.25% 
Arsenic 10 ppm 
Sulphate 0.96% 
Silicate 0.5% 
Sodium 
glycolate 
0.4% 
Starch + 
Sulfated ash 20.0 33.3%
Organic 
volatile 
impurities 
+ 
Assay (of 
sodium) 
6.5 8.5% 6.5 10.8% 6.5 9.5% 
 
Typical Properties  
Density (bulk)  
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0.52 g/cm3  
Density (tapped)  
0.78 g/cm3  
Dissociation constant: 
pKa = 4.30  
Melting point  
Browns at approximately 227°C, and chars at approximately 252°C.  
Moisture content  
Typically contains less than 10% water. However, carboxymethylcellulose sodium is hygroscopic and 
absorbs significant amounts of water at temperatures up to 37°C at relative humidities of about 80.  
Solubility  
Practically insoluble in acetone, ethanol, ether, and toluene. Easily dispersed in water at all 
temperatures, forming clear, colloidal solutions. The aqueous solubility varies with the degree of 
substitution (DS).   
Viscosity  
Various grades of carboxymethylcellulose sodium are commercially available that have differing 
aqueous viscosities. Aqueous 1% w/v solutions with viscosities of 5 13 000 mPa s (5 13 000 cP) may 
be obtained. An increase in concentration results in an increase in aqueous solution viscosity. 
Prolonged heating at high temperatures will depolymerise the gum and permanently decrease the 
viscosity. The viscosity of sodium carboxymethylcellulose solutions is fairly stable over a pH range of 
4 10. The optimum pH range is neutral.    
Stability and Storage Conditions  
Carboxymethylcellulose sodium is a stable, though hygroscopic material. Under high-humidity 
conditions, carboxymethylcellulose sodium can absorb a large quantity (>50%) of water. In tablets, 
this has been associated with a decrease in tablet hardness and an increase in disintegration time. 
Aqueous solutions are stable at pH 2 10; precipitation can occur below pH 2, and solution viscosity 
decreases rapidly above pH 10. Generally, solutions exhibit maximum viscosity and stability at pH 7
9. 
Carboxymethylcellulose sodium may be sterilized in the dry state by maintaining it at a temperature of 
160°C for 1 hour. However, this process results in a significant decrease in viscosity and some 
deterioration in the properties of solutions prepared from the sterilized material. 
Aqueous solutions may similarly be sterilized by heating, although this also results in some reduction 
in viscosity. After autoclaving, viscosity is reduced by about 25%, but this reduction is less marked 
than for solutions prepared from material sterilized in the dry state. The extent of the reduction is 
dependent on the molecular weight and degree of substitution; higher molecular weight grades 
generally undergo a greater percentage reduction in viscosity. Sterilization of solutions by gamma 
irradiation also results in a reduction in viscosity. 
Aqueous solutions stored for prolonged periods should contain an antimicrobial preservative. 
The bulk material should be stored in a well-closed container in a cool, dry place.    
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Incompatibilities  
Carboxymethylcellulose sodium is incompatible with strongly acidic solutions and with the soluble 
salts of iron and some other metals, such as aluminium, mercury, and zinc. Precipitation may occur at 
pH <2, and also when it is mixed with ethanol (95%). 
Carboxymethylcellulose sodium forms complex coacervates with gelatin and pectin. It also forms a 
complex with collagen and is capable of precipitating certain positively charged proteins.   
Safety  
Carboxymethylcellulose sodium is used in oral, topical, and some parenteral formulations. It is also 
widely used in cosmetics, toiletries, and food products, and is generally regarded as a non-toxic and 
non-irritant material. However, oral consumption of large amounts of carboxymethylcellulose sodium 
can have a laxative effect; therapeutically, 4 10 g in daily divided doses of the medium- and high-
viscosity grades of carboxymethylcellulose sodium have been used as bulk laxatives. 
The WHO has not specified an acceptable daily intake for carboxymethylcellulose sodium as a food 
additive since the levels necessary to achieve a desired effect were not considered to be a hazard to 
health. However, in animal studies, subcutaneous administration of carboxymethylcellulose sodium 
has been found to cause inflammation, and in some cases of repeated injection fibrosarcomas have 
been found at the site of injection.  
Hypersensitivity and anaphylactic reactions have occurred in cattle and horses, which have been 
attributed to carboxymethylcellulose sodium in parenteral formulations such as vaccines and 
penicillins.  
LD50 (guinea pig, oral): 16 g/kg 
LD50 (rat, oral): 27 g/kg   
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. 
Carboxymethylcellulose sodium may be irritant to the eyes. Eye protection is recommended.   
Regulatory Status  
GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Guide 
(dental preparations; inhalations; intra-articular, intrabursal, intradermal, intralesional, IM, 
intrasynovial and SC injections; oral capsules, drops, solutions, suspensions, syrups and tablets; 
topical and vaginal preparations). Included in nonparenteral medicines licensed in the UK.   
Related Substances  
Carboxymethylcellulose calcium.   
Sodium Chloride  
Non-proprietary Names  
BP: Sodium chloride 
JP: Sodium chloride 
PhEur: Natrii chloridum 
USP: Sodium chloride  
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Synonyms  
Alberger; chlorure de sodium; common salt; dendritis; hopper salt; murinate of sada; natural halite; 
rock salt; saline; salt; sea salt; table salt.   
Chemical Name   
Sodium chloride    
Molecular Formula and Molecular Weight  
NaCl 
Mw = 58.44 g/mol   
Functional Category  
Tablet and capsule diluents; tonicity agent.   
Description  
Sodium chloride occurs as a white crystalline powder or colourless crystals; it has a saline taste. The 
crystal lattice is a face-centered cubic structure. Solid sodium chloride contains no water of 
crystallization although, below 0 °C, salt may crystallize as a dihydrate.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for sodium chloride. 
Test JP 2001 PhEur 2002 (Suppl. 4.6) USP 26 
Identification + + + 
Appearance of 
solution 
+ + + 
Acidity or 
alkalinity 
pH 4.5 7.0 + + 
Loss on drying
 
0.5% 0.5% 0.5% 
Arsenic 2 ppm 1 ppm 1 g/g
Bromides + 100 ppm 0.01% 
Barium + + + 
Nitrites + + 
Aluminium 0.2 ppm(a) 0.2 g/g(a)
Calcium and 
magnesium 
+ 
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Magnesium 
and alkaline 
earth metals 
100 ppm 0.01% 
Iodide + + + 
Iron 2 ppm 2 g/g
Sulphate 200 ppm 0.02% 
Ferrocyanides + + 
Heavy metals 3 ppm 5 ppm 5 ppm 
Phosphate 25 ppm 0.0025% 
Potassium 500 ppm(a)(b) 0.05%(a)(b)
Organic 
volatile 
impurities 
Bacterial 
endotoxins 
5 IU/g(b) 
Assay (dried 
basis) 
99.5% 99.0 100.5% 99.5 100.5%
(a) If for use in peritoneal dialysis, hemodialysis or hemofiltration 
solutions. 
(b) If for parenteral use.   
Typical Properties  
Acidity/alkalinity  
pH = 6.7 7.3 (saturated aqueous solution)  
Boiling point  
1413 °C  
Density  
2.17 g/cm3 
1.20 g/cm3 for saturated aqueous solution  
Density (bulk)  
0.93 g/cm3  
Density (tapped)  
1.09 g/cm3  
Hygroscopicity  
Hygroscopic above 75% relative humidity.    
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Melting point  
804 °C  
Osmolarity  
A 0.9% w/v aqueous solution is iso-osmotic with serum.   
Solubility  
Table 2: Solubility of sodium chloride. 
Solvent Solubility at 20 °C 
unless otherwise stated
 
Ethanol Slightly soluble 
Ethanol (95%) 1 in 250 
Glycerin 1 in 10 
Water 1 in 2.8 
 
1 in 2.6 at 100 °C 
Viscosity  
A 10% w/v solution has a viscosity of 1.19 mPa s (1.19 cP).    
Stability and Storage Conditions  
Aqueous sodium chloride solutions are stable but may cause the separation of glass particles from 
certain types of glass containers. Aqueous solutions may be sterilized by autoclaving or filtration. The 
solid material is stable and should be stored in a well-closed container, in a cool, dry place. 
It has been shown that the compaction characteristics and the mechanical properties of tablets are 
influenced by the relative humidity of the storage conditions under which sodium chloride was stored.    
Incompatibilities  
Aqueous sodium chloride solutions are corrosive to iron. They also react to form precipitates with 
silver, lead, and mercury salts. Strong oxidizing agents liberate chlorine from acidified solutions of 
sodium chloride. The solubility of the antimicrobial preservative methylparaben is decreased in 
aqueous sodium chloride solutions and the viscosity of carbomer gels and solutions of hydroxyethyl 
cellulose or hydroxypropyl cellulose is reduced by the addition of sodium chloride.    
Safety  
Sodium chloride is the most important salt in the body for maintaining the osmotic tension of blood 
and tissues. About 5 12 g of sodium chloride is consumed daily, in the normal adult diet, and a 
corresponding amount is excreted in the urine. As an excipient, sodium chloride may be regarded as an 
essentially nontoxic and nonirritant material. However, toxic effects following the oral ingestion of 
0.5 1.0 g/kg body-weight in adults may occur. The oral ingestion of larger quantities of sodium 
chloride, e.g., 1000 g in 600 mL of water, is harmful and can induce irritation of the gastrointestinal 
tract, vomiting, hypernatremia, respiratory distress, convulsions, or death. 
In rats, the minimum lethal intravenous dose is 2.5 g/kg body-weight. 
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LD50 (mouse, IP): 6.61 g/kg 
LD50 (mouse, IV): 0.65 g/kg 
LD50 (mouse, oral): 4.0 g/kg 
LD50 (mouse, SC): 3.0 g/kg 
LD50 (rat, oral): 3.0 g/kg    
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. If 
heated to high temperatures, sodium chloride evolves a vapour irritating to the eyes.   
Regulatory Status  
GRAS listed. Included in the FDA Inactive Ingredients Guide (injections; inhalations; nasal, 
ophthalmic, oral, otic, rectal, and topical preparations). Included in nonparenteral and parenteral 
medicines licensed in the UK.   
Related Substances 
Potassium chloride.  
A saturated solution of sodium chloride can be used as a constant-humidity solution; at 25 °C, a 
relative humidity of 75% is produced. A specification for sodium chloride is contained in the Food 
Chemicals Codex (FCC).   
Saccharin Sodium  
Nonproprietary Names  
BP: Saccharin sodium 
JP: Saccharin sodium 
PhEur: Saccharinum natricum 
USP: Saccharin sodium  
Synonyms  
1,2-Benzisothiazolin-3-one 1,1-dioxide, sodium salt; Crystallose; E954; sodium o-benzosulfimide; 
soluble gluside; soluble saccharin; Sucaryl Sodium. 
Chemical Name 
1,2-Benzisothiazol-3(2H)-one 1,1-dioxide   
Molecular formula and Molecular Weight  
C7H4NNaO3S 
Mw = 205.16 g/mol 
C7H4NNaO3S H2O
Mw = (84%)   217.24 g/mol 
C7H4NNaO3S 2H2O (76%) 
Mw = 241.19 g/mol  
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Structural Formula  
  
Functional Category  
Sweetening agent.   
Description  
Saccharin sodium occurs as a white, odorless or faintly aromatic, efflorescent, crystalline powder. It 
has an intensely sweet taste, with a metallic aftertaste that at normal levels of use can be detected by 
approximately 25% of the population. Saccharin sodium can contain variable amounts of water.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for saccharin sodium. 
Test JP 2001 
PhEur 
2002 
(Suppl. 
4.3) 
USP 26 
Identification + + + 
Characters + + 
Clarity and colour of 
solution 
+ + 
Acidity or Alkalinity + + 
Water + 15.0% 15.0% 
Benzoate and 
salicylate 
+ + 
Arsenic 2 ppm 
Selenium + 
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Acidity or alkalinity + + + 
Toluenesulfonamides + + + 
Heavy metals 20 ppm 20 ppm 0.001% 
Readily carbonizable 
substances 
+ + 
Organic volatile 
impurities 
+ 
Assay (anhydrous 
basis) 
98.0% 99.0
101.0% 
98.0
101.0% 
Typical Properties  
Unless stated, data refer to either 76% or 84% saccharin sodium.  
Acidity/alkalinity  
pH = 6.6 (10% w/v aqueous solution)  
Density (bulk)  
0.8 1.1 g/cm3 (76% saccharin sodium) 
0.86 g/cm3 (84% saccharin sodium) 
Density (particle)  
1.70 g/cm3 (84% saccharin sodium)  
Density (tapped)  
0.9 1.2 g/cm3 (76% saccharin sodium) 
0.96 g/cm3 (84% saccharin sodium)  
Melting point  
Decomposes upon heating.  
Moisture content  
Saccharin sodium 76% contains 14.5% w/w water; saccharin sodium 84% contains 5.5% w/w water. 
During drying, water evolution occurs in two distinct phases. The 76% material dries under ambient 
conditions to approximately 5.5% moisture (84% saccharin sodium); the remaining moisture is then 
removed only by heating.        
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Solubility  
Table 2: Solubility of saccharin sodium. 
Solvent Solubility at 20° 
Buffer solutions:   
 
pH 2.2 (phthalate) 1 in 1.15 
 
1 in 0.66 at 60°C 
pH 4.0 (citrate phosphate) 1 in 1.21 
1 in 0.69 at 60°C 
pH 7.0 (citrate phosphate) 1 in 1.21 
1 in 0.66 at 60°C 
pH 9.0 (borate) 1 in 1.21 
1 in 0.69 at 60°C 
Ethanol 1 in 102 
Ethanol (95%) 1 in 50 
Propylene glycol 1 in 3.5 
Propan-2-ol Practically insoluble 
Water 1 in 1.2 
Stability and Storage Conditions 
Saccharin sodium is stable under the normal range of conditions employed in formulations. Only when 
it is exposed to a high temperature (125°C) at a low pH (pH 2) for over 1 hour does significant 
decomposition occur. The 84% grade is the most stable form of saccharin sodium since the 76% form 
will dry further under ambient conditions. 
Saccharin sodium should be stored in a well-closed container in a cool, dry place.   
Incompatibilities  
none   
Safety  
There has been considerable controversy concerning the safety of saccharin and saccharin sodium in 
recent years; however, it is now generally regarded as a safe, intense sweetener. The WHO has set a 
temporary acceptable daily intake of up to 2.5 mg/kg body-weight for saccharin, including its salts. In 
the UK, the Committee on Toxicity of Chemicals in Food, Consumer Products, and the Environment 
(COT) has set an acceptable daily intake for saccharin and its salts (expressed as saccharin sodium) at 
up to 5 mg/kg body-weight. 
LD50 (mouse, oral): 17.5 g/kg 
LD50 (rat, IP): 7.1 g/kg 
LD50 (rat, oral): 14.2 g/kg 
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Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye 
protection and a dust mask are recommended.   
Regulatory Status  
Accepted for use as a food additive in Europe E954 is applied to both saccharin and saccharin salts. 
Included in the FDA Inactive Ingredients Guide (buccal and dental preparations; IM and IV injections; 
oral and topical preparations). Included in nonparenteral medicines licensed in the UK.   
Related Substances  
Alitame, saccharin   
Comments  
The perceived intensity of sweeteners relative to sucrose depends upon their concentration, 
temperature of tasting, and pH, and on the flavour and texture of the product concerned. 
Intense sweetening agents will not replace bulk, textural, or preservative characteristics of sugar if 
sugar is removed from a formulation. 
Synergistic effects for combinations of sweeteners have been reported. Saccharin sodium is often used 
in combination with cyclamates and aspartame since the saccharin sodium content may be reduced to 
minimize any aftertaste.   
Glucose, Liquid  
Nonproprietary Names  
BP: Liquid glucose 
PhEur: Glucosum liquidum 
USPNF: Liquid glucose   
Synonyms 
Corn syrup; Flolys; Glucomalt; glucose syrup; Glucosweet; Mylose; Roclys; starch syrup.   
Chemical Name   
Liquid glucose.   
Functional Category  
Coating agent; sweetening agent; tablet binder. 
Description 
Liquid glucose is an aqueous solution of several compounds, principally dextrose, dextrin, fructose, 
and maltose. It is a colourless, odorless, and viscous sweet-tasting liquid. 
Liquid glucose is classified according to its dextrose equivalent (DE) into four types: 
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Type I: 20 38 DE 
Type II: 38 58 DE 
Type III: 58 73 DE 
Type IV: >73 DE   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for liquid glucose. 
Test PhEur 2002 (Suppl. 4.6) USPNF 21
 
Identification + + 
Characters + 
Acidity + 
pH 4.0 6.0 
Water 30.0% 21.0% 
Residue on 
ignition 
0.5 % 0.5% 
Sulphur 
dioxide 
20 ppm(a) 
Dextrose 
equivalent 
+ 
Sulphite + 
Heavy metals 10 ppm 0.001% 
Starch + 
Organic 
volatile 
impurities 
+ 
Assay (of 
dried matter) 
70.0% 
(a) Or 400 ppm if intended for the production of hard boiled candies, provided the final product 
contains 50 ppm.   
Typical Properties  
Density  
1.43 g/cm3 at 20°C  
Solubility  
Miscible with water; partially miscible with ethanol (90%).  
Viscosity (dynamic)  
13.0 14.5 mPa s (13.0 14.5 cP) at 21°C.   
Stability and Storage Conditions  
Liquid glucose should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities  
Incompatible with strong oxidizing agents.   
Safety  
Liquid glucose is used in oral pharmaceutical formulations and confectionery products and is 
generally regarded as a nontoxic and nonirritant material. It may be consumed by diabetics. 
LD50 (mouse, IV): 9 g/kg   
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of material handled.   
Regulatory Status  
The PhEur 2002 (Suppl. 4.6) also includes a specification for glucose, liquid, spray dried. Included in 
the FDA Inactive Ingredients Guide (oral solutions, syrups, and tablets; topical emulsions and gels). 
Included in nonparenteral medicines licensed in the UK.   
Related Substances  
Dextrin; dextrose; maltose.   
Comments  
A specification for glucose syrup is contained in the Food Chemicals Codex (FCC).   
Fructose  
Nonproprietary Names  
BP: Fructose 
JP: Fructose 
PhEur: Fructosum 
USP: Fructose   
Synonyms  
Advantose FS 95; Fructamyl; Fructofin; D-( )-fructopyranose; -D-fructose; fruit sugar; Krystar; 
laevulose; levulose.   
Chemical Name  
D-Fructose    
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Molecular Formula and Molecular Weight  
C6H12O6 
Mw = 180.16   
Structural Formula 
   
Functional Category  
Dissolution enhancer; flavour enhancer; sweetening agent; tablet diluent.   
Description  
Fructose occurs as odorless, colourless crystals or a white crystalline powder with a very sweet taste.   
Pharmacopeial Specifications  
Table 1: Pharmacopeial specifications for fructose. 
Test JP 2001 PhEur 2002 USP 26 
Identification + + + 
Characters + 
Colour of solution + + + 
Acidity + + + 
pH 4.0 6.5 
Specific optical 
rotation 
91.0° to 
93.5° 
Foreign sugars + 
Loss on drying 0.5% 0.5% 
Residue on ignition 0.1% 0.1% 0.5% 
Chloride 0.018% 0.018% 
Sulphate 0.024% 0.025% 
Sulphite + 
Water 0.5% 
Arsenic 1.3 ppm 1 ppm 
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Barium + 
Calcium and 
magnesium (as 
calcium) 
+ 0.005% 
Lead 0.5 ppm
Heavy metals 4 ppm 5 ppm 
Hydroxymethylfurfural + + + 
Assay (dried basis) 98.0% 98.0
102.0% 
 
Typical Properties  
Acidity/alkalinity  
pH = 5.35 (9% w/v aqueous solution)  
Density  
1.58 g/cm3  
Hygroscopicity  
At 25°C and relative humidities above approximately 60%, fructose absorbs significant amounts of 
moisture.  
Melting point  
102 105°C (with decomposition)  
Osmolarity  
a 5.05% w/v aqueous solution is isoosmotic with serum.  
Particle size distribution  
The average particle size of standard-grade crystalline fructose is 400 m (Fructofin C, Xyrofin). 
Other grades are available that have an average particle size of 170 m (Fructofin CM, Xyrofin). The 
average particle size of powdered fructose is 25 40 m (Krystar, AE Staley Mfg Co). Other grades are 
available: e.g., Krystar 300 and Krystar 450 with average particle sizes of 300 m and 450 m, 
respectively.   
Solubility  
Table 2: Solubility of fructose. 
Solvent Solubility at 20°C 
Ethanol (95%) 1 in 15 
Methanol 1 in 14 
Water 1 in 0.3 
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Viscosity (dynamic)  
Table 3: Physical properties of aqueous fructose solutions at 20°C. 
Concentration  
of aqueous fructose 
 solution (% w/w) 
Density 
(g/cm3) 
Refractive 
index 
Viscosity, 
dynamic 
(mPa s) 
10 1.04 1.3477 1.35 
20 1.08 1.3633 1.80 
30 1.13 1.3804 2.90 
40 1.18 1.3986 5.60 
50 1.23 1.4393 34.0 
60 1.29 1.4853 309.2 
  
Stability and Storage Conditions  
Fructose is hygroscopic and absorbs significant amounts of moisture at relative humidities greater than 
60%. Goods stored in the original sealed packaging at temperatures below 25°C and a relative 
humidity of less than 60% can be expected to retain stability for at least 12 months. 
Aqueous solutions are most stable at pH 3 4 and temperatures of 4 70°C; they may be sterilized by 
autoclaving.   
Incompatibilities  
Incompatible with strong acids or alkalis, forming a brown coloration. In the aldehyde form, fructose 
can react with amines, amino acids, peptides, and proteins. Fructose may cause browning of tablets 
containing amines.   
Safety  
Although it is absorbed more slowly than dextrose from the gastrointestinal tract, fructose is 
metabolized more rapidly. Metabolism of fructose occurs mainly in the liver, where it is converted 
partially to dextrose and the metabolites lactic acid and pyruvic acid. Entry into the liver and 
subsequent phosphorylation is insulin-independent. Further metabolism occurs by way of a variety of 
metabolic pathways. In healthy and well regulated diabetics, glycogenesis (glucose stored as 
glycogen) predominates. 
Excessive oral fructose consumption (>75 g daily) in the absence of dietary dextrose in any form (e.g., 
sucrose, starch, dextrin, etc.) may cause malabsorption in susceptible individuals, which may result in 
flatulence, abdominal pain, and diarrhea. Except in patients with hereditary fructose intolerance there 
is no evidence to indicate that oral fructose intake at current levels is a risk factor in any particular 
disease, other than dental caries.    
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of material handled. 
Fructose may be irritant to the eyes. Eye protection and gloves are recommended.   
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Regulatory Status  
Included in the FDA Inactive Ingredients Guide (oral solutions and suspensions; rectal preparations). 
Related Substances  
Dextrose; high-fructose syrup; liquid fructose; milled fructose; powdered fructose; pyrogen-free 
fructose; sucrose.   
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